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Abstract	  
	  
Stem	  cell	  homeostasis	  and	  differentiation	  are	  controlled	  by	  the	  complex	  interplay	  of	  
a	  wide	  range	  of	  signalling	  pathways	  and	  small	  molecules,	  including	  all-­‐trans-­‐retinoic	  
acid	   (ATRA).	   The	   endogenous	   effects	   elicited	   by	   ATRA,	   have	   led	   to	   its	   use	   in	  
numerous	   in	   vitro	   protocols	   as	   a	   tool	   for	   cell	   differentiation.	   However,	   ATRA	  
isomerises	  and	  degrades	  under	   standard	   laboratory	  conditions	  and	   furthermore,	   is	  
rapidly	  metabolised	   in	  vivo,	  which	  leads	  to	  pleotropic	  effects	  and	  a	  high	  efficacious	  
dose	   response.	   Consequently,	   synthetic	   analogues	   that	   are	   structurally	   and/or	  
functionally	   equivalent	   to	   ATRA	   have	   been	   developed,	   as	   alternative	  
pharmacological	   tools	   to	   further	   the	  understanding	  of	   this	  molecular	  pathway	  and	  
control	  cell	  differentiation.	  
	  
In	   this	   study	   a	   small	   library	   of	   synthetic	   retinoids	   were	   prepared,	   which	   were	  
designed	  to	  probe	  structural	  size,	  conformation	  and	  biological	  function,	  while	  being	  
more	   resistant	   to	   cellular	   metabolism	   and	   isomerisation.	   Their	   stability	   towards	  
fluorescent	   light	  was	   examined	   along	  with	   their	   activity	   in	   four	   different	   stem	   cell	  
models.	  Two	  compounds,	  AH60	  and	  AH61	  were	  found	  to	  inhibit	  cellular	  proliferation	  
and	   induce	   neural	   differentiation,	   through	   acting	   on	   the	   retinoic	   acid	   receptor	  
pathway.	   Compared	   to	   ATRA,	   AH60	  was	   approximately	   10-­‐fold	  more	   active,	  while	  
AH61	  was	  100-­‐fold	  more	  active	  in	  two	  of	  the	  cell	  models	  tested.	  These	  compounds	  
are	   described	   comprehensively	   herein,	   and	   should	   be	   suitable	   and	   convenient	  
alternatives	   to	   ATRA	   and	   13cRA	   for	   use	   in	   in	   vitro	   studies	   carried	   out	   by	   cell	   and	  
molecular	  biologists.	  	  
	  
In	   addition,	   an	   unrelated	   small	  molecule,	   neuropathiazol,	   has	   been	   synthesised	   to	  
further	  characterise	  both	  the	  chemistry	   involved	  in	   its	  production	  and	  its	  biological	  
activity	   in	   controlling	   cell	   differentiation.	   This	   compound	   was	   highlighted	   in	   the	  
literature	   as	   an	   alternative	   to	   ATRA,	   for	   inducing	   neural	   differentiation	   in	   neural	  
progenitor	   cells.	   We	   have	   further	   investigated	   its	   potential	   to	   differentiate	   other	  
neural	  stem	  cell	  types	  and	  pluripotent	  stem	  cells.	  In	  addition	  potential	  analogues	  of	  
neuropathiazol	   are	   discussed,	   as	   compounds	   of	   this	   nature	   are	   potentially	   highly	  
useful	  for	  selectively	  controlling	  neural	  differentiation.	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1.1 Introduction	  
	  
The	   study	   of	   how	   organisms	   grow	   and	   develop,	   encompassing	   cell	   growth,	  
differentiation	  and	  morphogenesis,	  is	  termed	  developmental	  biology.	  Stem	  cells	  play	  
a	   vital	   role	   in	   this	   field,	   in	   both	   embryogenesis	   and	   adult	   homeostasis.	   A	   detailed	  
understanding	   of	   both	   the	   pathways	   involved,	   and	   ways	   in	   which	   they	   can	   be	  
controlled	  is	  an	  integral	  part	  of	  advancing	  stem	  cell	  research.	  
	  
Multiple	   molecular	   mechanisms	   control	   stem	   cell	   renewal,	   proliferation	   and	  
differentiation,	  including	  signalling	  by	  Notch,	  Wnt,	  Hedgehog	  (Hh),	  FGF	  and	  retinoic	  
acid	  (RA)	  (see	  section	  1.3	  for	  a	  detailed	  discussion	  and	  references	  within).	  The	  use	  of	  
both	   natural	   and	   synthetic	   compounds	   specifically	   designed	   to	   act	   on	   these	  
individual	  pathways	  has	  recently	  played	  a	  substantial	  role	   in	  advancing	  this	  area	  of	  
research.	  Compounds	  are	  designed	  to	  act	  at	  a	  particular	  point	   in	  the	  pathway,	  at	  a	  
precise	  concentration,	  to	  bring	  about	  a	  set	  response.	  Thus,	  small	  molecules	  can	  be	  
administered	   to	   stem	   cell	   cultures	   to	   bring	   about	   controlled	   differentiation,	   self-­‐
renewal	   or	   proliferation.	   The	   overall	   aim	   of	   this	   area	   of	   research	   is	   therefore	   to	  
achieve	   the	   precise	   control	   of	   stem	   cells	   to	   generate	   new	   cells	   and	   tissues	   for	  
research.	  This	  would	  then	  allow	  for	  better	  drug	  screening	  assays,	  disease	  modelling	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1.2 Stem	  Cells	  
	  
The	   term	   ‘stem	   cell’	   is	   given	   to	   a	   cell	   if	   it	   has	   the	   ability	   to	   both	   self-­‐renew	   and	  
produce	  differentiated	  cellular	  subtypes.	  They	  can	  be	  derived	  from	  both	  the	  embryo	  
and	  distinct	  areas	  of	  the	  adult.1	  One	  method	  of	  classification,	  is	  based	  around	  their	  















Figure	  1.1	  Potency	  definitions.	  Adapted	  from	  Jaenisch	  et	  al.1	  
	  
In	   mammals,	   only	   the	   zygote	   and	   early	   blastomeres	   can	   generate	   the	   entire	  
organism,	   including	   extraembryonic	   tissue	   and	   are	   therefore	   termed	   totipotent.1	  
Most	  embryonic	  stem	  (ES)	  cells	  are	  an	  example	  of	  pluripotent	  cells,	  which	  both	  self-­‐
renew	   and	   have	   the	   ability	   to	   form	   any	   somatic	   fetal,	   or	   adult	   cell	   type.	   Initially	  
described	   over	   three	   decades	   ago	   in	   mouse,	   ES	   cells	   possess	   the	   ability	   to	  
differentiate	   into	  all	   three	  of	  the	  developing	  germ	  layers,	  the	  ectoderm,	  endoderm	  
and	  mesoderm.2,	  3	  They	  cannot	  however	  contribute	  to	  the	  extraembryonic	   lineages	  
of	  the	  trophoblast	  or	  primitive	  endoderm,	  therefore,	  differentiating	  them	  from	  the	  
totipotent	   cells	   of	   the	   zygote	   and	   early	   blastomere.4	   Stem	   cells	   derived	   from	   the	  
	  	  	  	  	  	  Totipotent	   	   Ability	  to	  form	  all	  lineages	  of	  an	  
	   	   	   	   organism	  e.g.	  zygote	  of	  mammals.	  
	   	   	  	  	  	  	  
Pluripotent	   Ability	  to	  form	  all	  lineages	  of	  the	  
body	  (endoderm,	  ectoderm	  and	  
mesoderm)	  e.g.	  ES	  cells.	  
	   	  	  	  	  	  	  
Multipotent	   Ability	  to	  form	  multiple	  cells	  types	  
of	  a	  single	  lineage	  e.g.	  adult	  stem	  
cells	  such	  as	  neural	  progenitor	  
cells	  (AHPC)	  or	  hematopoietic	  
stem	  cells.	  
	  
Unipotent	   Cells	  that	  form	  a	  single	  cell	  type	  
e.g.	  spermatogonial	  stem	  cells	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postnatal	   animal	   are	   termed	   adult	   stem	   (AS)	   cells.	   AS	   cells	   are	   generated	   during	  
embryogenesis	   and	   thereafter	   regulated	   by	   precise	   stage-­‐specific	   programs,	  
controlling	  both	  their	  homeostasis	  and	  differentiation.5	  AS	  cells	  are	  more	  restricted	  
than	  ES	  cells	  in	  that	  they	  can	  give	  rise	  to	  only	  a	  limited	  number	  of	  lineages,	  and	  thus	  
are	  termed	  multipotent.	  They	  are	  normally	  involved	  in	  homeostatic	  self-­‐renewal,	  but	  
additionally,	  have	  the	  ability	  to	  repair	  tissues	  upon	  injury.	  This	  role	  makes	  them	  an	  
exciting	   prospect	   for	   therapeutic	   uses	   and	   as	   drug	   targets.	   One	   example	   is	  
hematopoietic	  stem	  cells	  (HSCs),	  which	  reside	  in	  the	  bone	  marrow	  of	  adult	  mammals	  
and	  provide	  a	  life	  long	  source	  of	  blood	  precursors	  that	  subsequently	  differentiate	  to	  
produce	  mature	  blood	  cells.6	  Stem	  cells	  which	  posses	  the	  ability	  to	  form	  only	  a	  single	  
lineage	  are	  termed	  unipotent.	  Examples	  of	  theses	  include	  hepatocytes,	  found	  in	  the	  
liver	  and	  spermatogonial	  stem	  cells,	  which	  can	  only	  produce	  sperm.7	  	  
	  
1.2.1	  Induced	  Pluripotent	  Stem	  Cells	  
	  
In	   addition	   to	   the	   stem	   cells	   described	   above,	   there	   are	   two	   further	   categories	   of	  
stem	   cell.	   The	   first,	   induced	   pluripotent	   stem	   (iPS)	   cells,	   are	   stem	   cells	   that	   have	  
been	   created	   from	   somatic	   cells.	   These	   have	   the	   major	   advantage	   in	   that	  
therapeutically	  one	  could	  generate	  pluripotent	  stem	  cells	  directly	  from	  the	  somatic	  
cells	  of	  the	  patient.	  This	  would	  circumvent	  issues	  such	  as	  tissue	  rejection	  and	  ethical	  
issues	   associated	   with	   human	   embryos.	   Three	   strategies	   have	   to	   date	   been	  
employed	   in	   inducing	   pluripotency	   in	   mouse	   somatic	   cells,	   nuclear	   transfer	   (NT),	  
fusion	  and	  forced	  expression	  of	  defined	  factors	  (Figure	  1.2).8	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Figure	  1.2	  Methods	  of	  generating	  pluripotent	  stem	  cells	  from	  adult	  somatic	  cells.	  Adapted	  
from	  S.	  Yamanaka.8	  
	  
1.2.1.1	  Nuclear	  Transfer	  
	  
NT	   is	   defined	   as	   the	   introduction	   of	   a	   nucleus	   from	   a	   donor	   somatic	   cell	   into	   an	  
enucleated	   oocyte	   to	   generate	   a	   clone	   species.	   NT	  was	   first	   reported	   in	   the	   early	  
1950’s,	  although	  it	  was	  not	  until	  the	  late	  1990’s	  that	  a	  viable	  mammalian	  offspring,	  
derived	  from	  fetal	  and	  adult	  mammalian	  cells	  was	   first	  described	   in	  sheep.9,	  10	  This	  
was	  quickly	   followed	  by	  subsequent	  somatic	  cloning	   in	  additional	   species	   including	  
rabbit,	   cow,	  mouse,	   cat,	   pig	   and	   goat.11	  The	   generation	   of	   live	   animals	   confirmed	  
that	  terminally	  differentiated	  somatic	  cells	  could	  be	  reprogrammed	  to	  an	  embryonic	  
state,	  capable	  of	  directing	  the	  development	  of	  a	  healthy	  organism.	  	  
The	  process	  of	  nuclear	  cloning	  described	  above	  is	  inherently	  inefficient,	  resulting	  in	  
the	  death	  of	  most	  clones	  attributed	  to	  faulty	  reprogramming.12	  Generating	  ES	  cells,	  
rather	   than	   cloned	   animals,	   appreciatively,	   is	   significantly	   more	   efficient,	   as	  
demonstrated	  with	  mouse	  blastocytes.13	  No	  biological	  or	  molecular	  differences	  are	  
observed	   when	   comparing	   ES	   cells	   derived	   from	   either	   NT,	   or	   fertilised	   embryos,	  
suggesting	  NT	  ES	  cells	  are	  as	  useful	  as	  ES	  cells	  from	  fertilised	  embryos.14	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1.2.1.2	  Fusion	  with	  ES	  Cells	  
	  
Fusion	   is	   the	   process	   by	   which	   somatic	   nuclei	   are	   reprogrammed	   to	   an	  
undifferentiated	   state	   by	   combination	  with	   embryonic	   cells	   to	   show	   pluripotency.	  
The	  first	  example	  of	  this	  process	  was	  demonstrated	  in	  1976	  by	  fusion	  of	  thymocytes	  
(hematopoietic	  progenitor	  cells)	  with	  embryonic	  carcinoma	  (EC)	  cells.15	  Electrofusion	  
has	   subsequently	   been	   used	   with	   mouse	   ES	   cells,	   and	   more	   recently	   fusion	   with	  
human	   ES	   cells	   has	   been	   reported.16-­‐18	   Currently,	   little	   is	   known	   about	   the	  
mechanisms	  of	   reprogramming	  by	   fusion,	  and	   the	   full	  extent	   to	  which	   the	  somatic	  
genome	  is	  reprogrammed	  is	  unknown.	  
	  
1.2.1.3	  Reprogramming	  by	  Defined	  Factors	  	  
	  
The	   successful	   reprogramming	   of	   differentiated	   cells	   by	   both	   nuclear	   transfer,	   or	  
fusion	  suggests	  that	  ES	  cells	  contain	  the	  correct	  factors	  to	  induce	  the	  transformation.	  
In	  2006	  Takahashi	  and	  Yamanaka	  successfully	  identified	  four	  of	  these	  factors	  from	  a	  
wider	  screen	  of	  twenty	  four.19	  They	  demonstrated	  the	  successful	  reprogramming	  of	  
mouse	   embryonic	   fibroblasts,	   and	   adult	   fibroblasts,	   back	   to	   ES-­‐like	   cells	   by	  
introducing,	  Oct-­‐3/4,	  Sox2,	  c-­‐Myc	  and	  Klf4	  under	  ES	  cell	  culture	  conditions.	  The	  four	  
transcription	  factors	  were	  introduced	  through	  viral-­‐mediated	  transduction	  followed	  
by	   selection	   for	   the	   expression	   of	   Fbx15.19	   Although	   these	   cells	   displayed	   highly	  
analogous	   morphologies,	   proliferation	   patterns	   and	   teratoma	   formation	  
characteristics	   to	   ES	   cells,	   upon	   transplantation	   into	  blastocysts	   the	   iPS	   cells	   could	  
not	   generate	   adult	   or	   germline	   chimeras.	   Indicating	   that	   the	   reprogramming	   was	  
somewhat	   inadequate.19	  More	   recently,	   three	   groups	   generated	   iPS	   cells	   in	   which	  
the	  activation	  of	  endogenous	  Oct-­‐4	  or	  Nanog	  genes	  was	  used	  as	  a	  selection	  criterion.	  
This	  resulted	  in	  cells	  that	  were	  fully	  reprogrammed	  to	  a	  pluripotent	  ES	  cell	  state.20-­‐22	  
	  
A	  number	  of	  more	  recent	  studies	  have	  extended	  this	  research	  into	  human	  systems,	  
using	  both	  the	  four	  factors	  described	  above	  and	  others	  including	  Nanog	  and	  LIN28.23-­‐
25	  For	  the	  process	  to	  develop	  further	  the	  use	  of	  oncogenes	  needs	  to	  be	  resolved,	  as	  
cancer	   is	   a	   common	   side	   effect.21	   In	   an	   attempt	   to	   overcome	   this,	   a	   number	   of	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groups	   have	   demonstrated	   that	   the	   c-­‐Myc	   gene	   is	   dispensable.	   Both	   mouse	   and	  
human	   iPS	   cells	   have	   been	   attained	  without	   the	   c-­‐Myc	   transduction,	   albeit	  with	   a	  
lower	  efficiency	  and	  at	  a	  slower	  rate	  of	  reprogramming.25-­‐27	  The	  formation	  of	  c-­‐Myc	  
tumours	  can	  therefore	  be	  eliminated	  yet	  tumours	  developing	  from	  the	  transduction	  
of	   other	   retrovirus-­‐transduced	   transcription	   factors	   such	   as	   Oct-­‐4	   may	   arise.	   One	  
solution	  to	  this	  is	  to	  remove	  the	  use	  of	  retroviruses	  altogether	  and	  use	  gene	  transfer	  
or	   deliver	   the	   protein	   factors	   in	   cell-­‐permeant	   forms.28	   Another	   is	   to	   use	   small	  
molecules	   that	   interact	   with	   specific	   pathways,	   which	   has	   successfully	   been	  
demonstrated	   through	   the	   replacement	   of	   Sox2	   with	   the	   molecule	   SB	   431542	  	  
(discussed	  in	  the	  following	  section).29	  	  
	  
If	  these	  concerns	  were	  overcome	  iPS	  cells	  do	  hold	  a	  significant	  potential	  in	  that	  they	  
circumnavigate	  any	  ethical	  issues,	  as	  human	  embryos	  are	  not	  harmed.	  Furthermore,	  
they	   also	   have	   the	   potential	   to	   generate	   patient-­‐specific	   cells	   thus	   eliminating	  
rejection	  by	  the	   immune	  system	  of	  cell	   transplants.	  Finally,	   the	  technique	  could	  be	  
used	  to	  generate	  iPS	  cells	  from	  patients	  with	  specific	  diseases.	  These	  iPS	  cells	  could	  
then	   be	   differentiated	   into	   discrete	   cellular	   populations	   on	   which	   treatment	  
strategies	  and	  disease	  pathogenesis	  studies	  could	  be	  undertaken.28	  	  
	  
1.2.1.4	  Culture	  Induced	  Reprogramming	  
	  
In	   addition	   to	   the	   three	   methods	   described	   above,	   Matsui	   et	   al.	   reported	   that	  
pluripotent	   embryonic	   germ	   (EG)	   cells	   could	   be	   generated	   from	   the	   long-­‐term	  
culture	   of	   primordial	   germ	   cells	   (PGC).30	   Furthermore,	   additional	   work	   has	   been	  
reported	  on	  the	  generation	  of	  chimera-­‐competent	  pluripotent	  stem	  cells	  after	  long-­‐
term	  culture	  of	  bone	  marrow	  cells.31	  More	  recently,	  pluripotent	  stem	  cells	  have	  been	  
generated	  from	  culturing	  both	  germline	  stem	  (GS)	  cells	  from	  neonate	  mouse	  testes	  
and	   adult	   mouse	   testes.32,	   33	   These	   were	   designated	   multipotent	   germline	   stem	  
(mGS)	  cells	  and	  multipotent	  adult	  germline	  stem	  (maGS)	  cells	  respectively.	  mGS	  cells	  
were	   shown	   to	   be	   similar	   to	   ES	   cells	   over	   a	   number	   of	   criteria,	   including	  
proliferation,	  morphology	  and	  teratoma	  formation.32	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Though	   clearly	   reported	   in	   the	   literature,	   there	   is	   still	   some	   apprehension	   to	   the	  
significance	  of	  the	  data,	  with	  some	  questioning	  whether	  or	  not	  the	  process	  has	  been	  
clearly	  proven.	  While	  some	  somatic	  cell	   lineages	  may	  transdifferentiate,	  the	  events	  
are	  too	  rare	  to	  play	  any	  significant	  role	  in	  physiological	  repair,	  and	  until	  fully	  verified	  
could	  potentially	  be	  as	  a	  result	  of	  other	  cellular	  events,	  such	  as	  fusion.1	  	  	  	  
	  
1.2.2	  Cancer	  Stem	  Cells	  
	  
The	  final	  category	  of	  stem	  cells	  is	  the	  cancer	  stem	  (CS)	  cell.	  CS	  cells	  are	  dormant	  or	  
slow	   cycling	   tumour	   cells,	  which	   retain	   the	   ability	   to	   reconstitute	   tumours.34	   As	   in	  
normal	  tissue,	  tumours	  have	  a	  functional	  and	  morphologic	  heterogeneity	  hierarchy,	  
organised	   and	   supported	   by	   CS	   cells.	   Albeit,	   CS	   cells	   do	   not	   always	   constitute	   the	  
minor	   component	  of	   the	   tumour,	  with	  mouse	   studies	   indicating	   the	  amount	  of	  CS	  
cells	  vary	  dramatically	  between	  individual	  tumours.35	  	  	  	  
	  
CS	  cells,	   like	  all	  other	  stem	  cells,	  can	  both	  self-­‐renew	  and	  differentiate	  to	  form	  any	  
part	   of	   the	   tumor.36	   Due	   to	   their	   slower	   rate	   of	   proliferation,	   possessing	   either	   a	  
dormant	   or	   large	   slow	   growing	   phase,	   most	   anti-­‐cancer	   agents	   are	   inadequately	  
effective,	  as	  they	  are	  designed	  to	  target	  proliferation	  and	  cellular	  division.34	  Hence,	  
long	  gaps	  between	  relapses	  in	  certain	  cancers	  are	  attributed	  to	  CS	  cells.37	  
	  
At	  present,	   there	   is	  a	  vast	  array	  of	  evidence	  supporting	  the	  existence	  of	  CS	  cells	   in	  
many	  carcinomas,	  although	  there	  are	  still	  many	  issues	  to	  be	  resolved.	  Currently,	  CS	  
cells	  samples	  are	  relatively	  impure	  and	  there	  is	  a	  lack	  of	  outright	  markers	  to	  use	  for	  
identification.35	  Furthermore,	  still	  to	  be	  demonstrated	  is	  formation	  of	  solid	  tumours	  
developed	   from	   a	   single	   transplanted	   CS	   cell,	   such	   as	   those	   used	   to	   generate	  
teratocarcinoma	  cells.38	  
	  
1.2.3	  Adult	  Stem	  Cell	  Types	  
	  
In	  addition	  to	  the	  types	  of	  stem	  cells	  described	  thus	  so	  far,	  more	  specialised	  subset	  
categories	  of	   stem	  cells	   have	  been	   identified.	  As	  discussed,	  AS	   cells	   are	   generated	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during	   embryogenesis	   and	   subsequently	   regulated	   by	   precise	   stage-­‐specific	  
programs,	  controlling	  both	  their	  homeostasis	  and	  differentiation.5	  Thus,	  a	  number	  of	  
subsets	   of	  multipotent	   stem	   cells	   of	   particular	   tissues	   have	   been	   identified,	  which	  
will	  be	  discussed	  in	  more	  detail	  below.	  
	  
1.2.3.1	  Mesenchymal	  Stem	  Cells	  (MSCs)	  
	  
Mesenchymal	  stem	  cells	  are	  found	  in	  both	  the	  embryo	  and	  adult	  and	  are	  responsible	  
for	  the	  formation	  and	  repair	  of	  bone	  cells	  (osteocytes),	  cartilage	  cells	  (chondrocytes)	  
and	   fat	   cells	   (adipocytes),	   in	   addition	   to	   other	   connective	   tissues	   such	   as	   tendons	  
(tenocytes)	  and	  myo-­‐tubes.	  As	   the	  cells	  divide,	   they	  become	  more	  committed	   to	  a	  
specific	   lineage,	   with	   the	   end-­‐stage	   cells	   involved	   in	   the	   construction	   of	   a	   unique	  
tissue	   type.	   Studying	   both	   embryonic	   and	   adult	   MSCs	   has	   helped	   develop	   new	  
therapeutic	   strategies	   for	   the	   treatment	   of	   skeletal	   tissues,	  with	   self-­‐cell	   repair	   of	  
these	  conditions	  the	  ultimate	  aim.39-­‐41	  	  	  
	  
1.2.3.2	  Hematopoietic	  Stem	  Cells	  (HSCs)	  
	  
In	   addition	   to	  MSCs,	   the	   bone	  marrow	   contains	   one	   other	   discrete	   population	   of	  
adult	  stem	  cell,	  termed	  hematopoietic	  stem	  cells.	  This	  distinct	  population,	  are	  better	  
characterised	  and	  understood	  than	  MSCs	  and	  are	  solely	  responsible	  for	  the	  lifelong	  
production	   of	   blood	   cells.6,	  41,	  42	   They	   have	   the	   ability	   to	   self-­‐renew	   (generating	   at	  
least	  one	  daughter	  cell	  with	  HSC	  potential),	   in	  addition	  to,	  differentiating	   into	  both	  
lymphoid	  (T	  cell,	  B	  cell,	  natural	  killer	  cells	  and	  lymphoid	  dendritic	  cells)	  and	  myeloid	  
(all	   other	   lineages)	   blood	   cells.42	   As	   well	   as	   HSC,	   multipotent	   hematopoietic	  
progenitor	   cells	   (HPCs)	   have	   been	   identified.	   These	   have	   the	   same	   self-­‐renewal	  
ability	  and	   lineage	  potential	  but	  only	   for	  a	   limited	   time	  period,	   therefore	  HSCs	  are	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1.2.3.3	  Epithelial	  Stem	  Cells	  (ESCs)	  
	  
The	  epithelia	  is	  a	  continuous	  sheet	  of	  tightly	  linked	  cells	  that	  make-­‐up	  surfaces	  (e.g.	  
the	   epidermis)	   and	   linings	   (e.g.	   the	   respiratory	   and	   digestive	   tracts)	   of	   the	   body.	  
They	   provide	   protection,	   as	   well	   as,	   regulating	   nutrient	   and	   water	   uptake	   and	  
glandular	   secretions.	   As	   most	   epithelia	   are	   replaced	   constantly	   through	   out	   life	  
(know	  as	  tissue	  homeostasis)	  a	  subset	  of	  self-­‐renewing	  stem	  cells	  are	  required,	  and	  
these	   have	   been	   identified	   as	   epithelial	   stem	   cells	   (ESCs).	   These	   cells	   can	   produce	  
the	   entire	   cell	   phenotypes	   found	   in	   the	   epidermis,	   including	   goblet	   cells,	   paneth	  
cells,	  absorptive	  cells	  and	  enteroendocrine	  cells.	  For	  a	  detailed	  review	  on	  ESCs	  see	  
Blanpain	  et	  al..43	  	  
	  
1.2.3.4	  Skin	  Stem	  Cells	  (SSCs)	  
	  
More	   recently,	   a	   distinct	   subset	   of	   stem	   cells	   that	   maintain	   and	   repair	   the	   skin’s	  
epidermis	  have	  been	  identified.	  These	  skin	  stem	  cells	  have	  the	  ability	  to	  give	  rise	  to	  
different	  epidermal	  cell	  lineages,	  including	  the	  surface	  barrier	  (keratinocytes),	  sweat	  
glands,	  hair	  follicles	  and	  their	  associated	  sebaceous	  glands.	  To	  retain	  a	  homeostatic	  
environment,	  a	  constant	  cellular	  turnover	  is	  required.	  This	  process	  in	  now	  thought	  to	  
be	  controlled	  by	  several	  skin	  stem	  cells,	  located	  in	  specific	  epidermal	  regions,	  which	  
maintain	  discrete	  compartments	  of	  the	  skin.44-­‐46	  
	   	   	  
1.2.3.5	  Neural	  Stem	  Cells	  (NSCs)	  
	  
The	  final	  subset	  of	  stem	  cells	  to	  be	  discussed	  is	  neural	  stem	  cells.	  Initially	  identified	  
in	  the	  early	  1990s,	  in	  fetal	  rat	  and	  mouse	  brain,	  they	  are	  capable	  of	  generating	  the	  
three	  main	  phenotypes	  of	  the	  central	  nervous	  system	  (CNS),	  neurons,	  astrocytes	  and	  
oligodendrocites.47	   Neural	   differentiation	   is	   an	   early	   event	   in	   mammalian	  
embryogenesis,	  occurring	  soon	  after	  germ	   layer	  differentiation,	  with	  the	   formation	  
of	  the	  neural	  plate.	  Further	  development	  leads	  to	  the	  formation	  of	  the	  neural	  tube,	  
which	  initially	  consists	  of	  a	  morphologically	  similar	  set	  of	  cells,	  termed	  NSCs,	  which	  
form	  the	  neuroepithelial	  lining.	  These	  NSCs,	  like	  all	  other	  stem	  cells,	  have	  the	  ability	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to	   divide	   symmetrically	   (self-­‐renew)	   or	   differentiate	   into	   a	   progeny	   of	   cells	   from	  
which	   the	   mature	   cells	   of	   the	   CNS	   develop	   (for	   a	   detailed	   overview	   of	   CNS	  
development	  see	  Kennea	  and	  Mahmet).47,	  48	  
	  
In	  addition	  to	   fetal	  NSCs,	   the	  subsequent	  confirmation	  that	  neurogenesis	  occurs	   in	  
the	  adult	  brain,	  overturned	  a	   long	  term	  theory	  that	  we	  are	  born	  with	  all	   the	  nerve	  
cells	   we	   require.49	   Currently,	   neurogenesis	   has	   been	   shown	   to	   occur	   throughout	  
adulthood	  in	  two	  areas	  of	  the	  adult	  mammalian	  CNS:	  the	  olfactory	  bulb	  (OB)	  and	  the	  
dentate	  gyrus	  (DG)	  of	  the	  hippocampus.49	  Neuronal	  cells	  develop	  in	  the	  adult	  OB	  are	  
generated	   from	   neural	   progenitor	   cells	   (NPCs)	   found	   in	   the	   anterior	   part	   of	   the	  
subventricular	  zone	  (SVZ).50	  Neurogenesis	  occurring	  in	  the	  DG	  of	  the	  hippocampus	  in	  
adult	   humans	   is	   also	   controlled	  by	  NPCs	   generated	   in	   the	   subgranular	   zone	   (SGZ).	  
These	  progenitor	  cells	  have	   the	  ability	   to	  differentiate	   into	  both	  neuronal	  and	  glial	  
cells	  in	  the	  granular	  layer.51,	  52	  Additionally,	  similar	  neurogenesis	  has	  been	  shown	  to	  
occur	   in	  a	  number	  of	  other	  adult	  species,	   including	  rat	  and	  mouse	  (see	  Taupin	  and	  
Gage	   for	   a	   full	   review).49	   It	   remains	   completely	   unclear	   whether	   NPCs	   are	   truly	  
multipotent,	   although	   the	   demonstration	   that	   a	   population	   of	   self-­‐renewing	  
progenitor	   cells,	   cultured	   from	   NPCs	   from	   the	   adult	   brain	   regions	   discussed	  
previously,	   suggests	   that	   these	   cultures	   contain	  NSCs.49,	  53	   Furthermore	  NSCs	   have	  
the	  potential	   to	  be	  derived	   from	  more	  primitive	  cells,	   such	  as	  pluripotent	  ES	  or	  EC	  
cells,	  under	  the	  correct	  differentiation	  conditions.53	  	  
	  
NSCs	   and	   NPCs	   are	   very	   exciting,	   both	   therapeutically,	   and	   as	   a	   research	   tool	   for	  
developing	   our	   understanding	   of	   CNS	   development.	   In	   addition,	   the	   controlled	  
differentiation	   of	   cells	   already	   committed	   to	   a	   neuronal	   lineage	   may	   hold	   the	  
solution	   to	   a	   number	   of	   neurodegenerative	   diseases,	   such	   as	   Parkinson’s,	  
Alzheimer’s	   and	   Huntington’s	   diseases.54-­‐56	   Both	   embryonic	   NSCs,	   such	   as	   the	  
ReNcell	  VM	  line,	  and	  adult	  NPCs,	  such	  as	  the	  rat	  hippocampal	  HCN-­‐nitGFP	  cell	   line,	  
have	   been	   isolated	   and	   cultured	   successfully	   in	   vitro.57,	  58	   Differentiation	   protocols	  
have	   been	   published	   for	   these	   cell	   lines,	   including	   withdrawal	   of	   growth	   factors	  
(epidermal	  growth	   factor	   (EGF)	  and	   fibroblast	  growth	   factor	   (FGF))	  and	  addition	  of	  
small	   molecules	   (all-­‐trans	   retinoic	   acid	   (ATRA))	   and	   neurotrophins	   (NTs).57,	   59,	   60	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Currently	   these	   protocols	   are	   not	   highly	   efficient	   and	   reliable,	   meaning	   we	   are	  
someway	  off	  successfully	  utilising	  NSCs/NPCs	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  full	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1.3 Pathways	  Involved	  in	  Stem	  Cell	  Modulation	  
	  
To	   be	   able	   to	   design	   and	   synthesise	   small	   molecules	   to	   control	   stem	   cells,	   an	  
understanding	   of	   the	   molecular	   pathways	   involved	   in	   their	   maintenance	   and	  
differentiation	   is	   required.	   Alongside	   advances	   in	   stem	   cell	   biology,	   the	   roles	   of	   a	  
limited	   set	   of	   signaling	   cascades/pathways	   have	   been	   identified.	   This	   section	   will	  
cover	   the	   six	   main	   pathways	   involved	   in	   regulating	   stem	   cells,	   the	   canonical	  Wnt	  
cascade,	   hedgehog	   (Hh)	   signaling,	   the	   transforming	   growth	   factor-­‐β	   superfamily	  
(TGF-­‐β),	  Notch,	  fibroblast	  growth	  factor	  (FGF)	  and	  retinoic	  acid	  (RA)	  pathways.	  
	  
1.3.1 Canonical	  Wnt	  Cascade	  
	  
The	   canonical	   Wnt	   cascade	   is	   crucial	   to	   the	   regulation	   of	   both	   stem	   cells	   and	  
progenitors,	  having	  being	   linked	  to	  proliferation,	  self-­‐renewal	  and	  differentiation.61	  
Wnt	  signaling	  has	  been	  identified	  as	  having	  an	  integral	  role	  in	  cell	  maintenance	  and	  
growth	   in	   the	   epidermal,	   intestinal	   and	   haematopoietic	   systems.	   In	   addition,	  
dysregulation	   of	   the	   Wnt	   pathway	   has	   been	   associated	   with	   certain	   cancers,	  
specifically	  where	  cancer	  stem	  cells	  are	  believe	  to	  be	  involved	  (see	  Reya	  and	  Clevers	  
for	  a	  detailed	  review).61	  	  
	  
The	  canonical	  Wnt	  cascade,	  as	   it	   is	  now	  known,	   first	  began	  to	  be	  understood	  after	  
the	   discovery	   that	   the	   Drosophila	   polarity	   gene	  Wingless	   and	   the	   murine	   proto-­‐
oncogene	  Int-­‐1	  had	  a	  common	  origin.62	  Briefly,	  when	  Wnt	  is	  not	  bound,	  β-­‐catenin	  is	  
targeted	   for	   proteasomal	   degradation	   by	   a	   group	   of	   proteins	   known	   as	   the	  
destruction	   complex.	   This	   consists	   of	   two	   scaffolding	   proteins,	   axin	   and	  
adenomatous	   polyposis	   coli	   (APC),	   and	   two	   kinases,	   casein	   kinase	   1	   (CK1)	   and	  
glycogen	   synthase	   kinase	   3	   (GSK-­‐3).	   Newly	   synthesised	   β-­‐catenin,	   once	   bound,	   is	  
sequentially	   phosphorylated	   on	   a	   set	   of	   conserved	   serine	   and	   threonine	   residues.	  
The	   phosphorylation	   recruits	   ubiquitin	   ligase,	   which	   targets	   β-­‐catenin	   for	  
degradation	   and,	   in	   turn,	   inhibits	   the	   expression	   of	   the	   target	   genes.	   This	   has	   the	  
effect	  of	  inhibiting	  stem	  cell	  differentiation	  and	  self-­‐renewal.	  Upon	  Wnt	  binding,	  the	  
destruction	   complexes	   can	   no	   longer	   bind	   β-­‐catenin,	   as	   axin	   now	   interacts	   with	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lipoprotein	   receptor-­‐related	   protein	   (LRP)	   and/or	   disheveled	   (Dsh),	   although	   the	  
exact	  mechanism	  is	  currently	  unspecified.	  This	  leads	  to	  an	  accumulation	  of	  β-­‐catenin	  
within	  the	  cell,	  which	  is	  then	  transported	  to	  the	  nucleus	  where	  it	  interacts	  with	  T-­‐cell	  
factor	   (TCF)	   and	   lymphoid	   enhancer	   factor	   (LEF)	   to	  bring	   about	   gene	  expression.63	  




Figure	   1.3	   Canonical	  Wnt	   signaling	   pathway.	   Unbound	   (left	   cell)	   β-­‐catenin	   is	   targeted	   for	  
degradation	  by	  the	  destruction	  complex	  and	  genes	  remained	  switched	  off.	  Bound	  (right	  cell),	  
the	   destruction	   complex	   is	   uncoupled,	   β-­‐catenin	   builds	   up	   and	   relocates	   to	   the	   nucleus	  
where	   it	   initiates	  gene	   transcription	   through	   interaction	  with	   LEF/TCF.	  Adapted	   from	  Reya	  
and	  Clevers.61	  	  
	  	  
1.3.1.1	  Small	  Molecule	  Modulation	  of	  Wnt	  Pathway	  
	  
As	   the	  pathway	   effects	   stem	   cell	   differentiation	   and	  proliferation	   small	  molecules,	  
which	  can	   interact,	  have	  the	  potential	   to	  affect	   their	  outcome.	  One	  such	  class,	  are	  
the	  GSK-­‐3β	   inhibitors,	  which	   inhibit	   the	   phosphorylation/degradation	  of	  β-­‐catenin,	  
thus	  promoting	  target	  gene	  expression	  of	  the	  Wnt	  pathway.	  One	  example	  of	  such	  a	  
compound	  is	  CHIR	  99021,	  which	  has	  since	  been	  used	  in	  the	  generation	  of	  iPS	  cells	  in	  
both	   mouse	   and	   humans.64-­‐66	   In	   addition,	   the	   interaction	   of	   β-­‐catenin	   with	   the	  
transcription	   factors	   TCF/LEF	   has	   also	   been	   targeted	   by	   molecules	   such	   as	   PKF	  
115584,	   in	   an	   attempt	   to	   find	   alternative	   cancer	   treatments.67	   Approaching	   the	  
pathway	  in	  the	  opposite	  direction,	  small	  molecule	  screens	  have	  identified	  molecules	  
that	  inhibit	  the	  expression	  of	  Wnt	  genes,	  either	  through	  inhibiting	  Wnt	  production,	  
or	   promoting	   β-­‐catenin	   breakdown.	   Examples	   include	   IWP	   2	   and	   IWR	   1.68	   In	  
addition,	  the	  small	  molecule,	  XAV	  939,	  has	  been	  identified	  as	   inhibiting	  the	  growth	  
	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Chapter	  I	  
	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  14	  
of	  colorectal	  cancer	  cells,	  through	  stabilisation	  of	  the	  destruction	  complex,	  through	  a	  
mode	  of	  action	  mechanistically	  similar	  to	  that	  of	  IWR	  1.69	  The	  chemical	  structures	  of	  




Figure	  1.4	  Small	  molecule	  modulators	  of	  the	  Wnt	  pathway.	  
	  
1.3.2 Hedgehog	  Pathway	  
	  
The	  hedgehog	  (Hh)	  signalling	  pathway	  has	  an	  intrinsic	  role	  in	  numerous	  processes	  in	  
both	  embryogenesis	  and	  adult	  homeostasis,	  where	  it	  is	  involved	  in	  the	  maintenance	  
of	   stem	   cell	   populations.	   The	   gene	   was	   first	   identified	   in	   the	   1980s	   trying	   to	  
understand	   body	   segmentation	   in	   Drosophila.70	   Subsequently,	   additional	   proteins	  
have	   been	   identified	   as	   having	   roles	   within	   the	   pathway,	   which	   in	   turn	   has	  
highlighted	   differences	   in	   the	   pathway	   between	  Drosophila	   and	   vertebrates	   (for	   a	  
detailed	   review	   see	   Huangfu	   and	   Anderson).71	   In	   humans,	   irregularities	   in	   the	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holoprosencephaly,	   craniofacial	   defects	   and	   polydactyly.72	   Furthermore,	   incorrect	  
activation	  of	  the	  Hh	  pathway	  has	  been	  identified	  as	  being	  responsible	  for	  many	  basal	  
cell	   carcinomas	   and	   other	   tumours.73	   In	   addition, vertebrates	   possess	   three	   Hh	  
analogues	   Sonic,	   Indian	   and	   Desert	   Hh,	   however,	   current	   research	   suggests	   that	  
these	   analogues	   all	   use	   the	   same	   signaling	   pathway.	   Signaling	   differences	   occur	  
depending	  on	  the	  Hh	  molecule	  involved,	  for	  example	  Sonic	  Hh	  is	  involved	  in	  neural	  
cell	  fate,	  while	  Indian	  Hh	  regulates	  digit	  formation.74	  For	  a	  more	  detailed	  review	  of	  
the	  roles	  of	  the	  Hh	  family	  see	  Hooper	  and	  Scott.75	  
	  
In	   brief,	   Hh	   proteins	   are	   secreted	   morphogens	   that	   initiate	   a	   response	   through	  
binding	  of	  the	  Hh	  ligand	  to	  Patched-­‐1	  (Pct1),	  a	  12	  transmembrane	  protein	  receptor.	  
When	   unbound,	   Pct1	   inhibits	   Smoothened	   (Smo),	   but	   upon	   Hh	   binding	   Pct1	   is	  
inhibited,	   and	   Smo	   is	   activated.	   Downstream	   of	   Smo	   is	   a	   multi-­‐protein	   complex	  
known	  as	  the	  Hedgehog	  Signaling	  Complex	  (HhSC).	  This	  includes	  the	  Gli	  transcription	  
factors	   (after	   glioblastoma)	   in	   mammals,	   or	   the	   Cubitus	   interruptus	   	   (Ci)	   in	  
Drosophilia,	   bound	   to	   the	   Supressor	   of	   fused	   (Sufu)	   and	   serine/threonine	   kinase	  
Fused	   (Fu).	   As	   Smo	   is	   no	   longer	   inhibited,	   it	   becomes	   phosphorylated	   by	   protein	  
kinase	   A	   (PKA)	   and	   CK1.	   All	   three	   kinases,	   PKA,	   CK1	   and	   GSK-­‐3	   are	   then	   released	  
from	   the	   kinesin-­‐like	  molecule	   Costal	   2	   (Cos),	   which	   prevents	   the	   cleavage	   of	   the	  
transcription	   factors	   (Ci	   or	   Gli).	   Un-­‐cleaved	   Ci	   or	   activated	   Gli	   (GliAct)	   is	   no	   longer	  
inhibited	  by	  Sufu	  or	  Cos2	  and	  enters	   the	  nucleus	   to	   induce	  the	  transcription	  of	  Hh	  
target	  genes.	   In	   the	  absence	  of	   the	  Hh	   ligand,	  Smo	  remains	   repressed	  by	  Pct1	  and	  
the	   HSC	   remains	   bound	   together.	   Sequential	   phosphorylation	   leads	   to	   Ci	   being	  
cleaved	   and/or	   processing	   or	   Gli3	   into	   its	   repressor	   form	   (GliRep).	   These	  
cleaved/reprocessed	  transcription	  factors	  (Ci	  or	  GliRep)	  enter	  the	  nucleus	  and	  acts	  as	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Figure	   1.5	  Hedgehog	   signaling	   pathway	   in	  mammals.	   Unbound	   (left	   cell)	   Pct	   inhibits	   Smo	  
preventing	  its	  accumulation	  in	  the	  cilium.	  The	  activation	  of	  Gli	  proteins	  (GliAct),	  is	  inhibited	  by	  
Sufu	   and	   Cos2.	   Gli3	   is	   reprocessed	   into	   its	   repressor	   form	   (GliRep),	   which	   inhibits	   gene	  
expression.	   In	   the	   presence	   of	   Hh	   ligand	   (right	   cell),	   Pct	   inhibition	   is	   releaved.	   Smo	   is	  
targeted	   to	   the	   cilium	   and	   activates	   Gli	   proteins,	   while	   inhibition	   by	   Sufu	   and	   Cos2	   is	  
repressed.	  Gli3	  processing	   is	   inhibited	  and	  activated	  Gli	   initiated	  gene	  expression.	  Adapted	  
from	  Huangfu	  and	  Anderson	  and	  Østerlund	  and	  Kogerman.71,	  74	  	  
	  
1.3.2.1 Small	  Molecule	  Modulation	  of	  Hedgehog	  Pathway	  
	  
As	  discussed	  previously	   for	   the	  Wnt	  pathway,	   small	  molecules	  had	  been	   identified	  
that	  act	  on	  the	  Hh	  pathway.	  At	  present,	  this	  pathways	  has	  one	  of	  the	  largest	  groups	  
of	  small	  molecule	  activators,	  hence	  only	  a	  small	  number	  will	  be	  reviewed	  here.	  Most	  
of	  these	  modulators	  have	  ben	  identified	  as	  acting	  on	  Smo,	  including	  the	  antagonists	  
cyclopamine,77,	  78	  and	   the	  SANT	   family	  1-­‐4,79	  and	   the	  agonists	  purmorphamine,80,	  81	  
and	  SAG.79	  Molecules	  acting	  on	  alternative	  sites	  include	  GANT	  61,82	  which	  inhibits	  Gli	  
mediated	  gene	  transactivation	  and	  JK	  184,	  an	  antagonist	  of	  Hh	  activity	  which	  has	  no	  
activity	  at	  Smo.83	  The	  chemical	  structures	  of	  the	  Hh	  modulators	  are	  shown	  in	  Figure	  
1.6.	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Figure	  1.6	  Small	  molecule	  modulators	  of	  the	  Hedgehog	  pathway	  
	  
1.3.3 Transforming	  Growth	  Factor-­‐β	  Superfamily	  
	  
The	   transforming	   growth	   factor-­‐β	   (TGF-­‐β)	   superfamily	   is	   comprised	   of	   over	   60	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(BMPs),	  Activins,	  Nodal,	  growth	  and	  differentiation	  factors	  (GDFs)	  and	  TGF-­‐βs.84	  TGF-­‐
β,	   and	   other	   family	   members	   are	   expressed	   as	   disulfide-­‐linked	   homodimers	   or	  
heterodimers,	   and	   undergo	   proteolytic	   activation,	   a	   process	   which	   is	   highly	  
regulated.85	  They	   are	   expressed	  widely	   in	  many	   cell	   types	   and	  have	   roles	   in	   tissue	  
differentiation,	  affecting	  proliferation,	  migration	  and	  differentiation.86	  	  
	  
The	  factors	  act	  on	  an	  inherently	  simple	  pathway,	  binding	  to	  a	  heteromeric	  receptor	  
complex	  on	  the	  cell	  surface.87-­‐89	  The	  receptor	  consists	  of	  two	  type	  I	  and	  two	  type	  II	  
transmembrane	   serine/threonine	   kinases	   respectively,	   and	   upon	   growth	   factor	  
binding	   transphosphorylation	   of	   the	   type	   I	   receptor	   by	   the	   type	   II	   receptor	   is	  
induced.	  The	  activated	  type	   I	   receptors	   in	  turn	  phosphorylate	  selected	   intracellular	  
mediators	   (Smads)	   at	   the	   C-­‐terminus.	   The	   activated	   Smads	   then	   form	   a	   trimeric	  
complex	   with	   a	   common	   Smad4.	   This	   complex	   relocates	   to	   the	   nucleus	   where	   it	  
regulates	   the	   transcription	   of	   the	   target	   genes,	   through	   interactions	   with	   DNA	  
binding	   transcription	   factors	   (X)	   and	   CBP	   or	   p300	   coactivators.90	   The	   pathway	   is	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Figure	   1.7	   Transforming	   growth	   factor-­‐β	   pathway.	   At	   the	   cell	   surface,	   the	   ligands	   bind	   a	  
transmembrane	   receptor	   serine/threonine	   kinase	   complex	   (types	   I	   and	   II)	   which	   induces	  
transphosphorylation	   of	   the	   type	   I	   receptor	   by	   the	   type	   II	   receptor	   kinases.	   The	   activated	  
type	   I	   receptors	   phosphorylate	   selected	   Smads,	   and	   these	   receptor-­‐activated	   Smads	   (R-­‐
Smads)	  then	  form	  a	  complex	  with	  a	  common	  Smad4.	  Smad	  complexes	  translocate	  into	  the	  
nucleus,	  where	  they	  regulate	  transcription	  of	  target	  genes,	  through	  physical	  interaction	  and	  
functional	   cooperation	   with	   DNA-­‐binding	   transcription	   factors	   (X)	   and	   CBP.	   R-­‐Smads	   and	  
Smad4	  shuttle	  between	  nucleus	  and	  cytoplasm.	  Adapted	  from	  Derynck	  and	  Zhang.90	  
	  
The	  pathway	  is	  inherently	  simple,	  and	  although	  there	  are	  fewer	  receptors	  and	  even	  
less	   Smads,	   the	   pathway	   is	   still	   substantially	   versatile.90	   This	   is	   brought	   about	   by	  
interactions	   in	   the	   heteromeric	   receptor	   and	   Smad	   complexes,	   numerous	   proteins	  
that	  interact	  with	  the	  receptors	  and	  Smads,	  and	  connections	  with	  sequence-­‐specific	  
transcription	  factors.	  For	  a	  detailed	  review	  of	  this	  versatility	  and	  specificity	  see	  Feng	  
and	  Derynck.86	  	  
	  
1.3.3.1 Small	  Molecule	  Modulation	  of	  TGF-­‐β	  Superfamily	  
	  
Perhaps	  due	  to	  the	  simplicity	  of	  the	  pathway,	  there	  have	  been	  relatively	  few	  reports	  
of	  small	  molecules	  acting	  on	  the	  TGF-­‐β	  pathway.	  Of	  those	  that	  have	  been	  reported,	  
the	  first	  were	  inhibitors	  acting	  on	  the	  type	  I	  kinases	  of	  the	  hetertetrameric	  complex,	  
such	   as	   SB	   431542.91	   SB	   431542	   was	   initially	   characterised	   as	   stimulating	  
proliferation,	  differentiation	  and	  sheet	  formation	  in	  endothelial	  cells	  derived	  from	  ES	  
cells,	  although,	  more	  recently	  Ichida	  et	  al.	  demonstrated	  that	  it	  could	  replace	  Sox2	  in	  
reprogramming	  adult	  fibroblasts	  into	  iPS	  cells	  by	  inducing	  Nanog	  transcription.29,	  91	  In	  
	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Chapter	  I	  
	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  20	  
a	   separate	   chemical	   screen,	   Dorsomorphin,	   was	   identified	   as	   an	   inhibitor	   of	   BMP	  
signaling,	   promoting	   cardiomyogenesis	   in	   ES	   cells.92	   Similar	   to	   SB	   431542,	  
Dorsomorphin	   also	   blocks	   activin	   receptor-­‐like	   kinases.	   More	   recently,	   two	   small	  
molecule	  agonists	  of	  the	  TGF-­‐β	  pathway	  have	  been	  reported,	  namely	  IDE-­‐1,	  and	  IDE-­‐
2.	   These	   compounds	   were	   identified	   from	   a	   large	   compound	   screen	   (>4000)	   and	  
shown	   to	   direct	   endodermal	   differentiation	   in	   both	   mouse	   and	   human	   ES	   cells.93	  




Figure	  1.8	  Small	  molecule	  modulators	  of	  the	  TGF-­‐β	  pathway.	  
	  
1.3.4 Notch	  Signaling	  
	  
The	  Notch	  pathway	  acts	  differently	  to	  those	  pathways	  discussed	  previously,	  in	  that	  it	  
signals	   only	   to	   adjacent	   cells.	   The	   signaling	   cascade	   determines	   both	   cell	   fate	   and	  
pattern	  formation,	  a	  phenomenon	  key	  to	  reproducible	  development	  in	  multicellular	  
life.94,95	  First	  identified	  almost	  100	  years	  ago	  in	  fruit	  flies	  which	  had	  ‘notches’	  in	  their	  
wings,	   it	  has	   since	  been	   identified	  as	  being	   responsible	   for	  mediating	   local	   cell-­‐cell	  
communication,	  fate	  and	  pattern	  formation,	  in	  all	  known	  metazoans.96	  	  
	  
Notch	  is	  an	  unusual	  protein,	  as	  it	  functions	  at	  both	  the	  cell	  surface	  as	  a	  receptor	  but	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transmembrane	  protein,	  Notch	  contains	  an	  extracellular	  array	  of	  epidermal	  growth	  
factor	   (EGF)	   repeats.	   Activation	   of	   Notch	   is	   triggered	   by	   a	   Delta-­‐type	   ligand	   in	   a	  
neighboring	   cell,	   which	   prompts	   two	   proteolytic	   cleavages	   of	   Notch,	   of	  which	   the	  
second	  (S3)	  releases	  the	  Notch	  intracellular	  domain	  (Notchintra).	  	  This	  translocates	  to	  
the	  nucleus	  where	   its	  activates	  a	  transcription	  factor	  of	  the	  CBF1/Su(H)/LAG1	  (CSL)	  
family,	   by	   replacing	   the	   co-­‐repressor	   (Co-­‐R)	   complex	   with	   a	   co-­‐activator	   (Co-­‐A)	  
complex,	  thus	  leading	  to	  gene	  activation	  (Figure	  1.9).94	  	  
	  
	  
Figure	  1.9	  Fundamental	  actions	  of	  the	  Notch	  pathway.	  A	  Delta-­‐type	  ligand	  from	  an	  adjacent	  
cell	   activates	   the	   Notch	   receptor	   extracellular	   domain.	   This	   triggers	   two	   proteolytic	  
cleavages	   (S2	   and	   S3),	   which	   in	   turn	   releases	   the	   Notch	   intracellular	   domain	   (Notchintra).	  
Notchintra	   translocates	   to	   the	   nucleus	   where	   it	   initiates	   targeted	   gene	   expression	   through	  
replacement	  of	  the	  co-­‐repressor	  complex	  (Co-­‐R)	  with	  the	  co-­‐activator	  complex	  (Co-­‐A)	  on	  the	  
transcription	  factor	  CSL.	  Adapted	  from	  Lai.94	  
	  
1.3.4.1 Small	  Molecule	  Modulation	  of	  the	  Notch	  Pathway	  
	  
There	  are	   few	  reported	  small	  molecules	   that	   target	   the	  Notch	  pathway,	  albeit	   two	  
antagonists	   N-­‐[N-­‐(3,5-­‐difluorophenacetyl)-­‐1-­‐alanyl]-­‐S-­‐phenylglycine	   t-­‐butyl	   ester	  
(DAPT)	   and	   MRK	   003	   have	   been	   identified.	   DAPT	   was	   shown	   to	   reduce	   cell	  
differentiation,	   while	  MRK	   003	   induced	   programmed	   cell	   death.97,	   98	  The	   chemical	  
structures	  of	  both	  compounds	  are	  shown	  in	  Figure	  1.10.	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Figure	  1.10	  Small	  molecule	  modulators	  of	  the	  Notch	  pathway.	  
	  
1.3.5 Fibroblast	  Growth	  Factor	  Signaling	  
	  
The	   FGF	   signaling	   pathway	   incorporates	   22	   FGF	   members	   and	   4	   receptors.	  
Consequently,	   this	   elaborate	   signaling	   network	   has	   many	   roles	   in	   development,	  
including	  controlling	  proliferation,	  differentiation	  and	  migration,	  while	  in	  the	  adult	  it	  
is	   involved	   in	   tissue	   repair.99,	   100	   In	   addition	   to	   FGF	   involvement	   in	   many	  
developmental	   processes,	   its	   dysregulation	   is	   accordingly	   associated	   with	   many	  
cancers.101	  	  
	  
Briefly,	  FGF	  signaling	  is	  activated	  by	  one	  of	  its	  ligands	  binding	  to	  a	  specific	  receptor,	  
which	   causes	   the	   receptor	   to	   dimerise	   and	   the	   tyrosine	   kinase	   section	   to	  
phosphorylate.	  The	  activated	  tyrosine	  kinase	  receptor	  then	  recruits	  specific	  proteins	  
associated	   with	   the	   signaling	   cascade	   and	   activates	   them	   through	  
phosphorylation.102	   There	  are	  a	  number	  of	  proteins/pathways	  associated	  with	   FGF	  
signaling,	  including	  phospholipase	  Cγ	  (PLCγ),103	  Ras/mitogen-­‐activated	  protein	  kinase	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Figure	   1.11	   Simplified	   representation	   of	   the	   FGF	   pathway.	   An	   FGF	   ligand	   binds	   to	   the	  
receptors	   causing	   dimperisation	   and	   subsequent	   phosphorylation.	   The	   activated	   receptor	  
complex	  then	  phosphorylates	  downstream	  proteins,	  which	  elicit	  the	  FGF	  response.	  Adapted	  
from	  Powers,	  McLeskey	  and	  Wellstein.102	  
	  
1.3.5.1 Small	  Molecule	  Modulation	  of	  the	  FGF	  Pathway	  
	  
As	   the	   pathway	   diverges	   considerably,	   incorporating	   a	   number	   of	   other	   signaling	  
pathways,	  small	  molecules	  that	  specifically	  target	  FGF	  signaling	  generally	  act	  on	  the	  
early	   stages	   of	   the	   pathway.	   One	   example	   is,	   PD	   173074,	   which	   inhibits	   the	   FGF	  
receptor,	   effectively	   antagonizing	   the	   effects	   of	   FGF	   on	   proliferation	   and	  
differentiation.106	   Alternatively,	   small	   molecules	   have	   been	   identified/developed	  
that	  target	  specific	  downstream	  pathways	  within	  FGF	  signaling.	  Two	  such	  examples	  
are,	   PD	  0325901	  and	  CI-­‐1040,	   both	  of	  which	   target	   the	  MAPK	  pathway.107	  CI-­‐1040	  
has	  since	  undergone	  multicenter	  Phase	  II	  clinical	  trials	  for	  treatment	  of	  patients	  with	  
advanced	  non-­‐small-­‐cell	   lung,	  breast,	   colon	  and	  pancreatic	   cancer.108	  The	  chemical	  
structures	  of	  FGF	  modulators	  are	  shown	  in	  Figure	  1.12.	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Figure	  1.12	  Small	  molecule	  modulators	  of	  the	  FGF	  pathway.	  
	  
1.3.6 Retinoic	  Acid	  Signaling	  
	  
The	  final	  pathway	  to	  be	  discussed	  is	  the	  retinoic	  acid	  pathway.	  This	  pathway	  is	  very	  
complex	   and	   is	   involved	   in	   many	   developmental	   processes.	   Consequently,	   the	  
retinoic	  acid	  pathway	  has	  been	  the	  focus	  of	  many	  developmental	  studies	  to	  identify	  
small	   molecules	   with	   the	   ability	   to	   modulate	   specific	   responses.	   The	   following	  
section	  will	  review	  what	  constitutes	  a	  retinoid,	  natural	  retinoid	  metabolism,	  storage	  
and	   transportation	   and	   the	   mechanisms	   behind	   retinoid	   action,	   as	   these	  
fundamentals	   are	   required	   to	   understand	   the	   roles	   retinoids	   play	   in	   cell	  
differentiation	   and	   control.	   The	   functions	   of	   the	   endogenous	   ligands	   will	   be	  
reviewed	  including	  their	  roles	  both	   in	   in	  vivo	  and	   in	  vitro.	  Finally,	  the	   limitations	  of	  
the	  natural	   ligands	  will	   be	  discussed	  and	  how	   these	  have	  been	  addressed	   through	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1.3.6.1 Retinoids	  
	  
Vitamin	   A	   (retinol)	   was	   first	   identified	   in	   1913	   as	   an	   essential	   fat-­‐soluble	   nutrient	  
present	   in	   butter	   fat	   and	   cod	   liver	   oil	   (Figure	   1.13).109	   Over	   60	   years	   later,	   Sporn	  
proposed	   the	   term	   ‘retinoid’	   to	   broaden	   the	   base	   of	   thinking	   from	   just	   that	   of	  
vitamin	  A.	  He	  wished	  to	  emphasize	   the	  greater	  potential	  of	   this	  class	  of	  molecules	  
beyond	  that	  of	  nutrition	  and	  vision,	  and	  encourage	  understanding	  of	  the	  mechanistic	  
relationships	   between	   metabolites	   of	   retinol	   and	   steroids.110	   The	   description	   of	  
retinoids	   further	   evolved	   into	   the	   formal	   International	   Union	   of	   Pure	   and	   Applied	  
Chemistry	   (IUPAC)	   structure	   based	   definition,	   which	   is:	   ‘A	   class	   of	   compounds	  
consisting	  of	  four	  isoprenoid	  units	  joined	  in	  a	  head-­‐to-­‐tail	  manner.	  Formally	  derived	  
from	   a	  monocyclic	   parent	   compound	   containing	   five	   carbon-­‐carbon	   double	   bonds	  
and	  a	  functional	  group	  at	  the	  terminus	  of	  the	  acyclic	  portion’.111	  Subsequent	  use	  of	  
the	   term	   more	   widely	   has	   extended	   it	   to	   describe	   a	   family	   of	   compounds	   that	  
includes	   natural	   dietary	   vitamin	   A,	   its	  metabolites	   (ATRA,	   9cRA	   and	   13cRA	   (Figure	  
1.13))	  and	  several	  thousand	  synthetic	  analogues.	  This	  is	  based	  around	  the	  common	  
understanding	  that	  all	  molecules	   included,	  are	  either	  structurally	  related	  to	  retinol,	  
and/or	  can	  elicit	  specific	  biological	  responses	  through	  binding	  to	  one	  or	  more	  of	  the	  
retinoid	  receptors.112,	  113	  Further	  classification	  from	  IUPAC	  was	  published	  in	  the	  late	  
1990’s	   advising	   that	   retinoic	   acid	   analogues,	   which	   are	   unable	   to	   replace	   the	   full	  
range	   of	   biological	   activities	   of	   retinol,	   are	   to	   be	   distinguished	   as	   ‘retinoate	  
analogues’.114	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Figure	  1.13	  –	  Chemical	  structures	  of	  Retinol,	  ATRA,	  9cRA	  and	  13cRA.	  
	  
1.3.6.2 Retinoid	  Metabolism,	  Transport	  and	  Storage	  
	  
Humans	   along,	   with	   all	   other	   animal	   species,	   are	   incapable	   of	   de	   novo	   vitamin	   A	  
synthesis,	   thus	   it	   is	   an	   essential	   dietary	   requirement.	   It	   can	   be	   attained	   as	   pre-­‐
formed	  vitamin	  A,	  in	  the	  form	  of	  retinyl	  esters	  from	  animal	  fats	  (such	  as	  fish,	  liver	  or	  
dairy	  products),	  or	  as	  pro-­‐vitamin	  A	  carotenoids	  (β-­‐carotenoid).	  Once	  digested	  these	  
carotenoids	  can	  then	  be	  converted	  into	  apo-­‐carotenoids	  or	  retinal	  (Figure	  1.14).113	  	  
	  
The	  process,	   identified	  by	  Moore	   in	  the	  1930s,	  occurs	   in	  the	  small	   intestine.115	  The	  
enzyme	  that	  cleaves	  β-­‐carotene	  (Figure	  1.14)	  yielding	  two	  molecules	  of	  retinal,	  was	  
later	   identified	   as	   β,β-­‐carotene-­‐15,15’-­‐mono-­‐oxygenase.116,	   117	   An	   additional,	  
asymmetric	  carotene	  cleavage,	  has	  since	  been	  discovered	  that	  yields	  two	  molecules	  
of	  β-­‐apocarotenals	  with	  different	  chain	   lengths.118	  The	  enzyme	  responsible	   for	   this	  
cleavage,	   β,β-­‐carotene-­‐9’,10’-­‐di-­‐oxygenase,	   cleaves	   a	   number	   of	   carotenoids,	  
including	  β-­‐carotene	   and	   lutein	   (Figure	   1.14).119	   The	   larger	   fractionated	   section	   of	  
the	   molecule	   can	   then	   be	   enzymatically	   shortened	   into	   retinoic	   acid	   or	   retinal.	  
Retinal	  formed	  by	  these	  enzymes	  in	  the	  intestine	  is	  then	  reduced	  to	  retinol,	  although	  
the	   retinal	   reductases	   remain	   unidentified.113	   Retinol	   is	   then	   absorbed	   by	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known	   as	   RBP2).	   CRBP-­‐II	   facilitates	   retinol	   esterification,	   catalysed	   by	   the	   enzyme	  
lecithin:retinol	   acetyltransferase	   (LRAT).	   In	   addition,	   unbound	   cellular	   retinol	   is	  
esterified	   by	   acyl-­‐CoA	   retinol	   acyltransferase	   (ARAT),	   thus	   ensuring	   all	   retinol	   is	  
processed	   accordingly.120	   The	   biological	   significance	   of	   CRBP-­‐II,	   and	   subsequent	  
esterification,	   is	   to	  solubilise	   the	   ligand,	  ensuring	  correct	   transportation	  and	  action	  
while	   protecting	   it	   from	   degradation.120,	   121	  Most	   retinyl	   esters	   are	   then	   packaged	  
into	   chylomicrons,122	  which	   are	   large	   lipoprotein	   complexes	   that	   are	   subsequently	  
secreted	   into	   the	   intestinal	   lymph	   in	  which	   they	   form	   chylomicron	   remnants.123	   It	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Most	   chylmicrons	   are	   then	   transported	   to	   the	   liver,	   where	   the	   retinyl	   esters	   are	  
hydrolysed	   by	   retinyl	   ester	   hydrolase	   back	   to	   retinol.125	   Retinol	   is	   subsequently	  
bound	  by	  a	  second	  cellular	  retinol-­‐binding	  protein	  (CRBP-­‐I,	  also	  known	  as	  RBP1)	  and	  
processed	  for	  either	  secretion	  into	  the	  blood	  plasma	  or	  hepatic	  storage.126	  Retinol	  is	  
stored	  as	  an	  esterified	  form	  in	  perisinusoidal	  stellate	  cells	  within	  the	  liver,	   in	  which	  
both	  CRBP-­‐I	  and	  LRAT	  are	  highly	  expressed	  and	  play	  pivotal	  roles.113	  The	  liver	  plays	  a	  
key	   role	   in	  maintaining	   plasma	   retinol	   levels	   over	   a	   narrow	   range	   (constant	   blood	  
concentration	  of	  1-­‐2	  µM),	  storing	  50-­‐90%	  of	  the	  bodies	  total	  vitamin	  A	  content,	  and	  
releasing	  it	  when	  required.127	  	  
	  
Before	   secretion	   from	   the	   liver,	   retinol	   is	   bound	   to	   plasma	   retinol-­‐binding	   protein	  
(RBP4),	   and	   it	   remains	   associated	  with	   this	  protein	   as	   it	   is	   transported	  around	   the	  
vascular	   system.128,	  129	  The	  protein	   itself	   consists	  of	  a	  hydrophobic	  pocket	   that	   can	  
bind	   and	   protect	   retinol	   during	   transport.130	   RBP4	   can	   transport	   retinol	   alone,	  
however	  most	  retinol	  is	  transported	  from	  the	  liver	  as	  an	  RBP4-­‐transthyretin	  complex	  
(RBP4-­‐TTR),	   as	   this	   prevents	   glomerular	   filtration.131	   Retinol	   is	   then	   targeted	   to	  
specific	  cells	  that	  contain	  the	  RBP4	  cell	  membrane	  receptor,	  STRA6.	  STRA6	  facilitates	  
the	   transfer	   of	   retinol	   across	   the	   cell	   membrane	   to	   cytoplasmic	   cellular	   retinol-­‐
binding	  proteins	   (CRBPs).132-­‐135	   In	  addition	   to	  binding	   to	  STRA6,	  passive	  diffusion	   is	  
also	  believed	  to	  transport	  retinol	  across	  the	  cell	  membrane,	  as	  the	  general	  structure	  
of	   all	   retinoids	   enables	   them	   to	   easily	   partition	   into	   the	   lipid	   phase	   of	   the	  
membrane.136-­‐138	  Furthermore,	  as	  RBP4	  has	  been	  shown	  to	  have	  no	  binding	  affinity	  
for	   9cRA,	   13cRA	   or	   any	   synthetic	   retinoids	   screened,	   their	   progression	   from	   the	  
blood	   serum	   into	   cells/tissues	   is	   most	   likely	   to	   occur	   through	   indiscriminate	  
diffusion.138,	  139	  
	  
Once	  inside	  the	  cell,	  retinol	  contributes	  to	  the	  synthesis	  of	  the	  major	  active	  retinoid	  
metabolite,	  ATRA.	  Retinol	   is	   initially	  bound	  to	  CRBP,	  of	  which	  humans	  have	  four.140	  
Retinol	  bound	  to	  CRBP	  is	  then	  oxidised	  reversibly	  to	  retinal	  by	  retinol	  dehydrogenase	  
(ROLDH).141	  In	  vitro,	  many	  alcohol	  dehydrogenases	  (e.g.	  ADH1,	  ADH3	  and	  ADH4)	  and	  
members	   of	   the	   SDR	   (short-­‐chain	   dehydrogenase/reductase)	   family	   (e.g.	   RDH1,	  
RDH5	   and	   RDH11)	   have	   been	   characterised	   as	   catalysing	   this	   process	   (for	   a	  more	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detailed	  review	  refer	  to	  Blomhoff	  and	  Blomhoff).113	  The	  final	  oxidation	  of	  all-­‐trans-­‐
retinal	   to	   ATRA	   is	   catalysed	   by	   retinal	   dehydroganase	   (RALDH).	   There	   are	   three	  
different	   RALDH	   enzymes	   and	   their	   expression	   is	   varied	   through	   out	   different	   cell	  
types,	  depending	  on	  their	  specific	  requirement	  for	  ATRA	  synthesis.142	  CRBPs	  have	  a	  
high	  binding	  affinity	  for	  both	  retinol	  and	  retinal	  but	  not	  ATRA,	  thus	  ATRA	  is	  released	  
upon	  production	  and	  is	  subsequently	  bound	  to	  cellular	  retinoic	  acid	  binding	  proteins	  
I	  and	  II	  (CRABP-­‐I	  and	  CRABP-­‐II).143,	  144	  CRABP-­‐I	  has	  been	  shown	  to	  bind	  and	  store	  free	  
ATRA,	  thus	  inhibiting	  its	  potential	  biological	  activity,145	  whereas	  CRABP-­‐II	  is	  thought	  
to	  aid	  in	  the	  local	  transport	  of	  ATRA	  to	  its	  receptors,	  increasing	  the	  cellular	  response	  
to	   ATRA.146	   Thus,	   the	   CRABPs	   act	   to	   regulate	   the	   amount	   of	   intracellular	   ATRA	  
available	  to	  the	  nuclear	  receptors,	  protecting	  the	  cell	  from	  ATRA-­‐excess.	  Finally,	  the	  
biological	   actions	  of	   the	   retinoids	   (ATRA	  or	   its	   isomers	  9cRA	  or	  13cRA)	  are	  elicited	  
through	   binding	   to	   their	   cognitive	   nuclear	   receptors.	   These	   are	   classified	   into	   two	  
types,	  the	  retinoic	  acid	  receptors	  (RARs)	  and	  the	  retinoid	  X	  receptors	  (RXRs),	  both	  of	  
which	  will	  be	  reviewed	  in	  more	  detail	  later	  in	  this	  Chapter.147-­‐149	  The	  overall	  process	  
is	  summarised	  in	  Figure	  1.15.	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Figure	  1.15	  -­‐	  The	  major	  pathways	  of	  retinoid	  transportation,	  storage	  and	  signal	  transduction	  
in	  the	  body.	  Abbreviations:	  CRBP	  =	  cellular	  retinol	  binding	  protein,	  LPL	  =	  lipoprotein	  lipase,	  
LRAT	  =	  lecithin-­‐retinol	  acyltransferase,	  REH	  =	  retinyl	  ester	  hydroxylase,	  RBP	  =	  retinol	  binding	  
protein	  and	  TTR	  =	  transthyretin.	  Adapted	  from	  Blomhoff	  and	  Blomhoff.113	  
	  
1.3.6.3 Retinoid	  Receptors	  
	  
As	  discussed	  above,	  there	  are	  two	  types	  of	  retinoid	  receptor,	  the	  RARs	  and	  the	  RXRs,	  
both	   located	   in	   the	   nuclear	   envelope.148,	   149	   Both	   receptor	   types	   belong	   to	   the	  
steroid/thyroid	   superfamily	   of	   nuclear	   receptors,	   and	   act	   as	   ligand	   inducible	  
transcriptional	   regulation	   factors.150	   They	   are	   classified	   based	   on	   variations	   in	  
primary	  structure,	  the	  responses	  they	  have	  towards	  different	  ligands	  and	  their	  ability	  

































































	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Chapter	  I	  
	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  31	  
receptor	  contains	  five	  to	  six	  structural	  domains,	  termed	  A	  to	  F.151	  The	  two	  principal	  
domains	  are	   the	  DNA-­‐binding	  domain	   (DBD),	  and	   the	   ligand-­‐binding	  domain	   (LBD).	  
The	  DBD	  contains	  two	  highly	  conserved	  zinc-­‐finger	  motifs	  (two	  antiparallel	  β-­‐strands	  
and	  a	  α-­‐helix	  coordinated	  by	  a	  zinc	  atom),	  which	  enable	  the	  receptor	  to	  target	  DNA	  
sequences	  known	  as	  hormone	  response	  elements.	  The	  LBD	  controls	  transcriptional	  
regulation,	   and	   consists	   of	   the	   ligand-­‐binding	   pocket	   (LBP),	   a	   dimerisation	   surface	  
and	   a	   ligand-­‐dependant	   transcriptional	   activation	   function	   (AF-­‐2).	   The	   remaining	  
domains	  are	  less	  well	  defined,	  with	  the	  N-­‐terminal	  region	  (A/B	  domain)	  containing	  a	  
ligand-­‐independent	  activation	  function	  (AF-­‐1)	  and	  an	  activation	  domain	  (AD).	  The	  D	  
domain	  corresponds	   to	  a	   linker	   region,	  and	  hence	  has	  a	  pivotal	   role	   in	   the	  correct	  
orientation	   of	   the	   LBD,	   and	   DBD	   within	   the	   bound	   dimer.	   Finally,	   there	   is	   the	   C-­‐
terminal	   (F	  domain)	   for	  which	   there	   is	  no	  assigned	   function,	   and	  does	  not	  exist	   in	  




Figure	  1.16	  -­‐	  Structural	  and	  Functional	  organisation	  of	  a	  retinoid	  receptor.	  Adapted	  from	  de	  
Lera,	  Bourguet,	  Altucci	  and	  Gronemeyer.152	  
	  
Signalling	  through	  the	  retinoid	  pathway	  is	  predominantly	  induced	  through	  receptor	  
dimers,	  the	  most	  common	  being	  the	  RAR/RXR	  heterodimer,	  which	  is	  responsible	  for	  
eliciting	   retinoid	   signals	   in	   vivo.153,	   154	   In	   the	   absence	   of	   the	   retinoid	   agonist,	   the	  
RAR/RXR	   heterodimer	   is	   bound	   to	   co-­‐repressor	   proteins.	   These	   include	   nuclear	  
receptor	   co-­‐repressor	   (NCoR),	   silencing	   mediator	   for	   the	   retinoid	   and	   thyroid	  
receptor	   (SMRT),	   and	   other	   associated	   factors,	   including	   histone	   deacetylases	  
(HDACs)	   and	   DNA	  methyl	   transferases.	   The	   overall	   combination	   has	   the	   effect	   of	  
repressing	  gene	  transcription,	  due	  to	  a	  condensed	  chromatin	  structure.155-­‐157	  
	  





	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Chapter	  I	  
	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  32	  
The	  biological	  response	   is	  stimulated	  through	  the	  binding	  of	  an	  agonist	   (e.g.	  ATRA)	  
to	  the	  RAR	  site	  of	  an	  RAR/RXR	  heterodimer,	  not	  through	  binding	  to	  the	  RXR.158	  When	  
the	   agonist	   binds	   to	   the	   RAR,	   a	   conformational	   change	   occurs,	   in	   which	   the	   co-­‐
repressors	   are	   displaced,	   and	   co-­‐activators	   recruited.	   The	   ligand-­‐bound	   dimer	  
complex	   can	   now	   bind	   onto	   a	   specific	   DNA	   sequence	   with	   high	   affinity.	   These	  
sequences	   are	   in	   the	  promoter	   regions	  of	   specific	   genes,	   and	   termed	   retinoic	   acid	  
response	  elements	   (RARE).	  The	  RAREs	  are	  direct	   repeats	  of	   the	  canonical	  motif	  5’-­‐
PuG(G/T)TCA	  and	  are	  distinguished	  by	  their	  separation	  pattern	  of	   five,	   two,	  or	  one	  
nucleotides	  (termed	  DR5,	  DR2	  and	  DR1	  respectively).159	   In	  DR5	  and	  DR2	  sequences	  
the	  RAR/RXR	  dimer	  is	  associated	  with	  the	  RAR	  occupying	  the	  3’	  element	  and	  the	  RXR	  
the	   5’	   (5’-­‐RXR/RAR-­‐3’),	   and	   this	   leads	   to	   a	   positive	   transcription	   of	   those	   target	  
genes.	  The	  opposite	  is	  true	  for	  DR1	  sequences,	  with	  the	  heterodimer	  being	  reversed	  
(5’-­‐RAR/RXR-­‐3’).	  The	  consequence	  is	  that	  no	  transcription	  occurs,	  including	  when	  an	  
agonist	   binds,	   as	   the	   co-­‐repressors	   remain	   tightly	   bound.160,	   161	   DR2	   and	   DR5	  
elements	  have	  since	  been	  identified	  in	  many	  promoters	  of	  genes	  associated	  with	  the	  
biological	  responses	  brought	  about	  by	  the	  retinoids.148	  
	  
Binding	  of	   the	   ligand-­‐bound	  dimer	  generally	   leads	   to	  a	  basal	   level	  of	   transcription.	  
This	   encourages	   co-­‐activators,	   including	   histone	   acetyl	   transferases	   (HATs)	   and	  
histone	  arginine	  methyltransferases,	   to	  also	  bind	   to	   the	  complex.	  Once	  bound,	   the	  
complete	  complex	  can	  fully	  open	  the	  chromatin	  structure,	  which	  ultimately	  leads	  to	  
the	   transcription	   of	   the	   specific	   gene,	   and	   the	   required	   cellular	   response.155-­‐158,	  162	  
The	  process	  is	  summarised	  in	  Figure	  1.17.	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Figure	   1.17	   -­‐	   Mechanisms	   of	   repression,	   depression	   and	   activated	   transcription.	   In	   the	  
absence	   of	   agonists,	   co-­‐repressor	   complexes	   (CoR)	   link	   the	   receptor	   complex	   to	   histone	  
deacetylases	  (HDACs)	  through	  SIN3,	  resulting	  in	  chromatin	  condensation	  and	  gene	  silencing.	  
Upon	  agonist	  binding	  to	  the	  receptors,	  a	  conformational	  change	  is	  induced,	  destabilising	  the	  
CoR	   complex	   and	   allowing	   co-­‐activators	   (CoA)	   to	   bind.	   CoAs	   recruit	   histone	  
acetyltransferases	   (HAT)	   resulting	   in	   acetylation	   of	   histone	   amino-­‐terminal	   tails,	   thus,	  
inducing	  chromatin	  decondensation.	  Finally,	  a	  third	  multi-­‐subunit	  complex,	  termed	  Srb	  and	  
mediator	   protein-­‐containing	   complex	   (SMCC),	   or	   thyroid-­‐hormone-­‐receptor-­‐associated	  
protein	   (TRAP),	  or	  D-­‐receptor	   interacting	  protein	   (DRIP)	  establishes	   contact	  with	   the	  basal	  
transcriptional	   machinery,	   leading	   to	   increased	   transcription.	   Adapted	   from	   Altucci	   and	  
Gronemeyer.162	  
	  
In	  addition,	  to	  further	  complicate	  the	  pathway,	  it	  should	  also	  be	  noted	  that	  there	  are	  
multiple	  different	  types	  of	  RARs	  and	  RXRs	  (discussed	  in	  more	  detail	  in	  the	  following	  
section).	   These	   form	   multiple	   different	   RAR/RXR	   heterodimers,	   and	   homodimers	  
(RXRs	  only),	  and	  bind	  to	  different	  RAREs.	  Overall,	  these	  combined	  factors	  lead	  to	  the	  
vast	  complexicity	  seen	  within	  the	  retinoid	  signalling	  pathway.148,	  149	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1.3.6.3.1 Retinoic	  Acid	  Receptors	  	  
	  
The	   first	   receptor	   was	   discovered	   simultaneously	   by	   the	   groups	   of	   Chambon	   and	  
Evans	  in	  1987,	  and	  subsequently	  termed	  RAR-­‐α1.163,	  164	  RARs	  are	  presently	  classified	  
into	   three	   subtypes,	   RAR-­‐α,	   RAR-­‐β	   and	   RAR-­‐γ,	   all	   originating	   from	   three	   distinct	  
genes.163-­‐168	  A	  differential	  pattern	  of	  expression	  is	  observed	  for	  each	  of	  the	  subtypes,	  
with	   RAR-­‐α	   being	   ubiquitous	   in	   adults,	   whereas	   RAR-­‐β	   and	   RAR-­‐γ	   are	   more	  
specific.169	  Each	  subtype	  also	  contains	  several	  isoforms	  that	  differ	  from	  each	  other	  in	  
their	   N-­‐terminal	   region.	   These	   arise	   from	   alternative	   splicing	   patterns	   and	  
differential	  usage	  of	  two	  promoters.	  RAR-­‐α	  and	  RAR-­‐γ	  have	  two	  major	  isoforms	  (α1	  
and	  α2,	   and,	   γ1	   and	   γ2	   respectively),	   whereas	   RAR-­‐β	   has	   four	   (β1-­‐4).	   These	   four	  
isoforms	   are	   due,	   in	   part,	   to	   the	   initiation	   of	   two	   different	   promoters	   (β1	   and	  β3	  
being	   initiated	   from	   the	   P1	   promoter,	   while	   β2	   and	   β4	   are	   initiated	   from	   the	   P2	  
promoter).	  The	  P2	  promoter,	  is	  known	  as	  the	  downstream	  promoter,	  and	  is	  induced	  
by	  retinoids,	  owing	  to	  the	  presence	  of	  a	  RARE.148	  	  
	  
RARs	  must	   function	  as	  heterodimers,	  pairing	  with	  one	  of	   the	   three	  RXRs	  α,	  β	   or	  γ	  
(elaborated	  further	  in	  the	  following	  section).148	  Additionally,	  they	  require	  the	  binding	  
of	   a	   specific	   agonist	   to	   initiate	   transcription,	   although	   it	   has	   been	   suggested	   that	  
RAR-­‐β	   not	  bound	   to	   a	   ligand	  may	  act	   as	   a	   transcriptional	   regulator,	   as	   it	   has	  poor	  
association	   to	   the	   co-­‐repressors.158	   ATRA	   is	   an	   example	   of	   a	   pan-­‐RAR	   agonist,	  
binding	   with	   equal	   affinity	   to	   all	   three	   subtypes,	   although	   there	   are	   multiple	  
examples	   of	   subtype	   specific	   compounds.170	   The	   RAR/RXR	   heterodimer	   ligand	  
complex	   then	   binds	   to	   specific	   RAREs	   and	   initiates	   targeted	   gene	   expression	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1.3.6.3.2 Retinoic	  X	  Receptors	  	  
	  
The	  second	  type	  of	  nuclear	  receptors,	  the	  RXRs,	  where	   initially	  discovered	   in	  1990,	  
and	   can	   also	   be	   divided	   into	   three	   subtypes,	   RXR-­‐α,	   RXR-­‐β	   and	   RXR-­‐γ.171	   Each	  
subtype	  also	   contains	   at	   least	   two	   isoforms	   (α1	  and	  α2,	  β1	  and	  β2	  and	  γ1	  and	  γ2	  
respectively).172	  Like	  the	  RARs	  they	  also	  have	  differential	  and	  spatial	  patterning,	  with	  
RXR-­‐α	  being	  limited	  to	  expression	  in	  the	  liver,	  skin,	  kidney	  and	  lung,	  in	  both	  the	  adult	  
and	  embryo,	  with	  RXR-­‐β	  having	  a	  more	  ubiquitous	  expression	  pattern.148,	  149	  Unlike	  
the	   RARs	   they	   are	   not	  modulated	   by	   ATRA,	   instead	   they	   are	  modulated	   by	   9cRA,	  
which	  has	  the	  ability	  to	  bind	  all	  RARs	  and	  RXRs.170,	  173	  	  
	  
RXRs	   are	   able	   to	   act	   as	   both	   homodimers,	   pairing	   up	   with	   themselves,	   or	  
heterodimers,	  pairing	  with	  RARs,	  or	  other	  receptor	  compounds,	  such	  as	  peroxisome-­‐
proliferation-­‐activated-­‐receptors	  (PPARs),	  thyroid	  hormone	  and	  vitamin	  D3	  receptors	  
(VDRs).174	  In	  contrast	  to	  RAR	  agonists,	  RXR	  selective	  agonists	  (also	  termed	  rexinoids)	  
are	  unable	  to	  activate	  transcription	  upon	  binding	  to	  the	  RXR.	  This	  is	  because	  rexinoid	  
binding	  does	  not	  induce	  the	  co-­‐repressors	  to	  dissociate,	  so	  for	  transcription	  to	  occur	  
a	   RAR	   ligand	   must	   also	   be	   present.	   This	   is	   referred	   to	   as	   RXR	   subordination,	   or	  
silencing.149,	  158	  Although,	  as	  a	  heterodimer	  with	  an	  RAR	  receptor,	  their	  role	  is	  better	  
defined	  as	  synergistic,	  as	  they	  allosterically	  increase	  the	  potency	  of	  the	  RAR	  ligands	  
for	  their	  receptors.175,	  176	  
	  
As	  RXRs	  also	  form	  RXR/RXR	  homodimers,	  it	  was	  hypothesised	  they	  must	  additionally	  
act	  via	  another	  signalling	  pathway,	  possibly	  binding	  to	  retinoic	  X	  response	  elements	  
(RXREs).	   This	   hypothesis	   has	   since	   been	   validated,	   and	   RXR/RXR	   homodimers	   are	  
known	   to	   bind	   to	   specific	   DNA	   sequences	   through	   a	   DR1	   element,	   although	   their	  
exact	  role	  has	  yet	  to	  be	  defined.177	  
	  
Overall,	   RXRs	   have	   the	   ability	   to	   affect	   multiple	   hormone	   signalling	   pathways.	  
Additionally,	   with	   their	   varied	   tissue	   expression	   patterns	   this	   further	   helps	   to	  
illustrate	   the	   complexity	  and	  varied	   role	  played	  by	   retinoids	  and	   their	   receptors	   in	  
many	  biological	  systems.	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1.3.6.4 Endogenous	  Retinoid	  Function	  
	  
Natural	   retinoids	  are	  essential	   for	   the	   life	  of	  all	   chordates,	  and	  are	   involved	   in	   the	  
modulation	  of	  a	  wide	  variety	  of	  biological	  processes,	  during	  both	  embryogenesis	  and	  
adulthood.	  Some	  of	   these	  essential	   roles	   include	  vision,178	   immune	  competence,179	  
reproduction,180	   maintenance	   of	   epithelial	   surfaces,113	   embryonic	   growth	   and	  
development181	   and	   cellular	   regulation	   and	   differentiation.182-­‐184,	   In	   humans,	  
inadequate	   intake	   of	   vitamin	   A	   leads	   to	   vitamin	   A	   deficiency	   (VAD),	   which	   is	  
characterised	   by	   several	   ocular	   features,	   including	   xerophthalmia	   (dry	   eyes)	   and	  
night	   blindness,	   as	   well	   as	   poorer	   immune	   responses.113	   ATRA,	   the	   most	   potent	  
naturally	   occurring	   biological	   metabolite,	   can	   both	   prevent	   and	   resolve	   the	  
consequences	  of	  VAD.185	  	  
	  
In	  developmental	   terms,	   the	  ability	  of	   the	   retinoids,	  particularly	  ATRA,	   to	  promote	  
differentiation,182-­‐184	  apoptosis186	  and	  spatial	  positioning	  of	  cells,187	  means	  retinoids	  
play	  a	  key	  role	  in	  the	  growth	  of	  various	  tissues	  and	  organs.	  Specifically,	   in	  terms	  of	  
neurogenesis,	  retinoids	  have	  numerous	  roles	  in	  both	  the	  developing	  central	  nervous	  
system	   (CNS)	   within	   the	   embryo188	   and	   regeneration	   of	   the	   developed	   CNS	   in	  
adults.189	  Alterations	  to	  the	  levels	  of	  ATRA	  in	  the	  developing	  brain	  and	  CNS	  lead	  to	  
many	  abnormalities.188,	  190	  While	   in	   the	  adult	  CNS,	  ATRA	   is	   involved	   in	   the	  synaptic	  
plasticity	  seen	   in	   the	  hippocampus.191	  Certain	  areas	   in	   the	  adult	  CNS,	   including	  the	  
hippocampus,	   basal	   ganglia,	   olfactory	  bulbs	   and	   auditory	   afferents	   have	   also	  been	  
identified	   as	   possessing	   the	   capability	   to	   synthesise	   ATRA.192	   Furthermore,	   it	   has	  
been	   demonstrated	   that	   ATRA	   is	   required	   in	   an	   early	   phase	   of	   adult	   neuronal	  
differentiation,	  in	  the	  dentate	  gyrous.193	  	  
	  
In	  addition,	   further	  studies	  have	  also	  shown	  a	  clear	   link	  between	  the	  retinoids	  and	  
higher	  cognitive	  functions,	  including	  spatial	  learning	  and	  memory.	  This	  is	  believed	  to	  
be	  caused	  through	  neuronal	   remodelling	   in	   the	  hippocampus,	  which	  has	  also	  been	  
linked	   to	   long-­‐term	   depression	   (LTD)	   and	   long-­‐term	   potentiation	   (LTP).191	   In	   a	  
supporting	   study,	   VAD	   in	   rats	   induced	   a	   significant	   deficit	   in	   both	   memory	   and	  
spatial	   learning,	   which	   could	   be	   reversed	   by	   the	   re-­‐introduction	   of	   vitamin	   A.194	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Christie	  et	  al.	  provide	  a	  more	  detailed	  review	  of	  the	  role	  retinoids	  play	  in	  the	  adult	  




The	  vast	  biological	  profile	  exhibited	  by	  ATRA	  and	  its	  natural	  metabolites	  has	  lead	  to	  
much	  interest	  in	  using	  these	  molecules,	  and	  synthetic	  analogues,	  as	  both	  therapeutic	  
treatments	   and	   tools	   for	   research,	   particularly	   in	   controlling	   the	   differentiation	   of	  
stem	  cells.	  Consequently,	  more	   than	  4000	  compounds	   related	   to	   retinol	  and	  ATRA	  
have	   been	   synthesised	   and	   published,	   and	  many	   of	   these	   have	   been	   screened	   for	  
potential	   biological	   activity,	   an	   area	   that	  will	   be	   reviewed	   further	   in	   the	   following	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1.4	  Small	  Molecule	  Control	  of	  Cell	  Differentiation	  
	  
In	  attempts	  to	  harvest	  the	  full	  potential	  of	  stem	  cells,	  many	  groups	  have	   looked	  to	  
chemical	  control	  as	  a	  solution.	  There	  are	  many	  advantages	  to	  using	  small	  molecules	  
over	   more	   traditional	   genetic	   approaches	   to	   understanding	   a	   biological	  
phenomenon.	   These	   include	   the	   high	   degree	   of	   temporal	   control	   one	   can	   achieve	  
when	  using	  a	  small	  molecule,	  as	  it	  can	  potentially	  disturb	  specific	  functions	  of	  single	  
or	  multiple	  proteins.	  Furthermore,	  the	  effects	  can	  be	  finely	  regulated	  through	  simple	  
changes	  in	  concentration.196	  
	  
As	  technology	  in	  automation	  and	  analysis	  has	  developed,	  small	  molecule	  libraries	  of	  
compounds	   have	   been	   designed	   as	   a	   simple	   and	   cost	   effective	   approach	   to	  
identifying	   potential	   targets.	   These	   libraries	   span	   from	   large	   lead	   discovery	  
collections	  of	  over	  2	  million	  compounds,	  associated	  with	  pharmaceutical	  companies,	  
to	  smaller	   focused	  collections	  of	  approximately	  10	  thousand	  compounds,	  generally	  
comprised	   of	   one	   or	   two	   specific	   classes.197	   This	   is	   in	   an	   attempt	   to	   identify	   new	  
families	  of	  compounds,	  which	  would	  help	  unlock	  the	  full	  potential	  of	  these	  cells.	  As	  
there	   are	   multiple	   different	   potential	   fates	   for	   stem	   cells,	   specific	   libraries	   are	  
screened	   in	   an	   attempt	   to	   identify	   molecules	   with	   a	   particular	   desired	   biological	  
activity.	   In	  addition,	  there	  are	  different	  types	  of	  stem	  cell,	  from	  pluripotent	  ES	  cells	  
to	  multipotent	  stem	  cells	  of	  specific	  tissues,	  all	  of	  which	  are	  then	  species	  specific	  (see	  
previous	  sections	  for	  more	  detail).	  Consequently,	  the	  number	  of	  possible	  targets	  and	  
components	   is	   high	   and	   currently	   tens	  of	  molecules	  have	  been	   identified	   as	  being	  
controllers	  of	   stem	  cell	   fate,	   some	  of	  which	  have	  been	  highlighted	  throughout	   this	  
review,	  but	  for	  a	  more	  detailed	  review	  see	  Lyssiotis	  et	  al..197	  	  
	  
In	   addition	   to	   screening	   large	   novel	   libraries,	   other	   approaches	   include	   targeting	  
specific	  pathways,	  or	  known	  natural	  products	   in	  an	  attempt	  to	  enhance	  or	   identify	  
novel	  uses	   in	  vitro.	  Additionally,	  the	  screening	  of	  known	  drug	  compounds	  has	  been	  
carried	  out	   in	  an	  attempt	   to	   identify	  new	  uses	   for	   these	  known	  compounds.	  All	  of	  
these	  processes	  will	  now	  be	  reviewed	  in	  more	  detail.	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1.4.1 Retinoic	  Acid	  Control	  of	  Cell	  Differentiation	  
	  
Another	  approach	  is	  to	  utilise	  natural	  molecules	  and	  known	  pathways.	  One	  pathway	  
where	  this	  has	  been	  exploited	  successfully	  is	  the	  retinoic	  acid	  pathway	  (discussed	  in	  
detail	   in	   the	   previous	   section).	   The	   establishment	   of	   the	   role	   retinoids	   play	   in	  
differentiation	   in	   vivo,	   and	   the	   induction	   of	   plasminogen	   activator	   synthesis	   in	  
chicken	  embryo	   fibroblasts	  by	  ATRA,	   led	   to	   the	   first	  example	  of	   retinoic	  acid	  being	  
used	  to	  induced	  differentiation	  in	  vitro.184,	  198,	  199	  Teratocarcinoma	  stem	  cells	  treated	  
with	   ATRA	   were	   shown	   to	   display	   multiple	   phenotypic	   changes,	   consistent	   with	  
differentiation	  into	  endoderm.199	  Since	  then	  multiple	  EC	  cell	  lines	  have	  been	  induced	  
to	  differentiate	  using	  ATRA.	  These	   include	   the	  mouse	  EC	  cell	   lines,	  F9,	  which	  upon	  
ATRA	   treatment	   differentiates	   to	   primitive,	   parietal	   and	   visceral	   endodermal	   cells,	  
and	  P19,	  which	  differentiates	  to	  endodermal	  and	  neuronal	  cells.200-­‐202	  Other	  EC	  cell	  
lines	  include,	  GCT27	  and	  NCCIT,	  which	  displayed	  the	  ability	  to	  form	  extraembryonic	  
endoderm,	   and	   keratin,	   glial	   fibrillary	   acid	   protein	   (GFAP),	   and	   neurofilament-­‐
positive	  somatic	  cells, when	  exposed	  to	  ATRA	  respectively.203,	  204	  	  
	  
One	  of	  the	  more	  studied	  lineages	  is	  that	  derived	  from	  the	  EC	  stem	  cell	  line	  TERA2.	  In	  
1984	  Andrews	  published	  data	  that	  EC	  TERA2	  cell	   lines	  NTERA2/D1	  and	  NTERA2/B9,	  
could	  differentiate	  comprehensively	  when	  exposed	  to	  ATRA.	  This	  was	  characterised	  
by	   the	   disappearance	   of	   stage-­‐specific	   embryonic	   antigen-­‐3	   (SSEA-­‐3),	   routinely	  
expressed	   by	   human	   EC	   cells,	   in	   addition	   to	  morphological	   changes,	   including	   the	  
appearance	   of	   neurons	   that	   stain	   positive	   for	   neurofilament	   proteins.205-­‐207	  
Additionally,	   a	   later	   investigation	   looking	   at	   transcriptional	   profiling	   in	  NTERA2/D1	  
cells,	   showed	   ATRA	   regulated	   the	   expression	   of	   Pax6	   and	   Nkx6.1.	   These	   data	  
indicated	   that	   neurons	   derived	   from	   these	   pluripotent	   cells	   were	   characteristic	   of	  
neuroectodermal	   cells	   of	   the	   ventral	   phenotype.208	   Subsequently,	   further	  
sublineages	   were	   developed,	   most	   notably	   TERA2.cl.SP12,	   which	   upon	   ATRA	  
treatment	   lose	  their	  expression	  of	  cell-­‐surface	  pluripotent	  markers	   (SSEA-­‐3,	  SSEA-­‐4	  
and	   TRA-­‐1-­‐60),	   while	   simultaneously	   acquiring	   antigens	   associated	   with	  
neuroectodermal	   derivatives	   (VINIS-­‐56	   and	   A2B5).209-­‐211	   Further	   evaluation	   of	   the	  
TERA2.cl.SP12	  lineage	  showed	  that	  prolonged	  exposure	  to	  ATRA	  led	  to	  the	  formation	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of	   mature	   functioning	   neurons,	   containing	   functional	   receptors	   and	   ion	   channels	  
indicative	  of	  native	  neurons.212,	  213 ATRA	  induced	  differentiation	  is	  not	  confined	  just	  
to	  EC	  cells.	  There	  are	  a	  number	  of	  examples	  in	  which	  ES	  cells	  have	  been	  induced	  to	  
differentiate	  also	  using	  ATRA.200	  These	  include	  the	  generation	  of	  epithelial	  cells	  from	  
the AB1	  murine	  ES	  cell	   line,	  and	  the	  formation	  of	  neural	  progenitor	  cells	   (visualised	  
as	  neural	  rosettes)	  and	  motor	  neurons	  (analysis	  of	  HB9	  expression),	  from	  the	  human	  
ES	  cell	  line	  H9.59,	  214-­‐216	  Furthermore,	  the	  group	  of	  T.	  M.	  Jessell	  showed	  that	  mouse	  ES	  
cells	   could	  be	   induced	   to	  generate	  motor	  neurons	   (MNs)	  and	   the	  pathway	  used	   in	  
vitro	  recapitulates	  the	  steps	  of	  MN	  generation	  in	  vivo.	  Briefly,	  the	  protocol	  involved	  
primary	   neutralisation,	   followed	   by	   the	   caudalisation	   of	   neural	   cells	   before	  
ventralising	  the	  caudalised	  cells,	  using	  relevant	  signalling	  factors	  including	  ATRA.	  ES	  
cell-­‐derived	  MNs	  were	   then	   shown	   to	   populate	   embryonic	   spinal	   cord	   and	   target	  
muscles	  through	  extending	  axons	  and	  generating	  synapses.217 
	  
Furthermore,	  the	   isolation	  of	  NCSs	  and	  NPCs	  from	  both	  rodent	  and	  human	  species	  
has	  generated	  much	  interest,	  in	  particular	  in	  the	  development	  of	  new	  therapies	  for	  
neurodegenerative	  diseases.54-­‐58,	  60,	  218-­‐220	  At	  the	  forefront	  of	  this	  area	  of	  research	  is	  
the	   ability	   to	   manipulate	   these	   cell	   types	   in	   vitro	   to	   produce	   reliable	   and	  
reproducible	   differentiation,	   which	   subsequently	   may	   transpire	   into	   therapeutic	  
treatments.	  ATRA	  has	  a	  well-­‐characterised	   role	   in	  vivo	   in	  both	   the	  development	  of	  
the	   CNS	   during	   embryogenesis	   and	   synaptic	   plasticity	   seen	   in	   adults.188,	  190,	  191	  It	   is	  
therefore	   not	   surprising	   that	   isolated	   adult	   rat	   hippocampus	   stem	   cell	   cultures	  
differentiate	   to	   immature	   neurons	   upon	   exposure	   to	   ATRA,	   characterised	   by	   up-­‐
regulation	   of	   NeuroD,	   increased	   p21	   expression	   and	   concurrent	   exit	   from	   the	   cell	  
cycle.60	   Additionally,	   culturing	   of	   neurons	   without	   serum	   theoretically	   is	   more	  
appealing	  as	  the	  process	  has	  greater	  controls,	  as	  serum	  contains	  multiple	  undefined	  
factors.	  Defined	  supplements,	  such	  as	  B27,	  have	  become	  widely	  utilised	  because	  of	  
this,	  and	   in	  addition	  to	  many	  other	   factors	  commonly	   include	  ATRA.221	   In	  addition,	  
the	   differentiation	   of	   human	   neural	   progenitors	   has	   also	   shown	   to	   be	   enhanced	  
through	  additional	  supplementation	  of	  retinoid	  analogues,	  including	  ATRA.59	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1.4.1.1 Limitations	  of	  ATRA	  in	  Cell	  Differentiation	  
	  
The	  wide	  biological	  effects	  elicited	  by	  ATRA	  make	  it	  an	  obvious	  drug	  target	  for	  many	  
clinical	   applications	   and	   in	   vitro	   cell	   differentiation	   techniques.	   However,	   the	  
usefulness	  of	  ATRA	  in	  both	  disease	  treatment	  (for	  a	  review	  of	  this	  area	  see	  Christie	  
et	   al.)195	   and	   routine	   cell	   culture/differentiation,	   as	   described	   above,	   is	   severely	  
hampered	   by	   ATRA’s	   potent	   teratogenicity	   and	   rapid	   metabolism	   (see	   later	  
discussion	  and	  Figure	  1.19)	  in	  many	  cell	  types.222-­‐226	  One	  hypothesised	  reason	  behind	  
ATRA’s	  toxicity	  and	  high	  dosage	  requirements,	  is	  its	  susceptibility	  to	  isomerise.227	  As	  
ATRA	  (and	   indeed	  all	  natural	   retinoids)	  contain	  five	  conjugated	  double	  bonds,	   they	  
are	  inherently	  unstable.	  Each	  bond	  is	  capable	  of	  isomerising,	  with	  each	  species	  likely	  
to	  possess	  a	  different	  biological	  activity.	  Furthermore,	  it	  has	  since	  been	  determined	  
that	   not	   only	   does	  ATRA	   isomerise	   under	   standard	   laboratory	   conditions,	   but	   also	  
degrades	   into	   a	   number	   of	   other	   compounds.228	   A	   warning	   of	   this	   nature	   was	  
conveyed	  by	  Muryama	  et	  al.,229	  who	  highlighted	  the	  potential	  detrimental	  effects	  of	  
using	  ATRA	  as	  a	  tool	  for	  cell	  biology,	  as	  an	  investigator	  would	  not	  know	  exactly	  which	  
compounds	  were	  being	  using.	  	  	  
	  
1.4.2 Analogues	  of	  ATRA	  for	  Controlling	  Stem	  Cell	  Differentiation	  
	  
Consequently,	   both	   academic	   and	   commercial	   organisations	   have	   turned	   to	  
designing,	   synthesising	   and	   screening	   large	   numbers	   of	   molecules	   that	   are	  
structurally	   and/or	   functionally	   analogous	   to	   ATRA.	   The	   ultimate	   aim	   being	   that	  
these	  synthetic	  analogues	  display	  an	  improved	  biological	  response	  and	  in	  turn	  have	  
reduced	  adverse	  side	  effects.	  	  
	  
Roche	   carried	   out	   the	   first	   published	   work	   in	   this	   area,	   in	   the	   late	   1960s.	   They	  
prepared	  analogues	  of	  ATRA,	  through	  modification	  of	  the	  structure	  of	  retinol,	  where	  
their	  aim	  was	  to	  identify	  compounds	  with	  a	  better	  therapeutic	  ratio	  than	  that	  of	  the	  
parent	  compound.230	  Since	  then	  more	  than	  4000	  compounds	  related	  to	  retinol	  and	  
ATRA	  have	  been	  synthesised	  and	  published,	  and	  many	  of	  these	  have	  been	  screened	  
for	  potential	  biological	  activity.231	  Consequently,	  over	  the	  last	  forty	  years	  thousands	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of	   retinoids	   have	   been	   synthesised	   and	   screened.	   The	   main	   focus	   of	   researching	  
these	  molecules	   has	   been	   an	   attempt	   to	   demonstrate	   the	   clinical	   potential	   of	   the	  
retinoid	   pathway	   and	   provide	   pharmacological	   tools	   to	   probe	   the	   endogenous	  
functions	  of	  natural	  retinoids	  and	  their	  receptors.	  
	  
1.4.2.1	  	  Structural	  Requirements	  	  
	  
In	   the	   late	   1970s	   the	   relationship	   between	   structure	   and	   activity	   of	   different	  
retinoids	  was	   first	  published.232	   Since	   then	  many	  analogues	  have	  been	  synthesised	  
and	   screened,	   in	   an	   iterative	   approach,	   modifying	   key	   components	   in	   the	   basic	  
structure	  of	  ATRA.233-­‐236	  This	  research,	  alongside	  crystal	  structures	  of	  both	  the	  RAR	  
and	  RXR	  ligand	  binding	  domains,	  in	  both	  the	  bound	  (holo)	  and	  unbound	  (apo)	  form	  
(for	   a	   detailed	   review	   refer	   to	   Greschik	   and	   Moras237),	   has	   lead	   to	   the	   basic	  
understanding	  of	  the	  ATRA	  pharmacophore	  that	  we	  have	  today.	  Currently,	  retinoids	  
are	  considered	  to	  be	  comprised	  of	  three	  units	  (depicted	  in	  Figure	  1.18	  for	  ATRA),	  and	  




Figure	  1.18	  General	  perception	  of	  the	  structural	  units	  that	  comprise	  a	  retinoid.	  
	  
The	  three	  key	  structural	  components	  are	  as	  follows:	  
	  
1-­‐ A	   hydrophobic	   unit:	   relatively	   bulky	   in	   size,	   usually	   a	   planar	   lipophilic	  
cyclohexene	  with	  alkyl	  substituents	  that	  can	  form	  van	  der	  Waals	  interactions	  
with	  surrounding	  amino	  acid	  residues	  in	  the	  receptor	  binding	  pocket.	  
2-­‐ A	   conjugated	   linker	   unit:	   designed	   to	   confer	   the	   correct	   spacing	   and	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binding	   interaction.	   This	   region	   can	   incorporate	   heteroatoms,	   which	   may	  
confer	   isotype	   specificity	   and	   may	   be	   conformationally	   restricted,	   through	  
the	  incorporation	  of	  aromatic	  rings.	  
3-­‐ A	   polar	   terminus:	   usually	   a	   carboxylic	   acid	   involved	   in	   the	   formation	   of	  
hydrogen	  bonds	  and	  salt	  bridges.	  
	  
This	  knowledge	  of	  the	  pharmacophore	  has	  aided	  in	  our	  advanced	  understanding	  of	  
tolerable	   bioisosteric	   replacements	   for	   each	   of	   the	   fundamental	   structural	  
components	   (summarised	   by	   Altucci	   at	   al.233).	   Initially,	   early	   synthetic	   derivatives	  
were	   related	   closely	   to	   that	   of	   ATRA,	   while	   later	   generations	   display	   little	   if	   any	  
resemblance	  to	  the	  parent	  compound.	  	  
	  
Literature	   has	   shown	   that	   replacing	   the	   trimethylcyclohexenylvinyl	   unit	   (C1-­‐C8)	   of	  
ATRA,	  with	  a	   structurally	   similar	  1,1,4,4-­‐tetramethyl-­‐1,2,3,4-­‐tetrahydronaphthalene	  
(TMTN)	  moiety,	   increases	   the	   biological	   potential.238	   This	   can	   be	   explained	   by	   the	  
fact	   that	   the	   TMTN	  moiety	   helps	   to	   introduce	   greater	   stability,	   as	   it	   eliminates	   a	  
section	  of	   the	  unstable	  polyene	  chain,	   removing	  one	  of	   the	   isomerisable	  bonds.	   In	  
addition,	   and	   of	   greater	   importance,	   it	   no	   longer	   possesses	   any	   allylic	   protons	   or	  
alkene	  double	  bonds	  susceptible	  to	  radical	  oxidation	  or	  epoxidation	  by	  cytochrome	  
P450	   (CYPs)	   or	   related	   enzymes	   (see	   Figure	   1.19).239-­‐242	   Therefore	   synthetic	  
derivatives	   possessing	   this	   bioisostere	   are	   less	   susceptible	   to	  metabolism	   and	   are	  
thus	   more	   likely	   to	   remain	   at	   a	   constant	   concentration	   within	   the	   cellular	  
environment.	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Figure	   1.19	  Oxidative	   products	   of	   ATRA	  metabolism,	   blocked	   by	   replacement	   with	   TMTN	  
unit.	  
	  
In	  addition	   to	   the	  TMTN	  core,	  our	  group	  has	  previously	   replaced	   the	   remainder	  of	  
the	   polyene	   chain	   with	   a	   non-­‐isomerisable	   acetylene	   linker	   and	   an	   aromatic	   ring	  
functionalised	   at	   both	   the	  para	   (EC23)	   and	  meta	   (EC19)	   positions	   (Figure	   1.20).228	  
These	   modifications	   generate	   synthetic	   compounds	   know	   as	   arotinoids	   as	   they	  
contain	  one	  or	  more	  aromatic	  rings.	  There	  are	  many	  other	  examples	  of	  arotinoids,	  
including	   TTNPB	   and	   TTNN,	   refer	   to	   Barnard	   et	   al.	   for	   a	   more	   detailed	   review.231	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Figure	  1.20	  Chemical	  structures	  of	  EC23,	  EC19,	  TTNPB	  and	  TTNN.	  
	  
1.4.2.2	  	  Retinoic	  Acid	  Analogue	  Induced	  Neurogenesis	  
	  
As	  discussed	  previously,	  ATRA	  induces	  differentiation	  in	  many	  cell	  lines,	  particularly	  
down	  a	  neuronal	  lineage.59,	  60,	  200,	  202,	  204-­‐213,	  216,	  217	  Although,	  inherent	  limitations	  in	  its	  
structure,	  most	  notably	  its	  instability,	  and	  tendency	  to	  isomerise	  lead	  to	  pleiotropic	  
effects.222-­‐229	  Hence,	  many	  synthetic	  retinoids	  have	  been	  designed,	  and	  tested,	  in	  an	  
attempt	   to	   produce	   analogues	   that	   induce	   differentiation	   more	   efficiently	   and	  
reproducibly.	   This	   is	   especially	   important	   where	   reproduction	   of	   cell	   behaviour	   is	  
required,	  for	  example,	  the	  consistent	  differentiation	  of	  stem	  cells	  into	  homogeneous	  
populations	   of	   neuronal	   precursors	   and	   functioning	   neurons.	   These	   homogeneous	  
cell	   populations	   could	   then	   be	   used	   as	   research	   tools,	   for	   drug	   development	   and	  
screening.	  	  
	  
One	  example	  of	  a	  more	  potent	   inducer	  of	  neurogenesis	   is	  EC23.	   	   It	  displays	  both	  a	  
robust	   stability	   profile,	   as	   it	   cannot	   isomerise,	   as	   well	   as	   exhibiting	   a	   higher	  
neurogenesis	   inducing	   activity.59,	   228	   In	   a	   pluripotent	   stem	   cell	  model,	   exposure	   to	  
EC23	  formed	  populations	  of	  terminally	  differentiated	  neurons.	  Immunocytochemical	  
analysis	  of	  neurofilament-­‐200	  (NF-­‐200)	  in	  differentiated	  cultures	  showed	  EC23	  to	  be	  
a	  more	   potent	   inducer	   of	   neurogenesis	   than	  ATRA.	   In	   direct	   comparison	   to	  ATRA,	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has	   been	   shown	   to	   induce	   neuronal	   differentiation	   in	   both	   ES	   cell	   systems,	   fetal	  
NSCs	  and	  adult	  NPCs.59,	  243	  	  
	  
1.4.3 Alternative	  Small	  Molecule	  Inducers	  of	  Neurogenesis	  
	  
Other	   approaches	   in	   identifying	   small	   molecule	   inducers	   of	   neurogenesis	   include,	  
screening	   known	   natural	   products,	   for	   previously	   unknown	   effects.	   One	   early	  
example	   was	   the	   discovery	   that	   the	   PKA	   agonist,	   forskolin	   (FSK),	   promotes	  
neurogenesis	  of	  NSCs	  in	  vitro	  (structure	  shown	  in	  Figure	  1.21).	  The	  mode	  of	  action	  of	  
FSK,	   is	   to	   increase	   the	   intracellular	   cyclic	   adenosine	   monophosphate	   (cAMP)	  
concentration,	   which	   blocks	   Hh	   signalling.244	   In	   addition,	   when	   FSK	   is	   used	   in	  
combination	   with	   ATRA	   to	   differentiate	   NSCs,	   a	   greater	   number	   of	   neurons	   are	  
observed.245	  	  	  	  
	  
More	  recently,	  as	  the	  understanding	  of	  the	  CNS	  has	  developed,	  it	  was	  suggested	  that	  
drugs	  that	  confer	  antidepressant	  behaviour	  do	  this	  through	  stimulating	  hippocampal	  
neurogenesis	   in	   vivo.197	   Thus,	   screening	   chronic	   anti-­‐depression	   drugs,	   identified	  
fluoxetine,	  as	  being	  able	   to	   stimulate	  neurogenesis	   in	   the	  dentate	  gyrus	  of	   the	   rat	  
hippocampus	   (structure	   shown	   in	   Figure	   1.21).246	   This	   suggest	   that	   this	   molecule,	  
and	  possibly	  others	  with	  similar	  anti-­‐depression	  properties,	  are	  likely	  to	  promote	  the	  
neurogenesis	  of	  NPCs	  and	  NSCs	  not	  only	   in	  vivo	  but	  also	   in	  vitro,	  although	  this	  has	  
yet	  to	  be	  proved.	  
	  
In	   addition	   to	   targeting	   specific	   pathways,	   natural	   products	   or	   known	   drug	  
compounds,	  a	  greater	  understanding	  of	  the	  critical	  role	  chromatin	  modification	  plays	  
in	  the	  regulation	  of	  cell-­‐type-­‐specific	  gene	  expression	  identified	  HDAC	  inhibitors	  as	  a	  
likely	   target.	   Hsieh	   et	   al.,	   demonstrated	   this	   through	   small	   molecule	   inhibition	   of	  
HDACs,	   using	   valproic	   acid	   (VPA),	   promoted	   neuronal	   differentiation	   of	   adult	   rat	  
NSCs	   (structure	   shown	   in	   Figure	   1.21).247	   Furthermore,	   the	   NSCs	   differentiated	  
specifically	   into	  neurons	  even	  under	  astrocyte	  and	  oligodendrocyte	   lineage-­‐specific	  
differentiation	   conditions	   in	   vitro	   and	   had	   anti-­‐proliferative	   and	   neuronal	   inducing	  
properties	  in	  the	  dentate	  gyrus	  of	  adult	  rats	  in	  vivo.247	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In	   addition	   to	   the	   approaches	   described	   above,	   the	   screening	   of	   large	   compound	  
libraries	  has	   identified	  novel	  compounds	  and	  structures,	  some	  of	  which	  specifically	  
induce	  neurogenesis.	  One	  such	  screen,	  on	  a	  large	  heterocyclic	  library,	  carried	  out	  by	  
Ding	  et	  al.,	  identified	  TWS119,	  a	  4,6-­‐disubstituted	  pyrrolopyrimidine,	  which	  induced	  
neurogenesis	  in	  both	  mouse	  P19	  EC	  cells	  and	  the	  ESC	  line	  D3.	  They	  further	  went	  on	  
to	  identify	  the	  target	  of	  TWS119	  as	  glycogen	  synthase	  kinase-­‐3β	  (GSK-­‐3β)	  providing	  
the	  first	  evidence	  that	  GSK-­‐3β	  is	  involved	  in	  neurogenesis	  of	  ESCs.248	  	  	  	  
	  
A	  similar	  study	  carried	  out	  by	  Saxe	  et	  al.,	  identified	  the	  orphan	  ligand	  phosphoserine	  
(P-­‐Ser)	  as	  an	  inhibitor	  or	  murine	  NSC	  proliferation	  and	  self-­‐renewal,	  while	  enhancing	  
neurogenic	  commitment	  and	  improving	  neuronal	  survival	  (structure	  shown	  in	  Figure	  
1.21).	  P-­‐Ser	  was	  also	  shown	  to	  increase	  neurogenesis	  in	  human	  ES	  cell	  derived	  NPCs,	  
suggesting	  that	  rodent	  and	  human	  pathways	  are	  in	  some	  part	  similar.249	  	  
	  
Finally,	   in	   an	   additional	   study,	   using	   the	   same	   approach	   of	   screening	   a	   library	   of	  
50,000	  compounds,	  Warashina	  et	  al.	  identified	  a	  class	  of	  compounds	  that	  selectively	  
induced	   differentiation	   of	   hippocampal	   neural	   progenitors.250	   The	   class	   of	  
compounds,	   4-­‐aminothiazols,	   were	   then	   subjected	   to	   a	   small	   structure-­‐activity	  
relationship	   (SAR)	  study,	  which	   identified	  neuropathiazol	  as	  being	   the	  most	  potent	  
analogue	   (Figure	   1.21).	   Treatment	   of	   the	   cells	   with	   neuropathiazol	   slowed	   cell	  
proliferation	  and	  differentiated	  more	  than	  90%	  into	  TuJ1	  positive	  cells,	  with	  very	  few	  
GFAP-­‐positive	  cells	  visualised.	   In	  comparison,	  treatment	  with	  ATRA	  showed	  weaker	  
antiproliferation	   activity,	   and	   large	   numbers	   of	   both	   TuJ1	   and	   GFAP-­‐positive	   cells	  
were	   found.	   In	   addition,	   ATRA	   showed	   greater	   cytotoxicity	   compared	   to	   that	   of	  
neuropathiazol.	   Cells	   incubated	   for	   greater	   time	   periods	   with	   neuropathiazol	   also	  
demonstrated	   positive	   staining	   for	  mature	   neuronal	  markers	   neurofilament-­‐H	   and	  
MAP2ab,	  while	   real-­‐time	   quantitative	   polymerase	   chain	   reaction	   (RT-­‐PCR)	   analysis	  
demonstrated	   Sox2	   downregulation	   and	   NeuroD1	   upregulation.	   Finally,	   they	  
demonstrated	   that	   astroglial	   differentiation,	   induced	   by	   leukemia	   inhibitory	   factor	  
(LIF)	  and	  BMP2,	  was	  inhibited	  by	  neuropathiazol	  but	  not	  by	  ATRA.250	  
	  
	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Chapter	  I	  



















































	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Chapter	  I	  
	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  49	  
1.5 Conclusions	  
	  
A	   sizeable	  amount	  of	   research	  has	  been	  conducted	   to	  both	  understand	  stem	  cells,	  
and	   the	  molecular	   pathways	   which	   ultimately	   control	   their	   fate.	   One	   area	   of	   this	  
research	  has	  focussed	  on	  the	  discovery	  of	  new	  compounds,	  which	  can	  interact	  with	  
specific	   pathways	   to	   generate	   a	   desired	   outcome.	   To	   date,	   small	   molecules	   have	  
been	   identified	  and	  designed	   to	  act	  on	  each	  of	   the	  pathways	   involved	   in	   stem	  cell	  
modulation.	  	  
	  
There	  are	  two	  main	  ways	   in	  which	  the	   identification	  of	  novel	  modulators	  has	  been	  
approached.	  The	  first,	   is	  the	  screening	  of	   large	  libraries	  of	  known	  compounds	  in	  an	  
attempt	   to	   identify	   new	  molecular	   structures,	   which	   have	   the	   desired	   effect.	   The	  
second,	   is	   to	   study	   the	   individual	  pathway,	  understand	  how	   to	  control	   the	  desired	  
biological	   outcome,	   investigate	   the	   natural	   ligands,	   and	   design	   and	   screen	   new	  
compounds	   which	   address	   any	   issues	   associated	   with	   the	   natural	   compound.	  
Although	   both	   approaches	   have	   proven	   successful,	   with	   the	   identification	   of	  
numerous	  new	  compounds,	   some	  of	  which	  are	  highlighted	   in	   this	   review,	   the	   first	  
approach	   requires	   a	   significant	   amount	   of	   trial	   and	   error,	   specialised	   automated	  
equipment	   and	  access	   to	   vast	   chemical	   libraries.	   It	   is	   therefore	  not	   surprising	   that	  
the	  second	  approach	   is	  more	  widely	  used	   in	  academic	  situations,	  and	  one	  adopted	  
by	  our	  research	  group	  in	  Durham,	  specifically	  targeting	  the	  retinoid	  pathway.	  	  	  
	  
Currently,	  defined	  chemical	  control	  of	  stem	  cell	  fate	  is	  not	  completely	  reproducible	  
and	  reliable,	  but	  with	  continued	  research	  this	  should	  be	  resolved	  in	  the	  near	  future.	  
This	   will	   in	   turn	   hopefully	   lead	   to	   new	   therapeutic	   treatments	   and	   subsequently	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1.6 Project	  Aims	  
	  
The	  main	  aim	  of	  this	  work	  is	  to	  develop	  synthetic	  retinoids	  to	  increase	  the	  reliability	  
and	   reproducibility	   of	   stem	   cell	   differentiation,	   in	   particular,	   enhancing	   neural	  
differentiation	   in	  vitro.	  The	  compounds	  must	  be	  novel	   in	  structure,	  be	  more	  stable	  
than	   their	   natural	   equivalents,	   and	   more	   resistant	   to	   metabolism,	   as	   all	   these	  
properties	   have	   been	   highlighted	   as	   problematic	   in	   previous	   screens.	   They	  will	   be	  
designed	   around	   known	   limitations,	   and	   follow	   on	   from	   compounds	   previously	  
developed	  in	  Durham,	  which	  demonstrate	  a	  strong	  potential.	  
	  
The	   research	   detailed	   in	   this	   thesis	   builds	   on	   recent	   work	   into	   the	   synthesis	   and	  
stabilisation	   of	   conjugated	   polyene	   chains,	   structure-­‐activity-­‐relationships	   of	  
retinoids,	   and	   characterisation	   of	   their	   biological	   potential	   in	   both	   pluripotent	   cell	  
models	  and	  those,	  which	  are	  already	  committed	  to	  a	  neuronal	  lineage.	  	  
	  
In	  addition,	  molecules	  structurally	  unrelated	  to	  retinoids	  but	  with	  similar	  biological	  
effects	  will	   be	   investigated	   further,	   in	   an	   attempt	   to	  elucidate	   their	  mechanism	  of	  
action	   and	   identify	   compounds	   that	   induce	   reproducible	   and	   reliable	   cell	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2.1	  Introduction	  
	  
The	  major	  active	  metabolite	  of	  retinol,	  ATRA,	  (also	  known	  as	  tretinoin)	  was	  the	  first	  
to	  undergo	  total	   synthesis,	   in	  1946,	   followed	  shortly	  after	  by	   that	  of	   retinol	  a	  year	  
later.251,	   252	   At	   around	   the	   same	   time,	   the	   biological	   potential	   of	   this	   family	   of	  
molecules	   became	   apparent.	   Endogenous	   retinoids	   are	   distributed	   throughout	   the	  
embryo	  and	  adult	   in	  vivo.	  They	  regulate	  a	  wide	  array	  of	  essential	  processes	  during	  
both	   chordate	   embryogenesis	   and	   adult	   homeostasis	   including	   reproduction,190	  
vision,178	   immune	   competence,179	   embryonic	   development181,	   253	   and	   cellular	  
differentiation,	   proliferation	   and	   apoptosis182-­‐184,	   254	   (See	   Chapter	   I	   for	   a	   more	  
detailed	   discussion).	   These	   wide	   biological	   effects	   elicited	   by	   ATRA	   make	   it	   an	  
obvious	   drug	   target	   for	   many	   clinical	   applications.	   Unfortunately,	   as	   discussed	   in	  
Chapter	   I,	   there	   are	   a	   number	   of	   physical	   characteristics	   associated	   to	   ATRA	   that	  
inhibit	   its	  use	   further	   in	  both	   in	  vitro	   cell	   culture	  protocols,	  or	   therapeutically.	  Our	  
research	  group,	  and	  that	  of	  Muryama	  and	  colleagues,	  who	  highlighted	  the	  potential	  
detrimental	  effects	  of	  using	  ATRA	  as	  a	  tool	  for	  cell	  biology,	  have	  emphasised	  these	  
issues.228,	  229	  	  
	  
Consequently,	   both	   academic	   and	   commercial	   organisations	   have	   turned	   to	  
designing,	   synthesising	   and	   screening	   analogous	   of	   ATRA.	   This	   is	   with	   the	   aim	   of	  
identifying	   new	   retinoids	   with	   an	   improved	   biological	   response,	   overcoming	   the	  
problems	  associated	  with	  the	  natural	  retinoids.	  Notably,	  one	  solution	  is	  to	  synthesise	  
stable	  analogues,	  which	  have	  reduced	  isomerisation	  capabilities,	  thus,	  reducing	  the	  
possibility	  of	  unwanted	  isomerisation	  products.	  This	  is	  in	  addition	  to	  blocking	  known	  
metabolic	   sites	   to	   increase	   the	   half-­‐life	   of	   the	   compound	   within	   the	   cell,	   thus,	  
increasing	   its	   exposure	   to	   the	   receptors.	   This	   is	   possible	   through	   selecting	   known	  
bioisosteres,	   such	  as	   the	  TMTN	  group	  discussed	   in	  Chapter	   I.	  Both	  are	  approaches	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2.2	  Aims	  and	  Objectives	  
	  
Building	   on	   previous	   knowledge	   gained	   from	   work	   done	   on	   EC19	   and	   EC23,	   a	  
number	  of	   synthetic	   retinoid	  analogues	  were	   identified	  as	  potential	   targets.	   These	  
were	   novel	   molecules	   designed	   to	   investigate	   what	   effects	   the	   size	   and	  
conformation	  of	  the	  linker	  region	  would	  have	  on	  biological	  responses.	  As	  described	  
above,	   there	  are	  many	  known	  bioisosteres	   for	  each	  of	   the	  key	  regions,	  yet	  to	  date	  
the	  size	  of	  the	  linker	  region	  has	  not	  been	  fully	  investigated.	  We	  aimed	  to	  design	  and	  
synthesise	   a	   series	   of	   analogues,	   with	   different	   polyene	   chain	   lengths	   and	  
conformations	   to	   investigate	   both	   compound	   stability	   and	   biological	   efficacy.	   The	  




Figure	  2.1	  Proposed	  project	  targets.	  
	  
The	   objectives	   of	   this	   work	   were	   initially	   to	   demonstrate	   the	   successful	  
incorporation	  of	  a	  stable	  polyene	  chain	   into	  a	  retinoid	  analogue,	  mimicking	  that	  of	  
their	  natural	  counter	  parts	  more	  closely.	  This	  would	  be	  supported	  through	  enhanced	  
stabilisation,	  gained	  by	  using	  of	  other	  carefully	   selected	  bioisosteres.	  As	  previously	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group.	   This	   was	   chosen	   due	   to	   its	   increased	   stability	   and	   resistance	   to	   metabolic	  
oxidation.	   It	  was	   envisaged	   that,	   coupled	   to	   an	   acetylene	   linker	   group,	   this	  would	  
provide	   enough	   stabilisation	   to	   support	   one,	   two	   and	   possibly	   three	   conjugated	  
double	  bonds.	  Thus,	  allowing	  us	  access	  to	  novel	  retinoids,	  which	  would	  be	  shorter,	  
longer	  and	  of	  an	  identical	  length	  to	  their	  natural	  counter	  parts.	  Overall,	  providing	  us	  
with	  a	   tool	   for	  probing	   the	   relationship	   in	  distance	  between	   the	  hydrophobic	   core	  
and	  carboxylic	  acid	  group.	  The	  synthetic	  route	  used	  to	  synthesise	  these	  compounds	  
would	  also	  enable	  us	  to	  create	  both	  isomers	  at	  any	  of	  the	  bonds,	  further	  probing	  the	  
conformations	  of	   the	  binding	  pockets.	   Finally,	   the	   series	  would	  enlighten	  us	   in	   the	  
stability	  of	  these	  compounds	  and	  highlight	  the	  number	  of	  conjugated	  bonds	  that	  can	  
be	  tolerated	  in	  such	  as	  system.	  The	  overall	  objective	  was,	  therefore,	  to	  identify	  the	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2.3	  Synthesis	  
	  
2.3.1	  Construction	  of	  the	  Core	  
	  
The	   TMTN	   group	   has	   been	   synthesised,	   and	   the	   procedure	   optimised	   previously	  
within	  our	  research	  group.228	  Briefly,	  the	  synthesis	  began	  with	  selective	  iodination	  of	  
1,1,4,4-­‐tetramethyl-­‐1,2,3,4-­‐tetrahydronaphthalene	   7.	   This	   utilised	   an	   interesting	  
adapted	   literature	   method	   using	   iodine,	   periodic	   acid,	   glacial	   acetic	   acid	   and	  
concentrated	   sulphuric	   acid.255	   6-­‐Iodo-­‐1,1,4,4-­‐tetramethyl-­‐1,2,3,4-­‐tetrahydro-­‐
napthalene,	  8,	   was	   generated	   as	   a	   crystalline	   solid	   in	   an	   acceptable	   yield	   of	   66%.	  
Conversion	   of	   iodide,	   8,	   to	   the	   trimethylsilyl	   (TMS)	   protected	   acetylene,	   9,	   was	  
subsequently	   undertaken	   through	   a	   palladium	   coupling	   reaction	   employing,	   bis-­‐
(triphenylphosphine)palladium(II)	  chloride,	  copper(I)	   iodide	  and	  trimethylsilyl	   (TMS)	  
acetylene,	   under	   inert	   conditions.	   The	   product,	   6-­‐trimethylsilylethynyl-­‐1,1,4,4-­‐
tetramethyl-­‐1,2,3,4-­‐tetrahydronapthalene,	  9,	  was	   isolated	   in	   a	   satisfactory	   yield	   of	  
67%.	  Finally,	  removal	  of	  the	  TMS	  protecting	  group	  afforded	  the	  desired	  hydrophobic	  
core	   for	   the	   synthetic	   retinoids,	   6-­‐ethynyl-­‐1,1,4,4-­‐tetramethyl-­‐1,2,3,4-­‐
tetrahydronapthalene,	  10,	  in	  a	  excellent	  yield	  of	  97%.	  The	  synthesis	  is	  summarised	  in	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2.3.2	  Generation	  of	  the	  ‘Short’	  Retinoids	  
	  
With	   the	   hydrophobic	   core	   in	   hand,	   synthesis	   of	   the	   polyene	   chain	   section	   of	   the	  
synthetic	   retinoids	  began.	   Initially,	  methyl	  propiolate,	  11,	  was	   treated	  with	  sodium	  
iodide	  in	  acetic	  acid.	  The	  reaction	  is	  stereospecific	  and	  gave	  rise	  to	  the	  cis-­‐isomer	  of	  
the	  iodoacrylate,	  methyl	  3-­‐Z-­‐iodoacrylate,	  12,	  in	  an	  acceptable	  yield.	  A	  portion	  of	  the	  
cis-­‐iodoacrylate,	   12,	   was	   subsequently	   removed	   and	   stored,	   while	   the	   remainder	  
was	   converted	   to	   the	   trans-­‐iodoacrylate,	   13.	   This	   was	   achieved	   by	   refluxing	   in	  
hydroiodic	   acid	   and	   benzene,	   generating	   the	   desired	   compound,	   methyl	   3-­‐E-­‐




Scheme	  2.2	  Generation	  of	  the	  cis-­‐	  and	  trans-­‐iodoacrylates.	  
	  
With	   both	   isomers	   of	   the	   iodoacrylates	   available,	   each	   was	   subjected	   to	   two	  
different	   reaction	   sequences.	   Firstly,	   a	   series	   of	   couplings	   and	   deprotections	   to	  
extend	   the	   polyene	   chain	   by	   a	   further	   two	   carbons	   (this	   will	   be	   covered	   in	   the	  
following	   section),	   and	   secondly,	   a	   coupling	   reaction	   to	   the	   core	   followed	   by	  
deprotection	   to	   yield	   the	   ‘short’	   retinoid	   analogues.	   Standard	   Sonogashira	  
conditions	  were	  employed	   for	   the	  coupling	   reaction.256,	  257	  Both	   the	  cis-­‐	  and	   trans-­‐
isomers,	  12	  and	  13,	  underwent	  clean	  and	  efficient	  coupling	  to	  the	  core,	  10,	  with	  high	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Scheme	  2.3	  Synthesis	  of	  the	  short	  esters.	  
	  
Finally,	  a	   saponification	   reaction	  was	  employed	   to	  deprotect	   the	  methyl	  esters,	  14	  
and	   15,	   yielding	   their	   corresponding	   acids.	   Initially,	   conditions	   using	   sodium	  
hydroxide	   (20%)	  under	   reflux	   in	   tetrahydrofuran	   (THF)	  were	   investigated,	   as	   these	  
were	  previously	  used	  to	  generate	  EC23	  and	  EC19.228	  Unfortunately,	  these	  conditions	  
proved	  to	  be	  too	  severe,	  with	  the	  cis-­‐ester,	  14,	  degrading	  to	  a	  mixture	  of	  inseparable	  
compounds,	   with	   the	   only	   identifiable	   product	   being	   5,5,8,8-­‐tetramethyl-­‐5,6,7,8-­‐





Scheme	  2.4	  Initial	  unsuccessful	  saponification	  conditions	  
	  
Consequently,	  a	  milder	  set	  of	  conditions	  was	  required	  to	  keep	  the	  polyene	  section	  
intact.	   The	   reagents	   subsequently	   employed,	   were	   lithium	   hydroxide	   (up	   to	   5	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Both	   the	   cis-­‐	  and	   trans-­‐isomers,	  14	   and	  15,	  were	   successfully	   deprotected	   in	   high	  
yields	  of	  85%	  and	  85%	  respectively,	  to	  generate	  the	  retinoids	  AH62	  and	  AH36,	  2	  and	  




Scheme	  2.5	  Generation	  of	  the	  ‘short’	  analogues	  
	  
2.3.3	  Polyene	  Chain	  Extention	  
	  
With	   both	   isomers	   of	   the	   ‘short’	   retinoid	   analogues	   successfully	   synthesised,	   the	  
next	   target	   involved	   extending	   the	   polyene	   chain	   by	   two	   carbons	   to	   synthesise	  
analogues	  of	  an	  identical	  size	  to	  that	  of	  the	  natural	  retinoids.	  As	  briefly	  mentioned,	  
this	  initiated	  with	  coupling	  of	  the	  cis-­‐	  and	  trans-­‐iodoacrylates,	  12	  and	  13,	  previously	  
synthesised,	   to	   4,4,6-­‐trimethyl-­‐2-­‐vinyl-­‐1,3,2-­‐dioxaborane,	   17,	   through	   a	   Heck-­‐
Mizoroki	  coupling.260	  Both	  reactions	  were	  successful,	  with	  isolated	  yields	  of	  54%	  and	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Scheme	  2.6	  Generation	  of	  the	  boronate	  analogues	  
	  
Both	  the	  (2Z,4E)-­‐	  and	  (2E,4E)-­‐5-­‐(4,4,6-­‐trimethyl-­‐[1,3,2-­‐dioxaborinan-­‐2-­‐yl])-­‐penta-­‐2,4-­‐
dienoic	   acid	   methyl	   esters,	   18	   and	   19,	   were	   then	   subjected	   to	   iododeboronation	  
reactions.	  The	  conditions	  utilised	  were	  developed	  within	  the	  Whiting	  group,	  to	  allow	  
for	  the	  stereoselective	  replacement	  of	  the	  boron	  functionality	  with	  an	  iodine	  atom,	  
thereby	  providing	   an	   accessible	   synthetic	   route	   to	   vinyl	   iodides.262-­‐265	   The	  order	   in	  
which	   the	   reagents	   are	   added	   is	   imperative,	   as	   this	   allows	   for	   the	   correct	  
stereochemistry	  to	  be	  selected.	  The	  addition	  of	   iodine	  monochloride	  first,	  followed	  
by	  that	  of	  sodium	  methoxide,	   leads	  to	  inversion	  at	  the	  boronate	  double	  bond.	  This	  
comes	   about	   by	   the	   initial	   reaction	   of	   the	   olefin	   with	   iodine	   monochloride	   to	  
generate	  an	  iodonium	  ion,	  21.	  This	  species	  then	  has	  two	  ways	  of	  collapsing,	  either	  to	  
the	  saturated	  derivative,	  22,	  leading	  to	  anti-­‐addition	  or,	  to	  the	  zwitterion,	  24.	  In	  the	  
second	   instance	   this	   directs	   the	   chloride	   to	   the	   β-­‐position	   of	   the	   molecule	   and	  
ultimately	   leads	   to	   the	   formation	   of	   the	   vinyl	   chloride,	   26.	   Both	   pathways	   are	   in	  
direct	   competition,	   but	   inclusion	   of	   pyridine	   and	   electron-­‐rich	   R-­‐groups	   has	   been	  
shown	  to	  favour	  formation	  of	  the	  vinyl	  chloride,	  26.	  This	  can	  be	  rationalised	  in	  that	  
the	  pyridine	  helps	  to	  displace	  chloride	  from	  the	  ion	  pair,	  promoting	  formation	  of	  the	  
zwitterion,	  24.	  Conversely,	  when	  pyridine	  is	  omitted,	  and	  the	  R-­‐group	  is	  of	  a	  strong	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subsequently	   only	   the	   vinyl	   iodide,	   23,	   is	   detected.	   When	   the	   addition	   of	   the	  
reagents	  is	  reversed,	  retention	  of	  the	  stereochemistry	  is	  observed.	  This	  comes	  about	  
through	   addition	   of	   sodium	   methoxide	   to	   the	   boronate	   generating	   the	   ‘ate’-­‐
complex,	   27.	   This	   complex	   then	   acts	   as	   a	   nucleophile	   attacking	   the	   strongly	  
electrophilic	   iodine	  monochloride,	   and	   thus	   retaining	   the	   geometry	   of	   the	   double	  
bond.	  The	  mechanism	  of	  both	  these	  reactions	  is	  summarised	  in	  Scheme	  2.7.	  	  	  
	  




Scheme	  2.7	  Mechanistic	  rationalisation	  for	  the	  iododeboronation	  reactions.	  
	  
An	   example	   of	   each	   reaction	   has	   been	   performed,	   firstly	   when	   (2Z,4E)-­‐5-­‐(4,4,6-­‐
trimethyl-­‐[1,3,2-­‐dioxaborinan-­‐2-­‐yl])-­‐penta-­‐2,4-­‐dienoic	   acid	   methyl	   ester,	   18,	   was	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And,	   secondly	   when	   (2E,4E)-­‐5-­‐(4,4,6-­‐trimethyl-­‐[1,3,2-­‐dioxaborinan-­‐2-­‐yl])-­‐penta-­‐2,4-­‐
dienoic	  acid	  methyl	  ester,	  19,	  was	  treated	  with	  with	  sodium	  methoxide,	  followed	  by	  
iodine	  monochloride	  	  to	  give	  (2E,4E)-­‐5-­‐Iodopenta-­‐2,4-­‐dienoic	  acid	  methyl	  ester,	  30,	  





Scheme	  2.8	  Synthesis	  of	  the	  dienyl	  iodides	  
	  
Previous	   work	   within	   our	   group,261,	   266	   on	   both	   identical	   and	   similar	   dienyl	   iodide	  
substrates,	   had	   revealed	   that	   these	   systems	   are	   highly	   sensitive	   to	   both	   light	   and	  
air.267	   Both	   dienyl	   iodides,	   29	   and	   30,	   synthesised	   within	   this	   thesis	   showed	   high	  
stereoselectivity	  for	  the	  desired	  isomer,	  similar	  to	  that	  reported	  previously	  of	  around	  
96:4.	   The	   source	   of	   the	   isomerisation	   generating	   small	   quantities	   of	   the	   alternate	  
isomer	   is	  still	  uncertain.	  What	   is	  certain	   is	   that	   it	   is	  not	  down	  to	  poor	  selectivity	   in	  
the	  iododeboronation	  reaction,	  as	  the	  isomerisation	  is	  seen	  at	  double	  bond	  adjacent	  
to	   the	   carbonyl.	   Other	   explanations	   could	   include	   either	   reversible	   conjugate	  
addition	  of	  the	  iodide	  anion,	  or	  acid-­‐catalysed	  isomerisation.267	  	  
	  
Presented	   with	   this	   knowledge,	   the	   dienyl	   iodides,	   29	   and	   30,	   were	   immediately	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its	   least	  stable	   in	  the	   iodide	  form.	   Identical	  Sonogashira	  conditions	  were	  employed	  
to	  those	  used	  in	  the	  synthesis	  the	  ‘short’	  analogues,	  1	  and	  2.	  A	  coupling	  time	  of	  18	  
hours	   was	   initially	   chosen	   as	   a	   compromise	   between	   yield	   and	   potential	  
isomerisation	   that	   may	   occur,	   based	   on	   previous	   knowledge	   of	   their	   reactivity	  
(Scheme	   2.9).	   All	   reactions	   were	   carried	   out	   under	   reduced	   light	   conditions,	  
including	  work-­‐up	  and	  purification.	  	  
	  
Characterisation	   of	   both	   esters	   revealed	   that	   the	   coupling	  was	   successful,	   but	   the	  
high	  isomeric	  purity	  of	  the	  starting	  iodides,	  29	  and	  30,	  had	  been	  lost	  in	  the	  reaction	  
and	   both	   products	   were	   a	  mixture	   of	   isomers.	   Separation	   of	   the	   isomers	   by	   SiO2	  
silica	  gel	  column	  chromatography	  proved	  unsuccessful.	  Similarly,	  a	  reduction	  in	  the	  
reaction	   time,	   to	   5.5	   hours,	   did	   provide	   an	   improvement	   in	   the	   ratio	   of	   isomers	  
observed	   in	   the	  crude	  product,	  however,	  as	   the	   isomers,	  31,	  were	   inseparable	   this	  




Scheme	  2.9	  Unsuccessful	  coupling	  of	  the	  dienyl	  iodides	  to	  the	  hydrophobic	  core.	  
	  
Due	   to	   the	   inherent	   instability	  within	   the	  polyene	   system,	  an	  alternative	  approach	  
was	   required.	  One	  possible	   solution	  was	   to	   lock	   the	  double	  bonds	   in	   their	  desired	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more	  stable	  analogues,	  such	  as	  the	  boronate	  esters,	  18	  and	  19,	  a	  stable	  reagent	  to	  
couple	   to	   the	   hydrophobic	   core	   may	   have	   been	   achievable	   (Scheme	   2.10).	   One	  
problem	   with	   this	   proposed	   synthetic	   route	   was	   that	   it	   would	   destroy	   the	  




Scheme	  2.10	  Proposed	  cyclopropanation	  of	  unstable	  intermediates.	  
	  
Consequently,	  before	  we	  approached	  this	  route	  in	  any	  detail,	  we	  attempted	  a	  highly	  
analogous	   synthesis	   to	   that	   of	   our	   initial	   idea,	   but	   with	   the	   addition	   of	   an	   extra	  
methyl	   group.	  The	   idea	   stemmed	   from	   that	  displayed	  by	  nature,	   as	   all	   the	  natural	  
retinoids,	  ATRA,	  9cRA	  and	  13cRA,	  are	  all	  based	  on	  a	   skip-­‐methylated	  system.	  Even	  
though	   these	   molecules	   display	   an	   inherent	   instability,	   as	   discussed	   earlier,	   we	  
hypothesised	  the	  additional	  support	  gained	  through	  our	  chosen	  bioisosteres	  (TMTN	  
and	  acetylene	  linker),	  coupled	  with	  the	  extra	  stability	  brought	  in	  by	  the	  methyl	  group	  
would	  generate	  analogues	  with	  an	  overall	  improved	  stability	  profile.	  	  
	  
2.3.4	  Generation	  of	  ‘Short’	  Methylated	  Analogues	  
	  
The	  following	  synthesis	  is	  analogous	  to	  that	  of	  the	  one	  described	  previously.	  Briefly,	  
methyl	   tetrolate,	   33,	   was	   treated	  with	   sodium	   iodide	   in	   acetic	   acid	   to	   yield	   (Z)-­‐3-­‐
iodobut-­‐2-­‐enoic	   acid	  methyl	   ester,	  34,	   in	   an	  excellent	   yield	  of	  95%	  as	  described	   in	  
the	   literature.268	  As	   in	   the	   previous	   synthesis,	   a	   proportion	   of	   the	   compound	  was	  
removed	  and	  stored	  for	  either:	  (1)	  coupling	  to	  the	  core,	  10,	  or	  (2)	  coupling	  to	  a	  vinyl	  
boronate	  species	  to	  generate	  a	  dienyl	  iodide;	  while	  the	  remainder	  was	  converted	  to	  
the	  trans-­‐isomer,	  35.	  Isomerisation	  was	  carried	  out	  as	  described	  in	  the	  literature	  by	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reaction	   times	   of	   24-­‐48	   hours	   were	   employed,	   with	   the	   overall	   yield	   remaining	  
relatively	   poor	   at	   37%	   at	   best,	   with	   40%	   of	   the	   starting	   material	   recovered.	   This	  
resistance	  to	  isomerisation,	  compared	  to	  the	  un-­‐methylated	  system,	  was	  somewhat	  
encouraging,	   as	   we	   knew	   we	   desired	   a	   more	   rigid	   system.	   The	   reactions	   are	  




Scheme	  2.11	  Synthesis	  of	  the	  3-­‐iodobut-­‐2-­‐enoic	  acid	  methyl	  esters.	  
	  
For	   a	   comparison	   with	   the	   un-­‐methylated	   system	   on	   both	   stability	   and	   biological	  
potential,	  the	  synthesis	  of	  the	  methylated	  ‘short’	  retinoid	  analogues	  was	  attempted.	  
Coupling	   of	   both	   the	   cis-­‐	   and	   trans-­‐isomers	   of	   the	   3-­‐iodobut-­‐2-­‐enoic	   acid	   methyl	  
esters,	  35	  and	  36,	  to	  the	  TMTN	  core,	  10,	  was	  achieved	  using	  identical	  conditions	  as	  
previously	   described.	   The	   (Z)-­‐	   and	   (E)-­‐3-­‐methyl-­‐5-­‐(5,5,8,8-­‐tetramethyl-­‐5,6,7,8-­‐
tetrahydro-­‐naphthalen-­‐2-­‐yl)-­‐pent-­‐2-­‐en-­‐4-­‐ynoic	   acid	  methyl	   esters,	  37	   and	  38,	  were	  
isolated	  in	  63	  and	  99%	  yields,	  respectively,	  both	  after	  24	  hour	  reactions.	  The	  removal	  
of	  the	  methyl	  esters	  was	  achieved	  via	  the	  procedure	  previously	  described	  in	  the	  un-­‐
methylated	  analogue	   synthesis.	   This	  was	   successful	   for	   the	   trans-­‐methyl	   ester,	  38,	  
generating	   (E)-­‐3-­‐methyl-­‐5-­‐(5,5,8,8-­‐tetramethyl-­‐5,6,7,8-­‐tetrahydro-­‐naphthalen-­‐2-­‐yl)-­‐
pent-­‐2-­‐en-­‐4-­‐ynoic	  acid,	  40,	   termed	  AH66,	  as	  an	  off-­‐white	  solid	   in	  a	  poor	  yield.	  The	  
low	   yield	   shown	   in	   this	   thesis	   is	   probably	   not	   an	   appropriate	   value	   and	   upon	  




2-­‐en-­‐4-­‐ynoic	  acid	  methyl	  ester,	  37,	  was	  exposed	  to	  the	  same	  conditions	  the	  desired	  
product	  was	  not	  isolated.	  Instead,	  the	  reaction	  appeared	  to	  proceed	  via	  the	  addition	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(5,5,8,8-­‐tetramethyl-­‐5,6,7,8-­‐tetrahydro-­‐naphthalen-­‐2-­‐yl)-­‐5,6-­‐dihydro-­‐pyran-­‐2-­‐one,	  




Scheme	  2.12	  Summary	  of	  the	  synthesis	  of	  the	  ‘short	  methylated’	  analogues.	  
	  
Two	  proposed	  mechanisms	  for	  the	  cyclisation	  are	  depicted	  in	  Figure	  2.2.	  These	  are	  
the	  most	  viable	  routes	  to	  the	  product	  as	  the	  alternative,	  a	  Michael-­‐type	  addition,	  has	  
the	   potential	   to	   isomerise.	   An	   explanation	   for	   why	   the	   cyclisation	   occurs	   in	   this	  
system	  and	  not	  the	  un-­‐methylated	  system	  is	  that	  the	  methyl	  group	  increases	  the	  pKa	  
of	  the	  acid,	  thus	  allowing	  for	  its	  extraction	  more	  easily.	  For	  a	  direct	  comparison,	  both	  
saponification	  reactions	  on	  the	  un-­‐methylated	  and	  methylated	  esters	  were	  repeated	  
under	   identical	   conditions	   using	   three	   equivalents	   of	   lithium	   hydroxide	   in	   a	   3:1	  
THF:H2O	   mixture,	   with	   the	   same	   products	   identified	   as	   previously	   stated.	  
Consequently,	   only	   the	   trans-­‐isomer,	   AH66,	   40,	   of	   the	   ‘short’	   methylated	   system	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2.3.5	  Generation	  of	  ‘ATRA-­‐like’	  Analogues	  
	  
As	   in	  the	  previous	  attempted	  synthesis	  we	  next	  desired	  compounds	  of	  an	   identical	  
size	  to	  that	  of	  their	  natural	  counterparts.	  We	  envisaged	  that	  the	  extra	  methyl	  group	  
would	  provide	  enough	  stability	  to	  enable	  Sonogashira	  coupling	  to	  the	  core.	  Initially,	  
both	  the	  (Z)-­‐	  and	  (E)-­‐3-­‐iodobut-­‐2-­‐enoic	  acid	  methyl	  esters,	  35	  and	  36,	  were	  coupled	  
to	   4,4,6-­‐trimethyl-­‐2-­‐vinyl-­‐1,3,2-­‐dioxaborane,	   17,	   under	   identical	   Heck-­‐Mizoroki	  
conditions	  used	   in	   the	  previous	   synthesis.	  Both	   reactions	  were	   successful	  with	   the	  
corresponding	  cis-­‐	  and	  trans-­‐compounds,	  47	  and	  48,	  isolated	  in	  78%	  and	  74%	  yields,	  
respectively.267	   Identical,	   and	   simultaneous	   iododeboronation	   reactions	   were	   then	  
employed	   to	   generate	   (2Z,4E)-­‐	   and	   (2E,4E)-­‐5-­‐iodo-­‐3-­‐methyl-­‐penta-­‐2,4-­‐dienoic	   acid	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Scheme	  2.13	  Synthesis	  of	  the	  methylated	  stable	  dienyl	  iodides.	  
	  
Interestingly,	  both	  dienyl	   iodides,	  49	   and	  50,	  were	  obtained	  as	   single	   isomers,	  and	  
were	  far	  more	  stable	  when	  exposed	  to	  light	  and	  air	  compared	  to	  the	  un-­‐methylated	  
systems,	   based	   on	   1H	   nuclear	   magnetic	   resonance	   (NMR)	   spectroscopy.	   This	  
enhanced	   stability	  was	   subsequently	   transferred	   through	   the	   coupling	   step	   to	   the	  
core	  10,	  with	  both	  the	  (2Z,4E)-­‐	  and	  (2E,4E)-­‐2-­‐methyl-­‐7-­‐(5,5,8,8-­‐tetramethyl-­‐5,6,7,8-­‐
tetrahydro-­‐naphthalen-­‐2-­‐yl)-­‐hepta-­‐2,4-­‐dien-­‐6-­‐ynoic	   acid	   methyl	   esters,	   51	   and	   52,	  
isolated	  as	  single	  isomers	  in	  88%	  and	  76%	  yields	  respectively.	  There	  is	  still	  potential	  
to	   improve	   these	   yields	   as	   both	   reactions	  were	   run	   in	   5	   hours	   so	   as	   to	   avoid	   any	  
possible	  isomerisation.	  As	  these	  iodides	  now	  appear	  to	  be	  far	  more	  stable	  than	  any	  
previously	   synthesised,	   increasing	   the	   reaction	   time	   may	   be	   possible,	   which	   one	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Finally,	   saponification	   using	   lithium	   hydroxide	   followed	   by	   re-­‐crystallisation	   from	  
acetonitrile	  yielded	   the	   two	   ‘ATRA-­‐like’	  analogues,	   (2Z,4E)-­‐	  and	   (2E,4E)-­‐2-­‐methyl-­‐7-­‐
(5,5,8,8-­‐tetramethyl-­‐5,6,7,8-­‐tetrahydro-­‐naphthalen-­‐2-­‐yl)-­‐hepta-­‐2,4-­‐dien-­‐6-­‐ynoic	  
acid,	  53	  and	  54,	  termed	  AH60	  and	  AH61	  respectively,	  in	  good	  yields	  of	  77%	  and	  82%	  
respectively	  (reactions	  are	  summarised	  in	  Scheme	  2.14).	  	  	  
	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  AH60	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  AH61	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Scheme	  2.14	  Synthesis	  of	  the	  ‘ATRA-­‐like’	  analogues	  AH60	  and	  AH61.	  	  
	  
The	  desired	  stereochemistry	  was	  confirmed	  and	  can	  be	  clearly	  seen	  from	  the	  X-­‐ray	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Figure	  2.3	  X-­‐ray	  crystal	  structure	  of	  AH61.	  	  	  
	  
2.3.6	  Generation	  of	  Extended	  Analogues	  
	  
Having	  now	  prepared	   three	   ‘short’	   analogues,	  1,	  2	   and	  40	   (AH36,	  AH62	  and	  AH66	  
respectively),	   and	   two	   ‘ATRA-­‐like’	   analogues,	   53	   and	   54	   (AH60	   and	   AH61	  
respectively),	   an	   extended	   analogue	   was	   required	   to	   complete	   the	   outlined	  
objectives.	  As	  previously	  discussed,	  the	  longer	  the	  conjugated	  system	  the	  greater	  the	  
sensitivity	  of	   the	  compounds	  to	   light.	   It	  was,	   therefore,	  hypothesised	  that	  a	   trienyl	  
iodide	  would	  be	  potentially	  difficult	   to	  handle.	  As	  a	  result,	  unlike	  all	   the	  previously	  
discussed	   synthesise,	   only	   one	   isomer,	   the	   all-­‐trans	   system,	   would	   be	   initially	  
synthesised.	   This	   was	   chosen	   as	   it	   was	   perceived	   to	   be	   the	   most	   stable,	   and	  
therefore,	  most	  likely	  to	  succeed.	  
	  
Again,	   the	   synthesis	   is	   analogous	   to	   those	   already	   discussed.	   (2E,4E)-­‐5-­‐iodo-­‐3-­‐
methyl-­‐penta-­‐2,4-­‐dienoic	   acid	   methyl	   ester,	   50	   (synthesised	   previously),	   was	  
coupled	   to	  4,4,6-­‐trimethyl-­‐2-­‐vinyl-­‐1,3,2-­‐dioxaborane,	  26,	   under	   the	   standard	  Heck-­‐
Mizoroki	  conditions.	  This	  reaction	  generated	  (2E,4E,6E)-­‐3-­‐methyl-­‐7-­‐(4,4,6-­‐trimethyl-­‐
[1,2,3]-­‐dioxaborinan-­‐2-­‐yl)-­‐hepta-­‐2,4,6-­‐trienoic	   acid	   methyl	   ester,	   55,	   in	   an	  
acceptable	  yield.	  Under	  appropriate	  iododeboronation	  conditions	  the	  corresponding	  
trienyl	   iodide,	   (2E,4E,6E)-­‐7-­‐iodo-­‐3-­‐methyl-­‐hpta-­‐2,4,6-­‐trienoic	   acid	  methyl	   ester,	  56,	  
was	  isolated	  in	  65%	  yield.	  Due	  to	  the	  assumed	  potential	  poor	  stability	  profile	  of	  this	  
compound	   it	   was	   immediately	   coupled	   to	   the	   hydrophobic	   core,	   10.	   The	   reaction	  
took	  place	   in	   5	   hours,	   yielding	   the	  product	   in	   a	   satisfactory	   64%	  yield.	   Finally,	   the	  
ester	   was	   deprotected	   to	   generate	   the	   ‘extended’	   retinoid	   analogue	   (2E,4E,6E)-­‐3-­‐
methyl-­‐9-­‐(5,5,8,8-­‐tetramethyl-­‐5,6,7,8-­‐tetrahydro-­‐naphthalen-­‐2-­‐yl)-­‐nona-­‐2,4,6-­‐trien-­‐
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8-­‐ynoic	   acid,	   57,	   termed	   AH98,	   in	   a	   good	   yield,	   however,	   unfortunately	   as	   two	  




Scheme	  2.15	  Summary	  of	  the	  synthesis	  of	  the	  ‘extended’	  analogue,	  AH98.	  
	  
Due	  to	  the	  poor	  stability	  exhibited	  by	  the	  extended	  system,	  it	  was	  decided	  that	  only	  
one	  analogue	  would	  initially	  be	  synthesised.	  Pending	  further	  testing,	  including	  both	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2.4	  Stability	  Profiles	  	  	  
	  
Subsequent	   to	   the	   synthesis	   of	   the	   compound	   series,	   the	   photostability	   of	   the	  
synthetic	   retinoids	  was	   tested	  and	  compared	   to	   that	  of	  ATRA.	  The	  susceptibility	  of	  
ATRA	   to	   undergo	   photoisomerisation	   and	   degradation	   when	   exposed	   to	   ordinary	  
fluorescent	   light	   in	   the	   visible	   to	   near-­‐ultra	   violet	   (UV)	   range	   has	   been	   previously	  
demonstrated	  within	  our	  research	  group.228	  Briefly,	  1H	  NMR	  spectroscopy	  was	  used	  
to	   investigate	   how	   much	   the	   compounds	   degraded	   over	   a	   set	   time	   period	   of	  
continued	   exposure.	   Prolonged	   exposure	   to	   fluorescent	   light	   led	   to	   the	   advanced	  
degradation	   of	   ATRA,	   whereby	   after	   three	   days	   only	   ca.	   37%	   of	   the	   original	  
compound	   remained.	   From	   the	   1H	   NMR	   spectra	   it	   is	   clear	   that	   not	   only	   is	   the	  
molecule	  isomerising,	  but	  also	  degrading.	  On	  the	  other	  hand,	  ATRA	  was	  shown	  to	  be	  
completely	   stable	  when	   stored	   in	   the	  absence	  of	   light	   for	   three	  days,	   as	   shown	   in	  
Figure	  2.4.228	  Subsequent	  work	  has	  indicated	  that	  ATRA	  can	  be	  safely	  stored	  for	  long	  




Figure	  2.4	  1H	  NMR	  spectra	  at	  400	  MHz	  of	  ATRA	  in	  dimethyl-­‐sulfoxide-­‐d6	  (DMSO-­‐d6)	  (5.0-­‐8.5	  
ppm	  region)	  in	  the	  absence	  of	  light	  (A),	  and	  after	  3	  days	  exposure	  to	  white	  fluorescent	  light	  
at	   a	   distance	   of	   40	   cm	   (B).	   The	   percentage	   value	   represents	   the	   amount	   of	   the	   original	  
compound	  still	  present.	  	  
	  
When	  the	  synthetic	  retinoids	  were	  exposed	  to	  the	  same	  wavelength	  of	  fluorescent	  
light,	   also	   for	   three	  days,	   a	   clear	   relationship	   is	   seen	  between	   that	  of	   stability	  and	  
A) 
B) 37% 
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size.	   The	   ‘short’	   analogues	   both	   un-­‐methylated	   (AH36	   and	   AH62)	   and	  methylated	  
(AH66),	  1,	  2	  and	  40,	   show	  no	  signs	  of	   isomerisation	  or	  degradation	  after	   the	  three	  
days.	   The	   ‘ATRA-­‐like’	   analogues	   (AH60	   and	   AH61),	   53	   and	   54,	   display	   some	   slight	  
signs	   of	   isomerisation	   but	   more	   notably	   there	   is	   no	   degradation.	   The	   ‘extended’	  
analogue,	  (AH98)	  58,	  displays	  the	  worst	  profile,	  as	  one	  would	  expect,	  but	  again	  only	  
appears	   to	   shown	   signs	   of	   isomerisation	   rather	   than	   any	   degradation.	   The	   data	   is	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Figure	  2.5	  1H	  NMR	  spectra	  at	  400	  MHz	  of	  AH62	  2,	  AH36	  1,	  AH66	  40,	  AH60	  53,	  AH61	  54	  and	  
AH98	  58	  (1)-­‐(6)	  respectively,	  in	  DMSO-­‐d6	  (5.0-­‐8.5	  ppm	  region)	  in	  the	  absence	  of	  light	  (A),	  and	  
after	  3	  days	  exposure	  to	  white	  fluorescent	  light	  at	  a	  distance	  of	  40	  cm	  (B).	  The	  percentage	  





















	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Chapter	  II	  
	   	   	   	  74	  
When	   analysed	  more	   closely,	   AH61,	   54,	   only	   isomerises	   to	   one	   other	   compound,	  
AH60,	  53,	  with	  ca.	  83%	  of	  the	  original	  molecule	  remaining	  intact.	  Conversely,	  AH60,	  
53,	  isomerises	  to	  AH61,	  54,	  and	  one	  other	  isomer,	  the	  (2Z,4Z),	  displaying	  that	  the	  all	  




Figure	  2.6	  1H	  NMR	  spectra	  at	  400	  MHz	  of	  AH60	  and	  AH61	  in	  DMSO-­‐d6	  (5.0-­‐8.5	  ppm	  region)	  
after	   3	   days	   exposure	   to	   white	   fluorescent	   light	   at	   a	   distance	   of	   40	   cm.	   The	   overlayed	  
spectra	   clearly	   demonstrate	   that	   AH61	   only	   isomerises	   to	   AH60,	   whereas	   AH60	   also	  
isomerises	   to	   the	   other	   cis-­‐isomer,	   highlighted	   by	   the	   J	   coupling	   of	   12	   Hz,	   as	   illustrated	  
above.	  
	  
To	  examine	  whether	  AH60,	  53,	  and	  AH61,	  54,	  would	  reach	  equilibrium	   in	   terms	  of	  
isomerisation	  and	  at	  what	  ratio,	  NMR	  samples	  of	  both	  compound	  were	  continually	  
exposed	   to	   the	   fluorescent	   light	   for	   up	   to	   two	  weeks.	   During	   this	   time	   AH60,	   53,	  
became	   predominantly	   AH61,	   54,	   with	   one	   other	   isomer	   identified.	   AH61,	   54,	  
similarly	   isomerised	  to	  AH60,	  53,	  and	  one	  other	   isomer,	  however,	  at	  a	  slower	  rate,	  
with	  AH61,	  54,	  remaining	  the	  major	  isomer.	  The	  NMR	  plots	  and	  Table	  summarising	  
the	  data	  are	  displayed	  in	  Figure	  2.7.	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   AH60	  53	   AH61	  54	   Other	   	   	   AH61	  54	   AH60	  53	   Other	  
0	  hrs	   100	  %	   0	  %	   0	  %	   	   0	  hrs	   100	  %	   0	  %	   0	  %	  
24	  hrs	   85	  %	   11	  %	   4	  %	   	   24	  hrs	   94	  %	   6	  %	   0	  %	  
72	  hrs	   60	  %	   29	  %	   11	  %	   	   72	  hrs	   83	  %	   17	  %	   0	  %	  
120	  hrs	   42	  %	   37	  %	   21	  %	   	   120	  hrs	   71	  %	   24	  %	   5	  %	  (4	  %	  cis)	  
168	  hrs	   38	  %	   40	  %	   22	  %	   	   168	  hrs	   65	  %	   29	  %	   6	  %	  (5	  %	  cis)	  
336	  hrs	   30	  %	   45	  %	   25	  %	   	   336	  hrs	   47	  %	   40	  %	   13	  %	  (10	  %	  cis)	  
	  
Figure	  2.7	   1H	  NMR	  spectra	  at	  400	  MHz	  of	  AH60	  53	  and	  AH61	  54	   in	  DMSO-­‐d6	  (5.0-­‐8.5	  ppm	  
region)	  exposed	  to	  white	  fluorescent	  light	  at	  a	  distance	  of	  40	  cm	  for	  different	  time	  periods	  
up	  to	  two	  weeks.	  The	  data	  is	  displayed	  graphically	  and	  summarised	  in	  the	  Tables	  below	  each	  
set	  of	  spectra.	  Both	  compounds	  isomerise	  to	  each	  other	  and	  one	  other	  identifiable	  isomer.	  
The	  increased	  stability	  of	  the	  all-­‐trans	  system	  is	  highlighted	  as	  both	  in	  the	  parent	  mixture	  it	  
remains	   the	   most	   predominant	   compound,	   while	   the	   corresponding	   isomer	   solution	  
isomerises	  to	  a	  predominant	  solution	  of	  AH61	  54.	  Equilibrium	  was	  never	  reached	  but	  these	  
data	  suggests	  AH61	  54	  would	  be	  the	  most	  predominant	  isomer	  at	  around	  40-­‐45%,	  followed	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2.5	  Conclusions	  
	  
In	   summary,	   a	   series	   of	   novel	   related	   synthetic	   retinoids	   were	   successfully	  
synthesised.	  The	  original	  design	  was	  modified	  by	  inclusion	  of	  an	  extra	  methyl	  group	  
to	   allow	   for	   the	   synthesis	   of	   larger	   polyene	   chain	   containing	   molecules.	   Not	   all	  
possible	  isomers	  and	  conformations	  were	  made,	  due	  to	  chemical	  restrictions	  such	  as	  
self-­‐cyclistations	   demonstrated	   in	   the	   short	   methyl	   containing	   cis-­‐isomer.	   The	  
‘extended’	  analogues	  were	  also	  suspended	  after	  synthesising	  only	  one	  analogue,	  as	  
it	  was	  made	  up	  of	  a	  mixture	  of	  isomers.	  All	  further	  testing	  was	  then	  carried	  out	  on	  
the	  compound	  as	  a	  mixture,	  and	  once	  analysed	  it	  would	  be	  possible	  to	  return	  in	  an	  
attempt	  to	  optimise	  the	  system.	  One	  obvious	  target	  would	  be	  to	  add	  another	  methyl	  
group	   to	   the	   system,	   mimicking	   that	   of	   the	   skip-­‐methylated	   system	   displayed	   by	  






It	   is	   of	   note	   that	   all	   the	   synthetic	   compounds	   synthesised	   showed	   a	   significantly	  
improved	  stability	  profile	  compared	  to	  that	  of	  ATRA.228	  The	  ‘short’	  analogues	  (AH36,	  
AH62	  and	  AH66),	  1,	  2	   and	  40,	  display	  no	  signs	  of	  any	   isomerisation,	  whereas	  even	  
though	  the	  ‘ATRA-­‐like’	  compounds	  (AH60	  and	  AH61),	  53	  and	  54,	   isomerised,	  this	   is	  
greatly	  reduced	  compared	  to	  that	  of	  ATRA,	  and	  more	  importantly	  they	  show	  no	  signs	  
of	   degradation.	  What	   affect	   this	   had	  on	   any	  biological	   system	  was	   then	   examined	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2.6	  Structure	  Reference	  Guide	  
	  
The	   following	   compound	   names	  will	   be	   used	  when	   discussing	   the	   retinoids	   in	   the	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3.1	  Introduction	  
	  
3.1.1	  Pluripotent	  Stem	  Cells	  and	  Model	  Systems	  
	  
This	   Chapter	   aims	   to	   deal	   with	   the	   initial	   screening	   of	   the	   synthetic	   retinoids	  
synthesised	   in	   Chapter	   II.	   As	   previously	   discussed,	   ATRA,	   the	   natural	   parent	  
compound	  on	  which	  the	  synthesised	  compounds	  are	  based,	  possesses	  a	  wide	  range	  
of	   biological	   activities.	   Therefore,	   to	   probe	   the	   roles	   of	   the	   synthetic	   analogues,	   a	  
suitable	   model	   system	   linked	   to	   one	   of	   ATRA’s	   endogenous	   effects	   was	   selected.	  
ATRA	   is	   a	   well-­‐known	   and	   well-­‐published	   modulator	   of	   mammalian	   development	  
and	   in	  particular	  cellular	  differentiation	   in	  both	  EC	  and	  ES	  cells	   (see	  Chapter	   I	   for	  a	  
full	   discussion).199,	   200	   ATRA	   acts	   through	   binding	   to	   nuclear	   receptors	   (RARs),	   and	  
inducing	  the	  transcription	  of	  specific	  target	  genes.	  Ultimately,	  this	  leads	  to	  the	  cells	  
differentiating	   into	   a	   number	   of	   different	   endodermal	   and	   neuronal	   cell	  
derivatives.200	   Consequently,	   this	   makes	   these	   cell	   lines	   ideal	   model	   systems	   for	  
evaluating	  neuronal	  induction	  properties	  of	  the	  different	  analogues	  synthesised.	  	  
	  
The	  work	  covered	  in	  this	  Chapter	  has	  been	  carried	  out	  using	  mammalian	  EC	  cells,	  in	  
which	   two	   different	   cell	   lines	   have	   been	   utilised,	   one	  murine	   and	   one	   human.	   At	  
present,	  none	  of	  the	  compounds	  synthesised	  within	  this	  thesis	  have	  been	  evaluated	  
in	  an	  ES	  system.	  Although	  both	  murine	  ES	  cells,	  and	  human	  ES	  cells,	  have	  long	  been	  
isolated,	  there	  are	  still	  contentious	  ethical	  and	  source	  issues	  surrounding	  their	  use,	  
which	  makes	  primary	  studies	  challenging.2,	  3,	  269	  ES	  cells	  are	  derived	  from	  totipotent	  
cells	  of	  the	  mammalian	  embryo,	  and	  have	  subsequently	  been	  shown	  to	  be	  capable	  
of	   both	   rapid	   proliferation	   and	   the	   potential	   to	   differentiate	   into	   a	  wide	   range	   of	  
adult	  tissues,	  including	  germ	  cells.270,	  271	  Human	  ES	  cells	  are	  of	  particular	  interest	  due	  
to	   their	  possible	  valuable	   roles	   in	   improving	   in	   vitro	   toxicology,	   tissue	  engineering,	  
drug	  discovery	  and	  cell	  therapy.272-­‐275	  Additionally,	  it	  is	  widely	  believed	  that	  they	  may	  
hold	   the	   potential	   to	   treat	   a	   wide	   range	   of	   degenerative	   diseases,	   including	  
Alzheimer’s	  and	  Parkinson’s.276-­‐279	  Interestingly,	  both	  mouse	  and	  human	  ES	  cells	  also	  
exhibit	   many	   differences	   as	   well	   as	   similarities,	   and	   this	   can	   complicate	   matters	  
further	  as	  one	  then	  needs	  to	  analyse	  species	  specific	  roles.280	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Consequently,	   it	   is	   preferable	   to	   use	   a	   human	  model	   system	   to	   avoid	   any	   species	  
variety.	   As	   discussed,	   human	   ES	   lines	   are	   not	   only	   contentious,	   but	   also	   time	  
consuming	  and	  expensive	  to	  handle,	  due	  to	  their	  demanding	  cell	  culture	  protocols.	  
Consequently,	  there	  has	  been	  considerable	  interest	  and	  research	  into	  model	  systems	  
that	   can	  mimic	   ES	   cell	   behaviour.	   	   One	   such	   alternative,	   are	   EC	   cells.	   EC	   cells	   are	  
pluripotent	   stem	   cells	   derived	   from	   teratocarcinomas,	   which	   are	   tumours	   of	   the	  
germ	  cells.38	  They	  have	  been	  shown	  to	  be	  the	  malignant	  counterparts	  to	  ES	  cells	  and	  
share	   many	   characteristics.	   Additionally,	   there	   are	   many	   advantages	   to	   their	   use	  
over	  ES	  cells	  as	  they	  are	  more	  robust,	  not	  requiring	  feeder	  cells,	  and	  relatively	  easy	  
to	  culture	  and	  passage.281,	  282	  Furthermore,	  EC	  lines	  are	  the	  source	  of	  a	  large	  supply	  
of	  both	  proteins	  and	  RNA’s,	  and	  in	  general	  resist	  any	  spontaneous	  differentiation.283,	  
284	  It	  is,	  therefore,	  more	  appropriate	  that	  an	  EC	  cell	  line	  was	  chosen	  for	  this	  study.	  	  
	  
3.1.2	  Murine	  F9	  EC	  Cells	  
	  
The	   F9	   cell	   line	   is	   one	   of	   the	  most	   widely	   used	   EC	   cell	   lines	   for	   studying	   in	   vitro	  
differentiation.	  Isolated	  in	  1973	  from	  the	  teratocarcinoma	  OTT	  6050,	  and	  depending	  
on	  both	  reagents	  and	  culture	  conditions,	  these	  cells	  have	  the	  ability	  to	  differentiate	  
into	   endodermal-­‐like	   derivatives.	   It	   has,	   therefore,	   been	   widely	   used	   in	   many	  
laboratories	  as	  a	  model	  to	  study	  the	  molecular	  mechanisms	  of	  differentiation.285,	  286	  
The	   cells	   grow	   rapidly,	   with	   an	   average	   doubling	   time	   of	   8-­‐10	   hours	   in	   the	  
exponential	   growth	   phase.	   Upon	   treatment	   with	   ATRA,	   the	   cells	   differentiate	  
adopting	   a	   different	   phenotype.	   To	   identify	   compounds	   which	   activate	   retinoid	  
signalling	   pathways,	   we	   have	   used	   an	   F9	   cell	   line,	   chosen	   as	   these	   cells	   express	  
endogenous	  α,	  β,	  and	  γ	  retinoic	  acid	  receptors.167	  The	  cell	  line	  chosen	  also	  contains	  a	  
reporter	  assay	  that	  makes	  use	  of	  a	  retinoic	  acid	  response	  element	  (RARE)	  to	  drive	  a	  
lacZ	  reporter	  gene.287	  This	  RARE	  is	  located	  within	  the	  cis-­‐acting	  regulatory	  sequences	  
of	  the	  human	  β-­‐retinoic	  acid	  receptor	  gene.288	  It	  is	  comprised	  of	  64	  nucleotides,	  and	  
responds	  to	  the	  α,	  β,	  and	  γ	  RAR	  subtypes.289	  The	  RARE	  had	  been	  transfected	  directly	  
upstream	  of	  the	  E.	  coli	  lacZ	  gene,	  which	  confers	  retinoid	  responsivity	  to	  these	  genes.	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Thus,	  the	   lacZ	  gene	  is	  used	  for	  histochemical	  detection	  of	  retinoid-­‐responsive	  cells,	  
measured	  by	  assaying	  β-­‐galactosidase	  activity.	  
	  
3.1.3	  TERA2.cl.SP12	  EC	  cells	  
	  
One	  of	   the	  earliest,	  and	   frequently	  used	  human	  EC	  cell	   lines	   is	   the	  TERA2	  cell	   line,	  
initially	   isolated	   from	   a	   lung	   metastasis	   originating	   from	   a	   testicular	   germ	   cell	  
tumour.290	   Problems	   with	   the	   purity	   of	   the	   original	   human	   TERA2	   cell	   line	  meant	  
producing	  accurate	  and	  reproducible	  studies	  challenging,	  as	  only	  1-­‐2%	  of	  cells	  were	  
EC	  cells.	  Consequently,	  multiple	  cloned	  cell	  lines	  have	  been	  derived	  from	  the	  parent	  
culture.	  These	  cloned	  cell	  lines	  contain	  an	  increased	  number	  of	  EC	  cells,	  but	  still	  have	  
a	  varied	  ability	  to	  differentiate.	  Andrews	  et	  al.	  created	  the	  first	  such	  clone	  in	  1984,	  
by	  passage	  through	  a	  nude	  mouse,	  which	  displayed	  an	  adaption	  to	  growth	   in	  vitro,	  
alongside	   retaining	   the	   capacity	   to	   differentiate	   into	   a	   diverse	   array	   of	   somatic	  
tissues.	  This	  cell	  line	  was	  subsequently	  termed	  NTERA2.291	  A	  more	  recent	  sub-­‐clone	  
culture,	  termed	  TERA2.cl.SP12,	  was	  developed	  in	  2001	  by	  immunomagnetic	  sorting,	  
followed	  by	  single	  cell	  selection	  for	  SSEA-­‐3	  positive	  cells	  and	  subsequent	  culture.209	  
Characterisation	   of	   the	   TERA2.cl.SP12	   cell	   line	   showed	   that	   in	   an	   undifferentiated	  
state,	   the	   cells	   express	   SSEA-­‐3,	   -­‐4	   and	   TRA-­‐1-­‐60,	   signifying	   they	   are	   in	   an	   EC	   cell	  
state.	   Treatment	   with	   ATRA	   promotes	   the	   cells	   to	   differentiate,	   signified	   by	   the	  
down-­‐regulation	  of	  stem	  cell	  markers	  and	  up-­‐regulation	  of	  neural	  markers	  A2B5	  and	  
VINIS-­‐53.	  In	  addition,	  TERA2.cl.SP12	  stem	  cells	  have	  similarly	  been	  shown	  to	  regulate	  
neural	   genes,	   again	   in	   a	  well-­‐defined	  manner. Further	   indication	   of	   their	   ability	   to	  
differentiate	   was	   demonstrated	   upon	   grafting	   of	   the	   cells	   into	   severe	   combined	  
immunodeficient	   (SCID)	  mice.	  Complex	   xenograft	   tumours,	   containing	  multiple	   cell	  
types,	   including	   high	   proportions	   of	   both	   neural	   and	   epithelial	   derivatives	   were	  
subsequently	  produced.210,	  211	  Prolonged	  exposure	  to	  ATRA	  leads	  to	  the	  formation	  of	  
a	  heterogeneous	  cell	  population,	  containing	  multiple	  mature	  functioning	  neurons.212	  
Subsequent	   electrophysiological	   experiments	   show	   the	   neurons	   produced	   contain	  
an	   array	   of	   functional	   receptors	   and	   ion	   channels	   with	   a	   pharmacological	   profile	  
indicative	   of	   that	   defined	   for	   native	   neurons.213	   Consequently,	   this	   makes	   the	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TERA2.cl.SP12	   cell	   line	   an	   effective	   model	   system	   for	   the	   in	   vitro	   study	   of	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3.2	  Aims	  and	  Objectives	  
	  
The	   aim	   of	   this	   Chapter	   was	   to	   evaluate	   the	   synthetic	   analogues	   synthesised	   in	  
Chapter	  II	  on	  models	  of	  EC	  stem	  cells.	  From	  previous	  work,	  both	  within	  our	  research	  
group	   and	   those	   of	   others,	   we	   know	   ATRA	   and	   some	   of	   its	   synthetic	   analogues	  
induce	  neural	  differentiation	  in	  these	  stem	  cell	  model	  systems	   in	  vitro.	  More	  stable	  
synthetic	  analogues	  (EC23	  and	  EC19)	  have	  shown	  improved	  profiles	  to	  that	  of	  their	  
natural	  counterpart,	  ATRA,	  and	  we	  aimed	  to	  test	  the	  new	  analogues	  synthesised	  in	  a	  
similar	  manner.228	  
	  
The	  main	  objectives,	  therefore,	  were	  to:	  (1)	  initially	  demonstrate	  that	  the	  synthetic	  
compounds	  activated	  the	   inherent	  retinoic	  acid	  receptors,	  using	  the	  transfected	  F9	  
EC	   cell	   line;	   (2)	   analyse	   the	   compound’s	   potential	   to	   induce	   differentiation	   in	   the	  
TERA2.cl.SP12	  EC	  cell	  line,	  looking	  at	  both	  the	  expression	  of	  cell	  surface	  antigens	  and	  
gene	  profiles;	  (3)	  quantify	  the	  expressed	  markers;	  and	  (4)	  investigate	  concentration	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3.3	  Results	  
	  
3.3.1	  Effects	  of	  the	  Synthetic	  Retinoids	  on	  F9	  Murine	  EC	  Cells	  
	  
To	  compare	   the	  effects	  of	   the	   synthetic	   compounds	  versus	   known	  natural	   retinoid	  
responses,	   cultures	   of	   F9	   murine	   embryonal	   carcinoma	   cells	   containing	   a	   lacZ	  
reporter	   line	   were	   incubated	   with	   10	  µM	   concentrations	   of	   each	   test	   compound.	  
This	   was	   to	   determine	   whether	   the	   new	   analogues	   trigger	   the	   retinoid-­‐signalling	  
pathway,	   through	  binding	  of	  one	  or	  multiple	  RAR	   receptors	   (α,	  β,	  or	  γ).	  ATRA	  was	  
also	   screened	   as	   the	   positive	   control,	   alongside	   control	   cultures,	   consisting	   of	  
untreated	  F9	  cells,	  and	  those	  treated	  only	  with	  the	  vehicle,	  DMSO.	  DMSO	  has	  been	  
included	   in	   all	   investigations	   throughout	   this	   thesis	   as	   it	   is	   the	   solvent	   used	   to	  
dissolve	  the	  compounds	  and	  thus	  allow	  for	  their	  administration.	  	  
	  
The	   F9	   cells	   exposed	   to	   no	   compounds,	   i.e.	   the	   untreated	   control,	   showed	   no	  
positive	   results	   upon	   β-­‐galactosidase	   staining	   as	   expected	   (Figure	   3.1	   (A)).	   Those	  
exposed	  to	  the	  vehicle	  in	  general	  also	  displayed	  no	  positive	  cells,	  although	  in	  some	  
cultures	  a	  small	  proportion	  of	  the	  population	  did	  stain	  positive.	  This	  is	  in	  contrast	  to	  
F9	   cells	   treated	   with	   ATRA,	   which	   stained	   strongly	   in	   response	   to	  β-­‐galactosidase	  
with	   a	   high	   percentage	   of	   blue	   cells	   visible	   (Figure	   3.1	   (C)).	   The	   ‘short’	   retinoid	  
analogues,	   AH36,	   AH62	   and	   AH66,	   all	   displayed	   a	   very	   low	   percentage	   of	   cells	  
staining	  positive,	  suggesting	  they	  do	  not	  bind	  to	  the	  RAR	  receptors	  (Figure	  3	  (D)	  (E)	  
and	   (F)).	   Both	   the	   ‘ATRA-­‐like’	   analogues,	   AH60	   and	   AH61,	   produced	   a	   positive	  
number	   of	   cells	   similar	   to	   that	   of	   ATRA,	   (Figure	   3	   (G)	   and	   (H)).	   The	   ‘extended’	  
retinoid	   analogue,	   AH98,	   again	   showed	   a	   very	   low	   percentage	   of	   positive	   staining	  
cells,	   giving	   an	   early	   indication	   that	   it	   binds	   poorly,	   if	   at	   all,	   to	   the	   RAR	   receptors	  
(Figure	  3	  (I)).	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Figure	  3.1	  Phase	  micrographs	  showing	   lacZ	  gene	  expression	  visualised	  by	  X-­‐gal	  staining	  for	  
β-­‐galactosidase	  in	  F9	  murine	  EC	  cell	  cultures	  exposed	  to	  no	  compounds	  (un-­‐treated	  control),	  
vehicle	  (DMSO),	  10	  μM	  ATRA,	  AH36,	  AH62,	  AH66,	  AH60,	  AH61	  and	  AH98	  for	  18	  hours	  (A,	  B,	  
C,	  D,	  E,	  F,	  G,	  H	   and	   I	   respectively).	   Arrows	   show	  examples	   of	   labelled	   positive	   cells.	   Scale	  
Bars:	  100	  μm.	  
	  
To	  quantify	  the	  amount	  of	  positively	  stained	  cells	  within	  each	  sample	  group,	  random	  
triplicate	   images	   were	   recorded	   and	   analysed	   in	   ImageJ	   software.	   The	   number	   of	  
positive	   (blue)	   cells	   in	   each	   field	   of	   view	   was	   recorded.	   The	   data	   are	   displayed	  
graphically	   in	   Figure	   3.2.	   Both	   AH60	   and	   AH61	   display	   significantly	   more	   positive	  
cells	  than	  that	  of	  the	  vehicle,	  DMSO,	  therefore	  suggesting	  that	  they	  are	  inducing	  the	  
response,	  not	   the	  solvent.	  There	   is	  no	  significant	  difference	  seen	   in	   the	  number	  of	  
positive	  cells	  displayed	  for	  ATRA,	  AH60	  or	  AH61	  suggesting	  they	  all	  bind	  at	  a	  similar	  
affinity	  to	  the	  receptors	   in	  this	  system.	  The	   level	  of	  positive	  cells	   for	  the	   ‘short-­‐cis-­‐
analogue’	  is	  nearly	  identical	  for	  that	  seen	  for	  DMSO	  suggesting	  that	  any	  positive	  cells	  
in	  these	  cultures	  are	  likely	  to	  be	  as	  a	  result	  of	  the	  solvent,	  not	  the	  synthetic	  retinoid.	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Similarly,	  there	  is	  no	  significant	  difference	  in	  the	  data	  for	  either	  of	  the	  ‘short-­‐trans-­‐
analogues’,	   again	   suggesting	   that	   these	   too	   are	   incapable	   of	   binding	   to	   the	  
receptors.	   The	   ‘extended’	   analogue	   does	   display	   a	   significant	   up-­‐regulation	   of	   the	  
number	  of	  positive	  cells	  compared	  to	  DMSO,	  but	  this	  is	  significantly	  lower	  than	  that	  




Figure	  3.2	  Quantification	  of	  the	  number	  of	  positive	  cells	  per	  field	  of	  view	  for	  each	  retinoid	  
treatment.	  Results	   are	  presented	  with	  ±	   standard	  error	   (SEM),	  n=3.	   **	  p≤0.005,	   *	  p≤0.05,	  
Student’s	  t-­‐test	  corrected	  for	  multiple	  testing	  between	  compared	  sample	  populations	  using	  
the	  Bonferroni	  correction.	  	  	  
	  
The	   above	   figures	   give	   an	   early	   indication	   that	   both	   the	   ‘short’	   and	   ‘extended’	  
analogues	  do	  not	  display	  a	  biological	   response	  analogous	   to	   that	  of	  ATRA,	   as	   they	  
appear	  not	  to	  activate	  transcription	  associated	  with	  binding	  to	  the	  RAR	  receptors.	  An	  
early	   hypothesis,	   and	   explanation	   for	   this	   lack	   of	   activity	   displayed	   by	   the	   ‘short’	  
analogues	   would	   be	   that	   they	   are	   not	   large	   enough	   to	   enter	   the	   receptors	  
completely,	  and	  therefore,	  do	  not	  bind	  correctly.	  Further	  clarification	  of	  this	  data	  will	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3.3.2	   Viability,	   Toxicity,	   and	   Morphological	   Analysis	   of	   Synthetic	  
Retinoids	  on	  TERA2.cl.SP12	  Cells	  
	  
To	   analyse	   further	   the	   effects	   of	   the	   synthetic	   compounds	   versus	   both	   natural	  
retinoid	   responses	  and	  other	  synthetic	   retinoids,	  cultures	  of	  TERA2.cl.SP12	  EC	  cells	  
were	   incubated	  with	  10	  µM	  concentrations	  of	  each	  compound.	  Concurrently,	  as	   in	  
the	   previous	  model,	   control	   cultures	   were	   evaluated	   consisting	   of	   untreated,	   and	  
therefore	  undifferentiated,	  cells,	  along	  with	  cultures	  exposed	  to	  the	  vehicle,	  DMSO.	  
	  
3.3.2.1	  Number	  of	  Viable	  Cells	  	  
	  
Retinoid	   treated	   cultures	   were	   maintained	   for	   up	   to	   seven	   days,	   with	   the	   media	  
changed	   every	   three	   days.	   The	   number	   of	   viable	   cells	   was	   analysed	   at	   three	   and	  
seven	  days	  using	  a	   tetrazolium-­‐based	  proliferation	  assay	   (MTS	  assay).	   Proliferating	  
cells	  produce	  reducing	  equivalents	  such	  as	  NADPH	  and	  NADH,	  which	  reduce	  3-­‐(4,5-­‐
dimethylthiazol-­‐2-­‐yl)-­‐5-­‐(3-­‐carboxymethoxyphenyl)-­‐2-­‐(4-­‐sulfophenyl)-­‐2H-­‐tetrazolium,	  
from	  a	  yellow	  salt	  to	  a	  soluble	  blue	  formazan	  product.	  The	  amount	  of	  the	  formazan	  
product	  is	  then	  measured	  by	  reading	  the	  UV	  absorbance	  of	  the	  solution	  at	  490	  nm.	  
This	   absorbance	   value	   is	   proportional	   to	   the	   number	   of	   viable	   cells	   in	   the	   culture	  
(Figure	  3.3).	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Figure	   3.3	   Analysis	   of	   the	   number	   of	   viable	   cells	   using	   an	   MTS	   assay	   kit.	   Cultures	   were	  
exposed	   to	   10	  μM	  ATRA,	   AH36,	   AH62,	   AH66,	   AH60,	   AH61	   and	  AH98,	   alongside	   untreated	  
control	  and	  vehicle	  cultures.	  Analysis	  was	  done	  at	  3	  and	  7	  days.	  Cell	  number,	  expressed	  as	  
an	  absorbance	   value,	  was	  attenuated	   in	  ATRA,	  AH60	  and	  AH61	   cultures,	   compared	   to	   the	  
controls.	  However,	   those	   treated	  with	   the	   ‘short	   ‘	   analogues	  and	   the	   ‘extended’	   analogue	  
did	  not	   show	  a	   reduction	   in	   cell	   number	   compared	   to	   the	   controls.	   Results	   are	  presented	  
with	  ±	   standard	  error	   (SEM),	  n=3.	   *	  p≤0.05,	   Student’s	   t-­‐test	   corrected	   for	  multiple	   testing	  
between	  compared	  sample	  populations	  using	  the	  Bonferroni	  correction.	  	  	  
	  
Untreated	  cultures,	  and	   those	   treated	  with	  DMSO,	  continued	   to	  proliferate	   rapidly	  
and	  after	   seven	  days	   the	   cultures	  were	  highly	   confluent.	   Those	   treated	  with	  ATRA	  
displayed	  a	  significantly	  reduced	  cell	  number	  compared	  to	  the	  vehicle,	  DMSO.	  This	  
reduction	  in	  cell	  number	  is	  associated	  with	  a	  differentiating	  cell	  culture	  as	  the	  cells	  
no	   longer	   proliferate	   but	   exit	   the	   cell	   cycle	   and	   commit	   to	   a	   specific	   lineage.	  	  
Consistent	  with	  the	  data	  presented	  for	  the	  F9	  cell	  line,	  there	  was	  no	  reduction	  in	  cell	  
number	   for	  any	  of	   the	   ‘short’	  synthetic	  analogues	  or	   the	   ‘extended’	  analogue.	  This	  
further	  supports	  that	  they	  are	  incapable	  of	  activating	  the	  retinoid	  pathway,	  and,	  in-­‐
turn,	  unable	  to	  arrest	  cellular	  proliferation	  and	  induce	  differentiation.	  A	  decrease	  in	  
cell	   number	  was	  observed	   in	   cultures	   treated	  with	  AH60	  and	  AH61,comparable	   to	  
that	   of	   ATRA.	   This	   is	   consistent	   with	   both	   compounds	   initiating	   a	   response,	   as	  
displayed	  in	  the	  previous	  data	  set.	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3.3.2.2	  Toxicity	  	  
	  
Simultaneously,	   the	   toxicity	   of	   the	   compounds	   was	   assessed	   via	   measuring	   the	  
number	  of	  apoptopic	  and	  viable	  cells	   (Figure	  3.4	   (A)	  and	  (B)	   respectively).	  Retinoid	  
treated	   cultures	   were	   again	   maintained	   for	   seven	   days,	   with	   the	   media	   changed	  
every	   three.	   Analysis	   was	   performed	   using	   Guava	   ViaCount	   reagent,	   on	   a	   Guave	  
EasyCyteTM	   Plus	   System	   flow	   cytometer.	   All	   compounds	   assessed	   showed	   none	  
significantly	   different	   levels	   of	   apoptopic	   cells	   and	   viable	   cells,	   indicating	   that	   at	   a	  
concentration	  of	  10	  µM	  the	  compounds	  appear	   to	  not	  be	   toxic.	  Therefore,	   further	  
analysis	  can	  be	  carried	  out	  using	  concentrations	  equal	  or	  below	  10	  µM,	  to	  assess	  the	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Figure	   3.4	   (A)	   Analysis	   of	   the	  number	  of	   apoptopic	   cells	   displayed	   as	   a	   percentage	  of	   the	  
total	   population;	   (B)	   Analysis	   of	   the	   number	   of	   viable	   cells	   as	   a	   percentage	   of	   the	   total	  
population.	  All	  cultures	  were	  exposed	  to	  10	  μM	  ATRA,	  AH36,	  AH62,	  AH66,	  AH60,	  AH61	  and	  
AH98,	  alongside	  untreated	  control	  and	  vehicle	  cultures.	  Analysis	  was	  done	  at	  3	  and	  7	  days.	  
Results	   are	   presented	   with	   ±	   standard	   error	   (SEM),	   n=3.	   Per	   statistical	   analysis	   using	   the	  
Student’s	  t-­‐test	  corrected	  for	  multiple	  testing	  between	  compared	  sample	  populations	  using	  
the	   Bonferroni	   correction,	   there	   were	   no	   significant	   differences	   between	   any	   of	   the	  
treatments.	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3.3.2.3	  Morphologies	  of	  Induced	  Cell	  Types	  
	  
Analysis	  of	  the	  morphologies	  produced	  by	  each	  of	  the	  synthetic	  retinoids	  at	  10	  μM	  
showed	   dramatic	   differences	   after	   seven	   days	   of	   incubation.	   Undifferentiated	  
TERA2.cl.SP12	   cultures	   are	   characterised	   by	   a	   homogeneous	   ‘cobblestone’	  




Figure	   3.5	  Confluent	  undifferentiated	  TERA2.cl.SP12	  cells	  displaying	  a	   typical	   ‘cobblestone’	  
appearance.	  Scale	  Bar:	  100	  μm.	  
	  
If	   cultured	  past	  optimal	   density,	   the	   cells	   start	   to	  become	  over	   confluent,	   layering	  
upon	   one	   another,	   but	   still	   retaining	   a	   homogeneous	   phenotype.	   This	   is	   visible	   in	  
cultures	   that	   were	   undifferentiated	   after	   seven	   days	   (Figure	   3.6	   (A)).	   A	   similar	  
phenotype	  was	  seen	  for	  cultures	  treated	  with	  DMSO,	  and	  that	  of	  the	  ‘short’	  retinoid	  
analogues	   AH36,	   AH62	   and	   AH66	   (Figure	   3.6	   (B),	   (D),	   (E)	   and	   (F)	   respectively).	  
Cultures	   exposed	   to	   ATRA	   displayed	   a	   far	   greater	   degree	   of	   heterogeneity,	  
consistent	   with	   a	   differentiating	   culture	   (Figure	   3.6	   (C)).	   Although	   the	   culture	  
appeared	  to	  be	  differentiating,	  seven	  days	  is	  too	  short	  a	  time	  to	  visualise	  any	  neural	  
phenotypes,	  such	  as	  neural	  rosettes	  or	  individual	  neurons.	  This	  phenotype	  was	  also	  
visible	  in	  cultures	  treated	  with	  AH60	  and	  AH61,	  reinforcing	  their	  similarity	  to	  that	  of	  
ATRA	   (Figure	   3.6	   (G)	   and	   (H)).	   In	   line	  with	   previous	   data,	   the	   ‘extended’	   analogue	  
AH98	   displayed	   no	   phenotypic	   similarities	   to	   that	   of	   ATRA,	   and	   like	   the	   ‘short’	  
analogues	  the	  cells	  retained	  their	  undifferentiated	  phenotype	  (Figure	  3.6	  (I)).	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Figure	   3.6	   Morphologies	   of	   TERA2.cl.SP12	   cells	   after	   7	   days	   treatment	   with	   retinoids.	  
Undifferentiated	   cultures	   (A)	   retained	   a	   homogeneous	   appearance	   but	   with	   some	   cells	  
layering	   as	   they	   become	   over	   confluent	   and	   sub-­‐optimal.	   Treatment	   with	   DMSO	   (B),	   the	  
‘short’	   retinoids	   AH36,	   AH62	   and	   AH66	   ((D),	   (E)	   and	   (F)	   respectively)	   and	   the	   ‘extended	  
analogue	   AH98	   (I)	   all	   display	   an	   identical	   profile,	   indicating	   the	   cells	   remain	   in	   an	  
undifferentiated	   state.	   Cultures	   exposed	   to	   ATRA	   (C)	   exhibit	   an	   extremely	   heterogeneous	  
morphology,	   with	   significantly	   less	   cells	   per	   field	   of	   view,	   typical	   of	   a	   differentiating	   cell	  
culture.	   Similarly,	   cultures	   exposed	   to	   AH60	   (G)	   and	   AH61	   (H)	   also	   displayed	   this	  
morphology.	  Scale	  Bars:	  100	  μm.	  	  
	  
Cultures	  exposed	  to	  ATRA,	  AH60	  and	  AH61	  were	  cultured	  for	  up	  to	  twenty	  one	  days.	  
Those	   untreated	   and	   exposed	   to	  DMSO,	   and	   the	   ‘short’	   and	   ‘extended’	   analogues	  
became	  over	  confluent	  and	  sub-­‐optimal	  and	  were	  therefore	  not	  cultured	  past	  seven	  
days.	  	  Both	  AH60	  and	  AH61	  appeared	  to	  mimic	  the	  profile	  exhibited	  by	  ATRA.	  They	  
displayed	   a	   characteristic	   neural	   phenotype,	   with	   neural	   rosette-­‐like	   areas	   and	  
neurons	  visible	  under	  phase	  microscopy	  (Figure	  3.7).	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Figure	   3.7	  Phase	   images,	  both	   low	  and	  high	  magnification,	  of	  differentiated	  TERA2.cl.SP12	  
cultures	   after	   twenty	   one	   days	   of	   culture	   with	   ATRA	   (A/D),	   AH60	   (B/E),	   and	   AH61	   (C/F).	  
Cultures	   exposed	   to	   all	   three	   retinoids	   exhibit	   a	   highly	   heterogeneous	   morphology,	  
displaying	   many	   neural-­‐like	   phenotypes,	   including	   neural	   rosettes	   (bordered	   area)	   and	  
neuronal	   processes	   (arrows).	   Scale	   Bars:	   100	   μm	   low	   magnification,	   50	   μm	   high	  
magnification.	  	  	  
	  
Upon	   immunocytochemical	   staining	   with	   cytokeratin-­‐8,	   a	   general	   marker	   of	   the	  
cytoskeleton,	  this	  apparent	  similarity	  between	  all	  three	  compounds	  was	  reinforced.	  	  
Unlike	  some	  synthetic	  compounds,	  such	  as	  EC19,	  both	  synthetic	  analogues	  AH60	  and	  
AH61	   do	   not	   appear	   to	   induce	   the	   formation	   of	   a	   large	   flat	   cell	   type,	   which	  
subsequently	  form	  large	  ‘plaque’	   like	  areas.228	  Instead,	  they	  appeared	  to	  mimic	  the	  
natural	  biological	  profile	  of	  ATRA	  generating	  a	  highly	  heterogeneous	  cell	  population	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Figure	   3.8	   Cytokeratin-­‐8	   expression	   in	   cultures	   of	   TERA2.cl.SP12	   cells	   cultured	   for	   twenty	  
one	   days	   with	   either	   ATRA	   (A),	   AH60	   (B)	   or	   AH61	   (C).	   All	   cultures	   display	   a	   highly	  
heterogeneous	  cell	  population,	  with	  little	  formation	  of	  ‘plaques’	  consisting	  of	  large	  flat	  cells	  
(bordered	  area).	  Scale	  bars:	  50	  μm.	  
 
3.3.3	  Differential	  Regulation	  of	  Cell	  Surface	  Markers	  
	  
The	   ability	   of	   the	   synthetic	   compounds	   to	   induce	   cellular	   differentiation	   in	   the	  
TERA2.cl.SP12	  cell	  line	  was	  further	  evaluated	  by	  analysing	  the	  expression	  profiles	  of	  
known	  markers	   for	   both	   stem	   cell	   and	   differentiated	   phenotypes.	   Flow	   cytometry	  
was	  performed	  on	  samples	  of	  cells	   treated	  with	  10	  µM	  of	  each	  retinoid,	  alongside	  
untreated	  controls	  and	  those	  treated	  with	  DMSO.	  Cell	  profiles	  were	  analysed	  after	  3	  
and	   7	   days.	   Day	   0	   data	   represents	   confluent	   untreated,	   and	   therefore,	  
undifferentiated	  TERA2.cl.SP12	  cell	  cultures.	  The	  expression	   levels	  of	   two	  stem	  cell	  
antigens,	  SSEA-­‐3	  and	  TRA-­‐1-­‐60	  (keratin-­‐sulfate-­‐associated	  glycoprotein	  stem	  surface	  
marker)	   were	   investigated	   to	   assess	   loss	   of	   pluripotency	   (Figure	   3.9	   (A)	   and	   (B)	  
respectively).292,	  293	  	  
	  
In	  undifferentiated	  cell	  cultures,	  both	  SSEA-­‐3	  and	  TRA-­‐1-­‐60	  remain	  high	  as	  the	  cells	  
retain	  their	  stem	  cell	  phenotype.	  A	  decrease	  in	  the	  expression	  level	  of	  both	  indicates	  
that	  the	  cells	  are	  committing	  to	  differentiation.	  Consistent	  with	  known	  literature	  and	  
as	  discussed	  earlier,	  both	  markers	  decreased	  in	  response	  to	  treatment	  with	  ATRA.	  In	  
line	   with	   previous	   data	   discussed	   within	   this	   Chapter,	   similar	   expression	   profiles	  
were	   visualised	   for	   AH60	   and	   AH61,	   as	   was	   seen	   for	   ATRA.	   The	   only	   notable	  
difference	  was	  the	  significantly	  greater	  drop-­‐off	  in	  the	  expression	  of	  TRA-­‐1-­‐60	  upon	  
treatment	  with	  AH61.	  In	  cell	  cultures	  treated	  with	  the	  ‘short’	  analogues	  AH36,	  AH62	  
and	  AH66	  and	   ‘extended’	  analogue	  AH98,	  expression	  levels	  of	  SSEA-­‐3	  and	  TRA-­‐1-­‐60	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remained	   relatively	  high.	   	   These	  profiles	  match	   those	   seen	   for	  both	   the	  untreated	  
controls	  and	  DMSO,	  supporting	  the	  phenotypes	  visualised	  under	  phase	  microscopy	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(A)	   	   	   	   SSEA-­‐3	  
	  
	  
(B)	   	   	   	   TRA-­‐1-­‐60	  
	  
	  
Figure	   3.9	  Flow	  cytometric	  analysis	  of	  markers	  of	   stem	  cells,	   SSEA-­‐3	   (A)	  and	  TRA-­‐1-­‐60	   (B).	  
TERA2.cl.SP12	  cells	  were	  incubated	  with	  10	  µM	  concentrations	  of	  each	  retinoid	  for	  7	  days.	  
Analysis	   was	   carried	   out	   at	   day	   3	   and	   day	   7.	   Undifferentiated	   controls	   retained	   an	  
unchanged	  profile	  over	   the	  7	  days.	   There	  was	   little	   variation	   seen	   for	   cultures	  exposed	   to	  
DMSO,	   the	   ‘short’	   analogues	   AH36,	   AH62	   and	   AH66	   and	   the	   ‘extended’	   analogue,	   AH98.	  
Those	  treated	  with	  ATRA,	  AH60	  and	  AH61	  all	  showed	  a	  significant	  drops	  in	  the	  expression	  of	  
markers,	   particularly	   AH61.	   Results	   are	   presented	   with	   ±	   standard	   error	   (SEM),	   n=3.	   **	  
p≤0.005,	  *	  p≤0.05,	  Student’s	  t-­‐test	  corrected	  for	  multiple	  testing	  between	  compared	  sample	  
populations	  using	  the	  Bonferroni	  correction.	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As	  TERA2.cl.SP12	  cells	  are	  well	  known	  for	  their	  ability	  to	  form	  neurons	  in	  response	  to	  
treatment	  with	   retinoids,	  most	   notably,	   in	   response	   to	   ATRA,	   flow	   cytometry	  was	  
accordingly	   used	   to	   assess	   the	   expression	   of	   A2B5	   (ganglioseries	   antigen	  marking	  
early-­‐stage	  neural	  cells),	  as	  a	  measure	  of	  differentiation	  towards	  a	  neural	  lineage.206	  
Consistent	   with	   previous	   data	   discussed,	   ATRA,	   AH60	   and	   AH61	   induced	   the	  
expression	   of	   A2B5	   in	   a	   comparatively	   similar	   manner.	   All	   the	   ‘short’	   synthetic	  
retinoids	   tested,	   AH36,	   AH62	   and	   AH66,	   showed	   no	   increase	   in	   expression	   levels,	  
consistent	  with	  them	  having	  an	  inability	  to	  induce	  neurogenesis.	  There	  was	  a	  slight	  
increase	   in	   A2B5	   expression	   seen	   for	   those	   cultures	   exposed	   to	   the	   ‘extended’	  
analogue,	   AH98,	   although	   this	   was	   not	   comparable	   to	   that	   seen	   for	   ATRA,	   and	  
indeed	   AH60	   or	   AH61.	   As	   expected	   both	   the	   untreated	   control	   and	   those	   treated	  




Figure	   3.10	   Flow	   cytometric	   analysis	   of	   a	   marker	   for	   early	   stage	   neural	   cells,	   A2B5.	  
TERA2.cl.SP12	  cells	  were	  incubated	  with	  10	  µM	  concentrations	  of	  each	  retinoid	  for	  7	  days.	  
Analysis	  was	  carried	  out	  at	  day	  3	  and	  day	  7.	  Undifferentiated	  controls	  and	  DMSO	  exposed	  
cultures	   retained	  an	  unchanged	  profile	  over	   the	  7	  days	  as	  do	   those	  exposed	  to	   the	   ‘short’	  
analogues	  AH36,	  AH62	  and	  AH66.	  The	  ‘extended’	  analogue,	  AH98,	  did	  display	  an	  increase	  in	  
expression,	  although	  this	   is	  approximately	  50%	  of	  that	  seen	  for	  the	  positive	  control,	  ATRA.	  
Those	   treated	  with	   AH60	   and	   AH61	   all	   showed	   a	   significant	   increase	   in	   expression	   of	   the	  
marker,	  mimicking	   the	  profile	  seem	  for	  ATRA.	  Results	  are	  presented	  with	  ±	  standard	  error	  
(SEM),	   n=3.	   ***	   p≤0.0005,	   **	   p≤0.005,	   Student’s	   t-­‐test	   corrected	   for	   multiple	   testing	  
between	  compared	  sample	  populations	  using	  the	  Bonferroni	  correction.	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To	  summarise,	  both	  AH60	  and	  AH61	  appeared	  to	  mimic	  the	  biological	  profile	  of	  that	  
seen	   for	   ATRA.	   The	   ‘short’	   analogues	   AH36,	   AH62	   and	   AH66	   all	   demonstrated	   a	  
complete	   lack	   of	   ability	   to	   induce	   any	   form	  of	   biological	   response.	   The	   ‘extended’	  
analogue,	  AH98,	   did	   show	   some	  potential,	   but	   this	  was	   significantly	   less	   than	   that	  
exhibited	  by	  ATRA	   and	  both	  AH60	   and	  AH61.	   The	   ‘extended’	   analogue,	  AH98,	   has	  
also	   been	   tested	   as	   a	  mixture	   of	   two	   isomers,	   and	   has	   been	   demonstrated	   to	   be	  
unstable	   under	   standard	   laboratory	   conditions.	   Consequently,	   there	  was	   to	   be	   no	  
further	  examination	  into	  the	  biological	  potential	  of	  these	  molecules,	  and	  all	  further	  
work	   was	   focused	   around	   characterising	   the	   biological	   profile	   of	   both	   AH60	   and	  
AH61.	  	  	  
	  
Expanding	   on	   the	   previous	   flow	   cytometry	   study,	   ATRA,	   AH60	   and	   AH61	   cultures	  
were	   maintained	   for	   up	   to	   14	   days.	   All	   three	   markers	   screened	   previously	   were	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(B)	   	   TRA-­‐1-­‐60	  
	  
	  
(C)	   	   	  	  	  	  	  A2B5	  
	  
 
Figure	  3.11	  Flow	  cytometric	  analysis	  of	  markers	  of	  stem	  cells	  SSEA-­‐3	  (A)	  and	  TRA-­‐1-­‐60	  (B),	  
and	  a	  marker	  of	  early	  stage	  neural	  cells,	  A2B5	  (C).	  TERA2.cl.SP12	  cells	  were	  incubated	  with	  
10	  µM	  concentrations	  of	  each	  retinoid	  for	  14	  days,	  with	  analysis	  carried	  out	  at	  days	  3,	  7	  and	  
14.	  All	  retinoid	  treatments	  led	  to	  a	  decrease	  in	  both	  stem	  cell	  markers,	  and	  concurrently	  an	  
increase	   in	   A2B5	   expression.	   Results	   are	   presented	  with	   ±	   standard	   error	   (SEM),	   n=3.	   Per	  
statistical	   analysis	   using	   the	   Student’s	   t-­‐test	   corrected	   for	   multiple	   testing	   between	  
compared	   sample	   populations	   using	   the	   Bonferroni	   correction,	   there	   were	   no	   significant	  
differences	  between	  any	  of	  the	  treatments.	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The	   longer	   exposure	   time	   for	   all	   three	   retinoid	   treatments	   demonstrated	   that	   all	  
three	  compounds	  completely	  eliminated	   the	  expression	  of	  both	  stem	  cell	  markers,	  
while	  promoting	  the	  expression	  of	  A2B5	  to	  greater	  than	  95%.	  Overall,	  there	  was	  no	  
significant	  difference	   in	   the	  expression	  profiles	  of	  SSEA-­‐3,	  TRA-­‐1-­‐60	  or	  A2B5,	  when	  
exposed	  to	  all	  three	  compounds.	  
	  
3.3.4	  Analysis	  of	  Associated	  Gene	  Profiles	  
	  
Further	   assessment	   of	   cellular	   differentiation	   in	   response	   to	   treatment	   with	   the	  
synthetic	   retinoids	  was	  evaluated	   through	   the	  expression	  profiles	  of	   known	  genes.	  
To	  allow	  for	  a	  direct	  comparison,	  samples	  of	  the	  cells	  analysed	  for	  flow	  cytometry	  at	  
3,	  7	  and	  14	  days	  were	  simultaneously	  analysed	  through	  real-­‐time	  polymerase	  chain	  
reaction	   (RT-­‐PCR).	   Therefore,	   the	   analysis	   was	   undertaken	   on	   TERA2.cl.SP12	   cells	  
treated	  with	  retinoids	  at	  a	  concentration	  of	  10	  µM.	  Three	  known	  genes	  of	   interest	  
were	   chosen	   to	   be	   examined,	   Nanog,	   Oct-­‐4	   and	   Pax6.	   The	   first	   two	   are	   essential	  
regulators	   of	   early	   development	   and	   connected	   to	   the	   self-­‐renewal	   of	  
undifferentiated	   stem	   cells,	   in	   addition	   to	   being	   rapidly	   silenced	   during	   cellular	  
differentiation.294-­‐297	   The	   third,	   the	   paired-­‐domain,	   homeodomain-­‐containing	  
transcription	   factor	  Pax6, was	  chosen	   to	  assess	   the	  neurogenesis	  properties	  of	   the	  
retinoids,	   as	   it	   is	   essential	   for	   the	   development	   of	   much	   of	   the	   central	   nervous	  
system.298-­‐301	   The	   expression	   profiles	   of	   each	   gene	   over	   the	   14	   days	   are	   shown	   in	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Figure	  3.12	  RT-­‐PCR	  analysis	  of	  two	  genes	  associated	  with	  pluripotency,	  Nanog	  (A)	  and	  Oct-­‐4	  
(B),	  and	  one	  associated	  with	  motor	  and	  ventral	  phenotypes,	  Pax6	  (C).	  ATRA,	  AH60	  and	  AH61	  
all	  supressed	  Nanog	  and	  Oct-­‐4	  to	  a	  similar	  extent,	  whereby	  after	  day	  7	  there	  was	  no	  longer	  
any	  expression.	  In	  addition,	  both	  AH60	  and	  AH61	  led	  to	  an	  expression	  profile	  of	  Pax6	  similar	  
to	  that	  of	  ATRA.	  All	  gene	  levels	  are	  expressed	  as	  a	  relative	  quantity,	  which	  is	  the	  difference	  
in	   gene	   expression	   between,	   undifferentiated	   TERA2.cl.SP12	   cells	   and	   those	   exposed	   to	   a	  
retinoid	  treatment.	  Results	  are	  presented	  with	  ±	  standard	  deviation	  (SD),	  n=3.	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The	   expression	   of	   Nanog	   and	  Oct-­‐4	  was	   suppressed	   in	   cultures	   treated	  with	   both	  
ATRA	  and	  synthetic	  analogues,	  AH60	  and	  AH61,	  all	  in	  a	  similar	  manner.	  Consistently,	  
Pax6	  expression	  increased	  up	  to	  just	  after	  day	  7,	  after	  which	  it	  decreased	  slightly	  to	  
day	   14.	   Again,	   all	   three	   retinoids,	   both	   natural	   and	   synthetic,	   showed	   a	   similar	  
profile,	  thus	  further	  indicating	  that	  both	  AH60	  and	  AH61	  play	  a	  key	  role	  in	  inducing	  
differentiation	  of	  TERA2.cl.SP12	  cells.	  
	  
Previous	  work	  carried	  out	  within	  the	  Przyborski	  research	  group	  (un-­‐published	  work	  
by	  Daniel	  Tams)	  on	  synthetic	  retinoid	  EC23	  had	  shown	  that	   it	  displayed	  a	  different	  
gene	  expression	  profile	  to	  that	  of	  ATRA.	  Analysis	  of	  early	  changes	  in	  gene	  expression	  
(days	  0-­‐7),	  demonstrated	  that	  EC23	  attenuated	  a	  change	  at	  a	  slower	  rate	  than	  that	  
of	   ATRA.	   More	   significantly,	   it	   had	   become	   apparent	   that	   EC23	   displayed	   a	  
significantly	   different	   Pax	   6	   expression	   profile	   to	   that	   of	   ATRA,	   highlighting	   a	  
difference	   in	   the	   molecules	   mode	   of	   action	   yet	   to	   be	   discussed	   in	   the	   literature.	  
Therefore,	   the	   profiles	   of	   ATRA,	   AH60,	   AH61	   and	   EC23	   were	   examined	  
simultaneously	   at	   days	   1,	   3,	   5	   and	   7	   (Figure	   3.13).	   It	   was	   hypothesised	   that	   the	  
increased	  molecular	  similarity	  of	  the	  AH	  series	  of	  compounds	  would	  lead	  to	  profiles	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Figure	  3.13	  RT-­‐PCR	  analysis	  of	  two	  genes	  associated	  with	  pluripotency,	  Nanog	  (A)	  and	  Oct-­‐4	  
(B),	   and	   one	   associated	   with	   motor	   and	   ventral	   phenotypes,	   Pax6	   (C).	   ATRA	   appears	   to	  
suppress	  both	  Nanog	  and	  Oct-­‐4	  at	  a	  slightly	  faster	  than	  the	  synthetic	  compounds.	  Both	  AH60	  
and	  AH61	  show	  little	  differences	  and	  mimic	  the	  profile	  exhibited	  by	  ATRA	  closely.	  EC23	  also	  
has	  a	  highly	  analogous	  profile,	  yet	  attenuates	  a	  response	  the	  slowest.	  Similarly,	  ATRA,	  AH60	  
and	   AH61	   all	   lead	   to	   insignificant	   differences	   in	   levels	   of	   Pax	   6	   expression	   after	   7	   days,	  
whereas	   EC23	   is	   significantly	   lower.	   All	   gene	   levels	   are	   expressed	   as	   a	   relative	   quantity,	  
which	   is	   the	   difference	   in	   gene	   expression	   between,	   undifferentiated	   TERA2.cl.SP12	   cells	  
and	  those	  exposed	  to	  a	  retinoid	  treatment.	  Results	  are	  presented	  with	  ±	  standard	  deviation	  
(SD),	  n=3.	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From	  the	  expression	  profiles,	  it	  is	  clear	  that	  the	  suppression	  of	  Nanog	  and	  Oct-­‐4	  due	  
to	  retinoid	  treatment	  appears	   to	  occur	  more	  rapidly	  when	  using	  ATRA.	  Although	   it	  
must	  be	  noted	  both	  AH60	  and	  AH61	  have	  profiles	  that	  are	  not	  significantly	  different.	  
As	  demonstrated	  previously	  within	  the	  research	  group,	  EC23	  is	  the	  slowest	  to	  have	  
an	   effect,	   but	   after	   5	   days	   has	   suppressed	   both	   genes	   to	   the	   same	   extent	   as	   the	  
other	   synthetic	   compounds.	   The	  most	   significant	  difference	   is	   in	   the	  expression	  of	  
Pax6.	  EC23	  does	  attenuate	  a	  relative	  increase	  in	  the	  expression	  of	  Pax6	  compared	  to	  
that	  of	  the	  control	  cultures,	  yet	  it	  is	  approximately	  50%	  less	  than	  those	  seen	  for	  the	  
other	   treatments.	   This	   is	   in	   contrast	   to	  both	   synthetic	  analogues,	  AH60	  and	  AH61,	  
which	   both	   display	   profiles	   not	   significantly	   different	   to	   that	   of	   ATRA	   after	   7	   days	  
treatment.	  
	  
As	  hypothesised,	  both	  AH60	  and	  AH61	  display	  profiles	  somewhere	  in	  between	  that	  
of	   ATRA	   and	   EC23.	   This	   is	   perhaps	   not	   entirely	   unexpected	   due	   to	   their	   similar	  
molecular	   structures,	   and	   could	   give	   an	   early	   indication	   into	   the	   affinity	   of	   each	  
compound	   for	   the	   retinoid	   receptors.	   It	   should	  be	  emphasised	   though,	   that	   this	   is	  
speculation	   and	   that	   to	   support	   this	   hypothesis,	   molecular	   binding	   studies	   would	  
need	  to	  be	  carried	  out.	  	  	  
	  
3.3.5	  Induction	  of	  Neurogenesis:	  Visualisation	  of	  Neural	  Proteins	  
	  
Confirmation	   that	   TERA2.cl.SP12	   cells	   differentiate	   into	   a	   neuronal	   population	   in	  
response	   to	   AH60	   and	   AH61	   was	   demonstrated	   by	   immunocytochemical	   staining.	  
The	  expression	  of	  neuronal	  specific	  proteins	  was	  investigated	  using	  antibodies	  raised	  
against	   the	   neuronal	   specific	   β-­‐III-­‐tubulin	   marker,	   TuJ1.	   In	   undifferentiated	  
TERA2.cl.SP12	  cells,	  low	  levels	  of	  expression	  are	  visualised,	  but	  upon	  treatment	  with	  
ATRA	   there	   is	   a	   significant	   up-­‐regulation.	   In	   conjunction	   with	   TuJ1	   staining,	   the	  
expression	   of	   the	   200	   kDa	   neurofilament	   protein	   (NF-­‐200)	   was	   simultaneously	  
examined.	  NF-­‐200	   is	   a	   cytoskeletal	  marker	   for	  mature	  neurons	   and	  often	  used	   for	  
evaluating	   neurogenesis.	   Undifferentiated	   TERA2.cl.SP12	   cells	   do	   not	   express	   NF-­‐
200,	  but	  NF-­‐200	  positive	  neurons	  have	  been	  identified	  in	  cultures	  treated	  with	  ATRA.	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Cultures	  of	  TERA2.cl.SP12	  cells	  were	  treated	  with	  both	  AH60	  and	  AH61	  at	  10	  µM	  for	  
21	   days,	   alongside	   positive	   control	   cultures	   exposed	   to	   ATRA	   at	   10	   µM.	   Both	  
synthetic	   analogues,	   AH60	   and	   AH61,	   display	   a	   significant	   up-­‐regulation	   of	   both	  
markers	  consistent	  with	  that	  of	  ATRA	  (Figure	  3.14).	  To	  quantify	  the	  data,	  the	  number	  
of	  positive	  cell	  bodies	   (perykarya)	  per	   field	  of	  view	  for	  each	  culture	  treatment	  was	  
counted,	  with	   the	  aid	  of	   ImageJ	   software.	  The	  data	   is	  displayed	  as	   the	  mean	   from	  
three	   randomly	   selected	   immunostained	   images,	   for	  both	  TuJ1	  and	  NF-­‐200	   (Figure	  
3.15).	  There	  is	  no	  significant	  difference	  seen	  in	  the	  expression	  of	  TuJ1	  over	  the	  three	  
retinoid	  treatments,	  with	  all	  three	  expressing	  the	  marker	  highly.	  Upon	  analysing	  NF-­‐
200	   expression,	   cultures	   treated	  with	   AH61	   have	   a	   significantly	   higher	   number	   of	  
positive	   perykarya,	   compared	   to	   both	   ATRA	   and	   AH60.	   There	   appears	   to	   be	   no	  
difference	  in	  the	  expression	  of	  NF-­‐200	  between	  both	  ATRA	  and	  AH60,	  inferring	  they	  
are	   equally	   as	   active.	   Thus,	   at	   equal	   concentrations	   under	   the	   conditions	   tested	  
AH61	   appears	   to	   be	   a	  more	   potent	   inducer	   of	   neuronal	   differentiation	   than	  ATRA	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Figure	  3.14	  Conformation	  of	  neural	  differentiation	   in	  TERA2.cl.SP12	  cell	  cultures	   incubated	  
with	   10	  µM	   ATRA	   (A	   and	   B),	   AH60	   (C	   and	  D)	   or	   AH61	   (E	   and	   F).	   All	   retinoid	   treatments	  
resulted	   in	   high	   expression	   of	   both	   TuJ1	   and	   NF-­‐200	   markers.	   Control	   cultures	   (vehicle	  
controls	  treated	  only	  with	  DMSO	  and	  no	  retinoid)	  displayed	  no	  expression	  of	  either	  marker.	  
Scale	  bars:	  50	  μm.	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Figure	   3.15	  Plot	   displaying	   the	  quantification	  of	   the	   immunological	   data,	   as	   performed	  by	  
counting	  labelled	  positive	  cell	  bodies.	  Cultures	  of	  TERA2.cl.SP12	  EC	  stem	  cells	  incubated	  with	  
10	   µM	   ATRA,	   AH60	   or	   AH61	   for	   21	   days,	   subsequently	   fixed	   and	   immunocytochemically	  
stained	  for	  TuJ1	  and	  NF-­‐200.	  Using	  ImageJ	  software	  the	  number	  of	  positive	  cell	  bodies	  were	  
counted	  on	  3	  random	  fields	  per	  treatment	  condition.	  AH61	  induced	  a	  significant	  increase	  in	  
expression	  of	  NF-­‐200	  over	  both	  ATRA	  and	  AH60	  treatments.	  Values	  shown	  represent	  mean	  +	  
standard	   error	   (SEM),	   n=3.	   **p≤0.005,	   *p≤0.05,	   Student’s	   t-­‐test	   corrected	   for	   multiple	  
testing	  between	  compared	  sample	  populations	  using	  the	  Bonferroni	  correction.	  	  	  
	  
This	   data	   collectively	   demonstrated	   that	   both	   ATRA	   and	   the	   synthetic	   retinoids	  
behave	  in	  a	  similar	  manner,	  and	  induced	  the	  differentiation	  of	  pluripotent	  stem	  cells	  
to	   form	  mature	  neural	  derivatives.	   In	  addition,	   the	  AH	  series	  appeared	  to	   induce	  a	  
biological	   response	   closer	   to	   that	   seen	   for	   the	   natural	   ligand,	   ATRA,	   compared	   to	  
that	   induced	   by	   EC23.	   In	   conjunction	   with	   their	   improved	   chemical	   stability,	   the	  
current	   data	   indicated	   that	   the	   synthetic	   compounds	   are	   a	   credible	   alternative	   to	  
ATRA	  as	  a	  biological	  tool	  for	  inducing	  neurogenesis	  in	  a	  pluripotent	  stem	  cell	  model	  
system.	   Furthermore,	   some	  of	   the	   early	   data,	   including	   the	   reduced	   expression	   of	  
the	  pluripotent	   cell	   surface	  marker	  TRA-­‐1-­‐60,	   and	   increased	  expression	  of	   the	   late	  
neuronal	  marker,	   NF-­‐200,	   point	   to	   an	   increased	   activity	   for	   the	   synthetic	   retinoid	  
AH61.	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3.3.6	  Dose	  Response	  of	  the	  Synthetic	  Retinoids	  
	  
To	   further	   probe	   the	   effectiveness	   of	   the	   synthetic	   compounds,	   a	   concentration	  
study	  was	  undertaken	   to	   investigate	   their	  dose	   response.	   It	  was	  hypothesised	   that	  
due	  to	  the	  modifications	  of	  the	  core,	  which	  block	  known	  metabolic	  oxidation	  sites,	  
discussed	   in	   Chapter	   II,	   the	   compounds	   would	   be	   more	   effective	   at	   lower	  
concentrations	  than	  that	  of	  ATRA.	  Previous	  research	  had	  demonstrated	  that	  ATRA	  is	  
as	  effective	  at	  1	  µM	  as	  it	  is	  at	  10	  µM.	  Therefore,	  to	  investigate	  the	  dose	  response,	  a	  
concentration	   range	   from	   1	   µM	   decreasing	   by	   a	   factor	   of	   10	   to	   0.001	   µM	   was	  
chosen.	  	  
	  
3.3.6.1	  Flow	  Cytometry	  Analysis	  
	  
As	  an	   initial	  screen,	  TERA2.cl.SP12	  cells	  were	  cultured	  for	  7	  days	  with	  ATRA,	  AH60,	  
AH61	  and	  EC23	  at	  1	  µM,	  0.1	  µM,	  0.01	  µM	  and	  0.001	  µM	  concentrations.	  Analysis	  of	  
the	   cell	   population	   was	   undertaken	   at	   days	   3	   and	   7,	   where	   day	   0	   represents	  
untreated,	  and	  therefore,	  undifferentiated,	  TERA2.cl.SP12	  EC	  cells.	  As	  in	  all	  previous	  
studies,	  the	  same	  three	  markers	  were	  investigated,	  SSEA-­‐3,	  TRA-­‐1-­‐60	  and	  A2B5.	  The	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Figure	  3.16	  Flow	  cytometric	  analysis	  of	  markers	  of	  stem	  cells	  SSEA-­‐3	  (A)	  and	  TRA-­‐1-­‐60	  (B),	  
and	  a	  marker	  of	  early	  stage	  neural	  cells,	  A2B5	  (C).	  TERA2.cl.SP12	  cells	  were	  incubated	  with	  
each	  retinoid	  for	  7	  days	  at	  either	  1	  µM,	  0.1	  µM,	  0.01	  µM	  or	  0.001	  µM,	  with	  analysis	  carried	  
out	   at	   days	  3	   and	  7.	  All	   retinoid	   treatments	   at	   1	  µM	   lead	   to	   a	  decrease	   in	  both	   stem	  cell	  
markers,	  and	  concurrently	  an	  increase	  in	  A2B5	  expression.	  Upon	  reducing	  the	  concentration	  
to	   0.1	   µM	   the	   potency	   of	   ATRA	   is	   markedly	   reduced,	   while	   retained	   for	   both	   AH60	   and	  
AH61.	  At	  0.01	  µM	  only	  AH61	  retains	  its	  ability	  to	  induce	  differentiation,	  while	  at	  0.001	  µM	  
all	  the	  compounds	  are	  inactive.	  Results	  are	  presented	  with	  ±	  standard	  error	  (SEM),	  n=3.	  **	  
p≤0.005,	   Student’s	   t-­‐test	   corrected	   for	   multiple	   testing	   between	   compared	   sample	  
populations	  using	  the	  Bonferroni	  correction.	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A	   clear	   dose	   response	   curve	   was	   visualised	   for	   ATRA	   as	   the	   concentration	   was	  
reduced	  by	  a	  factor	  of	  ten	  from	  1	  µM	  to	  0.001	  µM.	  	  At	  1	  µM,	  the	  expression	  levels	  of	  
all	   three	   markers	   were	   at	   similar	   levels	   to	   those	   seen	   when	   using	   10	   µM	   (data	  
presented	   previously),	   indicating	   the	   TERA2.cl.SP12	   cells	   are	   differentiating.	  
Reducing	   the	   concentration	   to	   0.1	   µM	   significantly	   increases/reduces	   expression	  
levels	  of	  all	  three	  markers	  accordingly,	  indicating	  that	  only	  a	  small	  percentage	  of	  the	  
cellular	   population	   were	   differentiating.	   Upon	   reducing	   the	   concentration	   to	   0.01	  
µM	   and	   0.001	   µM,	   expression	   levels	   of	   all	   three	   markers	   was	   identical	   to	   the	  
undifferentiated	  control	  cultures	  (representative	  of	  day	  0).	  Therefore,	  for	  ATRA	  to	  be	  
an	   effective	   tool	   for	   cellular	   differentiation,	   a	   concentration	   of	   1	  µM	   or	   higher	   is	  
required.	  As	  clearly	  demonstrated,	  any	  further	  reduction	  leads	  to	  a	  severe	  decline	  in	  
activity.	  	  
	  
The	  profile	  seen	  for	  AH60	  is	  similar	   in	   its	  overall	  trend,	  with	  the	  exception	  that	  the	  
TERA2.cl.SP12	   cells	   appeared	   to	   differentiate	   when	   exposed	   to	   0.1	   µM	   AH60.	  
Suggesting	   that	   this	   analogue	   is	   approximately	   10	   fold	   more	   potent.	   More	  
interesting,	   however,	   is	   the	   expression	   profile	   exhibited	   by	   AH61.	   This	   synthetic	  
analogue	  retained	  its	  biological	  potency	  in	  this	  system	  even	  when	  the	  concentration	  
was	  reduced	  to	  0.01	  µM,	  overall	  making	  it	  approximately	  100	  fold	  more	  active	  than	  
natural	  ATRA.	  	  
	  
When	  comparing	  the	  activity	  of	  AH61	  to	  EC23,	  which	  was	  screened	  previously	  for	  a	  
dose	  response,	  a	  clear	  similarity	  was	  observed.	  Both	  compounds	  displayed	  a	  nearly	  
identical	  profile	  for	  all	  three	  markers,	  with	  no	  significant	  differences	  visualised.	  This	  
data	   is	   consistent	   with	   both	   being	   100	   fold	   more	   active	   than	   their	   natural	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Figure	  3.17	  Flow	  cytometric	  analysis	  of	  markers	  of	  stem	  cells	  SSEA-­‐3	  (A)	  and	  TRA-­‐1-­‐60	  (B),	  
and	  a	  marker	  of	  early	  stage	  neural	  cells,	  A2B5	  (C).	  TERA2.cl.SP12	  cells	  were	  incubated	  with	  
either	  AH61	  or	  EC23	  for	  7	  days	  at	  either	  1	  µM,	  0.1	  µM,	  0.01	  µM	  or	  0.001	  µM,	  with	  analysis	  
carried	  out	  at	  days	  3	  and	  7.	  Both,	  AH61	  and	  EC23,	  supress	  SSEA-­‐3	  and	  TRA-­‐1-­‐60	  expression	  
to	  a	  similar	  extent	  over	  the	  concentration	  range.	  Similarly,	  they	  promote	  the	  expression	  of	  
A2B5	   in	   an	   identical	  manner.	   Overall,	   both	   compounds	   display	   activity	   down	   to	   0.01	  µM.	  
Results	   are	   presented	   with	   ±	   standard	   error	   (SEM),	   n=3.	   Per	   statistical	   analysis	   using	   the	  
Student’s	  t-­‐test	  corrected	  for	  multiple	  testing	  between	  compared	  sample	  populations	  using	  
the	   Bonferroni	   correction,	   there	   were	   no	   significant	   differences	   between	   any	   of	   the	  
treatments.	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3.3.6.2	  RT-­‐PCR	  Analysis	  
	  
As	   in	   the	  previous	  studies,	  a	  sample	  of	   the	  cell	  population	   for	  each	   treatment	  was	  
removed	   and	   lysed	  before	   the	   remaining	   sample	  was	   analysed	  via	   flow	   cytometry	  
(see	  section	  3.3.4).	  RT-­‐PCR	  was	  then	  employed	  to	  analyse	  the	  expression	  profiles	  of	  
three	  genes	  of	   interest.	  Therefore,	  cell	  populations	  after	  treatment	  for	  7	  days	  over	  
the	   concentration	   ranges	   1	   –	   0.001	   µM	   for	   ATRA,	   AH60,	   AH61	   and	   EC23	   were	  
analysed.	   Again,	   the	   three	   genes	   of	   interest	   were,	   Nanog,	   Oct-­‐4	   and	   Pax6,	   as	  
collectively	   these	   exhibit	   changes	   in	   the	   genotype	   associate	   with	   neural	  
differentiation.	  
	  
The	  first	  gene	  of	   interest	  to	  be	  analysed	  was	  Nanog.	  As	  the	  concentration	  of	  ATRA	  
was	  reduced,	  the	  expression	  levels	  of	  Nanog	  increased,	  indicating	  a	  more	  pluripotent	  
state.	  The	  expression	  profile	  was	  similar	  to	  that	  generated	  from	  the	  flow	  cytometry	  
data,	   displaying	   a	   consistency	   across	   the	   two	   techniques	   (Figure	   3.18	   (A)).	   When	  
exposed	   to	   AH60,	   both	   1	   µM	   and	   0.1	   µM	   concentrations	   completely	   suppressed	  
Nanog	   expression,	   demonstrating	   that	   this	   molecule	   maybe	   more	   potent	   than	  
previously	   thought.	   However,	   at	   0.01	   µM,	   Nanog	   expression	   was	   significantly	  
reduced	  (Figure	  3.18	  (B)).	  Both	  AH61	  and	  EC23	  displayed	  highly	  analogous	  profiles.	  
Both,	   completely	   suppressed	   any	   expression	   of	   Nanog	   after	   7	   days	   at	   a	  
concentration	   of	   0.01	   µM	   or	   higher.	   As	   discussed	   previously	   within	   this	   Chapter,	  
AH61	   appeared	   to	   be	   able	   to	   bring	   about	   a	   change	   a	   gene	   expression	   faster	   than	  
EC23,	  as	  seen	  by	  the	  expression	  levels	  at	  day	  3.	  The	  reason	  for	  this	  is	  still	  unknown,	  
although	   one	   hypothesis	   could	   be	   AH61’s	   closer	  molecular	   resemblance	   to	   ATRA,	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(A)	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(C)	   	   	  	  	  	  	  	  	  	  	  AH61	   	   	   (D)	   	   	  	  	  	  	  	  EC23	  
	  
	  
Figure	   3.18	   RT-­‐PCR	   analysis	   of	   a	   gene	   associated	   with	   pluripotency,	   Nanog.	   Analysis	   was	  
undertaken	  at	  days	  3	  and	  7,	  after	  treatment	  with	  ATRA	  (A),	  AH60	  (B),	  AH61	  (C)	  and	  EC23	  (D)	  
at	  1	  µM,	  0.1	  µM,	  0.01	  µM	  or	  0.001	  µM.	  As	  the	  concentration	  of	  ATRA	  is	  reduced,	  expression	  
of	  Nanog	   increased	  accordingly.	  A	  similar	  profile	  was	  seen	  with	  AH60,	  except	  for	  a	  greater	  
decrease	   in	   expression	   seen	   at	   0.01	   µM.	   Both	   AH61	   and	   EC23	   displayed	   near	   identical	  
profiles	  with	  complete	  suppression	  seen	  at	  0.01	  µM	  or	  higher	  concentrations,	  with	  the	  only	  
difference	  being	  a	  slightly	  faster	  response	  when	  using	  AH61.	  All	  gene	  levels	  are	  expressed	  as	  
a	   relative	   quantity,	   which	   is	   the	   difference	   in	   gene	   expression	   between,	   undifferentiated	  
TERA2.cl.SP12	  cells	  and	  those	  exposed	  to	  a	  retinoid	  treatment.	  Results	  are	  presented	  with	  ±	  
standard	  deviation	  (SD),	  n=3.	  
	  
The	  second	  gene	  of	  interest	  was	  Oct-­‐4.	  Being	  a	  gene	  associated	  with	  pluripotency	  in	  
stem	  cells,	  the	  expression	  profiles	  were	  hypothesised	  to	  be	  similar	  to	  those	  seen	  for	  
Nanog.	  Again,	  all	  the	  compounds	  reduced	  the	  expression	  of	  the	  Oct-­‐4	  gene	  at	  1	  µM,	  
with	   ATRA	   displaying	   a	   gradual	   increase	   in	   expression	   as	   the	   concentration	   was	  
dropped.	  The	   synthetic	   compounds	  all	   displayed	  profiles	  and	   characteristics	  nearly	  






















ATRA 1 uM 
ATRA 0.1 uM 
ATRA 0.01 uM 






































































	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Chapter	  III	  
	   113	  
	  	  (A)	   	   	  	  	  	  	  	  	  	  ATRA	   	   	   (B)	   	   	  	  	  	  	  	  AH60	  
	  
	  
	  	  	  (C)	   	   	  	  	  	  	  	  	  	  	  AH61	   	   	   (D)	   	   	  	  	  	  	  	  EC23	  
	  
	  
Figure	   3.19	   RT-­‐PCR	   analysis	   of	   a	   gene	   associated	   with	   pluripotency,	   Oct-­‐4.	   Analysis	   was	  
undertaken	  at	  days	  3	  and	  7,	  after	  treatment	  with	  ATRA	  (A),	  AH60	  (B),	  AH61	  (C)	  and	  EC23	  (D)	  
at	   1	   µM,	   0.1	   µM,	   0.01	   µM	   or	   0.001	   µM.	   As	   the	   concentration	   of	   ATRA	   was	   reduced,	  
expression	  of	  Oct-­‐4	  increased	  accordingly.	  A	  similar	  profile	  was	  seen	  with	  AH60,	  except	  for	  a	  
greater	   decrease	   in	   expression	   seen	   at	   0.01	   µM.	   Both	   AH61	   and	   EC23	   displayed	   near	  
identical	  profiles	  with	  complete	  suppression	  seen	  at	  0.01	  µM	  or	  higher	  concentrations.	  The	  
only	  difference	   is	   that	  AH61	  attenuates	   a	   response	   slightly	   faster,	   as	   seen	  when	  analysing	  
day	   3	   expression	   levels.	   All	   gene	   levels	   are	   expressed	   as	   a	   relative	   quantity,	   which	   is	   the	  
difference	   in	   gene	   expression	   between,	   undifferentiated	   TERA2.cl.SP12	   cells	   and	   those	  
exposed	  to	  a	  retinoid	  treatment.	  Results	  are	  presented	  with	  ±	  standard	  deviation	  (SD),	  n=3.	  
	  
One	  point	  to	  note	  was	  the	  sudden	  drop-­‐off	  in	  activity	  seen	  for	  both	  AH61	  and	  EC23.	  
ATRA,	  and	  to	  some	  extent	  AH60,	  showed	  gradually	  increasing	  levels	  of	  expression	  as	  
their	  active	  concentration	  was	   reduced.	  Conversely,	   cultures	  exposed	   to	  AH61	  and	  
EC23	  either	  showed	  complete	  suppression	  of	  both	  Nanog	  and	  Oct-­‐4,	  when	  treated	  at	  
concentrations	   higher	   than	   0.01	   µM,	   or	   relatively	   no	   suppression,	   when	   the	  
concentration	   was	   reduced	   to	   0.001	   µM.	   This	   would	   suggest	   the	   active	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Finally,	  the	  induction	  of	  Pax6	  expression	  was	  investigated	  (Figure	  3.20).	  This	  initially	  
highlighted	   the	   inability	   of	   the	   parent	   compound	   ATRA	   to	   induce	   neural	  
differentiation	   as	   only	   at	   1	   µM	  was	   there	   any	   induction	   of	   Pax6	   expression.	   The	  
profile	   displayed	   by	   AH60	   correlated	   with	   that	   seen	   in	   the	   expression	   of	   the	   cell	  
surface	  marker	   A2B5,	   with	   increased	   expression	   seen	   at	   both	   1	  µM	   and	   0.1	  µM.	  
There	  was	   no	   induction	   of	   Pax6	   expression	  when	   AH60	  was	   administered	   at	   0.01	  
µM,	   displaying	   that	   reduction	   of	   Nanog	   and	   Oct-­‐4	   is	   not	   entirely	   associated	   with	  
neural	   differentiation.	   Previously,	   Pax6	   expression	   had	   highlighted	   the	   only	  
difference	  between	  the	  biological	  activity	  of	  AH61	  and	  EC23.	  Whilst	  AH61	  and	  ATRA	  
both	   displayed	   a	   gradual	   and	   sequential	   drop	   off	   in	   Pax6	   expression	   as	   the	  
concentration	  was	  lowered,	  levels	  of	  expression	  at	  0.01	  µM	  AH61	  were	  equivalent	  to	  
levels	   seen	   at	   1	  µM	  ATRA.	   This	   strongly	   suggests	   a	   greater	   potential	   for	   AH61	   to	  
induce	   Pax6	   expression	   over	   ATRA.	   EC23	   displayed	   a	   more	   convoluted	   profile,	   in	  
which	  the	  expression	  levels	  of	  Pax6	  peaked,	  when	  EC23	  was	  administered	  at	  0.1	  µM.	  
As	  the	  concentration	  was	  increased	  to	  1	  µM,	  levels	  Pax6	  expression	  reduced.	  It	  has	  
subsequently	  been	  demonstrated	  within	  the	  group	  (un-­‐published	  data	  produced	  by	  
Daniel	  Tams)	  that	  10	  µM	  levels	  of	  EC23	  further	  reduce	  the	  expression	  levels	  of	  Pax6,	  
consistent	  with	  levels	  seen	  in	  the	  preliminary	  RT-­‐PCR	  analysis	  discussed	  earlier	  in	  this	  
chapter.	  At	  0.01	  µM,	  EC23	  has	  a	   similar	  effect	  as	   that	  of	  0.01	  µM	  AH61	  and	  upon	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(A)	   	   	  	  	  	  	  	  	  	  	  ATRA	   	   	   (B)	   	   	  	  	  	  	  	  	  AH60	  
	  
	  
(C)	   	   	  	  	  	  	  	  	  	  	  AH61	   	   	   (D)	   	   	  	  	  	  	  	  	  EC23	  
	  
	  
Figure	  3.20	  RT-­‐PCR	  analysis	  of	  a	  gene	  associated	  with	  motor	  and	  ventral	  phenotypes,	  Pax6.	  
Analysis	  was	  undertaken	  at	  days	  3	  and	  7,	  after	  treatment	  with	  ATRA	  (A),	  AH60	  (B),	  AH61	  (C)	  
and	  EC23	   (D)	   at	  1	  µM,	  0.1	  µM,	  0.01	  µM	  or	  0.001	  µM.	  Treatment	  with	  ATRA	  only	   induced	  
expression	  of	   Pax6	  at	   1	  µM.	  AH60	   led	   to	   increased	  expression	  at	  both	  1	  µM	  and	  0.1	  µM,	  
while	  AH61	  also	  showed	  a	  slight	  increase	  when	  incubate	  at	  0.01	  µM.	  EC23	  overall	  displayed	  
a	  very	  different	  profile,	  with	  the	  highest	   levels	  of	  Pax6	  expression	  realised	  when	  incubated	  
at	   0.1	  µM,	   followed	  by	  1	  µM	  then	  0.01	  µM.	  No	   compounds	   showed	  any	   increase	   in	  Pax6	  
expression	   at	   0.001	  µM.	  All	   gene	   levels	   are	   expressed	   as	   a	   relative	   quantity,	  which	   is	   the	  
difference	   in	   gene	   expression	   between,	   undifferentiated	   TERA2.cl.SP12	   cells	   and	   those	  
exposed	  to	  a	  retinoid	  treatment.	  Results	  are	  presented	  with	  ±	  standard	  deviation	  (SD),	  n=3.	  
	  
The	  similarities	  in	  the	  expression	  profiles	  of	  both	  Nanog	  and	  Oct-­‐4	  in	  TERA2.cl.SP12	  
cells	   when	   treated	  with	   AH61	   and	   EC23	   are	   highlighted	  when	   plotted	   on	   a	   single	  
graph	   looking	   at	   expression	   only	   on	   day	   7	   (Figure	   3.21	   (A)	   and	   (B)	   respectively).	  
Concurrently,	  examining	  the	  data	  in	  this	  format	  also	  highlights	  the	  stark	  differences	  
in	  their	  Pax6	  expression	  profiles.	  The	  greatest	  of	  which	  is	  the	  sharp	  peak	  seen	  at	  0.1	  
µM	   for	   EC23.	   This	   data	   highlights	   the	   potential	   use	   for	   EC23	   at	   that	   specific	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  (A)	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Nanog	   	   	   	  
	  
	  
	  	  	  	  (B)	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Oct-­‐4	  
	  
	  
	  	  	  	  (C)	   	   	   	  	  	  	  	  Pax	  6	  
	  
	  
Figure	  3.21	  RT-­‐PCR	  analysis	  of	  two	  genes	  associated	  with	  pluripotency,	  Nanog	  (A)	  and	  Oct-­‐4	  
(B),	  and	  one	  associated	  with	  motor	  and	  ventral	  phenotypes,	  Pax	  6	  (C).	  Both	  AH61	  and	  EC23	  
displayed	  identical	  profiles	  for	  Nanog	  and	  Oct-­‐4	  expression.	  EC23	  was	  significantly	  better	  at	  
inducing	   Pax	   6	   expression	   at	   0.1	   µM	   than	   any	   other	   retinoid	   tested.	   All	   gene	   levels	   are	  
expressed	   as	   a	   relative	   quantity,	   which	   is	   the	   difference	   in	   gene	   expression	   between,	  
undifferentiated	  TERA2.cl.SP12	  cells	  and	  those	  exposed	  to	  a	  retinoid	  treatment.	  Results	  are	  
presented	  with	  ±	  standard	  deviation	  (SD),	  n=3.	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3.3.6.3	  Analysis	  of	  Cellular	  Morphologies	  	  
	  
The	   differences	   in	   the	   potency	   of	   AH60	   and	   AH61	   versus	   that	   of	   ATRA	   can	   be	  
visualised	  by	  phase	  microscopy	  after	   just	  7	  days.	  Cultures	  exposed	   to	  1	  µM	  for	  all	  
three	   treatments,	   show	   a	   heterogeneous	   cell	   population,	   indicative	   of	   cells	  
differentiating	   (Figure	  3.22	   (A),	   (D)	   and	   (G)	   respectively).	  This	   is	   consistent	  with	  all	  
the	  data	  presented	  for	  flow	  cytometry	  and	  RT-­‐PCR.	  Treatment	  at	  a	  concentration	  of	  
0.1	  µM	  and	  0.01	  µM	  for	  ATRA	  leads	  to	  an	  over	  confluent	  cell	  population	  (Figure	  3.22	  
(B)	  and	  (C)	  respectively).	  Thus	  suggesting	  the	  compound	  is	  less	  effective	  at	  inducing	  
differentiation	  as	  the	  general	  cell	  population	  continues	  to	  proliferate,	  supporting	  the	  
data	   discussed	   above.	   When	   AH60	   was	   applied	   to	   the	   cells	   at	   0.1	   µM,	   there	  
appeared	   to	   be	   areas	   of	   heterogeneous	   cells	   but	   also	   areas	   that	   were	   highly	  
confluent	   (Figure	  3.22	   (E).	  This	   suggests	   that,	  at	   this	   concentration	   the	  molecule	   is	  
partly	   effective	   having	   lost	   a	   degree	   of	   its	   activity.	  Once	   reduced	   to	   0.01	  µM,	   the	  
entire	   cell	   population	   appeared	   to	   continue	   to	   proliferate,	  with	   large	   areas	   of	   cell	  
growing	   layered	  on	   top	  of	   one	   another	   (Figure	   3.22	   (F)).	   Consistent	  with	  both	   the	  
data	   presented	   for	   the	   flow	   cytometry	   and	   RT-­‐PCR,	   AH61	   displayed	   a	   phenotype	  
consistent	   with	   differentiating	   cells	   across	   all	   the	   whole	   concentration	   range	   of	   1	  
µM,	  0.1	  µM	  and	  0.01	  µM	  (Figure	  3.22	  (G),	  (H)	  and	  (I)	  respectively).	  All	  three	  images	  
display	  a	  heterogeneous	  cell	  population,	  with	  fewer	  cells	  per	  field	  of	  view.	  No	  data	  is	  
shown	  for	  any	  compounds	  applied	  at	  a	  concentration	  of	  0.001	  µM	  as	  this	  lead	  to	  an	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   1	  µM	  	  	   	   	  	  	  	  	  	  	  	  	  0.1	  µM	  	   	   	  	  	  0.01	  µM	   	  
	  
	  
Figure	  3.22	  Phase	   images	  of	  TERA2.cl.SP12	  cells	  after	  7	  days	  of	  culture	  with	  ATRA	  ((A),	   (B)	  
and	   (C)),	  AH60	   ((D),	   (E)	  and	   (F))	  and	  AH61	   ((G),	   (H)	  and	   (I))	  at	  1	  μM,	  0.1	  μM	  and	  0.01	  μM.	  
Cultures	   exposed	   to	   all	   three	   retinoids	   at	   1	   μM	   exhibited	   a	   highly	   heterogeneous	  
morphology.	  This	  morphology	   is	   also	   seen	   in	   cultures	   incubated	  with	  AH61	  at	  0.1	  μM	  and	  
0.01	   μM,	   displaying	   that	   this	   retinoid	   retained	   its	   potency	   at	   these	   concentrations.	   AH60	  
displayed	  very	   low	   levels	  of	  differentiation	   seen	  at	  0.1	  μM,	  and	   in	  general	  both	  ATRA	  and	  
AH60	  at	  0.1	  μM	  and	  0.01	  μM	  are	  significantly	  over	  grown,	   indicative	  of	  a	  proliferative	  cell	  
population.	  Scale	  Bars:	  100	  μm.	  	  	  
	  
3.3.6.4	  Immunocytochemical	  Analysis	  	  
	  
Finally,	  the	  potential	  of	  each	  compound	  to	  induce	  the	  expression	  of	  neuronal	  specific	  
proteins	   over	   a	   range	   of	   concentrations	   was	   examined	   by	   immunocytochemical	  
staining.	  The	  expression	  was	  again	   investigated	  using	  antibodies	   raised	  against	   the	  
neuronal	  specific	  β-­‐III-­‐tubulin	  marker,	  TuJ1,	  and	  the	  200	  kDa	  neurofilament	  protein,	  
NF-­‐200.	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Cultures	  of	  TERA2.cl.SP12	  cells	  were	  treated	  with	  ATRA,	  AH60	  and	  AH61	  at	  1	  µM,	  0.1	  
µM	  and	  0.01	  µM	  for	  21	  days.	  Media	  was	  refreshed	  every	  3	  days,	  but	  cultures	  treated	  
with	  ATRA	  and	  AH60	  at	  0.01	  µM	  became	  over	   confluent	   and	   sub-­‐optimal	   after	  14	  
days	  and	  were,	  consequently,	  abandoned.	  Both	  markers	  were	  strongly	  expressed	  in	  
cells	   incubated	   with	   1	  µM	  ATRA,	   AH60	   and	   AH61,	   with	  many	   neuronal	   processes	  
visible	   in	   all	   three	   cultures.	   A	   similar	   number	   of	   positive	   neuronal	   processes	  were	  
visible	   in	  both	  0.1	  µM	  and	  0.01	  µM	  AH61	  cultures.	  However,	  at	  0.1	  µM	  ATRA	  and	  
AH60	   fewer	   neuronal	   processes	   were	   apparent	   (Figure	   3.23	   and	   Figure	   3.24).	   As	  
carried	   out	   previously	   to	   quantify	   the	   data,	   the	   number	   of	   positive	   cell	   bodies	  
(perykarya)	  per	  field	  of	  view	  for	  each	  culture	  treatment	  was	  counted,	  with	  the	  aid	  of	  
ImageJ	   software.	   The	  data	   is	  displayed	  as	   the	  mean	   from	   three	   randomly	   selected	  
immunostained	   images,	   for	   both	   TuJ1	   and	   NF-­‐200	   (Figure	   3.25	   (A)	   and	   (B)	  
respectively).	   There	   is	  no	   significant	  difference	   seen	   in	   the	  expression	  of	  TuJ1	  at	  1	  
µM	  over	  the	  three	  retinoid	  treatments,	  with	  all	   three	  expressing	  the	  marker	  highly	  
as	  seen	  for	  10	  µM.	  Dropping	  the	  concentration	  to	  0.1	  µM	  sees	  levels	  of	  positive	  TuJ1	  
neurons	   drop	   in	   both	   ATRA	   and	   AH60	   cultures,	   but	   remain	   high	   in	   AH61.	  
Consequently	  the	  number	  of	  positive	  perykarya	   in	  0.1	  µM	  AH61	  treated	  cultures	   is	  
significantly	  higher	  then	  those	  treated	  with	  0.1	  µM	  ATRA	  or	  AH60.	  Furthermore,	  the	  
number	  of	  positive	  perykarya	  remains	  significantly	  higher	   in	  0.01	  µM	  AH61	  treated	  
cultures	  compared	  to	  0.1	  µM	  ATRA	  and	  AH60.	  Upon	  analysing	  NF-­‐200	  expression,	  a	  
similar	   pattern	   emerges,	   with	   AH61	   cultures	   displaying	   significantly	   more	   positive	  
perykarya	  over	  the	  same	  treatments	  as	  described	  for	  TuJ1.	  In	  addition,	  1	  µM	  AH61	  
treatment	  displays	  significantly	  more	  positive	  NF-­‐200	  perykarya	  than	  1	  µM	  	  ATRA	  or	  
AH60	   cultures.	   This	   is	   consistent	   with	   the	   data	   present	   previously	   at	   the	   10	   µM	  
concentration	   range.	   Thus,	   at	   low	   (0.1	   and	   0.01	   µM)	   concentrations,	   under	   the	  
conditions	   tested,	   AH61	   appears	   to	   be	   a	   more	   potent	   inducer	   of	   neuronal	  
differentiation	   than	   ATRA	   and	   AH60,	   as	   inferred	   by	   the	   significantly	   increased	  
number	   of	   neurons,	   both	   positive	   for	   TuJ1	   and	   NF-­‐200.	   AH61	   remains	   nearly	   as	  
active	  at	  a	  100-­‐fold	  drop	  in	  concentration.	  Furthermore,	  AH61	  induces	  a	  significant	  
increase	   in	   the	   expression	   of	   mature	   (NF-­‐200)	   neurons	   across	   the	   entire	  
concentration	  range	  investigated	  in	  this	  Chapter	  (10	  µM-­‐0.01	  µM).	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Figure	   3.23	   Induction	   of	   neural	   differentiation	   in	   TERA2.cl.SP12	   cells.	   Cultures	   were	  
incubated	  with	  either	  ATRA	  at	  1	  µM	  and	  0.1	  µM	  (A	  and	  B),	  AH60	  at	  1	  µM	  and	  0.1	  µM	  (C	  and	  
D)	  and	  AH61	  at	  1	  µM,	  0.1	  µM	  and	  0.01	  µM	  (E,	  F	  and	  G)	  for	  21	  days.	  All	  cultures	  were	  stained	  
for	   the	   neuronal	  marker	  β-­‐III-­‐tubulin.	   All	   cultures	   incubated	  with	   1	  µM	   concentrations	   of	  
retinoid	   highly	   expressed	  β-­‐III-­‐tubulin,	  with	   long	   neuronal	   processes	   visible.	   In	   21	   day	   0.1	  
µM	  ATRA	  and	  0.1	  µM	  AH60	  cultures	  very	  few	  β-­‐III-­‐tubulin	  neurons	  were	  observed.	  However,	  
0.1	  µM	   and	   0.01	  µM	  AH61	   incubated	   cultures	   both	   exhibited	   expression	   profiles	   of	  β-­‐III-­‐
tubulin	  similar	  to	  that	  seen	  in	  1	  µM	  ATRA.	  Control	  cultures	  (vehicle	  only)	  stain	  negative	  for	  
β-­‐III-­‐tubulin.	  Scale	  bars:	  50	  μm.	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Figure	   3.24	   Induction	   of	   neural	   differentiation	   in	   TERA2.cl.SP12	   cells.	   Cultures	   were	  
incubated	  with	  either	  ATRA	  at	  1	  µM	  and	  0.1	  µM	  (A	  and	  B),	  AH60	  at	  1	  µM	  and	  0.1	  µM	  (C	  and	  
D)	  and	  AH61	  at	  1	  µM,	  0.1	  µM	  and	  0.01	  µM	  (E,	  F	  and	  G)	  for	  21	  days.	  All	  cultures	  were	  stained	  
for	   the	   late	   neuronal	  marker	   NF-­‐200.	   All	   cultures	   incubated	  with	   1	  µM	   concentrations	   of	  
retinoid	   highly	   expressed	  NF-­‐200,	  with	   long	   neuronal	   processes	   visible.	   In	   21	   day	   0.1	  µM	  
ATRA	  and	  0.1	  µM	  AH60	  cultures	  very	  few	  NF-­‐200	  neurons	  were	  observed.	  However,	  0.1	  µM	  
AH61	   exhibited	   an	   expression	   profile	   of	   NF-­‐200	   similar	   to	   that	   seen	   in	   1	   µM	   ATRA.	  
Furthermore	  at	  0.01	  µM	  AH61	  NF-­‐200	  positive	  neurons	  were	  still	  highly	  expressed.	  Control	  
cultures	  (vehicle	  only)	  stain	  negative	  for	  NF-­‐200.	  Scale	  bars:	  50	  μm.	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   (A)	   	   	   	   	   TuJ1	  
	  
	  
(B)	   	   	   	   	   NF-­‐200	  
	  
	  
	  Figure	   3.25	  Plots	  displaying	   the	  quantification	  of	   the	   immunological	  data	   for	   (A)	  TuJ1	  and	  
(B)	  NF-­‐200,	  as	  performed	  by	  counting	  labelled	  positive	  cell	  bodies.	  Cultures	  of	  TERA2.cl.SP12	  
EC	  stem	  cells	  incubated	  with	  1	  µM	  or	  0.1	  µM	  ATRA,	  AH60	  and	  AH61,	  plus	  0.01	  µM	  AH61,	  for	  
21	  days,	  subsequently	  fixed	  and	  immunocytochemically	  stained	  for	  TuJ1	  and	  NF-­‐200.	  Using	  
ImageJ	   software	   the	   number	   of	   positive	   cell	   bodies	  were	   counted	  on	   3	   random	   fields	   per	  
treatment	  condition.	  AH61	  induced	  a	  significant	  increase	  in	  expression	  of	  both	  TuJ1	  and	  NF-­‐
200	   over	   both	   ATRA	   and	   AH60	   treatments	   at	   0.1	   µM.	   The	   number	   of	   positive	   NF-­‐200	  
perykarya	  in	  1	  µM	  AH61	  treated	  cultures	  was	  also	  significantly	  higher	  than	  in	  1	  µM	  ATRA	  or	  
AH60	  treatments.	   	  Values	  shown	  represent	  mean	  +	  standard	  error	   (SEM),	  n=9.	  **p≤0.005,	  
*p≤0.05,	   Student’s	   t-­‐test	   corrected	   for	   multiple	   testing	   between	   compared	   sample	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3.3.7	  Metabolic	  Studies	  
	  
All	  data	  presented	  thus	  far	  demonstrates	  that	  both	  synthetic	  compounds	  are	  more	  
active	   than	   their	   natural	   analogue,	   ATRA.	   One	   hypothesis	   for	   their	   increase	   in	  
potency	   is	   that	   they	   have	   a	   greater	   resistance	   to	   metabolism.	   This	   hypothesis	   is	  
based	   on	   their	   adapted	   molecular	   structure,	   which	   has	   been	   designed	   to	   block	  
natural	   metabolic	   sites,	   as	   discussed	   previously	   in	   Chapter	   II.	   To	   investigate	   this	  





Figure	  3.26	  Chemical	  structure	  of	  Liarozole	  Hydrochloride.	  
	  
Liarozole	   is	   a	   retinoic	   acid	   metabolism	   blocking	   agent	   (RAMBA),	   which	   is	   a	  
compound	  designed	  to	  inhibit	  cytochrome	  P450	  enzymes,	  effectively	  reducing	  ATRA	  
metabolic	   oxidation.	   There	   are	   many	   known	   RAMBAs	   but	   the	   most	   studied	   is	  
liarozole,	  and	  therefore,	   it	  was	  chosen	  for	  this	  study.302-­‐304	  Liarozole	  has	  been	  used	  
to	   treat	   patients	   with	   solid	   tumours	   undergoing	   ATRA	   therapy,	   in	   which	   it	   was	  
demonstrated	  to	  increase	  the	  plasma	  concentrations	  of	  ATRA	  two-­‐fold.305	  Clinically,	  
this	   is	   important,	  as	  continual	  dosing	  of	  ATRA	   in	  patients	  with	  acute	  promyelocytic	  
leukemia	  (APL)	  shows	  a	  progressive	  decline	  in	  the	  plasma	  concentration,	  suggesting	  
ATRA	   induces	   its	   own	   catabolism	   in	   vivo.306,	   307	   One	   solution	   to	   retaining	   a	   high	  
plasma	  concentration	  throughout	  the	  treatment	  is	  to	  inactivate	  these	  enzymes	  with	  
compounds	  such	  as	  liarozole.	  	  
	  
Therefore,	  the	  study	  hoped	  to	  demonstrate,	  using	  the	  TERA2.cl.SP12	  model,	  that	  the	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liarozole.	   Our	   hypothesis	   for	   increased	   potency	   at	   lower	   concentrations	   was	   that	  
ATRA	  would	  be	  metabolised	  upon	  introduction	  to	  the	  cell	  culture,	  and	  only	  at	  high	  
concentrations	  would	  enough	  remain	  to	  produce	  a	  response.	  With	  liarozole	  present,	  
this	  effective	  concentration	  would	  be	  maintained,	  thus	  validating	  that	  liarozole	  was	  
effective	   at	   inhibiting	   the	  metabolism	  of	   ATRA	   in	   this	   cellular	  model.	   Successively,	  
the	   potency	   of	   the	   synthetic	   compounds	   would	   be	   assessed,	   again	   at	   previous	  
concentrations	  shown	  to	  be	  inactive.	  	  
	  
Hence,	  the	  study	  was	  carried	  out	  using	  ATRA	  at	  0.1	  µM	  and	  0.01	  µM,	  AH60	  at	  0.01	  
µM	  and	  0.001	  µM	  and	  both	  AH61	  and	  EC23	  at	  0.001	  µM.	  All	  the	  compounds	  at	  the	  
concentrations	   stated	   above	   had	   no	   effect	   on	   TERA2.cl.SP12	   cells,	   therefore,	   any	  
changes	  seen	  are	  as	  a	  result	  of	  the	  addition	  of	  liarozole.	  The	  results	  are	  presented	  in	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   (A)	   	   	   SSEA-­‐3	  
	  
	  
	   	   (B)	   	   	  	  	  	  	  	  	  	  	  	  	  TRA-­‐1-­‐60	  
	  
	  
	   	   (C)	   	   	   	  A2B5	  
	  
	  
Figure	  3.27	  Flow	  cytometric	  analysis	  of	  markers	  of	  stem	  cells	  SSEA-­‐3	  (A)	  and	  TRA-­‐1-­‐60	  (B),	  
and	  a	  marker	  of	  early	  stage	  neural	  cells,	  A2B5	  (C).	  TERA2.cl.SP12	  cells	  were	  incubated	  with	  
ATRA,	   AH60,	   AH61	   or	   EC23	   for	   7	   days	   at	   either	   0.1	   µM,	   0.01	   µM	   or	   0.001	   µM.	  
Simultaneously,	  identical	  cultures	  were	  incubated	  with	  the	  addition	  of	  liarozole	  at	  10	  µM	  in	  
addition	   to	   the	  above	   retinoid	   treatments.	  Addition	  of	   liarozole	   significantly	   increased	   the	  
potency	  of	  ATRA	  at	  0.1	  µM	  over	  all	  three	  markers.	  A	  smaller	  effect	  was	  seen	  at	  0.01	  µM	  but	  
still	  significant	  for	  some	  of	  the	  markers	  tested.	  There	  were	  no	  significant	  differences	  in	  any	  
of	  the	  results	  for	  the	  synthetic	  compounds	  when	  treated	  with	  or	  without	  liarozole	  present.	  
Analysis	   carried	  out	   at	  day	  7.	  Results	   are	  presented	  with	  ±	   standard	  error	   (SDE),	   n=3.	   ***	  
p≤0.0005,	  **	  p≤0.005,	  *	  p≤0.05,	  Student’s	  t-­‐test	  compared	  to	  no	  liarozole.	  	  
	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Chapter	  III	  
	   126	  
From	  the	  data	  presented	  Figure	  3.27,	  the	  only	  significant	  changes	  upon	  addition	  of	  
liarozole	  into	  the	  culture	  medium,	  occurred	  in	  those	  incubated	  with	  ATRA	  at	  0.1	  µM.	  
Both	  stem	  cell	  markers	  SSEA-­‐3	  and	  TRA-­‐1-­‐60	  were	  down	  regulated,	  while	  in	  parallel	  
A2B5	  was	  up-­‐regulated.	  At	  0.01	  µM,	  ATRA	  there	  were	  slight	  changes	  seen,	  which	  for	  
some	  of	  the	  markers	  represented	  a	  significant	  change,	  but	  overall	  liarozole	  appeared	  
to	  have	  little	  effect	  at	  this	  concentration	  of	  ATRA.	  For	  all	  the	  synthetic	  compounds,	  
both	   treated	   and	  un-­‐treated,	   liarozole	   conditions	  displayed	  no	   significant	   changes,	  
thereby	   suggesting	   liarozole	   cannot	   improve	   their	   biological	   potential.	   These	   data	  
suggests	  that	  the	  synthetic	  compounds	  may	  be	  more	  stable	  and	  resistant	  to	  cellular	  
metabolism	   by	   cytochrome	   P450	   enzymes,	   which	   in	   part	   could	   explain	   their	  
improved	  biological	  potency	  at	  lower	  concentrations.	  It	  should	  be	  stressed	  that	  this	  
was	  only	  a	  preliminary	  study	   into	  the	  metabolism	  of	  these	  compounds	  and	  further	  
studies	   in	  additional	  model	  systems	  would	  need	  to	  be	  carried	  out	  before	  we	  could	  
be	  sure	  that	  they	  are	  not	  metabolised	  in	  vivo.	  	  	  	  
	  
3.3.8	  Biological	  Potency	  of	  AH60	  
	  
Throughout	   this	   Chapter,	   the	   biological	   profile	   exhibited	   by	   AH60	   has	   been	  
approximately	  10	  fold	  less	  potent	  than	  that	  of	  AH61,	  but	  additionally,	  10	  fold	  greater	  
than	   ATRA.	  Upon	   administration,	   AH60	   is	   a	   single	   pure	   isomer	   as	   identified	   by	   1H	  
NMR	  spectroscopy,	  but	  from	  the	  stability	  studies	  carried	  out	  in	  Chapter	  II,	  we	  know	  
the	  double	  bond,	  closest	  to	  the	  carbonyl,	   isomerises	  relatively	  readily	  to	  give	  AH61	  
under	  equilibrium.	  It	   is,	  therefore,	  not	   impossible	  that	  the	  effects	  elicited	  by	  AH60,	  
as	   seen	   throughout	   this	  Chapter,	   are	  actually	   as	   a	   result	  of	   a	   small	   amount	  of	   the	  
molecule	  isomerising	  to	  AH61	  within	  the	  cell	  or	  culture	  media	  over	  the	  time	  course	  
of	  an	  investigation.	  
	  
To	   examine	   this,	   a	   flow	   cytometry	   study	   comparing	   ATRA,	   AH60	   and	   13cRA	   was	  
undertaken.	   The	   purpose	   being:	   (1)	   to	   see	   if	   13cRA	   was	   effective	   at	   inducing	  
differentiation	  within	  the	  TERA2.cl.SP12	  cell	  model	  system;	  (2)	  how	  this	  compared	  to	  
that	   elicited	   by	   ATRA;	   and	   (3)	   how	   they	   both	   compared	   to	   AH60.	   The	   hypothesis	  
being,	   if	   13cRA	  has	   no	   effect,	   or	   a	   significantly	   reduced	   affect	   compared	   to	  ATRA,	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then	   it	  would	  be	   likely	   that	   the	  effects	   seen	   for	  AH60	  are	  actually	  due	   to	  AH61.	   If	  
13cRA	  does	  elicit	  a	  biological	   response,	   then	   that	  seen	   for	  AH60	   is	  potentially	  as	  a	  
result	   of	   itself,	   not	   that	   of	   AH61,	   and	   any	   increase	   in	   potency	   over	   13cRA	   would	  
theoretically	  be	  as	  a	  result	  of	  the	  molecule	  being	  less	  susceptible	  to	  metabolism.	  	  
	  
Therefore,	  the	  ability	  of	  ATRA,	  13cRA	  and	  AH60	  to	  induce	  cellular	  differentiation	  in	  
the	  TERA2.cl.SP12	  cell	  line	  was	  evaluated	  by	  analysing	  the	  expression	  profile	  of	  SSEA-­‐
3,	   TRA-­‐1-­‐60	  and	  A2B5.	   Flow	  cytometry	  was	  performed	  on	   samples	  of	   cells	   treated	  
with	   10	   µM,	   1	   µM,	   0.1	   µM	   and	   0.01	   µM	   of	   each	   retinoid,	   alongside	   untreated	  
controls	  and	  those	  treated	  with	  DMSO.	  Cell	  profiles	  were	  analysed	  after	  7	  days	  and	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(A)	   	   	   	  	  	  	  	  	  SSEA-­‐3	  
	  
	  
(B)	   	   	   	  	  	  	  	  	  TRA-­‐1-­‐60	  
	  
	  
(C)	  	   	   	   	  	  	  	  	  	  	  	  A2B5	  
	  
	  
Figure	  3.28	  Flow	  cytometric	  analysis	  of	  markers	  of	  stem	  cells	  SSEA-­‐3	  (A)	  and	  TRA-­‐1-­‐60	  (B),	  
and	  a	  marker	  of	  early	  stage	  neural	  cells,	  A2B5	  (C).	  TERA2.cl.SP12	  cells	  were	  incubated	  with	  
either	   ATRA,	   13cRA	   or	   AH60	   for	   7	   days	   at	   either	   10	  µM,	   1	  µM	  0.1	  µM	  or	   0.01	  µM,	  with	  
analysis	   carried	   out	   at	   day	   7.	   For	   controls,	   both	   untreated	   and	   DMSO	   treated	   cells	   were	  
cultured	   simultaneously.	   The	   expression	   profiles	   of	   both	   ATRA	   and	   13cRA	   are	   nearly	  
identical	   across	   all	   three	   markers,	   with	   no	   significant	   differences.	   AH60	   appears	   to	   be	  
approximately	   10	   fold	   more	   potent,	   consistent	   with	   previous	   data	   presented.	   AH60	  
displayed	  a	  significantly	  larger	  number	  of	  A2B5	  positive	  cells	  at	  0.1	  µM	  compared	  to	  DMSO,	  
whereas	  ATRA	  and	  13cRA	  display	  no	  significant	  differences	  to	  DMSO	  at	  this	  concentration.	  
Results	  are	  presented	  with	  ±	  standard	  error	  (SDE),	  n=3.	  *	  p≤0.05,	  Student’s	  t-­‐test	  corrected	  
for	  multiple	  testing	  between	  compared	  sample	  populations	  using	  the	  Bonferroni	  correction.	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From	  the	  above	  graphs	  it	  is	  clear	  that	  13cRA	  had	  a	  dose	  response	  similar	  to	  that	  of	  
ATRA.	   As	   in	   previous	   studies,	   AH60	   had	   a	   similar	   dose	   response	   albeit	   being	  
approximately	  10-­‐fold	  more	  potent.	  Therefore,	  from	  this	  study	  we	  can	  infer	  that	  the	  
terminal	   bond	   can	   have	   cis-­‐stereochemistry	   and	   still	   induce	   differentiation	   in	   the	  
TERA2.cl.SP12	  model	  system.	  Additionally,	  the	  enhanced	  biological	  profile	  exhibited	  
by	   AH60	   over	   13cRA,	   can	   be	   explained	   as	   a	   result	   of	   this	   molecule	   being	   more	  
resistant	  to	  metabolism,	  due	  to	  its	  structural	  modifications.	  Unfortunately,	  this	  does	  
not	   explain	   the	   lower	   potency	   compared	   to	   that	   of	   AH61,	   upon	   which,	   further	  
studies	  would	   be	   required,	   such	   as	   looking	   at	   individual	   binding	   affinities.	   It	   does,	  
however,	  indicate	  that	  potentially,	  this	  molecule	  does	  induce	  a	  response	  of	  its	  own,	  
and	   that	   within	   the	   culture	   media,	   isomerisation	   may	   not	   be	   occurring.	   Again,	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3.4	  Discussion	  	  
	  
The	   aim	   of	   this	   Chapter	   was	   to	   test	   the	   biological	   activities	   of	   the	   AH	   synthetic	  
retinoid	   series	   on	   model	   human	   pluripotent	   stem	   cells.	   ATRA	   has	   been	   used	   to	  
modulate	   EC	   stem	   cell	   fate	   for	   over	   thirty	   years,	   inducing	   many	   well-­‐defined	  
immunological	   and	  morphological	   changes.199	   The	   EC	   cell	   line	   chosen	   to	   carry	   out	  
most	  of	  the	  investigations	  within	  this	  Chapter,	  TERA2.cl.SP12,	  retains	  the	  capacity	  to	  
differentiate	   in	   vitro.209	   In	   addition,	   the	   ability	   of	   ATRA	   to	   induce	   neural	  
differentiation	  in	  the	  TERA2.cl.SP12	  cell	  line	  has	  been	  well	  documented.211,	  212	  Upon	  
exposure	   to	   ATRA,	   TERA2.cl.SP12	   cells	   differentiate	  with	   approximately	   10-­‐15%	   of	  
cells	  committing	  to	  become	  neurons.308	  Furthermore,	  it	  has	  been	  demonstrated	  that	  
synthetic	  retinoid	  analogues,	  such	  as	  EC23,	  have	  enhanced	  biological	  profiles	  when	  
compared	  to	  ATRA	  in	  this	  cell	  line.228	  This	  background	  knowledge	  therefore	  formed	  
the	   basis	   for	   carrying	   out	   investigations	   into	   the	   differentiation	   capabilities	   of	   the	  
synthetic	  retinoid	  AH	  series.	  	  	  
	  
In	   all	   the	   investigations	   presented	   in	   this	   Chapter,	   initial	   retinoid	   treatment	   was	  
carried	   out	   at	   a	   concentration	   of	   10	  µM,	   followed	   by	   subsequent	   dilutions	   when	  
investigating	  their	  dose	  response.	  This	  concentration	  was	  chosen	  as	  it	  has	  previously	  
been	   successfully	  used	   to	  differentiate	  TERA2.cl.SP12	  cells.211,	  228	   Furthermore,	   this	  
concentration	   is	  at	  the	  higher	  end	  of	  those	  used	  for	   in	  vitro	  experiments	  that	  have	  
currently	  been	  published,	  with	  higher	  concentrations	  leading	  to	  cell	  death.309	  	  	  	  
	  
Initially,	   as	   the	   AH	   synthetic	   retinoids	   were	   designed	   to	   act	   on	   the	   retinoic	   acid	  
pathway,	  an	   investigation	  was	  carried	  out	  to	  see	   if	   they	  bound	  RAR	  receptors.	  This	  
utilised	  a	  different	  EC	  stem	  cell	  model,	  F9	  EC	  cells,	  which	  expressed	  endogenous	  RAR	  
receptors,	  but	  additionally	  contained	  a	  reporter	  assay,	  which	  used	  the	  RARE	  to	  drive	  
a	   lacZ	   reporter	   gene.	   This	   model	   did	   not	   assess	   whether	   the	   synthetic	   retinoids	  
would	  bind	  to	  RXRs,	  although,	  this	  was	  not	  detrimental	  to	  the	  investigation	  as	  RARs	  
must	   function	   as	   heterodimers,	   pairing	  with	   one	  of	   the	   three	  RXRs	  α,	  β	   or	   γ.148	  In	  
addition,	   the	   biological	   effects	   being	   assessed	   are	   those	   known	   to	   be	   elicited	   by	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ATRA,	  and	  RXRs	  are	  not	  modulated	  by	  ATRA,	  but	   instead	  by	  9cRA.170,	  173	  As	  all	   the	  
compounds	  in	  the	  AH	  series	  were	  linear	  in	  structure	  (i.e.	  similar	  to	  ATRA/13cRA)	  and	  
the	   shape	   of	   the	   RXR	   ligand	   binding	   domain	   is	   an	   ‘L’	   shape,	   binding	   to	   these	  
receptors	   was	   thought	   of	   as	   highly	   unlikely.237	   Activation	   of	   the	   retinoid	   pathway	  
was	  monitored	  and	  quantified	  by	  counting	  the	  number	  of	  positive	  cells	  per	  field	  of	  
view.	  This	  clearly	  distinguished	  the	  ‘ATRA-­‐like’	  analogues,	  AH60	  and	  AH61,	  from	  both	  
the	   ‘short’	   and	   ‘extended’	   analogues,	   AH36,	   AH62,	   AH66	   and	   AH98,	   as	   only	   the	  
‘ATRA-­‐like’	   compounds	   displayed	   a	   positive	   result.	   As	   there	   was	   no	   significant	  
difference	   in	  the	  number	  of	  positive	  cells	  seen	  for	  treatment	  with	  ATRA,	  AH60	  and	  
AH61	  there	  are	  no	  further	  conclusions	  that	  can	  be	  drawn.	  As	  ATRA	  is	  a	  pan-­‐agonist,	  
binding	   all	   the	   receptors	   with	   equal	   affinity,	   and	   both	   AH60	   and	   AH61	   are	   highly	  
structurally	  similar,	  we	  would	  also	  hypothesise	  them	  to	  be	  pan-­‐agonists.170	  Although,	  
for	   this	   to	   be	   scientifically	   proven,	   binding	   studies	   for	   each	   of	   the	   individual	  
receptors	  would	  be	  required.	  
	  
The	   compounds	   were	   next	   tested	   in	   the	   TERA2.cl.SP12	   EC	   cell	   model.	   Initially	   a	  
tetrazolium	  colourimetic	  assay	  (MTS)	  was	  employed,	  to	  investigate	  the	  effects	  of	  the	  
compounds	   on	   cell	   toxicity	   and	   proliferation.310-­‐314	   The	   tetrazolium	   compound	   is	  
reduced	  by	  viable	  cells	  to	  a	  soluble	  coloured	  product	  measured	  by	  UV	  absorbance.	  
Compounds	   that	   induce	   differentiation	   should	   show	   a	   decreased	   proliferative	  
capacity,	  and	  therefore	  this	  is	  a	  good	  early	  indicator	  in	  assessing	  the	  potential	  of	  any	  
novel	  compound	  series.243	  The	   literature	  also	  suggests	  that	  differentiating	  cells	  still	  
retain	   the	   capabilities	   to	   reduce	   the	   tetrazolium	   compound	   and,	   therefore,	   only	  
compounds	   toxic	   to	   the	   cells	   would	   lead	   to	   no	   reduction,	   as	   there	   are	   no	   ‘living’	  
cells.315	  Those	  treated	  with	  DMSO,	  the	  ‘short’	  analogues,	  AH36,	  AH62	  and	  AH66,	  and	  
the	   ‘extended’	  analogue,	  AH98,	  all	  displayed	  an	  sharp	   increase	   in	  absorbance	  from	  
day	   3	   to	   day	   7,	   identical	   to	   that	   of	   the	   un-­‐treated	   control.	   This	   shows	   these	  
treatments	  have	  no	  effect	  on	  the	  growth	  of	  the	  TERA2.cl.SP12	  cells,	   indicating	  that	  
they	   do	   not	   induce	   any	   effects.	   The	   result	   that	   DMSO	   had	   no	   effect	   was	   also	  
promising,	   as	   in	   some	   cell	   lines	   it	   has	   been	   reported	   that	   DMSO	   has	   both	   anti-­‐
proliferative	  and	  differentiating	  effects.316-­‐318	  The	  cells	  treated	  with	  ATRA,	  AH60	  and	  
AH61	  all	  displayed	  a	  similar	  absorbance	  for	  both	  day	  3	  and	  day	  7,	  indicating	  that	  the	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cells	   were	   not	   proliferating,	   and	   potentially	   differentiating.	   This	   is	   consistent	   with	  
previous	  MTS	  assay	  data	  generated	  for	  other	  natural	  and	  synthetic	  retinoids,	  such	  as	  
9cRA,	  13cRA,	  EC23	  and	  EC19.243,	  319	  Furthermore,	  the	  MTS	  data	  indicated	  that	  none	  
of	  the	  treatments	  were	  toxic.	  This	  was	  also	  backed-­‐up	  by	  a	  toxicity	  assay	  measuring	  
the	  number	  of	  apoptopic	  and	  viable	  cells	  using	  Guava	  ViaCount	  reagent,	  on	  a	  Guave	  
EasyCyteTM	   Plus	   System	   flow	   cytometer.	   This	   supports	   previously	   published	  
literature,	  whereby,	  a	  concentration	  of	  10	  µM	  for	  retinoid	  treatment	  is	  tolerated	  in	  
this	  system.211,	  228,	  243,	  309	  	  
	  
The	   morphology	   of	   any	   induced	   cell	   type	   was	   next	   investigated.	   Supporting	   all	  
previous	   data,	   both	   the	   ‘short’	   and	   ‘extended’	   analogues,	   AH36,	   AH62,	   AH66	   and	  
AH98,	   displayed	   morphologies	   similar	   to	   both	   the	   un-­‐treated	   control	   and	   DMSO,	  
suggesting	  they	  have	  no	  effect	  on	  cellular	  proliferation	  or	  differentiation.	  Consistent	  
with	   previously	   reported	   literature,	   treatment	  with	  DMSO	   (0.1%	   v/v)	   proved	   to	   be	  
both	  non-­‐toxic	  and	  not	  induce	  any	  signs	  of	  differentiation.316,	  318	  This	  is	  important	  as	  
any	  effects	  seen	  are	  therefore	  now	  as	  a	  result	  of	  the	  compound	  treatment,	  not	  the	  
vehicle,	   DMSO.	   It	   is	   also	   important	   that	   for	   any	   future	   studies,	   a	   higher	   DMSO	  
concentration	  is	  avoided	  as	  1%	  v/v	  DMSO	  has	  been	  reported	  to	  induce	  differentiation	  
in	  TERA2	  cells.320	  Consistent	  with	  the	  data	  obtained	  in	  the	  F9	  cell	   line	  and	  the	  MTS	  
assay,	   ATRA,	   AH60	   and	   AH61	   all	   induced	   phenotypic	   changes	   consistent	   with	  
differentiation.	  Long-­‐term	  culture	   (21	  days)	   led	  to	   the	   formation	  of	  columnar	  cells,	  
described	  as	  neural	  rosettes.	  These	  have	  been	  reported	  before,	  in	  both	  this	  cell	  type,	  
and	  human	  and	  mouse	  ES	  cells,	  and	  are	  described	  as	  the	  developmental	  signature	  of	  
neural	  progenitors.321,	  322	  Therefore,	  AH60	  and	  AH61	  appear	   to	  mimic	  both	  natural	  
and	  previously	  screened	  synthetic	  retinoids	  in	  their	  ability	  to	  induce	  neurogenesis	  in	  
this	   cell	   line.228,	   243,	   319	   Furthermore,	   they	   appear	   to	   mimic	   the	   normal	   neuro-­‐
ectodermal	  development	  as	  seen	  in	  the	  human	  embryo.323	  	  
	  
In	   addition	   to	   phase	   images,	   immunocytochemical	   staining	   was	   employed	   to	  
investigate	  the	  formation	  of	  a	  larger	  flat	  cell	  type,	  known	  to	  form	  ‘plaque’	  like	  areas.	  
Previous	  studies	  had	  shown	  that	  the	  synthetic	  retinoid,	  EC19,	  in	  which	  the	  carboxyl	  
group	  slightly	  shorter	  and	  pointing	  down,	  in	  relation	  to	  ATRA,	  favoured	  this	  cell	  type	  
	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Chapter	  III	  
	   133	  
over	   neural	   differentiation.228,	   243	   As	   AH60	   has	   a	   cis-­‐terminal	   bond,	   this	   makes	   it	  
somewhat	   structurally	   similar	   to	   EC19,	   although	   it	   is	   slightly	   larger	   in	   size	   by	   one	  
atom.	  It	  was	  therefore	  investigated	  whether	  AH60	  would	  induce	  these	  ‘plaque’	  like	  
areas.	  Consistent	  with	  all	   the	  data	  discussed	  previously,	  AH60	  did	  not	  produce	  any	  
more	   ‘plaque’	   like	   areas	   than	   ATRA	   or	   AH61,	   suggesting	   that	   it	   acts	   in	   a	   similar	  
manner	   to	  both	  of	   these	   retinoids	   and	  others	  which	   induce	  neurogenesis,	   such	   as	  
EC23,	  and	  that	  EC19	  has	  a	  separate	  biological	  profile,	  not	  seen	  in	  the	  AH	  series.228,	  243	  	  	  
	  
Finally,	   to	   confirm	   that	   both	   the	   ‘short’,	   AH36,	   AH62	   and	   AH66,	   and	   ‘extended’,	  
AH98,	   analogues	   did	   not	   induce	   differentiation	   in	   this	   pluripotent	   EC	   stem	   cell	  
system,	  the	  expression	  of	  characteristic	  cell	   surface	  markers	  was	   investigated.	  Two	  
stem	  cell	  markers,	  SSEA-­‐3	  and	  TRA-­‐1-­‐60,	  and	  a	  neural	  marker,	  A2B5,	  were	  chosen	  as	  
they	   are	   well	   established	   in	   studying	   EC	   cell	   differentiation.206,	   292,	   293	   In	   addition,	  
these	  markers	  have	  been	  used	  successfully	  to	  assess	  the	  differentiation	  capabilities	  
of	  a	  number	  of	  retinoids	  in	  the	  TERA2.cl.SP12	  cell	  line,	  including	  EC19,	  EC23,	  TTNN,	  
9cRA,	  13cRA	  and	  ATRA.228,	  243,	  319	  	  
	  
Flow	   cytometric	   analysis	   of	   the	   three	   antigens,	   supported	   all	   the	   data	   gathered	  
previously,	   clearly	   distinguishing	   those	   compounds	   which	   induced	   differentiation	  
from	  those	  that	  did	  not.	  Treatment	  with	  the	  ‘short’	  and	  ‘extended’	  analogues,	  AH36,	  
AH62,	  AH66	  and	  AH98,	  showed	  no	  changes	  in	  expression	  of	  the	  three	  markers,	  with	  
both	  stem	  cell	  antigens	  retaining	  high	   levels	  of	  expression,	  while	  expression	  of	   the	  
neuronal	  antigen	  remained	   low.	  This	   is	   identical	  to	  the	  expression	  seen	  for	  the	  un-­‐
treated	   control.	   Appreciatively,	   there	   was	   also	   no	   change	   in	   expression	   seen	   for	  
those	  treated	  with	  DMSO,	  again	  reinforcing	  the	  literature	  that	  at	  this	  concentration	  
it	   does	  not	   induce	  differentiation.316,	  318	   In	   line	  with	   the	  morphological	   data,	   those	  
treated	  with	  ATRA,	  AH60	  and	  AH61	  all	   induced	  up-­‐regulation	  of	  the	  neural	  marker,	  
with	   consistent	   down	   regulation	   of	   the	   stem	   cell	   markers.	   As	   all	   data	   obtained,	  
indicated	   that	   both	   the	   ‘short’	   and	   ‘extended’	   analogues,	   AH36,	   AH62,	   AH66	   and	  
AH98,	   had	   no	   beneficial	   differentiation	   properties,	   no	   further	   analysis	   on	   these	  
compounds	  was	  undertaken.	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Analysis	   of	   the	   three	   antigens	   by	   flow	   cytometry	   over	   a	   14	   day	   period	   for	   ATRA,	  
AH60	   and	   AH61	   showed	   that	   all	   three	   treatments	   completely	   suppressed	   the	  
expression	  of	  both	  stem	  cell	  antigens,	  while	  promoting	  the	  expression	  of	  the	  neural	  
antigen	   to	   greater	   than	  95%.	   This	   is	   consistent	  with	  data	  published	   for	  both	  ATRA	  
and	   EC23.228	  The	   level	   of	   expression	   of	   TRA-­‐1-­‐60	  was	   lost	   significantly	   faster	   upon	  
treatment	   with	   AH61,	   compared	   to	   that	   of	   ATRA	   or	   AH60.	   There	   was	   no	   direct	  
comparison	  done	  with	  EC23,	  although	  comparing	  data	  presented	  in	  this	  Chapter	  to	  
that	  of	  the	  published	  literature,	  AH61	  appears	  to	  supresses	  TRA-­‐1-­‐60	  levels	  quicker	  
than	  any	  other	  synthetic	  retinoid	  tested	  in	  the	  system.228	  The	  exact	  reason	  for	  this	  is	  
unknown,	  although	  it	  does	  suggest	  that	  AH61	  might	  be	  slightly	  more	  active.	  	  
	  
To	  further	  assess	  cellular	  differentiation	  in	  response	  to	  treatment	  with	  the	  synthetic	  
retinoids	  expression	  profiles	  of	  known	  genes	  were	  analysed.	  Three	  genes	  of	  interest	  
were	  examined.	  Nanog	  and	  Oct-­‐4	  are	  essential	  regulators	  of	  early	  development	  and	  
connected	  to	  the	  self-­‐renewal	  of	  undifferentiated	  stem	  cells.	  Furthermore	  they	  have	  
been	   shown	   to	   be	   rapidly	   silenced	   during	   cellular	   differentiation.294-­‐297	   The	   third,	  
Pax6, was	   chosen	   to	   assess	   the	   neurogenesis	   properties	   of	   the	   retinoids,	   as	   it	   is	  
essential	   for	   the	   development	   of	   much	   of	   the	   central	   nervous	   system.298-­‐301	  
Treatment	  with	  ATRA,	  AH60	  and	  AH61	  all	  lead	  to	  a	  rapid	  suppression	  of	  both	  Nanog	  
and	  Oct-­‐4,	  with	  no	   significant	  differences	   seen	   in	   any	  of	   the	   treatments.	   Previous,	  
un-­‐published	  work	  within	  the	  Przyborski	  research	  group	  (carried	  out	  by	  D.	  Tams)	  had	  
highlighted	  the	  sluggish	  effect	  of	  EC23,	  seen	  when	  analysing	  these	  genes.	  This	  data	  
was	  supported,	  although	  after	  5	  days	  of	  treatment	  all	  four	  retinoids	  showed	  identical	  
gene	   profiles.	   The	   gene	   expression	   profile	   of	   Pax6	   displayed	   the	   largest	   variation.	  
This	   supports	   un-­‐published	   data,	   that	   EC23	   attenuated	   a	   relative	   increase	   in	  
expression	  of	  Pax6	  approximately	  50%	  less	  than	  ATRA.	  As	  for	  both	  AH60	  and	  AH61	  
their	   expression	   profiles	   are	   not	   significantly	   different	   to	   that	   of	   ATRA.	   This	   data	  
highlights	  the	  similarity	  of	  the	  biological	  profile	  exhibited	  by	  the	  AH	  compound	  series	  
to	  that	  of	  the	  natural	  ligand	  ATRA,	  in	  addition	  to	  showing	  variations	  in	  that	  of	  EC23	  
not	  seen	  before.	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Finally,	   the	   induction	   of	   neurogenesis	   was	   confirmed	   through	   the	   visualisation	   of	  
neural	  proteins.	  The	  expression	  of	  neuronal	  specific	  proteins	  was	  investigated	  using	  
antibodies	  raised	  against	  the	  neuronal	  specific	  β-­‐III-­‐tubulin	  marker,	  TuJ1	  and	  the	  200	  
kDa	   neurofilament	   protein,	   NF-­‐200.	   Both	   of	   which	   have	   been	   used	   to	   assess	   the	  
neurogenesis	  properties	  of	  retinoids	   in	  TERA2.cl.SP12	  line	  previously.228	  All	  retinoid	  
treatments	   led	   to	   high	   levels	   of	   expression	   in	   both	   markers.	   In	   addition,	   AH61	  
treated	  cultures	  expressed	   levels	  of	  NF-­‐200	  significantly	  higher	  than	  those	  seen	  for	  
AH60	  or	  ATRA,	  again	  suggesting	  this	  analogue	  is	  more	  active.	  Comparing	  the	  level	  of	  
NF-­‐200	  expression	  of	  AH61	  to	  that	  of	  EC23,	  which	  has	  been	  published,	  suggests	  they	  
would	   not	   be	   significantly	   different.228	   Although	   a	   direct	   comparison	   would	   be	  
required	  to	  confirm	  this	  observation.	  Both	  treatments	  have	  also	  been	  quantified	  by	  
cell	   counts,	  whereas	   a	  more	   accurate	  quantification	  method	  would	  be	   to	   examine	  
the	   total	   protein	   content,	   through	   a	  Western	   Blot.	   This	   then	   has	   the	   potential	   to	  
highlight	  any	  differences	  between	  AH61	  and	  EC23.	  
	  
The	  dose	  response	  of	  AH60	  and	  AH61	  was	  subsequently	  investigated,	  using	  identical	  
techniques	   to	   those	   describe	   previously.	   Analysing	   cell	   surface	   markers,	   gene	  
expression	  profiles,	  cellular	  morphologies	  and	  expression	  of	  neural	  proteins	  showed	  
that	   AH60	  was	   approximately	   10-­‐fold	  more	   active,	  while	   AH61	  was	   approximately	  
100-­‐fold	   more	   active,	   than	   ATRA.	   Reasons	   behind	   this	   are,	   ATRA	   is	   rapidly	  
metabolised	   in	   many	   cell	   types,	   in	   addition	   to	   being	   highly	   susceptible	   to	  
isomerisation.222-­‐227	   Furthermore,	   it	   has	   since	   been	   published	   that	   not	   only	   does	  
ATRA	   isomerise	   under	   standard	   laboratory	   conditions,	   but	   also	   degrades	   into	   a	  
number	   of	   other	   compounds.228	   Therefore,	   it	   can	   be	   hypothesised	   that	   at	   lower	  
concentrations	  of	  ATRA,	   its	   initial	  activity	   is	   lost	  quickly,	  as	   the	  compound	   is	  either	  
rapidly	   metabolised	   or	   isomerised/degraded.	   The	   data	   presented	   in	   Chapter	   II,	  
indicates	   that	   even	   though	   AH60	   and	   AH61	   do	   isomerise,	   this	   isomerisation	   is	  
significantly	   slower	   than	   that	   seen	   for	   ATRA.	   Therefore	   higher	   levels	   of	   the	   active	  
compound	   will	   remain	   in	   culture	   for	   longer,	   even	   under	   exposure	   to	   light.	   In	  
addition,	   their	   structural	   modifications,	   specifically	   replacing	   the	  
trimethylcyclohexenylvinyl	   unit	   (C1-­‐C8)	   of	   ATRA,	   with	   a	   structurally	   similar	   TMTN	  
moiety,	  has	  been	  demonstrated	  to	  increase	  biological	  potential.238	  This	  modification	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helps	  in	  two	  ways:	  (1)	  It	  helps	  to	  introduce	  greater	  stability,	  as	  it	  eliminates	  a	  section	  
of	  the	  unstable	  polyene	  chain,	  removing	  one	  of	  the	  isomerisable	  bonds;	  and	  (2)	  It	  no	  
longer	   possess	   any	   allylic	   protons	   or	   alkene	   double	   bonds	   susceptible	   to	   radical	  
oxidation	   or	   expoxidation	   by	   cytochrome	   P450	   (CYPs)	   or	   related	   enzymes.239-­‐242	  	  
Preliminary	  experiments	  have	  displayed	  that	  both	  AH60	  and	  AH61	  appear	  not	  to	  be	  
metabolised	  in	  TERA2.cl.SP12	  cells,	  although	  further	  studies	  are	  required	  to	  confirm	  
this.	  Therefore,	   the	  greater	  activities	  of	  both	  AH60	  and	  AH61	  over	  ATRA	  may	  be	  a	  
result	   of	   either	   their	   increased	   stability	   under	   standard	   laboratory	   conditions	   (UV	  
light)	   (as	   displayed	   in	   Chapter	   II),	   or	   their	   increased	   resistance	   to	   cellular	  
metabolism.	   Either	   scenario	   would	   contribute	   to	   higher	   active	   levels	   of	   these	  
retinoids	  being	  present	  in	  media/cells	  over	  a	  longer	  time	  period,	  and	  could	  therefore	  
explain,	   in	   part,	   the	   enhanced	   levels	   of	   differentiation	   observed	   in	   the	   lower	  
micromolar	  range.	  	  
	  
An	  explanation	   for	   the	   improved	  potency	  of	  AH61	  over	  AH60	   is	   that	   its	  molecular	  
structure	   confers	   greater	   affinity	   with	   and/or	   activation	   of	   the	   cognate	   cellular	  
receptors.	   This	   is	   also	   consistent	   with	   the	   activity	   displayed	   by	   EC23,	   which	  
structurally,	   is	   equivalent	   to	   an	   all-­‐trans-­‐system	   and	   subsequently	   displays	   near	  
identical	  biological	  profile	  to	  that	  of	  AH61.228,	  243	  Their	  only	  difference	  is	  their	  ability	  
to	   induce	   the	  expression	  of	  Pax6.	  AH61	  has	  a	   linear	  dose	   response,	   so	   that	  as	   the	  
concentration	  is	  lowered,	  the	  levels	  of	  Pax6	  expression	  also	  reduce.	  EC23	  has	  a	  very	  
distinct	  profile	  in	  that	  Pax6	  expression	  peaks	  at	  0.1	  µM,	  although	  the	  reason	  for	  this	  
is	  currently	  unknown.	  
	  
In	  addition,	  if	  future	  experiments	  did	  confirm	  the	  initial	  theory	  that	  the	  AH	  series	  of	  
compounds	  are	  resistant	  to	  metabolism,	  then	  synthetic	  analogues	  like	  AH61	  may	  be	  
an	   alternative	   solution	   for	   the	   treatment	   of	   APL.	   For	   successful	   APL	   treatment,	   a	  
continuous	   effective	   concentration	   of	   plasma	   ATRA	   is	   desirable	   as	   it	   reduces	   the	  
chances	   of	   patient	   relapse.	   Although	   the	   use	   of	   liarozole	   has	   shown	   promising	  
results,	  as	  discussed	  earlier	  in	  this	  Chapter,	  constant	  plasma	  levels	  of	  ATRA	  are	  never	  
maintained	   over	   the	   full	   course	   of	   treatment.305	   One	   alternative	   may	   be	   to	   use	  
synthetic	  analogues	  of	  ATRA	   that	  are	   resistant	   to	  metabolism,	   such	  as	  AH61.	  They	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would	   maintain	   their	   effective	   dose	   for	   longer	   as	   the	   body	   would	   be	   unable	   to	  
remove	   them.	   Understandably,	   for	   this	   to	   be	   viable,	   they	   would	   also	   need	   to	  
potentiate	   the	   same	   biological	   response	   exhibited	   by	   ATRA,	   which	   is	   to	   induce	  
complete	  remission	  of	  the	  cancer.324-­‐326	  Early	  data	  indicates	  the	  possible	  use	  of	  such	  
synthetic	  analogues	  in	  cancer	  treatment	  looks	  potentially	  interesting.	  	  
	  
Finally,	  it	  is	  likely	  that	  the	  biological	  effects	  elicited	  by	  AH60	  are	  indeed	  as	  a	  result	  of	  
the	  molecule,	   and	   not	   any	   isomerisation	   occurring	   in	   the	   cell	   or	   culture	  media	   to	  
small	   quantities	   of	   AH61.	   Although	   it	   must	   be	   noted	   this	   is	   based	   on	   preliminary	  
data,	   and	   the	   assumption	   that	   AH60	  will	   behave	   and	   bind	   in	   a	   similar	  manner	   to	  
13cRA,	   as	   structurally	   they	   have	   been	   designed	   to	   be	   equivalent.	   Further	   analysis	  
would	  be	  required	  if	  this	  was	  to	  be	  proved	  beyond	  reasonable	  doubt,	  although	  early	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3.5	   Conclusions	  
	  
The	   first	   conclusion	   that	   can	   be	   drawn	   is	   that	   the	   length	   of	   the	   retinoids	   is	   of	  
paramount	   importance.	  All	   the	   ‘short’	   analogues	  displayed	  no	  biological	   activity	   in	  
any	   of	   the	   model	   systems	   that	   were	   screened.	   Therefore,	   the	   most	   obvious	  
conclusion	  is	  that	  they	  are	  incapable	  of	  binding	  to	  the	  receptors,	  which	  bring	  about	  
the	  biological	  response.	  The	  ‘extended’	  analogue	  also	  displayed	  a	  very	  similar	  profile,	  
with	  little,	  if	  any,	  activity	  seen	  in	  all	  the	  model	  systems.	  This	  could	  also	  be	  down	  to	  a	  
lack	  of	  binding	  affinity	  for	  the	  receptors,	  and	  in	  this	  case	  possibly	  brought	  about	  by	  
the	  increased	  instability	  in	  the	  polyene	  chain.	  Any	  isomerisation	  may	  lead	  to	  isomers	  
which	   have	   a	   reduced	   affinity,	   and	   therefore,	   the	   low	   levels	   of	   activity	   that	   were	  
seen	   in	   some	  of	   the	  biological	   screens	  may	  be	   as	   a	   result	   of	   any	   remaining	   active	  
isomer.	   As	  we	  were	   unable	   to	   control	   the	   isomerisation	   to	   retain	   a	   single	   isomer,	  
proving	   this	  would	   be	   very	   difficult.	  Overall	   this	   highlights	   an	   important	   structural	  
feature,	  which	  up	  until	  now	  not	  been	  investigated.	  
	  
The	   observed	   biological	   induced	   similarity	   of	   AH60	   and	   AH61	   to	   ATRA	   and	   EC23	  
highlights	  them	  as	  highly	  useful	  and	  exciting	  molecules	  for	  controlling	   in	  vitro	  stem	  
cell	  differentiation.	   In	  particular,	   the	   increased	  activity	  of	  AH61	  over	   that	  of	  ATRA,	  
and	   its	  ability	  to	  mimic	  the	  biological	  profile	  of	  ATRA	  closer	  than	  that	  of	  EC23	  may	  
prove	  significantly	  useful.	  EC23	  is	  known	  to	  be	  highly	  toxic,	  therefore	  limiting	  its	  use	  
in	   vivo.	  Whether	   AH61	   is	   as	   toxic	   is	   unknown	   and	   further	   research	   is	   required	   to	  
investigate	   this,	   although,	   the	   inbuilt	   instability	   of	   the	   polyene	   chain	   may	   prove	  
beneficial.	   Further	   investigations,	   in	   alternative	   cell	   systems,	   are	   now	   required	   to	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4.1	  Introduction	  
	  
Currently,	  all	  analysis	  of	   the	  biological	  potential	  of	   this	  series	  of	  synthetic	  retinoids	  
has	  concentrated	  around	  their	  ability	  to	  induce	  differentiation	  in	  a	  pluripotent	  stem	  
cell	   system.	   This	   Chapter	   follows	   on	   from	   previous	   work	   carried	   out	   within	   our	  
research	  group,	  in	  which	  the	  ability	  of	  retinoids	  to	  direct	  differentiation	  of	  cells	  that	  
are	  already	  committed	  to	  a	  neuronal	  lineage	  is	  evaluated.	  	  
	  
NPCs	   and	   NSCs	   are	   highly	   valuable	   as	   they	   provide	   a	   renewable	   supply	   of	  
differentiating	   neural	   cells.	   In	   recent	   years,	   there	   has	   been	   increased	   focus	   on	  
utilising	   these	   cells	   as	   both	   a	   powerful	   research	   tool,	   and	   in	   the	   development	   of	  
therapies	   for	   neurodegenerative	   diseases,	   such	   as	   Parkinson’s,	   Alzheimer’s	   and	  
Huntington’s	  diseases.54-­‐56	  As	  discussed	   in	  Chapter	   I,	  ATRA	  has	  a	  well-­‐characterised	  
role	   in	   vivo	   in	   the	   developing	   CNS	   and	   subsequent	   synaptic	   plasticity	   seen	   in	   the	  
adult.188,	   190,	   191	   Consequently,	   ATRA	   has	   been	   used	   as	   a	   tool	   for	   inducing	   or	  
enhancing	   the	   differentiation	   of	   NPC/NSC	   lines	   in	   vitro.59,	   60	   In	   addition,	   synthetic	  
retinoids,	   including	   EC23,	   have	   demonstrated	   an	   enhanced	   activity,	   over	   ATRA	   in	  
these	  cell	  lines.59	  
	  
Two	  model	  systems	  have	  been	  assessed,	  one	  a	  human	  embryonic	  cell	   line,	   termed	  
ReNcell	   VM,	   and	   the	   other	   an	   adult	   cell	   line	   from	   rat	   hippocampus,	   termed	   adult	  
hippocampal	  progenitor	  cells	  (AHPC).	  
	  
4.1.1	  Human	  Embryonic	  Neural	  Stem	  Cells.	  
	  
Most	   early	   work	   carried	   out	   on	   NSCs	   was	   on	   those	   derived	   from	   rodent	   sources,	  
from	  which	  the	  potential	  of	  these	  cells	  was	  realised.	  Subsequently,	  there	  have	  been	  
a	  handful	  of	  studies	  which	  have	  used	  human	  neural	  stem	  cells	  (hNSCs),	  identified	  by	  
their	  ability	  to	  self-­‐renew	  and	  multipotency.	  During	  the	  beginning	  of	  the	  last	  decade,	  
Piper	  at	  al.	  demonstrated	  the	  production	  of	  neurons,	  possessing	  ligand	  and	  voltage-­‐
gated	   channels,	   derived	   from	   fetal	   NSCs.219	   Further	   studies	   demonstrated	   similar	  
results,	  with	   the	  most	  successful	  being	   that	  developed	  by	  Wu	  et	  al.,	   in	  which	   fetal	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hNSCs	  were	  differentiated	  into	  cholinergic	  neurons	  with	  action	  potentials,	  followed	  
by	  successful	  grafts	   into	  adult	  rats.220	  The	  major	  limitation	  in	  these	  studies	  was	  the	  
high	  mortality	  rate	  of	  the	  cells	  when	  grown	  in	  culture,	  with	  many	  cell	  lines	  unable	  to	  
be	  passaged	  more	  than	  five	  times.327	  	  	  	  
	  
More	  recently,	  Donato	  et	  al.	  described	  the	  production	  of	  two	  stable	  multipotent	  NSC	  
lines,	  which	  can	  be	  continuously	  cultured	  and	  expanded	  as	  a	  monolayer,	  with	  no	  loss	  
in	   viability.57	   The	   studies	   described	   previously	   were	   all	   limited	   to	   low	   passage	  
numbers,	  whereas	  Donato	  et	  al.	  successfully	  demonstrated	  long-­‐term	  culture,	  up	  to	  
passage	  46.	  The	  approach	  adopted	  was	  to	  immortalise	  the	  cells	  through	  insertion	  of	  
a	  myc	  transcription	  factor,	  as	  this	  had	  been	  previously	  demonstrated	  to	  increase	  the	  
normal	  life	  span	  of	  hNSCs	  in	  vitro.328,	  329	  One	  cell	  line	  developed,	  the	  ReNcell	  VM	  line,	  
was	  derived	  from	  the	  ventral	  mesencephalon	  of	  ten-­‐week	  gestation	  fetal	  midbrains.	  
The	   cell	   line	  was	   immortalised	  with	   v-­‐myc,	   as	   this	   is	   thought	   to	   be	   the	   ‘stemness’	  
gene,	   thus	   deriving	   both	   proliferation	   and	  multipotency	   in	   the	   stem	   cells.19	  Under	  
standard	   growth	   conditions,	   the	   cells	   appear	   as	   small	   polygonal	   cells	   with	   limited	  
processes,	   indicative	  of	  an	   immature	  neural	  morphology,	  and	  stain	  positive	   for	   the	  
neural	   stem	   cell	   marker,	   nestin.	   	  When	   differentiated,	   through	   withdrawal	   of	   the	  
growth	  factors,	  FGF	  and	  EGF,	  positive	  immunohistological	  staining	  was	  visualised	  for	  
neurons,	   astrocytes	   and	   oligodendrocytes.	   Adaption	   of	   this	   protocol,	   led	   to	   the	  
development	  of	  electrophysiologically	  functional	  neurons	  signified	  with	  an	   increase	  
in	  dopaminergic	  neurons.57	  	  
	  
In	   a	   follow	   up	   study	   performed	   in	   our	   research	   laboratory,	   the	   incorporation	   of	  
retinoids	  into	  the	  differentiation	  protocol	  was	  investigated.59	  It	  has	  been	  previously	  
published	   that	   cells	   derived	   from	   this	   area	   of	   the	   brain	   are	   responsive	   to	   retinoic	  
acid.330	   Consequently,	   the	   incorporation	   of	   both	   ATRA	   and	   the	   synthetic	   retinoid	  
EC23	  was	   investigated	  by	  administration	  at	   the	  point	  of	   growth-­‐factor	  withdrawal.	  
Both	   retinoids	   were	   shown	   to	   visually	   enhance	   neuronal	   differentiation,	   inducing	  
increased	  maturation	  and	  stabilisation	  of	  the	  axonal	  cytoskeleton.	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4.1.2	  Adult	  Neural	  Progenitor	  Cells	  
	  
In	  adults,	  neurogenesis	  declines	  until	  it	  ceases	  in	  the	  young	  adult	  mammalian	  brain,	  
except	  in	  two	  areas,	  the	  olfactory	  bulb	  and	  the	  hippocampus,	  both	  of	  which	  produce	  
new	  neurons	  throughout	  adult	  life.245	  The	  discovery	  of	  this	  phenomenon	  has	  led	  to	  a	  
number	  of	  cells	  lines	  being	  established	  in	  an	  attempt	  to	  exploit	  this	  novel	  area.	  One	  
of	  the	  earliest	  was	  a	  population	  of	  FGF-­‐2	  responsive	  neural	  progenitor	  cells	  isolated	  
and	  cultured	  from	  adult	  rat	  hippocampus.	  The	  cell	  line	  was	  initially	  transfected	  with	  
green	   fluorescent	   protein	   (GFP)	   and	   termed	   HCN-­‐nitGFP,	   although	   it	   has	  
subsequently	   been	   termed	   AHPC.	   When	   cultured	   in	   vitro,	   the	   cells	   expressed	  
precursor,	  glial	  and	  neuronal	  cell	  markers	  and	  subsequent	  implantation	  into	  adult	  rat	  
hippocampus	  demonstrated	  that	  not	  only	  could	  the	  cells	  survive,	  but	  they	  could	  also	  
differentiate	  into	  terminal	  mature	  glia	  and	  neurons.58	  Further	  studies	  demonstrated	  
analogous	   populations	   of	   neural	   progenitor	   cells	   could	   be	   isolated	   from	   both	  
germinal	  zones	  and	  parenchyma	  of	  adult	  rat	  brain,	  and	  that	  FGF-­‐2	  played	  a	  vital	  role	  
in	  both	  recruiting	  and	  maintaining	  the	  progenitor	  population	  in	  vitro.218	  Subsequent	  
genetic	   marking	   of	   individual	   cells	   demonstrated	   that	   some	   of	   these	   progenitors	  
isolated	   were	   self-­‐renewing	  multipotent	   stem	   cells,	   supporting	   evidence	   that	   the	  
adult	  brain	  does	  consist	  of	  some	  highly	  plastic	  central	  nervous	  system	  stem	  cells.245	  
Withdrawal	  of	  FGF-­‐2	  was	  shown	  to	  stimulate	  some	  neuronal	  differentiation,245	  but	  
additional	   treatment	   with	   ATRA	   or	   neurotrophins	   (NTs)	   further	   potentiated	   the	  
process,	  with	  the	  end	  result	  of	   treatment	  with	  ATRA	  being	  a	   three	   fold	   increase	   in	  
the	  number	  of	  neurons	  produced	  compared	  to	  FGF-­‐2	  withdrawal	  alone.60	  This	  is	  not	  
surprising	  considering	  the	  retinoic	  acid	  pathway	  has	  since	  been	  identified	  as	  having	  a	  
major	  role	  in	  the	  active	  re-­‐modelling	  of	  the	  adult	  hippocampus.191	  	  
	  
The	   cell	   line	  described	  above	  gives	   a	   good	   idea	  of	   the	  potential	   adult	   neural	   stem	  
cells	  hold,	  but	   it	  must	  also	  be	  noted	   that	  differences,	   compared	   to	   those	   found	   in	  
humans,	  may	  also	  transpire.	  This	  may	  be	  assumed	  as	  differences	   in	  rat	  and	  mouse	  
progenitor	  cell	  lines	  have	  been	  described.331	  Therefore,	  it	  is	  also	  desirable	  to	  have	  a	  
human	  model	   system	   to	  work	  with.	  One	   solution	   is	   that	   of	   the	   cell	   line	   described	  
previously	   in	  4.1.1,	  although	  using	  embryonic	  tissues	  often	  encounters	  societal	  and	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ethical	  issues.	  Consequently,	  there	  has	  been	  much	  interest	  in	  isolating	  human	  adult	  
hippocampal	   progenitor	   cells.	   For	   obvious	   reasons,	   obtaining	   living	   healthy	   adult	  
brain	   tissue	   is	   not	   easily	   achieved.	   To	   date,	   two	   potential	   methods	   have	   been	  
described	   in	   the	   literature.	   The	   first	   used	   surgically	   resected	   hippocampus	   from	   a	  
range	   of	   male	   patients	   undergoing	   temporal	   lobe	   resections	   for	   medication-­‐
refractory	  epilepsy,	  aneurysm	  repair	  and	  traumatic	  edema.	  Neural	  progenitors	  cells	  
were	   successfully	   identified	   and	   sorted	   in	   good	   numbers	   and	   purity,	   remained	  
mitotically	  competent	  and	  matured	  into	  functional	  neurons.332	  The	  second,	  involved	  
the	  isolation	  and	  successful	  propagation	  of	  neural	  progenitor	  cells	  from	  the	  human	  
brain	  after	  death.	  Again,	  multiple	  tissue	  samples	  were	  taken	  from	  a	  range	  of	  patients	  
of	   differing	   ages,	   with	   the	   post-­‐mortem	   interval	   not	   exceeding	   20	   hours.	   The	  
successful	   isolation	   of	   neural	   progenitor	   cells	  was	   demonstrated	  with	   the	   greatest	  
numbers	   isolated	   from	   the	   hippocampus.	   Differentiation	   into	   neurons	   was	  
subsequently	   induced	   with	   withdrawal	   of	   growth	   factors	   followed	   by	   addition	   of	  
forskolin	  and	  retinoic	  acid.333	  Both	  methods	  hold	  the	  potential	  of	  providing	  a	  reliable	  
source	   of	   adult	   human	   progenitor	   cells,	  which	   could	   then	   be	   used	   to	   assess	   adult	  
neurogenesis	  in	  humans.	  	  
	  
However,	  it	  can	  be	  assumed	  that	  evidence	  obtained	  from	  animal	  models	  will	  relate	  
to	  some	  extent	  to	  humans,	  although	  the	  potential	  for	  differences	  should	  always	  be	  
considered.	   Currently,	   especially	   for	   the	   preliminary	   screening	   of	   new	   potential	  
modulators	  such	  as	  described	  within	  this	  thesis,	  animal	  models	  such	  as	  the	  AHPC	  line	  
described	  above	  remain	  the	  most	  accessible	  and	  appropriate	  source	  of	  adult	  neural	  
progenitors	  cells.	  Previous	  work	  within	  the	  group	  has	  used	  this	  cell	  line	  to	  assess	  the	  
potential	  of	  both	  EC19	  and	  EC23.	  AHPCs	  were	  shown	  to	  differentiate	  upon	  addition	  
of	  ATRA	  and	  synthetic	  derivatives,	  with	  the	  expression	  of	  the	  neuronal	  marker	  TuJ1	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4.2	  Aims	  and	  Objectives	  
	  
The	  aim	  of	  the	  research	  presented	   in	  this	  Chapter	  was	  to	   investigate	  the	  effects	  of	  
both	   AH60	   and	   AH61,	   on	   both	   embryonic	   and	   adult	   neural	   progenitor	   cells,	   and	  
compare	   them	   to	   the	   known	   responses	   of	   both	   ATRA	   and	   EC23.	   The	   rationale,	  
behind	  repeating	  this	  investigation	  with	  both	  AH60	  and	  AH61,	  was	  that	  they	  have	  a	  
closer	  structural	  resemblance	  to	  ATRA,	  may	  potentially	  be	  less	  toxic	  than	  EC23,	  and	  
therefore	   could	   be	   a	   better	   alternative	   for	   in	   vitro	   investigations	   in	   these	   cell	  
systems.	  
	  
The	   main	   objectives	   were	   to:	   (A)	   demonstrate	   that	   both	   AH60	   and	   AH61	   induce	  
differentiation	  in	  both	  neural	  progenitor	  systems	  and	  compare	  this	  to	  that	   induced	  
by	   both	   ATRA	   and	   EC23;	   (B)	   to	   investigate	   the	   dose	   response	   of	   the	   synthetic	  
compounds	   and	   compare	   this	   to	   that	   previously	   seen	   in	   the	   EC	  model	   system;	   (C)	  
compare	  the	  activity	  of	  AH60	  to	  AH61	  and	  see	  if	  trends	  seen	  within	  the	  EC	  stem	  cells	  
are	  also	  visualised	   in	   the	  neural	  progenitors;	  and	   (D)	   investigate	   the	  toxicity	  of	   the	  
compounds,	  to	  determine	  whether	  they	  appear	  less	  toxic	  than	  EC23	  and	  mimic	  the	  
profile	   of	   ATRA,	   or	   because	   they	   appear	   to	   be	  metabolically	   stable,	   have	   a	   profile	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4.3	  Results	  
	  
4.3.1	   Analysis	   of	   the	   Potential	   of	   AH60	   and	   AH61	   to	   Induce	   Neural	  
Differentiation	  of	  ReNcell	  VM	  Cell	  Cultures.	  
	  
This	  section	  deals	  with	  the	  effects	  of	  incorporating	  AH60	  or	  AH61	  into	  a	  commercial	  
neural	   cell	   differentiation	   protocol.	   As	   discussed	   earlier,	   methods	   have	   been	  
published	  regarding	  the	  differentiation	  of	  these	  cells	  into	  neural	  sub-­‐types	  including	  
a	   method	   involving	   retinoid	   incorporation	   undertaken	   in	   our	   laboratory.	   These	  
known	  protocols	  make	  this	  cell	  line	  an	  ideal	  model	  to	  screen	  the	  novel	  retinoids.	  The	  
standard	   differentiation	   protocol	   involves	   the	   removal	   of	   the	   two	   growth	   factors,	  
FGF	   and	   EGF,	   from	   the	   proliferation	   media.	   Subsequent,	   addition	   of	   ATRA	   at	   the	  
same	  time	  as	  removing	  the	  growth	  factors	  has	  been	  shown	  to	  significantly	  increase	  
the	   number	   of	   differentiated	   cells,	   assessed	   through	   analysing	   neuronal	   markers.	  
ATRA	   not	   only	   accelerates	   neurogenesis,	   but	   also	   the	   maturity	   of	   neuronal	  
derivatives	  is	  enhanced	  after	  seven	  days	  in	  retinoid-­‐supplemented	  media.59	  	  
	  
As	   in	   the	   previous	   study,	   retinoids	   were	   added	   at	   the	   point	   of	   growth	   factor	  
withdrawal,	   which	   signifies	   the	   initiation	   of	   differentiation	   in	   the	   commercial	  
protocol.	   ReNcell	   VM	   cells	   were	   cultured	   under	   standard	   conditions	   in	   laminin	  
coated	   flasks,	   as	   previously	   described	   by	   Donato	   et	   al.	   and	   Christie	   et	   al..57,	   59	  
Undifferentiated	   cultures,	   and	   control-­‐differentiated	   cultures,	   were	   prepared	  
alongside	  those	  treated	  with	  ATRA	  and	  the	  synthetic	  retinoids,	  AH60	  and	  AH61.	  The	  
control	  differentiation	  method	  used	  followed	  the	  standard	  differentiation	  protocol,	  
involving	   the	   withdrawal	   of	   growth	   factors	   from	   the	   culture	   media.	   For	   cultures	  
where	  retinoids	  are	  incorporated	  as	  part	  of	  the	  differential	  protocol,	  1	  μM	  ATRA,	  1	  
μM	  AH60	  or	  1	  μM	  AH61	  were	  administered	  at	  the	  same	  time	  as	  the	  growth	  factors	  
were	   withdrawn.	   All	   cultures	   were	   maintained	   in	   their	   respective	   media	  
formulations	   for	   seven	   days,	  with	   the	  media	   replaced	   at	   the	   halfway	   point	   of	   the	  
experiment.	  Phase	  micrographs	  were	  analysed	  after	  7	  days,	  Figure	  4.1.	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  UNDIFF	   	   	   CON	  DIFF	   	   	  	  	  	  	  	  	  +	  ATRA	  (1	  µM)	  
	  
	  
	  	  	  	  	  	  	  	  	  +	  AH60	  1	  µM	   	   	  	  	  	  	  	  	  	  +	  AH61	  1	  µM	   	   	  	  	  	  	  	  +	  AH61	  1	  µM	  	  
	  	  (high	  magnification)	  
	  
	  
	  Figure	   4.1	   Morphologies	   of	   ReNcell	   VM	   cells	   after	   7	   days	   treatment.	   Undifferentiated	  
cultures	   (UNDIFF)	   retained	  a	  homogeneous	  appearance	  with	  cells	   layering	  as	   they	  become	  
over	   confluent	   and	   sub-­‐optimal.	   Control	   differentiated	   cultures	   (CON	   DIFF),	   in	   which	   the	  
growth	  factors,	  EGF	  and	  FGF	  were	  removed,	  showed	  areas	  of	  proliferative	  cells	  surrounded	  
by	  more	   sparsely	   populated	   areas	  with	   numerous	   neural	   processes	   visible.	   Those	   treated	  
with	   the	   retinoids,	  ATRA,	  AH60	  and	  AH61	  at	  1	  µM	  also	  showed	  high	  numbers	  of	  neuronal	  
processes	   (see	   high	  magnification	   image)	   but	   retained	   a	   homogeneous	   differentiated	   cell	  
population	  with	   no	   areas	   of	   proliferative	   cells	   visualised.	   Scale	   Bars:	   100	  μm	   (50	  μm	  high	  
magnification).	  	  	  
	  
As	  described	  previously	  in	  the	  literature,57,	  59	  removal	  of	  the	  growth	  factors	  (control	  
differentiation)	   resulted	   in	   a	   shift	   from	  a	  homogeneous	  population	  of	  proliferative	  
cells	   with	   a	   uniform	   morphology,	   to	   a	   heterogeneous	   cell	   population.	   This	   was	  
characterised	  by	  areas	  of	  cells	  that	  appeared	  similar	  to	  those	  in	  the	  undifferentiated	  
cultures	  i.e.	  proliferative	  cells,	  surrounded	  by	  areas	  of	  neuron-­‐like	  cells,	  which	  were	  
more	  thinly	  populated.	  Overall,	  on	  average,	  there	  is	  a	  68%	  drop	  in	  cell	  number	  from	  
the	   undifferentiated	   culture,	   confirming	   the	   cells	   are	   exiting	   the	   cell	   cycle	   and	  
differentiating.	  Addition	  of	  the	  retinoids	  (either	  ATRA,	  AH60	  or	  AH61)	  overall	  led	  to	  
greater	   homogeneity	   in	   the	   cell	   population.	   In	   addition	   the	   total	   number	   of	   cells	  
visible	  was	  also	  lower,	  with	  an	  average	  drop	  in	  cell	  number	  of	  75%,	  compared	  to	  the	  
undifferentiated	  control.	  This	  suggests	  the	  retinoids	  further	  enhance	  differentiation	  
through	  promoting	   the	  cells	   to	  exit	   the	  cell	   cycle.	  Furthermore,	   the	  morphology	  of	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the	  cells	  also	  changed,	  with	  the	  majority	  predominantly	  having	  neuron-­‐like	  features	  
(see	  Figure	  4.1	  high	  magnification	  image).	  Unlike	  the	  control-­‐differentiated	  cultures,	  
which	  still	  contained	  areas	  of	  cells	   that	  appeared	  to	  be	  proliferating,	   those	  treated	  
with	   the	   retinoids	  appeared	   to	  have	   inhibited	   this	  cell	   type.	  This	   is	   consistent	  with	  
data	  previously	  published	  for	  ATRA	  and	  EC23,	  indicating	  early	  on	  that	  both	  AH60	  and	  
AH61	  appear	  to	  mimic	  the	  activity	  of	  these	  retinoids.	  	  
	  
To	  further	  assess	  the	  potential	  of	  AH60	  and	  AH61,	  immunocytochemical	  staining	  was	  
performed	   to	   analyse	   the	   expression	   of	   the	   neuronal	  marker	  β-­‐III	   tubulin,	  mature	  
neuronal	  protein	  marker	  NF-­‐200	  and	  MAP2ab,	  a	  microtubule	  protein	  associated	  with	  
neurogenesis.	   Fluorescence	   micrographs	   for	   β-­‐III	   tubulin,	   NF-­‐200	   and	   MAP2ab	  
expression,	   alongside	   inlayed	   images	   of	   the	   corresponding	   nuclear	   stains	   (Hoechst	  
33342),	  from	  cells	  grown	  under	  undifferentiated,	  control-­‐differentiated	  and	  retinoid-­‐
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From	   the	   images	   in	   Figure	   4.2,	   it	   is	   clear	   to	   see	   that	   retinoid	   incorporation	  
significantly	   up-­‐regulates	   the	   expression	   of	   all	   three	   markers.	   Christie	   et	   al.	  
published	   that	   the	   standard	   differentiation	   protocol	   resulted	   in	   approximately	   a	  
2.75-­‐fold	   increase	   in	   the	  number	  of	   cells	   that	   stain	  positive	   for	  β-­‐III-­‐tubulin,	   and	  a	  
4.5-­‐fold	   increase	   in	  the	  number	  of	  cells	  staining	  positive	  for	  MAP2ab,	  compared	  to	  
undifferentiated	  samples.	  Notably,	   they	  did	  not	   see	  any	   increase	   in	   the	  expression	  
for	   NF-­‐200.	   	   Incorporation	   of	   ATRA	   at	   100	   nM	   (and	   similarly	   EC23)	   resulted	   in	   a	  
dramatic	   and	   highly	   significant	   increase	   in	   all	   three	   markers,	   with	   β-­‐III-­‐tubulin	  
expression	  increasing	  9-­‐fold,	  NF-­‐200	  40-­‐fold	  and	  MAP2ab	  15-­‐fold.59	  	  
	  
After	   immunocytochemical	   staining	   of	   AH60	   and	   AH61	   cultures,	   all	   images	   were	  
quantified	   through	   cell	   counts	   and	   the	   number	   of	   positive	   cells	   expressed	   as	   a	  
percentage	  of	  the	  total	  population	  visible	  per	  field	  of	  view.	  As	  in	  all	  previous	  work,	  
three	   biological	   triplicates	  were	   obtained	   along	  with	   three	   independent	   images	   of	  
each	   repeat.	   The	   data	   agreed	   with	   that	   previously	   published	   with	   regards	   to	   the	  
control	  differentiation	  protocol,	  with	  similar	   levels	  of	   increase	  seen	  for	  β-­‐III-­‐tubulin	  
and	   MAP2ab.	   As	   hypothesised	   for	   the	   synthetic	   compounds,	   and	   in	   line	   with	  
previous	   screening,	   the	   incorporation	  of	   the	   synthetic	   retinoids	   led	   to	  a	   significant	  
increase	  in	  the	  expression	  of	  all	  three	  markers.	  The	  concentration	  chosen	  to	  screen	  
the	  synthetic	   retinoids	   initially	  was	  10×	  higher	   than	  that	  previously	  published,	  so	  a	  
direct	  comparison	  cannot	  yet	  be	  deduced.	  The	  reason	  for	  screening	  these	  molecules	  
at	   an	   initially	   higher	   concentration	   was	   that	   previous	   work	   within	   our	   group	  
(unpublished)	   had	   demonstrated	   that	   the	   cell	   line	   could	   tolerate	   some	   retinoids,	  
such	   as	   ATRA,	   at	   this	   higher	   concentration.	   However,	   some	   synthetic	   retinoids,	  
including	  EC23,	  were	  found	  to	  be	  toxic	  at	  this	  higher	  concentration	  and	  so	  were	  only	  
analysed	   at	   100	   nM	   and	   lower.	   As	   both	   AH60	   and	   AH61	   are	   closer	   in	   molecular	  
structure	   to	   ATRA,	   with	   some	   inbuilt	   instability,	   we	   hypothesised	   that	   they	   could	  
possibly	   be	   tolerated	   at	   higher	   concentrations	   than	   the	   more	   stable	   synthetic	  
analogue,	  EC23.	  This	  also	  allowed	  us	  to	  assess	  their	  toxicity,	  and	  build	  a	  comparison	  
to	  that	  of	  EC23.	  From	  the	  images	  displayed	  in	  Figures	  4.1	  and	  4.2,	  it	   is	  evident	  that	  
both	  synthetic	  retinoids	  AH60	  and	  AH61	  are	  not	  toxic	  at	  1	  μM,	  supporting	  our	  theory	  
that	   they	   act	   more	   like	   ATRA	   than	   the	   other	   previously	   screened	   synthetic	  
	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Chapter	  IV	  
	   149	  
analogues.	  The	  increase	  in	  expression	  of	  each	  of	  the	  markers	  was	  quantified	  through	  
cell	   counts	   and	   expressed	   graphically	   as	   a	   percentage	   of	   the	   total	   cell	   population,	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(A)	  	   	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  β-­‐III-­‐tubulin	   	   	   	  
	  
	  
(B)	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  NF-­‐200	  
	  
	  
(C)	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  MAP2ab	  
	  
	  
Figure	   4.3	   Plots	   displaying	   quantification	   of	   the	   immunological	   data	   as	   performed	   by	  
counting	  positively	   labelled	  cells.	  The	   increased	  number	  of	  β-­‐III-­‐tubulin	  (A),	  NF-­‐200	  (B)	  and	  
MAP2ab	  (C)	  positive	  cells	  in	  retinoid	  supplemented	  cultures	  was	  highly	  significant	  compared	  
to	   control	   differentiated	   cultures	   (Con-­‐Diff).	   Triplicate	   analysis	   was	   performed	   for	  
reproducibility.	   Values	   shown	   represent	  mean	   +	   standard	   error	   (SDE),	   n=9.	   **	   p≤0.005,	   *	  
p≤0.05	   Student’s	   t-­‐test	   corrected	   for	   multiple	   testing	   of	   sample	   populations	   using	   the	  
Bonferroni	  correction.	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Upon	  quantification,	   the	   increase	   in	  expression	  of	  all	   three	  markers	  was	  significant	  
upon	  inclusion	  of	  all	  three	  retinoids.	  The	  profiles	  exhibited	  for	  ATRA	  and	  AH60	  were	  
identical	   with	   similar	   increases	   across	   all	   three	   markers	   visualised.	   More	   notably,	  
AH61	   induced	   further	   significant	   increases	   compared	   to	   that	  of	  ATRA	  and	  AH60	   in	  
both	  β-­‐III-­‐tubulin	  and	  NF-­‐200	  expression.	  This	  supports	  data	  previously	  obtained	   in	  
the	   EC	   model	   suggesting	   that	   this	   synthetic	   analogue	   is	   appreciably	   more	   potent	  
than	   its	   natural	   counterpart	   and	   its	   isomer	  AH60.	  Overall,	   these	   results	   show	   that	  
retinoid	   supplementation	  using	  AH60	  and	  AH61	   increases	   the	  number	  of	  neuronal	  
cells	  derived	  from	  ReNcell	  VM	  cultures	  and	  significantly	  increases	  neuronal	  maturity,	  
as	   evidenced	   by	   NF-­‐200	   expression,	   comparable	   to	   that	   of	   ATRA	   for	   AH60	   and	  
significantly	  better	  when	  treated	  with	  AH61.	  	  	  
	  
To	   investigate	   the	   dose	   response	   of	   incorporating	   retinoids	   into	   differentiating	  
ReNcell	  VM	  cultures,	  retinoids	  were	  added	  at	  0.1	  μM,	  0.01	  μM	  and	  0.001	  μM.	  These	  
concentrations	   were	   chosen	   as	   they	   represent	   those	   used	   in	   previous	   studies	  
investigating	  the	  dose	  response	  of	  EC23.59	  As	   in	  the	  previous	  set	  of	  experiments	  at	  
the	  higher	  concentration,	   the	  numbers	  of	  cells	  expressing	  β-­‐III-­‐tubulin,	  NF-­‐200	  and	  
MAP2ab	  were	  measured.	  Both	   immunofluorescent	  micrographs	  and	  quantified	  cell	  
counts	  display	  a	   clear	  dose	   response	  of	   all	   the	   retinoids,	  displayed	   in	   Figures	  4.4	   -­‐	  
4.7.	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Figure	  4.4	  Cultures	  of	  ReNcell	  VM	  cells	  were	   induced	  to	  differentiate	   for	  7	  days	  under	  the	  
standard	  differentiation	  protocol	  with	  the	  addition	  of	  ATRA	  at	  0.1	  µM,	  0.01	  µM	  or	  0.001	  µM.	  




Figure	  4.5	  Cultures	  of	  ReNcell	  VM	  cells	  were	   induced	  to	  differentiate	   for	  7	  days	  under	  the	  
standard	   differentiation	   protocol	  with	   the	   addition	   of	   AH60	   at	   0.1	  µM,	   0.01	  µM	  or	   0.001	  
µM.	  Scale	  bar:	  50	  μm.	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Figure	  4.6	  Cultures	  of	  ReNcell	  VM	  cells	  were	   induced	  to	  differentiate	   for	  7	  days	  under	  the	  
standard	   differentiation	   protocol	  with	   the	   addition	   of	   AH61	   at	   0.1	  µM,	   0.01	  µM	  or	   0.001	  
µM.	   Immunological	   evaluation	   of	   β-­‐III-­‐tubulin,	   NF-­‐200	   and	   MAP2ab	   showed	   enhanced	  
expression	  in	  AH61	  treated	  cultures	  Scale	  bar:	  50	  μm.	  
	  
From	  the	   immunofluorescent	  micrographs	   there	   is	  a	   clear	  and	  notable	  drop	   in	   the	  
expression	  levels	  of	  all	  three	  markers	  for	  ATRA	  and	  AH60,	  compared	  to	  that	  seen	  at	  
the	  higher	   concentration.	   This	   suggests	  both	  molecules	   are	   significantly	   less	   active	  
once	   their	   concentration	   is	   reduced.	   Upon	   examination	   of	   cultures	   treated	   with	  
AH61,	   this	  effect	  appears	   to	  be	  significantly	   reduced,	  with	  all	   three	  concentrations	  
displaying	   strong	   immunofluorescent	   images,	   especially	   those	   stained	   for	   β-­‐III-­‐
tubulin.	   This	   supports	   the	   data	   displayed	   in	   the	   previous	   EC	   model	   system,	   and	  
therefore,	  again	  suggests	  that	  AH61	  is	  more	  active	  at	  lower	  concentrations.	  
	  
Upon	   quantification	   (as	   was	   done	   for	   the	   higher	   concentration),	   a	   clear	   dose	  
response	   for	   all	   three	   compounds	   can	   be	   seen	   (Figure	   4.7).	   AH61	   produces	  
significantly	  more	  positive	  staining	  for	  all	  three	  markers	  at	  both	  0.1	  μM	  and	  0.01	  μM.	  
There	  is	  a	  sudden	  drop	  off	  at	  0.001	  μM	  but	  levels	  remain	  not	  significantly	  different	  
to	   ATRA	   at	   0.1	   μM.	   This	   further	   supports	   our	   previous	   conclusion	   that	   AH61	   is	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approximately	   100-­‐fold	   more	   active	   than	   ATRA.	   There	   is	   no	   difference	   in	   the	  
expression	   of	   β-­‐III-­‐tubulin	   or	   NF-­‐200	   for	   both	   ATRA	   and	   AH60,	   while	   AH60	   only	  
shows	   a	   slight,	   but	   significant,	   increase	   in	   MAP2ab	   expression	   at	   0.1	   μM.	   This	  
suggests	  that	  AH60	  is	  potentially	  less	  active	  in	  this	  system	  compared	  to	  the	  EC	  model	  
used	  in	  Chapter	  3.	  Currently,	  there	  is	  no	  data	  for	  13cRA;	  this	  would	  be	  an	  interesting	  
comparison	   to	   undertake	   in	   the	   future	   as	   13cRA	   is	   more	   structurally	   comparable	  
with	   AH60.	   Data	   collected	   from	   the	   EC	   model	   suggests	   that	   13cRA	   is	   as	   equally	  
potent	   to	  ATRA,	   and	   since	  AH60	  and	  ATRA	   showed	  nearly	   identical	   profiles	   in	   this	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(C)	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  MAP2ab	  
	  
	  
Figure	   4.7	   Plots	   displaying	   quantification	   of	   the	   immunological	   data	   as	   performed	   by	  
counting	  positively	   labelled	  cells.	  The	   increased	  number	  of	  β-­‐III-­‐tubulin	  (A),	  NF-­‐200	  (B)	  and	  
MAP2ab	  (C)	  positive	  cells	  in	  AH61	  supplemented	  cultures	  was	  highly	  significant	  compared	  to	  
ATRA	   supplemented	   cultures.	   Triplicate	   analysis	  was	   performed	   for	   reproducibility.	   Values	  
shown	   represent	  mean	   +	   standard	   error	   (SDE),	   n=9.	   ***	   p≤0.0005,	   **	   p≤0.005,	   *	   p≤0.05	  
Student’s	   t-­‐test	   corrected	   for	  multiple	   testing	   of	   sample	   populations	   using	   the	   Bonferroni	  
correction.	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Finally,	  a	  direct	  comparison	  of	  the	  potency	  of	  AH61	  compared	  to	  that	  of	  EC23	  was	  
desired.	  Analysing	  the	  current	  data,	  and	  comparing	  this	  to	  work	  previously	  published	  
on	  EC23	  suggests	  that	  AH61	  is	  a	  more	  potent	  inducer	  of	  neuronal	  differentiation	  in	  
the	  ReNcell	   VM	  cell	   system.59	   To	   confirm	   this	   observation,	   cultures	  of	   ReNcell	   VM	  
cells	  were	  incubated	  with	  ATRA,	  AH61	  and	  EC23	  at	  0.1	  μM	  and	  0.01	  μM,	  alongside	  
both	   undifferentiated	   and	   standard	   control	   differentiated	   cells.	   The	   two	  
concentrations	   chosen	   were	   those	   that	   exhibited	   the	   greatest	   differences	   when	  
comparing	  data	  presented	   in	   this	   thesis	   to	   that	  previously	  published	  by	  Christie	  et	  
al.59	  As	   in	   the	  previous	  experiment,	  ReNcell	  VM	  cells	  were	  cultured	   for	  seven	  days	  
before	   being	   stained	   for	   the	   three	   neuronal	   markers,	   β-­‐III-­‐tubulin,	   NF-­‐200	   and	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From	  the	  immunofluorescent	  micrographs,	  an	  increase	  in	  β-­‐III-­‐tubulin	  expression	  in	  
cultures	   treated	  with	  AH61	   is	  most	  notable.	   In	  addition,	  both	  NF-­‐200	  and	  MAP2ab	  
expression	  appear	   to	  be	  up	   regulated	   in	  AH61	   treated	  cultures,	   compared	   to	  both	  
ATRA	  and	  EC23.	  Upon	  quantification	  (Figure	  4.9),	  achieved	  through	  cell	  counts,	  the	  
enhanced	   potency	   of	   AH61	   over	   EC23	   in	   inducing	   neural	   differentiation	   is	   clearly	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  NF-­‐200	  
	  
	  
(C)	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  MAP2ab	  
	  
	  
Figure	   4.9	   Plots	   displaying	   quantification	   of	   the	   immunological	   data	   as	   performed	   by	  
counting	  positively	   labelled	  cells.	  The	   increased	  number	  of	  β-­‐III-­‐tubulin	  (A),	  NF-­‐200	  (B)	  and	  
MAP2ab	  (C)	  positive	  cells	  in	  AH61	  supplemented	  cultures	  was	  highly	  significant	  compared	  to	  
EC23	   supplemented	   cultures.	   Triplicate	   analysis	  was	   performed	   for	   reproducibility.	   Values	  
shown	  represent	  mean	  +	  standard	  error	  (SDE),	  n=9.	  ***	  p≤0.0005,	  Student’s	  t-­‐test	  corrected	  
for	  multiple	  testing	  of	  sample	  populations	  using	  the	  Bonferroni	  correction.	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Having	   displayed	   that	   synthetic	   analogue	   AH61	   significantly	   enhances	   neuronal	  
differentiation	   in	  human	  fetal	  neuroprogenitor	  cells,	  we	  next	  wished	  to	   investigate	  
its	  effects	  on	  an	  adult	  neuroprogenitor	  system.	  
	  
4.3.2	   Analysis	   of	   the	   Potential	   of	   AH60	   and	   AH61	   to	   Induce	   Neural	  
Differentiation	  in	  Adult	  Hippocampal	  Neural	  Progenitor	  Cells.	  
	  
The	   final	   section	   of	   this	   Chapter	   deals	  with	   the	   effects	   of	   incorporating	  AH60	   and	  
AH61	   into	   differentiation	   protocols	   derived	   for	   the	   AHPC	   cell	   line.	   As	   discussed,	  
treatment	  of	   this	   cell	   line	  with	  ATRA	   led	   to	  a	   three-­‐fold	   increase	   in	   the	  number	  of	  
neurons	   produced	   compared	   to	   FGF-­‐2	   withdrawal	   alone.60	   Therefore,	   we	  
hypothesised	   that	   treatment	  with	   the	   synthetic	   AH	   analogues	  would	   increase	   this	  
further,	  and	  potentially	  provide	  a	  homogeneous	  population	  of	  mature	  neurons.	  	  
	  
For	   the	   cells	   to	   proliferate,	   FGF	   must	   be	   present,	   therefore,	   the	   standard	  
differentiation	  protocol	   involves	  significantly	  reducing	  the	  concentration	  of	  FGF	  (20	  
ng/mL	   to	   1	   ng/mL),	   alongside	   the	   addition	   of	   retinoids.	   Undifferentiated,	  
proliferative	  cells	  retain	  a	  homogeneous	  morphology,	  with	  each	  cell	  being	  distinctly	  
rounded.	  The	  cell	  number	  is	  very	  high	  since	  they	  have	  continued	  to	  proliferate,	  with	  
the	   final	   cell	  population	   sub-­‐optimal	  as	   they	  are	  over	   confluent	  and	  begin	   to	   layer	  
upon	   one	   another.	   Cultures	   in	   which	   only	   the	   concentration	   of	   FGF	   has	   been	  
lowered	   exhibit	   an	   identical	   morphology,	   with	   no	   noticeable	   differences	   to	   those	  
cultured	  in	  a	  high	  FGF	  concentration.	  Addition	  of	  the	  vehicle,	  DMSO,	  similarly	  shows	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  PROLIF	   	   	  	  	  	  	  	  	  	  	  	  	  PROLIF	  –	  FGF	   	   	   	  	  	  +	  DMSO	  
	  
	  
Figure	  4.10	  Morphologies	  of	  AHPC	  cells	  after	  7	  days	  culture,	  plated	  at	  20,000	  cells	  per	  well	  in	  
a	   4-­‐well	   plate.	   Proliferative	   (undifferentiated)	   cultures	   (PROLIF)	   retained	   a	   homogeneous	  
appearance	  of	  a	  rounded	  cell	  type	  where	  there	  are	  few	  cellular	  processes.	  Cultures	  in	  which	  
the	   FGF	   concentration	   had	   been	   lowered	   to	   1	   ng/mL	   (PROLIF-­‐FGF)	   displayed	   an	   identical	  
morphology.	   Those	   treated	   with	   additional	   DMSO	   (same	   concentration	   as	   retinoid	  
treatments)	  again	  displayed	  no	  morphological	  changes.	  Scale	  Bars:	  100	  μm.	  	  
	  
To	  investigate	  the	  dose	  response	  of	  incorporating	  retinoids	  into	  differentiating	  AHPC	  
cultures,	  retinoids	  were	   incorporated	  at	  10	  μM,	  1	  μM,	  0.1	  μM	  and	  0.01	  μM.	  These	  
concentrations	   were	   chosen	   as	   they	   represent	   a	   broad	   spectrum	   in	   which	   we	  
hypothesised	  the	  compounds	  would	  be	  active.	  Previous	  studies	  also	  undertaken	  on	  
this	   cell	   line	   had	   demonstrated	   that	   it	   was	   highly	   sensitive	   to	   certain	   retinoids,	  
notably	  EC23.243	  We	  have	  subsequently	  investigated	  whether	  the	  AH	  series	  would	  be	  
tolerated	  more	  favourably.	  AHPC	  cells	  were	  cultured	  for	  seven	  days,	  with	  the	  media	  
changed	   at	   the	   halfway	   time	   point.	   Phase	   images	   were	   then	   recorded	   and	   are	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Incubation	  of	  all	   the	   retinoids	  at	  10	  μM	  led	   to	  complete	  cell	  death,	   indicating	   that	  
they	  are	  toxic	  at	  this	  concentration.	  Consequently,	  no	  further	  evaluation	  was	  carried	  
out	  at	   such	  high	   levels.	  At	  1	  μM,	  cell	  death	  was	  not	  observed	  and	   the	  general	   cell	  
population	   appeared	   heterogeneous.	   A	   considerable	   number	   of	   cells	   expressing	  
neuronal	   processes	   were	   visible	   throughout	   all	   the	   cultures	   (Figure	   4.12).	   The	  
number	  of	  cells	  present	  in	  these	  cultures	  appeared	  lower	  than	  those	  only	  exposed	  to	  
the	  vehicle,	  DMSO,	   suggesting	   they	  also	  had	  an	  anti-­‐proliferative	  activity.	  This	  was	  
quantified	  through	  counting	  the	  number	  of	  nuclei	  per	  field	  of	  view	  for	  each	  culture	  
treatment,	  with	  the	  aid	  of	  ImageJ	  software	  and	  DAPI	  immunocytochemical	  staining.	  
The	  data	  are	  displayed	  as	   the	  mean	   from	  three	   randomly	   selected	   immunostained	  
images	   (Figure	  4.13).	  As	   the	  concentration	  was	   lowered,	   these	  effects	  became	   less	  
visible,	  with	  all	  treatments	  displaying	  larger	  areas	  of	  cells	  with	  morphologies,	  similar	  
to	  that	  of	  the	  cultures	  not	  subjected	  to	  retinoid	  treatments.	  The	  number	  of	  cells	  also	  
increased	   indicative	   of	   the	   cells	   proliferating,	   rather	   than	   differentiating	   (Figure	  
4.13).	   However,	   for	   further	   clarification	   purposes	   a	   proliferation	   assay,	   such	   as	   a	  
BrdU	  assay,	  would	  need	  to	  be	  completed	  to	  confirm	  this	  observation.	  Unlike	  any	  of	  
the	  previous	  cellular	  screens,	  AH61	  did	  not	  appear	  to	  have	  any	  advantageous	  effects	  
at	   any	   concentration,	   compared	   to	   that	   of	   any	   of	   the	   other	   treatments,	   with	   all	  




Figure	  4.12	  High	  magnification	  image	  of	  the	  cellular	  morphology	  of	  differentiated	  AHPC	  cell	  
cultures	   after	   7	   days	   treatment	   with	   ATRA	   at	   1	   μM.	   Arrows	   indicate	   neuronal	   processes.	  
Scale	  bar:	  50	  μm.	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Figure	  4.13	  Plot	  displaying	  the	  quantification	  of	  cell	  number,	  as	  performed	  by	  counting	  DAPI	  
labelled	  nuclei.	  Cultures	  of	  AHPCs	   incubated	  with,	  either	  1	  µM,	  0.1	  µM	  or	  0.01	  µM	  ATRA,	  
13cRA,	   AH60,	   AH61	   or	   EC23	   for	   7	   days,	   subsequently	   fixed	   and	   immunocytochemically	  
stained	  for	  DAPI.	  Using	  ImageJ	  software	  the	  number	  of	  positive	  cell	  bodies	  were	  counted	  on	  
3	   random	   fields	   per	   treatment	   condition.	   1	   µM	   treatment	   of	   each	   retinoid	   appeared	   to	  
induce	   a	   decrease	   in	   the	   number	   of	   cells,	   suggesting	   at	   this	   concentration	   they	   were	  
inducing	   differentiation.	   Values	   shown	   represent	   mean	   +	   standard	   error	   (SDE),	   n=3.	   Per	  
statistical	   analysis	   using	   the	   Student’s	   t-­‐test	   corrected	   for	   multiple	   testing	   of	   sample	  
populations	  using	  the	  Bonferroni	  correction,	  there	  were	  no	  significant	  differences.	  	  
	  
To	   further	   evaluate	   the	   effects	   of	   the	   retinoid	   treatments,	   immunocytochemical	  
staining	   was	   carried	   out	   looking	   at	   the	   expression	   of	   both	   neuronal	   and	   glial	  
markers.	  These	  two	  markers	  were	  chosen	  because	  previously,	  the	  AHPC	  cell	  line	  had	  
been	  characterised	  as	  being	  able	   to	  differentiate	   into	  both	   lineages.	  Thus,	  cultures	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Those	   that	  were	  not	   treated	  with	  any	  of	   the	   retinoids	   (PROLIF	   and	  PROLIF-­‐FGF)	   in	  
general	  did	  not	  stain	  positive	  for	  either	  β-­‐III-­‐tubulin	  or	  GFAP.	  Upon	  addition	  of	  DMSO	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there	  was	  no	  apparent	  increase	  in	  β-­‐III-­‐tubulin	  expression,	  although	  a	  slight	  increase	  
in	   GFAP	   expression	  was	   noted.	   All	   cultures	   treated	  with	   1	  μM	  of	   retinoid	   stained	  
highly	   for	   both	   markers.	   As	   the	   concentration	   was	   reduced,	   the	   cell	   population	  
became	   denser	   and	   the	   number	   of	   positive	   β-­‐III-­‐tubulin	   cells	   decreased.	   GFAP	  
expression	  also	  decreased	   to	   levels	   consistent	  with	   that	   seen	   for	  DMSO	   treatment	  
alone.	  Quantification,	   through	   counting	   positively	   labelled	   cell	   bodies,	  was	   carried	  
out	  on	  the	  active	  concentration	  of	  1	  μM	  (Figure	  4.15).	  This	  preliminary	  quantification	  
data	   suggest	   that	   there	   are	   no	   significant	   differences	   between	   any	  of	   the	   retinoid	  
treatments,	   with	   each	   of	   them	   leading	   to	   a	   significant	   increase	   in	   the	   number	   of	  




Figure	   4.14	   Plot	   displaying	   the	   quantification	   of	   the	   percentage	   expression	   of	   TuJ1	   and	  
GFAP,	  as	  performed	  by	  counting	  labelled	  cell	  bodies.	  Cultures	  of	  AHPCs	  incubated	  with	  1	  µM	  
ATRA,	  13cRA,	  AH60,	  AH61	  or	  EC23	  for	  7	  days,	  subsequently	  fixed	  and	  immunocytochemically	  
stained.	   Using	   ImageJ	   software	   the	   number	   of	   positive	   cell	   bodies	   were	   counted	   on	   3	  
random	   fields	   per	   treatment	   condition.	   1	   µM	   treatment	   of	   each	   retinoid	   induced	   a	  
significant	   increase	   in	   the	   percentage	   expression	   of	   TuJ1	   labelled	   cells,	   suggesting	   at	   this	  
concentration	  they	  were	  inducing	  differentiation.	  Values	  shown	  represent	  mean	  +	  standard	  
error	   (SDE),	   n=3.	   *p≤0.05,	   Student’s	   t-­‐test	   corrected	   for	   multiple	   testing	   of	   sample	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To	  fully	  characterise	  the	  effects	  of	  the	  AH	  compounds	  and	  that	  of	  EC23	  further,	  both	  
repeats	   of	   the	   above	   experiments,	   followed	   by	   further	   cellular	   counts	   for	  
quantification	  are	  required.	  In	  addition,	  quantifying	  the	  total	  protein	  content	  present	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4.4	  Discussion	  
	  
This	   chapter	   aimed	   to	   evaluate	   the	   effects	   of	   AH60	   and	   AH61	   in	   stem	   cell	  model	  
systems	  already	  committed	  to	  a	  neuronal	  lineage,	  mainly	  NSCs	  and	  NPCs.	  These	  are	  
cell	  types	  commonly	  found	  in	  the	  CNS,	  and	  are	  known	  to	  be	  influenced	  by	  a	  number	  
of	   small	  molecules	   in	   vivo,	   in	   particular	   ATRA.188,	  189	  Due	   to	   these	  well	   established	  
roles	  in	  vivo,	  ATRA	  has	  subsequently	  been	  used	  as	  a	  tool	  to	  direct	  the	  differentiation	  
of	   NSCs/NPCs	   in	   vitro	   (see	   Chapter	   I	   for	   full	   discussion).	   It	   was	   therefore	  
hypothesised	   that	   the	   synthetic	   compounds,	   AH60	   and	   AH61,	   would	   be	   able	   to	  
mimic	  or	  improve	  the	  profiles	  exhibited	  by	  ATRA.	  
	  
The	   first	   model	   chosen	   to	   be	   assessed,	   was	   a	   commercially	   available	   human	  
embryonic	   NSC	   line,	   ReNcell	   VM.	   This	   cell	   line,	   as	   discussed	   previously,	   is	   derived	  
from	   the	  VM	  of	   human	   foetuses,	   an	   area	   known	   to	   respond	   to	   endogenous	  ATRA	  
during	  neurulation	   in	   the	  early	   embryo.334	  Subsequently,	   this	  was	  demonstrated	   in	  
vitro	   by	   the	   differentiation	   of	   ventral	   mesencephalon	   progenitors	   into	   dopamine	  
neurons.	   Addition	   of	   ATRA	   to	   the	   defined	   dopamine-­‐inducing	   differentiation	  
protocol	  significantly	  enhanced	  the	  number	  of	  neurons.335	  More	  recently,	  using	  the	  
ReNcell	   VM	   cell	   line,	   addition	   of	   ATRA	   was	   shown	   to	   significantly	   enhance	   the	  
number	  of	  both	  TuJ1	  and	  NF-­‐200	  positive	  neurons.	  This	  displayed	  that	  not	  only	  did	  
ATRA	   accelerate	   neurogenesis,	   but	   enhance	   the	   maturity	   of	   the	   neuronal	  
derivatives.	   Furthermore,	   substituting	   ATRA	   for	   the	   more	   stable	   analogue,	   EC23,	  
showed	   significant	   further	   improvements.59	  Therefore,	   it	   was	   predicted	   that	   AH60	  
and	  AH61	  should	  show	  similar	  effects.	  	  
	  
Experiments	  were	  initially	  carried	  out	  to	  investigate	  whether	  AH60	  and	  AH61	  would	  
induce	  similar	  phenotypes	  seen	  to	  those	  of	  ATRA	  and	  EC23.	  Media	  supplementation	  
at	   1	  μM	   led	   to	   a	  neuronal	   phenotype	   in	  both	  AH60	  and	  AH61	   treated	   cultures.	   In	  
addition,	  the	  total	  cell	  number	  (calculated	  from	  DAPI	  counts)	  was	  attenuated	  in	  both	  
treatments,	  similar	  to	  that	  seen	  for	  ATRA.	  This	  is	  consistent	  with	  MTS	  data	  previously	  
collected	   in	  our	   research	   laboratory.243	  Although	   for	   a	  direct	   comparison	  a	   further	  
MTS	  assay	   investigating	  AH60,	  AH61	  and	  EC23	  would	  be	   required.	   In	  addition,	   cell	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death	  has	  not	  been	  investigated,	  although	  the	  morphological	  data	  suggests	  the	  cells	  
are	  differentiating,	  it	  would	  be	  valuable	  to	  investigate	  the	  toxicity	  profiles	  of	  each	  of	  
the	   retinoids.	   This	   may	   also	   highlight	   higher,	   more	   active,	   concentrations	   of	  
tolerated	  retinoid,	  which	  may	  further	  enhance	  differentiation.	  	  
	  
Upon	   immunocytochemical	  staining,	  up-­‐regulation	  of	  all	   three	  chosen	  markers	  was	  
visualised.	  In	  addition,	  AH61	  was	  highlighted	  as	  being	  significantly	  more	  active	  than	  
both	  ATRA	  and	  AH60	  at	  1	  μM.	  Although	  previously	  AH61	  has	  been	  demonstrated	  as	  
being	  significantly	  more	  active	  than	  both	  ATRA	  and	  AH60,	  this	  has	  come	  at	  reduced	  
concentrations.	   The	   effects	   seen	   therefore	   in	   this	   cell	   model,	   suggest	   AH61’s	  
increased	  activity,	   is	  not	  only	  down	  to	  an	   improved	  stability	  and	  metabolic	  profile.	  
Upon	  investigating	  the	  dose	  response	  of	  AH60	  and	  AH61,	  a	  similar	  profile	  as	  to	  that	  
seen	  in	  the	  TERA2.cl.SP12	  EC	  cell	  line	  was	  observed	  for	  AH61,	  with	  AH61	  being	  seen	  
to	   be	   100-­‐fold	   more	   active	   than	   both,	   ATRA	   and	   AH60.	   Although,	   the	   observed	  
higher	  activities	  of	  AH60,	  seen	  in	  the	  EC	  cell	  model,	  were	  not	  transpired	  to	  this	  NSC	  
model,	   as	   both	   AH60	   and	   ATRA	   showed	   similar	   dose	   response	   profiles.	   This	  
highlights	   the	   differences	   between	   different	   stem	   cell	   types,	   and	   underlines	   why	  
compounds	  designed	  to	  act	  on	  specific	  stem	  cell	  types	  maybe	  required.197	  
	  
Finally,	   a	   direct	   comparison	   of	   the	   activity	   of	   AH61	   to	   that	   of	   EC23	   was	   desired.	  
Comparing	   published	   data	   of	   EC23	   to	   that	   seen	   for	   AH61	   suggested	   AH61	   was	  
significantly	   more	   active	   than	   its	   more	   stable	   predecessor.59	   Upon	   repeating	   the	  
experiments	  this	  was	  proved	  with	  all	  three	  markers	  being	  significantly	  up-­‐regulated	  
in	  AH61	  treated	  cultures	   to	  EC23.	  Moreover,	   the	  higher	   levels	  of	  expression	  of	   the	  
late	  neuronal	  markers	  NF-­‐200	  and	  MAP2ab	  suggest	  that	  AH61	  also	  further	  enhances	  
the	  maturation	  of	   the	  differentiating	  neurons.	  These	   findings	  also	  suggest	   that	   the	  
increased	   activity	   of	   AH61	   is	   not	   as	   a	   result	   of	   either	   reduced	   metabolism,	   or	  
enhanced	   stability,	   as	   EC23	   is	   considered	   to	   be	   the	   more	   rigid	   and	   stable	  
analogue.228	   Therefore	  one	  hypothesis	   is	   that	  AH61’s	   enhanced	  activity	  over	  ATRA	  
would	   be	   conferred	   through	   its	   increased	   stability	   towards	   isomerisation	   and	  
reduced	  metabolism,	  thus	  allowing	  it	  to	  remain	  at	  an	  active	  cellular	  concentration.	  In	  
addition,	   its	   further	   increased	   activity	   over	   EC23	   is	   conferred	   through	   its	   greater	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structural	   resemblance	   to	   ATRA,	   and	   therefore	   its	   higher	   binding	   affinity	   for	   the	  
cognate	  nuclear	   receptors.	  Although,	   for	   this	   to	  be	   confirmed	  RAR	  binding	   studies	  
would	  need	  to	  be	  carried	  out.	  	  	  	  	  	  
	  
Therefore	   replacing	  ATRA	  or	  EC23	  with	  AH61	   should	  allow	   for	   the	  production	  of	  a	  
greater	   number	   of	   mature	   neurons	   from	   the	   NSC	   line,	   ReNcell	   VM.	   This	   is	   highly	  
useful,	  as	  cell	  lines	  derived	  from	  this	  area	  of	  the	  brain	  have	  been	  highlighted	  as	  being	  
particularly	   important	   for	   therapeutic	   transplantation	   therapies.	   In	   particular,	   in	  
developing	   therapies	   associated	   with	   Parkinson’s	   disease.336,	   337	   Furthermore,	   the	  
enhance	   differentiation	   seen	   upon	   utilising	   AH61	   allows	   for	   a	   greater	   yield	   of	  
neuronal	   subtypes,	  which	  are	   required	   for	   transplantation,	   therefore,	   reducing	   the	  
number	  of	  foetuses	  that	  are	  needed.338	  
	  
The	  final	  cell	   line	  chosen	  to	  analyse	  the	  activities	  of	  AH60	  and	  AH61	  was	  the	  adult	  
hippocampal	   NPC	   line,	   AHPC.	   This	   cell	   line	   was	   chosen	   as	   it	   had	   been	   shown	   to	  
respond	  to	  ATRA	  and	  differentiate	  down	  a	  neural	  lineage.59	  In	  addition,	  un-­‐published	  
work	  within	  our	  research	  group	  had	  demonstrated	  that	  this	  cell	  line	  also	  responded	  
to	   13cRA,	   and	   EC23	   induced	   differentiation.243	   Furthermore,	   it	   had	   been	   used	   to	  
identify	  other	  neuro-­‐inducing	  small	  molecules,	  such	  as	  neuropathiazol,	   reviewed	   in	  
Chapter	  I.250	  	  
	  
Previous	  work	  both	  within	  our	  research	  group,	  and	  that	  Nakumara,	  had	  highlighted	  
the	   sensitivity	   of	   the	   AHPC	   cell	   line	   to	   high	   concentrations	   of	   retinoids.243,	   339	  This	  
data	  had	  shown	  that	  upon	  high	  doses	  of	  retinoids,	  neuronal	  survival	  decreased,	  with	  
cultures	   becoming	   sub-­‐optimal	   with	   eventually	   apoptosis/cell	   death	   ensuing.	   In	  
addition,	  previous	  work	  has	  also	  emphasised	  that	  cell	  density	  was	  important,	  with	  a	  
high	  cell	  density	  required.243	  Taking	  these	  considerations	  into	  account,	  the	  best	  know	  
conditions	  were	  used	  to	  assess	  the	  activities	  of	  AH60	  and	  AH61.	  
	  
Initially,	  a	  broad	  concentration	  range	  was	  chosen	  to	  examine	  whether	  the	  AH	  series	  
was	  any	  less	  toxic	  than	  those	  that	  have	  been	  previously	  screened.	  The	  data	  obtained	  
for	   10	   μM	   follows	   the	   trend	   that	   ATRA,	   and	   other	   retinoids,	   are	   toxic	   at	   this	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concentration.	   At	   1	   μM	   all	   the	   retinoid	   treatments	   promoted	   neurogenesis,	   with	  
morphological	  features	  apparent	  throughout	  the	  cell	  cultures.	  Upon	  quantifying	  the	  
total	  cell	  number,	  a	  significant	  drop	  was	  seen	  compared	  to	  that	  of	  the	  DMSO	  treated	  
cultures.	   This,	   in	   addition	   to	   the	   morphological	   data,	   suggests	   the	   cells	   are	  
committing	   to	   differentiation.	   The	   apparent	   lack	   of	   any	   physiological	   changes	   in	  
treatment	   with	   DMSO	   also	   signifies	   that	   these	   changes	   are	   from	   the	   retinoid	  
treatment	   and	   not	   the	   solvent.	   Upon	   immunocytochemical	   staining,	   for	   both	  
neuronal	  and	  glial	  markers,	  a	  significant	  increase	  in	  expression	  was	  visualised	  across	  
all	   retinoid	   treatments.	   There	  was	  no	   significant	   difference	   in	   any	  of	   the	   synthetic	  
compounds,	   compared	   to	   ATRA,	   suggesting	   they	   are	   equally	   as	   active	   at	   this	  
concentration.	  One	  aspect,	  which	  has	  not	  been	   investigated	   fully,	   is	  validating	  that	  
the	  reduction	   in	  cell	  number	   is	  not	  down	  to	  cell	  death.	  This	   is	  especially	   important	  
considering	  the	  sensitivity	  of	  this	  cell	  line.339	  Therefore,	  to	  further	  validate	  this	  work	  
a	   toxicity	   screen,	   as	   carried	   out	   on	   the	   TERA2.cl.SP12	   EC	   cell	   line,	   should	   be	  
undertaken.	  	  
	  
As	   the	   concentration	   was	   reduced,	   all	   the	   retinoid	   treatments	   appeared	   to	   lose	  
activity,	  with	  the	  cultures	  gaining	  morphologies	  similar	  to	  those	  of	  the	  proliferative	  
controls	  and	  DMSO.	  This	  was	  confirmed	  through	  quantifying	  the	  total	  cell	  number	  in	  
which	  all	   treatments	  did	  not	  differ	   significantly	   from	  the	  control	  cultures.	  This	  was	  
further	   reinforced	   through	   immunocytochemical	   staining,	   in	   which	   the	   number	   of	  
positive	  neuronal	  and	  glia	  cells	  dropped.	  This	  is	  preliminary	  data,	  and	  would	  require	  
repeat	   experiments	   to	   fully	   validate	   the	   results	   described	   within	   this	   thesis,	   both	  
through	  more	  cellular	  counts	  and	  total	  protein	  expression	  quantification.	  Although,	  
these	   preliminary	   results	   do	   suggest,	   for	   the	   first	   time	   there	   appears	   to	   be	   no	  
beneficial	  effect	  of	  AH61	  or	  EC23	  over	  that	  of	  ATRA.	  	  	  
	  
A	  full	  explanation	  as	  to	  why	  AH61	  is	  so	  potent	  in	  the	  ReNcell	  VM	  line	  but	  not	  so	  in	  
the	  AHPC	  line	  could	  be	  due	  to	  species	  specificity,	  as	  differences	  have	  been	  described	  
in	  the	  literature.331	  All	  the	  cells	  lines	  screened	  up	  to	  the	  AHPC	  line	  have	  been	  human,	  
apart	  from	  the	  initial	  screen	  in	  the	  murine	  F9	  cells.	  It	  would	  be	  interesting	  to	  screen	  
AH61	   in	   an	   adult	   human	   hippocampal	   cell	   line	   to	   see	   if	   the	   same	   effects	   were	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observed.	  Due	  to	  current	  limitations,	  i.e.	  the	  availability	  of	  adult	  human	  brain	  tissue,	  
as	   discussed	   earlier	   within	   this	   Chapter,	   this	   is	   currently	   not	   possible.	   Therefore,	  
alternative	   models	   will	   need	   to	   be	   investigated	   to	   further	   characterise	   the	   full	  
biological	  role	  of	  this	  synthetic	  retinoid.	  	  
	  
Furthermore,	   to	   allow	   for	   highly	   specific	   differentiation	   of	   neural	   progenitor	   cells,	  
such	  as	  the	  AHPC	  cell	  line,	  alternative	  small	  molecules	  may	  need	  to	  be	  employed,	  as	  
stimulation	   of	   the	   retinoid	   signalling	   pathway	   does	   not	   induce	   complete	   and	  
unambiguous	   neurogenesis.	   One	   possible	   alternative	   has	   been	   highlighted	   in	   the	  
literature	  as	  neuropathiazol	  (reviewed	  in	  Chapter	  I),	  and	  this	  will	  be	  further	  analysed	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4.5	  Conclusions	  
	  
The	   first	   conclusion	   that	   can	   be	   drawn	   is	   that	   both	   AH60	   and	   AH61	   can	   induce	  
differentiation	  of	  neural	  progenitor	   cells.	   In	   the	  human	   fetal	  neural	  progenitor	   cell	  
line	   examined,	   AH61	   induces	   differentiation	   significantly	   better	   then	   any	   other	  
compound	  screened	  in	  this	  model.	  The	  exact	  reasons	  behind	  this	  improved	  biological	  
profile	   are	   unknown,	   but	   could	   be	   hypothesised	   to	   be	   as	   a	   result	   of	   improved	  
binding	   affinity	   for	   the	   receptors/transport	   proteins	   involved	   in	   the	   signalling	  
pathway,	  coupled	  with	  increased	  metabolic	  and	  physical	  stability.	  Again,	  identical	  to	  
previous	   stem	   cell	   systems	   screened,	   AH60	   has	   a	   weaker	   profile	   than	   that	   of	   its	  
isomer,	  AH61.	  The	  effects	  seen	  in	  this	  system	  are	  also	  less	  apparent	  than	  in	  previous	  
investigations,	  with	  AH60	  having	  a	  near	  identical	  biological	  profile	  to	  that	  of	  ATRA.	  	  
	  
Upon	  investigating	  their	  biological	  activity	  in	  an	  adult	  hippocampal	  NPC	  system,	  the	  
same	  profiles	  were	  not	  observed.	  For	  the	  first	  time,	  there	  was	  no	  greater	  potency	  of	  
either	  of	  the	  AH	  series	  over	  ATRA.	  They	  both	  appeared	  to	  have	  similar	  toxicity	  levels,	  
somewhere	  between	  1	  μM	  and	  10	  μM,	  and	  while	  they	  did	  induce	  differentiation	  of	  
the	   AHPC	   cells	   into	   positive	   β-­‐III-­‐tubulin	   and	   GFAP	   cells,	   there	   was	   no	   apparent	  
increase	  in	  the	  activity	  of	  the	  synthetic	  analogues	  over	  ATRA	  as	  their	  concentration	  
was	   lowered.	   In	  addition,	  the	  ability	  of	  all	   the	  compounds	  screened	  was	  not	  highly	  
specific,	  inducing	  high	  levels	  of	  both	  neuronal	  and	  astrocyte	  differentiation.	  	  
	  
Thus	   to	   fully	   realise	   the	   potential	   of	   AHPCs,	   and	   understand	   their	   differentiation	  
pathways	  more	   accurately	   the	  use	  of	   alternative	   small	  molecules	  maybe	   required,	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5.1	  Introduction	  
	  
Currently	   the	   focus	   of	   this	   thesis	   has	   resolved	   around	   a	   class	   of	   small	   molecules	  
termed	   retinoids,	   and	   their	   ability	   to	   induce	  differentiation	   in	  both	  embryonic	  and	  
neural	   progenitor	   cell	   lines.	   As	   the	   potential	   of	   stem	   cells	   has	   become	   more	  
apparent,	  ways	  in	  which	  they	  can	  be	  utilised	  have	  generated	  significant	  amounts	  of	  
interest.	  Pluripotent	  ES	  cells	  potentially	  represent	  an	  inexhaustible	  source	  of	  all	  cell	  
types,	   if	   the	   knowledge	   to	   differentiate	   them	   reproducibly	   and	   efficiently	   exists.28	  
Currently,	  this	  is	  not	  the	  case,	  but	  one	  solution	  to	  the	  problem	  involves	  using	  small	  
molecules,	  and	  it	  has	  generated	  significant	  interest	  over	  the	  past	  decade.340	  	  
	  
In	  attempts	  to	  harvest	  the	  full	  potential	  of	  stem	  cells,	  many	  groups	  have	   looked	  to	  
chemical	  control	  as	  a	  solution	  (see	  Chapter	  I	   for	  full	  discussion).	  Although	  retinoids	  
are	   classified	   as	   small	   molecules,	   and	   there	   are	   many	   published	   differentiation	  
protocols	   that	  utilise	   them	   (see	  Chapters	   I,	   III	   and	   IV	  and	   references	  within),	  more	  
recently	   focus	   has	   turned	   to	   identifying	   different	   classes	   of	   compound.	   Small	  
molecule	  libraries	  of	  compounds	  have	  been	  designed	  as	  a	  simple	  and	  cost	  effective	  
approach	   to	   identifying	   potential	   targets.197	   This	   is	   in	   an	   attempt	   to	   identify	   new	  
families	  of	  compounds,	  which	  would	  help	  unlock	  the	  full	  potential	  of	  these	  cells,	  as	  
molecules	  are	  screened	  for	  a	  particular	  biological	  activity,	  in	  a	  particular	  cell	  type	  (for	  
a	  detailed	  review	  see	  Lyssiotis	  et	  al.).197	  	  
	  
A	   number	   of	   traditional	   methods	   of	   neural	   differentiation	   have	   shown	   success,	  
utilising	   natural	   signalling	   components,	   such	   as	   ATRA.	   For	   example,	   one	   effective	  
protocol	   developed	   demonstrated	   the	   successful	   differentiation	   of	  mouse	   ES	   cells	  
into	  motor	   neurons.	   Briefly,	   the	   protocol	   involved	   firstly	   neuralising	   the	   cells	   into	  
neural	   progenitors	   through	   concomitant	   ATRA	   treatment,	   followed	   by	   caudalising	  
the	  cells,	  also	  with	  ATRA.	  Finally,	  an	  agonist	  of	  the	  Hh-­‐mediating	  signal	  pathway	  was	  
employed	   to	   ventralise	   the	   caudilised	   neural	   cells	   to	   become	   motor	   neurons.217	  
However,	   as	   ATRA	   in	   general	   is	   pleiotropic,	   the	   identification	   of	   other	   small	  
molecules	   that	   allow	  precise	   regulation	  of	   stem	  cell	   differentiation	  down	  neuronal	  
lineages	  was,	  and	  still	  is,	  desirable.	  This	  led	  to	  a	  number	  of	  groups	  screening	  libraries	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of	  compounds	  to	  identify	  novel	  compounds	  to	  further	  direct	  neurogenesis	  (reviewed	  
in	  Chapter	  I).	  	  
	  
One	  such	  study,	  carried	  out	  by	  Warashina	  et	  al.	  identified	  a	  class	  of	  compounds	  that	  
selectively	  induced	  differentiation	  of	  hippocampal	  neural	  progenitors.250	  The	  class	  of	  
compounds,	   4-­‐aminothiazols,	   were	   then	   subjected	   to	   a	   small	   SAR	   study,	   which	  
identified	  neuropathiazol,	  60,	  as	  being	  the	  most	  potent	  (Figure	  5.1).	  As	  discussed	  in	  
Chapter	  I,	  treatment	  of	  AHPCs	  with	  neuropathiazol,	  60,	  slowed	  cell	  proliferation	  and	  
differentiated	  more	   than	  90%	   into	  TuJ1	  positive	   cells,	  with	  very	   few	  GFAP-­‐positive	  
cells	   visualised.	   In	   comparison,	   treatment	   with	   ATRA	   showed	   weaker	   anti-­‐
proliferation	  activity,	  and	   large	  numbers	  of	  both	  TuJ1	  and	  GFAP-­‐positive	  cells	  were	  
seen.	   Furthermore,	   ATRA	   showed	   greater	   cytotoxicity	   compared	   to	   that	   of	  
neuropathiazol,	   60.	   After	   longer	   incubation	   periods	   AHPCs	   demonstrated	   positive	  
staining	   for	  mature	  neuronal	  markers	  neurofilament-­‐H	  and	  MAP2ab,	  while	  RT-­‐PCR	  
analysis	  demonstrated	  Sox2	  downregulation	  and	  NeuroD1	  upregulation.	  Warashina	  
et	   al.	   also	   demonstrated	   that	   astroglial	   differentiation,	   induced	   by	   LIF	   and	   BMP2,	  





Figure	  5.1	  Structure	  of	  neuropathiazol.	  
	  
Modifications	   to	   the	   retinoid	   structure,	   as	   carried	   out	   within	   this	   thesis,	   has	   had	  
some	  very	  positive	  results,	  although	  these	  were	  not	  transpired	   in	  adult	  NPCs	  using	  
the	  AHPC	  cell	  line.	  Therefore,	  carrying	  on	  from	  Chapter	  IV,	  in	  which	  the	  potential	  of	  
the	   retinoid	   series	  of	   compounds	  was	  assessed	   in	   an	  AHPC	   cell	   line,	   a	   comparison	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neuropathiazol	  at	  the	  time	  had	  not	  identified	  a	  mode	  of	  action,	  but	  suggested	  from	  
the	  observations	   seen	   that	   it	   functioned	   through	  a	  different	  pathway	   to	  ATRA	  and	  
had	  a	  more	  specific	  neurogenic	  inducing	  activity.250	  Furthermore,	  the	  synthetic	  route	  
to	   neuropathiazol	   lacked	   any	   characterisation	   data	   for	   all	   the	   intermediates,	   with	  
only	  limited	  characterisation	  data	  provided	  for	  neuropathiazol	  itself.	  This	  suggested	  
that	  further	  work	  was	  required	  on	  this	  molecule,	  and	  other	  chemical	  analogues,	  to	  
assess	  the	  full	  potential	  of	  these	  compounds.	  Additionally,	  as	  a	  mode	  of	  action	  had	  
not	  been	  identified,	  so	  potentially	  neuropathiazol,	  60,	  could	  induce	  neurogenesis	  in	  
other	   NPCs	   lines,	   NSCs	   lines	   and	   even	   pluripotent	   stem	   cell	   systems,	   further	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5.2	  Aims	  and	  Objectives	  
	  
The	  aim	  of	  this	  Chapter	  was	  to	  further	  evaluate	  the	  small	  molecule	  neuropathiazol.	  
Initially,	   the	  synthesis	  and	  screening	  of	   its	  biological	  potential,	   in	  both	   the	  cell	   line	  
characterised	   in	   the	   literature,	  and	  others	  used	  within	  our	   laboratory	  was	  desired.	  
Additionally,	   the	   synthesis	   of	   further	   analogues,	   which	   were	   perceived	   to	   have	   a	  
greater	  biological	  potential	   and	  allow	  us	   to	  hypothesise	   the	  potential	  pathway	   the	  
molecule	  acts	  through	  were	  desired.	  
	  
The	   objectives,	   were	   therefore,	   to	   repeat	   the	   synthesis	   of	   neuropathiazol,	  
completely	  characterising	   the	  product	  and	  all	   intermediates.	  Demonstrate	   that	   the	  
molecule	   behaved	   at	   least	   as	   described	   in	   the	   literature,	   and	   conduct	   a	   more	  
thorough	  characterisation	  of	   its	  activity	   in	  the	  AHPC	  cell	   line.	  We	  also	  assessed	  the	  
potential	   for	   neuropathiazol	   to	   differentiate	   other	   stem	   cell	   lines,	   including	   the	  
human	  embryonic	  neural	   stem	  cell	   line,	  ReNcell	  VM	  and	   the	  embryonal	   carcinoma	  
stem	   cell	   line,	   TERA2.cl.SP12.	   In	   addition,	   the	   synthesis	   of	   specific	   neuropathiazol	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5.3	  Synthesis	  of	  Neuropathiazol	  and	  Associated	  Analogues	  
	  
The	   literature	   protocol	   for	   the	   synthesis	   of	   neuropathiazol,	   60,	   began	   with	   the	  
cyclisation	   of	   4-­‐(2-­‐chloro-­‐acetylamino)-­‐benzoic	   acid	   ethyl	   ester,	   61,	   with	  




Scheme	  5.1	  Synthesis	  of	  neuropathiazol.	  Reagents:	  (a)	  Dimethylformamide	  (DMF)	  or	  EtOH,	  
80	  oC,	  overnight;	  (b)	  NaH,	  MeI,	  room	  temperature,	  2	  hours.250	  
	  
4-­‐(2-­‐Chloro-­‐acetylamino)-­‐benzoic	  acid	  ethyl	  ester,	  61,	   is	  not	  commercially	  available,	  
thus	  the	  synthesis	  began	  with	  a	  direct	  amide	  bond	  formation,	  between	  benzocaine,	  
64,	   and	   chloroacetic	   acid,	   65	   (Equation	   5.1).	   Two	   different	   catalysts	   were	  
investigated	   and	   compared	   with	   that	   of	   1’1-­‐carbonyldiimidazole	   (CDI),	   67.	   The	  
results	   are	   presented	   in	   Table	   5.1,	  with	   the	   structure	   of	   the	   bi-­‐functional	   catalyst,	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Reaction	   Catalyst	  or	  Reagent	   Time	  (Hours)	   Isolated	  Yield	  (%)	  
1	   Boric	  Acid	   48	   61	  
2	   Bi-­‐functional	  Catalyst	   48	   51	  
3	   CDI	   18	   49	  





	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  5.2	  Structures	  of	  N,N-­‐diisopropylamino-­‐benzyl	  boronic	  acid	  (66)	  and	  CDI	  (67).	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
The	  best	  result	  was	  obtained	  using	  boric	  acid,	  achieving	  an	  acceptable	  yield	  of	  61%	  
after	  48	  hours.	  In	  an	  attempt	  to	  improve	  the	  yield,	  the	  reaction	  time	  was	  increased	  
to	   96	   hours,	   and	   although	   there	   was	   an	   increase	   in	   yield	   to	   67%,	   this	   was	   not	  
noteworthy.	  	  
	  
With	  all	  the	  reagents	  required	  for	  the	  synthesis	  of	  neuropathiazol,	  60,	  obtained,	  the	  
literature	  method	  was	  followed.250	  This	  initially	  involved	  reacting	  thiobenzamide,	  62,	  
with	   4-­‐(2-­‐chloro-­‐acetylamino)-­‐benzoic	   acid	   ethyl	   ester,	  61,	   in	  DMF	   at	   80	   oC	   for	   12	  
hours.	  The	  reaction	  mixture	  went	  through	  a	  number	  of	  colour	  changes,	  from	  yellow	  
through	   to	   red	   before	   ending	   as	   a	   dark	   green	   to	   black	   mixture.	   Analysis	   of	   the	  
reaction	   by	   TLC	   clearly	   demonstrated	   that	   a	   minimum	   of	   five	   compounds	   were	  
present.	  After	  subsequent	  work-­‐up	  and	  removal	  of	  the	  DMF	  under	  high	  vacuum,	  the	  
resulting	   crude	   product	   was	   re-­‐crystallised	   from	   IPA.	   Unfortunately,	   this	   proved	  
unsuccessful,	   thus	   SiO2	   column	   chromatography	   was	   attempted	   to	   access	   the	  
desired	   product	   in	   a	   pure	   state.	   As	   in	   all	   previous	   attempts,	   this	   again	   proved	  
unsuccessful,	   with	   multiple	   compounds	   eluting	   together.	   The	   literature	   also	  
suggested	   ethanol	   as	   an	   alternative	   solvent,	   and	   thus,	   this	   was	   subsequently	  
attempted.	  The	  reaction	  was	  initially	  tried	  at	  room	  temperature,	  but	  no	  reaction	  was	  







	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Chapter	  V	  
	   180	  
previous	  reaction,	  employing	  DMF,	  multiple	  compounds	  could	  be	  visualised	  by	  TLC.	  
Overall,	  the	  highest	  yielding	  method	  identified	  was	  obtained	  when	  the	  reaction	  was	  
carried	   out	   in	   DMF	   at	   80	   oC	   under	   argon,	   followed	   by	   re-­‐crystallisation	   from	   IPA,	  
subsequent	   SiO2	   column	   chromatography	   and	   finally,	   repeated	   re-­‐crystallisation	  
from	  IPA.	  This	  method	  yielded	  a	  dark	  green	  solid	  in	  65%	  yield.	  While	  it	  was	  unable	  to	  
fully	  isolate	  the	  compound,	  it	  was	  deemed	  suitable	  for	  the	  next	  step	  in	  the	  reaction	  






The	   only	   literature	   available	   on	   this	   compound	   provided	   no	   characterisation	   data,	  
suggesting	   that	   it	   was	   never	   directly	   isolated.	   This	   is	   consistent	   with	   the	   results	  
described	   above,	   as	   this	   compound	   appears	   to	   have	   a	   number	   of	   stability	   issues.	  
Multiple	   attempts	   at	   carrying	   out	   the	   above	   reaction	   provided	   a	   number	   of	  
compounds	  all	  very	  different	   in	  colour	  but	  with	  near	   identical	  proton	  NMRs	  of	   the	  
desired	   compound.	   This	   suggests	   that	   the	   actual	   compound	   is	   most	   likely	  
colourless/off-­‐white	  and	   that	   the	  vivid	   colours	  obtained	  are	   from	  minor	   impurities	  
carried	  through.	  It	  was,	  therefore,	  accepted	  that	  isolation	  and	  full	  characterisation	  of	  
the	   intermediate	   was	   not	   feasible,	   and	   thus,	   methylation	   was	   carried	   out	   on	   the	  
material	  obtained	  from	  the	  previous	  reaction.	  This	  was	  as	  described	  in	  the	  literature,	  
using	  sodium	  hydride	  and	  methyl	  iodide	  to	  give,	  neuropathiazol,	  60,	  in	  a	  good	  yield	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Simultaneously,	   two	   related	   intermediates	   were	   synthesised	   in	   an	   attempt	   to	  
develop	   more	   analogues	   previously	   not	   investigated.	   The	   first	   analogue	   chosen,	  
involved	   the	   incorporation	   of	   a	   TMTN	   group	   into	   neuropathiazol,	   60.	   This	   would	  
replace	   the	   benzyl	   group	   present	   in	   neuropathiazol,	   60,	   adding	   greater	   bulk,	   and	  
potentially	  steering	  the	  molecule	  into	  acting	  down	  the	  retinoid	  receptor	  pathway.	  To	  
incorporate	   the	  TMTN	  group,	   the	   corresponding	   thioamide	  was	   required.	  This	  was	  
achieved	   from	   initially	   preparing	   6-­‐iodo-­‐1,1,4,4-­‐tetramethyl-­‐1,2,3,4-­‐
tetrahydronapthalene,	   8,	   achieved	   through	   identical	   procedures	   as	   previously	  
published	  and	  described	   in	  Chapter	   II.228	   This	  was	   followed	  by	   a	  Grignard	   reaction	  







Initially,	   attempts	   to	   generate	   the	   amide	   directly	   from	   this	   compound,	   including	  
using	   an	   excess	   of	   35%	   ammonia,	   failed.341	   As	   direct	   amide	   formation	   proved	  
unsuccessful,	   saponification	   to	   the	   acid,	   69,	   followed	   by	   formation	   of	   the	   acid	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the	  saponification,	  in	  a	  1:1	  THF	  and	  water	  mixture,	  which	  led	  to	  the	  formation	  of	  the	  




The	   acid	   chloride	   was	   generated	   in	   situ	   through	   treatment	   with	   oxalyl	   chloride,	  
before	   reacting	  directly	  with	  an	  excess	  of	  35%	  aqueous	  ammonia	   solution	   to	   yield	  




Scheme	  5.6	  	  
The	  final	  step	  involved	  the	  conversion	  of	  the	  amide,	  70,	   to	  the	  thio-­‐amide,	  71,	  and	  
due	   to	   its	   ease	   of	   handling	   and	   availability,	   Lawesson’s	   Reagent	   was	   chosen.	   The	  
initial	   procedure	   followed,	   involved	   refluxing	   in	   benzene,	   although	   this	   was	  
substituted	  for	  toluene.342	  The	  procedure	  gave	  two	  major	  products	  by	  TLC	  (excluding	  
the	   spots	   identified	   as	   the	   bi-­‐products	   of	   the	   Lawesson’s	   reagent).	   These	   were	  
subsequently	   identified	   as	   the	   desired	   product,	   5,5,8,8-­‐tetramethyl-­‐5,6,7,8-­‐
tetrahydro-­‐naphthalene-­‐2-­‐carbothioic	  acid	  amide,	  71,	  as	  the	  minor	  product	  in	  a	  19%	  
yield	   and	   the	   nitrile,	   5,5,8,8-­‐tetramethyl-­‐5,6,7,8-­‐tetrahydro-­‐naphthalene-­‐2-­‐
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above	   reaction	   conditions	  were	   too	   severe,	   as	   the	   desired	   compound	  was	   further	  




To	   increase	   the	  yield	  of	   the	  desired	  product,	   the	   reaction	  was	   re-­‐run	   in	   toluene	  at	  
room	   temperature.	  After	  18	  hours,	   the	  desired	  product	  was	   visible	  by	  TLC,	   and	  as	  
soon	   as	   the	   nitrile,	   72,	   appeared	   to	   be	   forming,	   the	   reaction	   was	   stopped	   and	  
purified.	  This	  yielded	  the	  thio-­‐amide,	  71,	  as	  a	  yellow	  solid	  in	  an	  excellent	  97%	  yield.	  
Upon	  scale	  up,	  the	  same	  procedure	  was	  followed,	  again	  running	  the	  reaction	  for	  18	  
hours.	   This	   reaction	   was	   less	   successful	   with	   the	   yield	   dropping	   to	   80%,	   as	   the	  
reaction	  rate	  appeared	  to	  increase,	  which	  in	  turn	  led	  to	  more	  of	  the	  nitrile,	  72,	  being	  
produced	  (Scheme	  5.8).	  	  	  
	  
	  
Scheme	  5.8	  	  
The	   second	   analogue	   desired,	   was	   one	   containing	   a	   fluorine	   atom	   ortho	   to	   the	  
carbonyl	  on	  the	  benzene	  ring.	  This	  was	  thought	  to	  be	  desirable,	  as	  recent	  published	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atom	   was	   present	   at	   this	   position.343	   The	   compound	   synthesised,	   AC-­‐261066,	   73,	  
was	   similar	   to	   neuropathiazol	   in	   that	   it	   was	   based	   around	   a	   thiazol	   unit	   with	   an	  
aromatic	  group	  and	  a	  para	  carbonyl	  functional	  group,	  but	  minus	  the	  N-­‐linker	  atom,	  
and	   a	   different	   hydrophobic	   end	   (Figure	   5.3).	   Of	   more	   interest,	   was	   that	   these	  
compounds	   had	   been	   shown	   to	   activate	   RAR	   β2	   receptors,	   something	   which	  





Figure	  5.3	  Structure	  of	  AC-­‐261066.	  
	  
To	  incorporate	  the	  fluorine	  atom	  into	  neuropathiazol,	  60,	  the	  synthesis	  started	  from	  
4-­‐amino-­‐2-­‐fluorobenzoic	  acid,	  74,	  which	  was	  converted	  directly	  into	  the	  ethyl	  ester,	  
75,	  using	  thionyl	  chloride	  and	  ethanol,	  in	  a	  high	  yield	  of	  93%	  (Scheme	  5.9).344	  	  
	  
	  
Scheme	  5.9	  	  
The	   optimal	   conditions	   for	   the	   direct	   amide	   bond	   formation,	   discussed	   previously	  
within	   this	   Chapter,	   were	   subsequently	   employed	   to	   generate	   4-­‐(2-­‐chloro-­‐
acetylamino)-­‐2-­‐fluoro-­‐benzoic	   acid	   ethyl	   ester,	   76,	   as	   an	   off-­‐white	   solid,	   in	   a	   64%	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An	   initial	   attempt	   at	   the	   formation	   of	   2-­‐fluoro-­‐4-­‐(2-­‐phenyl-­‐thiazol-­‐4-­‐ylamino)-­‐
benzoic	   acid	   ethyl	   ester,	   77,	  was	   attempted	   along	   side	   earlier	   thiazole	   formation	  
reactions,	   as	   discussed	   previously.	   Initially,	   this	   was	   done	   under	   sub-­‐optimal	  
conditions	  leading	  to	  the	  formation	  of	  the	  highly	  coloured	  impurities,	  which	  in	  turn	  
led	  to	  purification	  issues.	  Consequently,	  this	  compound	  has	  yet	  to	  be	  identified	  and	  
characterised	  fully	  since	  a	  pure	  sample	  was	  never	  obtained.	  Following	  on	  from	  the	  
synthesis	   of	   neuropathiazol,	   60,	   the	   crude	   compound	   was	   carried	   through,	   to	  
generate	  the	  N-­‐methyl	  derivative,	  78,	  as	  it	  was	  thought	  this	  might	  aid	  in	  purification.	  
Unfortunately,	   this	   was	   not	   observed,	   and	   a	   single,	   pure,	   isolated	   sample	   of	   the	  
fluorinated	   analogue,	   78,	   was	   never	   isolated.	   The	   reactions	   are	   summarised	   in	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Due	  to	  the	  volume	  of	  material	  available	  at	  the	  time,	  both	  reactions	  were	  undertaken	  
on	   a	   small	   scale,	   therefore,	   would	   require	   repeating	   once	   more	   material	   was	  
available,	  and	  once	  the	  thiazole	  formation	  step	  had	  been	  improved.	  	  	  
	  
In	  addition	  to	  trying	  to	  generate	  the	  fluorine	  analogue,	  78,	  of	  neuropathiazol,	  60,	  an	  
identical	   reaction	   was	   investigated	   using	   5,5,8,8-­‐tetramethyl-­‐5,6,7,8-­‐tetrahydro-­‐
naphthalene-­‐2-­‐carbothioic	  amide,	  71,	  as	  a	  substitute	  for	  thiobenzamide,	  62	  (Scheme	  
5.12).	   Again,	   the	   current	   best-­‐known	   conditions	   were	   employed,	   which	   were	  
identical	   to	   those	   used	   for	   synthesising	   neuropathiazol,	   60.	   As	   in	   all	   previous	  
reactions	   attempting	   to	   form	   the	   thiazole,	   the	   reaction	   degraded	   into	   multiple	  
components	   and	   products	   and	   successful	   isolation	   of	   the	   product	   was	   never	  
achieved.	   Due	   to	   the	   higher	   costs	   and	  multiple	   steps	   involved	   in	   synthesising	   the	  
components	   required	   for	   these	   two	   analogues,	   there	   was	   insufficient	   material	  






Consequently,	  since	  analogues	  were	  going	  to	  be	  required,	   it	  became	  apparent	  that	  
the	  thiazol	  formation	  reaction	  required	  modifying,	  in	  order	  to	  avoid	  the	  formation	  of	  
the	  highly	  coloured	  impurities	  and	  large	  losses	  of	  mass	  associated	  with	  this	  step.	  The	  
coloured	  species	  are	  most	  likely	  N-­‐oxide	  species,	  formed	  from	  the	  high	  temperatures	  
of	   either	   the	   reaction,	   or	   work-­‐up	   procedure	   involved	   in	   removing	   the	   DMF,	  
although	   this	   is	   unproven.	   To	   try	   and	   avoid	   these	  by-­‐products,	   the	  procedure	  was	  
modified	   to	   remove	   the	  DMF	   through	  aqueous	  washes,	  other	   than	  under	  vacuum,	  
while	  extracting	  the	  product	  into	  ether.	  This	  was	  followed	  by	  reducing	  the	  reaction	  
time,	   which	   resulted	   in	   the	   reaction	   being	   worked-­‐up	   before	   turning	   to	   a	   dark	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product	  purified	  by	   flash	  SiO2	   column	  chromatography.	  This	  gave	   the	  product	  as	  a	  
pale	   yellow	   solid,	   in	   approximately	  25%	  yield,	  but	   as	  before,	  not	  100%	  pure	  by	   1H	  
NMR.	   The	   reaction	   had	   also	   not	   gone	   to	   completion,	   although	   there	   were	   less	  
purification	  issues	  than	  before.	  	  
	  
Although	   the	  modified	  work-­‐up	  had	   some	   success,	   there	  was	   still	   the	   issue	  of	   the	  
high	  temperatures	  employed	  in	  the	  reaction	  itself.	  At	  low	  temperatures,	  the	  reaction	  
was	   not	   initiated,	   and	   at	   the	   higher	   temperatures	   required	   for	   the	   reaction	   to	  
complete,	  highly	  coloured	  impurities	  were	  generated.	  In	  an	  attempt	  to	  increase	  the	  
reaction	  rate,	  molecular	  sieves	  were	  used	  to	  remove	  the	  water	  generated,	  hoping	  to	  
shift	  the	  equilibrium	  and	  drive	  the	  reaction	  forward.	  The	  temperature	  had	  to	  be	  kept	  
lower,	  as	  once	  above	  60-­‐70	  oC,	   the	  water	  molecules	  can	  move	  freely	   in	  and	  out	  of	  
the	  molecular	   sieves,	   thus	   rendering	   them	   inactive.	   Unfortunately,	   at	   50	   0C	   there	  
was	   no	   change	   in	   the	   reaction	   by	   TLC,	   while	   at	   60	   oC	   there	   was	   some	   product	  
formation.	  Upon	  work-­‐up,	  the	  DMF	  was	  successfully	  removed	  through	  the	  modified	  
process	  of	  aqueous	  washing,	   leaving	  a	  dark	  red	  oil,	  which	  once	  purified	  by	  column	  
chromatography,	   yielded	   the	  desired	  product,	   as	   a	  pale	   yellow	   solid,	   but	   in	   a	   very	  
poor	   yield	   (<20%).	   As	   the	   compound	  was	   still	   not	   100%	   pure	   by	   1H	  NMR	   and	   the	  
yield	  was	  significantly	  lower,	  this	  method	  was	  abandoned.	  
	  
The	  use	  of	  a	  mild	  base	  was	  next	  attempted,	  using	  pyridine	  (1	  equivalent)	  added	  to	  
the	  reaction	  mixture.	  Again	  the	  reaction	  was	  followed	  at	  a	  lower	  temperature	  of	  50	  
oC,	  and	  again	  no	  product	  was	  observed.	  The	  reaction	  temperature	  was	  increased	  to	  
70	  oC,	  but	  still	  reaction	  turn	  over	  by	  TLC	  appeared	  very	  slow.	  
	  
As	   all	   attempts	   to	   form	   the	   thiazole	   in	   high	   yield,	   and	   in	   isolation,	   had	   proven	  
unsuccessful	  an	  alternative	  approach	  was	  investigated.	  Both	  the	  literature,	  and	  our	  
own	   work,	   had	   demonstrated	   the	   instability	   of	   the	   un-­‐methylated	   nitrogen	  
associated	  with	  all	  the	  intermediates,	  therefore	  methylation	  of	  the	  nitrogen	  before	  
cyclisation	  was	  explored.250	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Initially,	   this	   was	   attempted	   directly	   on	   to	   4-­‐(2-­‐chloro-­‐acetylamino)-­‐benzoic	   acid	  
ethyl	  ester,	  61,	   since	   large	  quantities	  had	  been	  prepared	  previously	   through	  direct	  
amide	  bond	  formation.	   Initially,	  the	  reaction	  conditions	  employed	  were	  those	  used	  
in	   the	   literature	   preparation	   of	   neuropathiazol,	   60.250	   The	   compound	  was	   treated	  
with	  a	  large	  excess	  of	  methyl	  iodide	  and	  5	  equivalents	  of	  sodium	  hydride	  in	  dry	  THF	  
at	   0	   oC	   (Scheme	   5.13).	   This	   reaction	   was	   unsuccessful,	   with	   multiple	   compounds	  
identified	   in	   the	   crude	   that	  did	  not	   separate	  by	  SiO2	   column	  chromatography.	   The	  
reaction	   was	   subsequently	   repeated	   with	   one	   and	   two	   equivalents	   of	   sodium	  
hydride,	   both	   with	   one	   equivalent	   of	   methyl	   iodide,	   but	   again,	   this	   proved	  
unsuccessful	  due	  to	  too	  many	  competing	  side	  reactions.	  	  
	  
	  
Scheme	  5.13	  	  
As	  treatment	  of	  4-­‐(2-­‐chloro-­‐acetylamino)-­‐benzoic	  acid	  ethyl	  ester,	  61,	  with	  NaH	  gave	  
a	  mixture	  of	  compounds,	  methylation	  of	   the	  original	   starting	  material,	  benzocaine,	  
65,	   was	   tried.	   One-­‐pot	   reductive	   mono-­‐N-­‐alkylation	   of	   the	   aniline	   using	   the	  
corresponding	  aldehyde	  was	  attempted.	  2-­‐Propanol	  was	  added	  to	  a	  flask	  containing	  
10	   mol%	   Pd/C	   followed	   by	   the	   addition	   of	   ammonium	   formate	   (5	   eqivalents)	  
dissolved	   in	   water	   (Scheme	   5.14).	   The	   mixture	   was	   stirred	   for	   approximately	   1	  
minute	   to	   activate	   the	   Pd/C,	   followed	   by	   the	   addition	   of	   para-­‐formaldehyde,	   and	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Literature	   investigations	   suggested	   the	   free	   carboxylic	   acid	   would	   be	   more	  
reactive,345	   thus	   identical	   conditions	   were	   attempted	   on	   4-­‐aminobenzoic	   acid,	   82.	  
The	  reaction	  was	   left	   for	  1	  hour	  and	  after	  purification	  by	  column	  chromatography,	  
the	  product,	  83,	  was	  identified	  as	  a	  white	  solid	  in	  a	  poor	  yield	  of	  18%.	  In	  an	  attempt	  
to	  improve	  the	  yield	  the	  reaction	  time	  was	  extended	  from	  1	  hour	  to	  18	  hours,	  which	  
improved	   the	   yield	   to	   30%.	   Increasing	   the	   number	   of	   equivalents	   of	   the	   aldehyde	  
was	  subsequently	   investigated,	  but	  with	   little	   improvement	  seen	  as	  10	  equivalents	  
only	   increased	   the	  yield	   to	  33%	   (Scheme	  5.14).	  As	  materials	   for	   the	   reaction	  were	  






The	  carboxylic	  acid,	  83,	  was	  then	  protected	  as	  the	  ethyl	  ester,	  using	  thionyl	  chloride	  
in	   ethanol.344	   The	   product,	  81,	  was	   identified	   as	   an	   off-­‐white	   solid	   in	   an	   excellent	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Scheme	  5.15	  	  
The	   next	   step	   of	   the	   synthesis	   involved	   forming	   an	   amide	   bond	   on	   the	   nitrogen.	  
Previously,	  direct	  amide	  bond	  formation	  had	  been	  employed	  using	  boric	  acid	  as	  the	  
catalyst,	  which	  achieved	  a	  yield	  of	  67%.	  The	  current	  synthesis	  was	  being	  carried	  out	  
on	  a	  greatly	  reduced	  scale,	  thus	  a	  more	  efficient	  coupling	  was	  required	  to	  maintain	  a	  
viable	  amount	  of	  material	  to	  investigate	  the	  important	  thiazol	  formation	  step.	  Use	  of	  
the	  acid	  chloride	  was,	  therefore,	  chosen,	  since	  this	  was	  expected	  to	  give	  the	  highest	  
yield.	   Although	   all	   the	   starting	  material	   was	   consumed	   by	   analysis	   using	   TLC,	   the	  





With	   the	   N-­‐methylated	   amide	   species	   now	   available,	   the	   final	   step	   of	   the	   new	  
synthetic	   approach	  was	   attempted.	   Identical	   conditions	   for	   the	   ring	   closing	   thiazol	  
step	   were	   employed	   as	   described	   earlier.	   Briefly,	   thiobenzamide,	   62,	   and	   4-­‐[2-­‐
chloro-­‐acetyl)-­‐methyl-­‐amino]-­‐benzoic	   acid	   ethyl	   ester,	   80,	   were	   heated	   in	   DMF	  
overnight	   (Scheme	   5.17).	   As	   the	   reaction	  would	   go	   directly	   to	   neuropathiazol,	  60,	  
previously	   identified	   as	   a	   yellow	   solid,	   no	   coloured	   by-­‐products	   were	   expected.	  
Disappointingly,	   the	   reaction	   remained	   a	   mixture	   of	   mainly	   starting	   materials,	   a	  
small	   amount	  of	   the	  desired	  product	  and	  one	  other	   compound,	   thought	   to	  be	   the	  
open	   chain	   compound,	   84.	   Further	   heating	   for	   up	   to	   one	  week	   lead	   to	   no	   visible	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would	  mean	  further	  work	  was	  required	  in	  this	  area	  to	  fully	  characterise	  this	  reaction.	  
Early	   indications	   are	   that	   it	   also	   has	   a	   very	   poor	   turn	   over,	   with	   a	   very	   low	  






From	   all	   the	   work	   carried	   out	   within	   this	   chapter,	   formation	   of	   the	   thiazole	   ring	  
proved	  most	  challenging,	  and	  as	  of	  yet,	  has	  been	  relatively	  unsuccessful	  with	  poor	  
yields	   and	   impure	   products	   obtained.	   Consequently,	   the	   only	   compound	   to	   be	  
assessed	  biologically	  was	  neuropathiazol,	  60,	  as	  currently,	  no	  other	  analogues	  were	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5.4	  Biological	  Characterisation	  	  
	  
5.4.1	  Effect	  on	  Human	  EC	  Stem	  Cell	  Differentiation	  
	  
Initially	  neuropathiazol	  was	  screened	  in	  the	  EC	  stem	  cell	  line,	  TERA2.cl.SP12	  to	  assess	  
whether	  it	  could	  induce	  differentiation	  of	  pluripotent	  stem	  cells.	  This	  line	  was	  chosen	  
as	   it	   has	   been	  well	   characterised,	   and	   responds	  well	   to	   small	  molecules,	   including	  
retinoid	  treatment	  (see	  Chapter	  I	  for	  full	  discussion).	  In	  addition,	  this	  would	  give	  us	  
an	  early	  indication	  into	  the	  molecular	  pathway	  associated	  with	  neuropathiazol,	  as	  if	  
it	   were	   to	   bind	   to	   the	   retinoid	   receptors	   and	   active	   them,	   we	   would	   see	   a	   clear	  
response.	   This	   would	   allow	   us	   to	   confirm,	   or	   disprove,	   the	   theory	   stated	   in	   the	  
current	   literature	   that	   neuropathiazol	   acts	   on	   a	   different	   pathway	   to	   ATRA.250	  
Furthermore,	  the	  current	  literature	  on	  neuropathiazol	  compared	  it	  directly	  to	  ATRA,	  
but	  only	   in	   a	  hippocampal	  model.	  We	  have	  demonstrated	   in	   the	  previous	  Chapter	  
that	   the	  AHPC	  cell	   line	   is	  not	   that	   responsive	   to	  retinoids.	  Therefore	   to	  allow	  for	  a	  
more	   complete	   comparison	   of	   neuropathiazol	   to	   ATRA,	   investigations	   in	   known	  
models,	  which	  are	  highly	  responsive	  to	  retinoids,	  was	  required.250	  	  
	  
Initially,	  protein	  expression	  was	  examined	  to	  monitor	  cell	  differentiation,	  performed	  
using	  flow	  cytometry.	  Flow	  cytometry	  was	  chosen,	  as	  this	  would	  show	  any	  changes	  
in	  the	  cell	  type.	  Cultures	  of	  TERA2.cl.SP12	  cells	  were	  incubated	  for	  seven	  days	  with	  
both	  ATRA	  and	  neuropathiazol	   from	  10	  μM	  to	  0.001	  μM.	  The	  concentration	   range	  
chosen	  was	  based	  on	  prior	  knowledge	  gained	  from	  screening	  retinoids	  in	  this	  model.	  
Phase	  micrograph	  images	  were	  recorded	  at	  day	  7	  prior	  to	  the	  cells	  being	  analysed	  by	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The	   phase	   images	   indicated	   that	   neuropathiazol,	   over	   the	   entire	   concentration	  
range,	   had	   no	   effect,	   with	   the	   cells	   retaining	   a	  morphology	   similar	   to	   that	   of	   the	  
proliferative	   undifferentiated	   control.	   To	   confirm	   this	   observation,	   flow	   cytometry	  
was	  undertaken,	  investigating	  the	  expression	  levels	  of	  two	  stem	  cell	  antigens,	  SSEA-­‐3	  
and	   TRA-­‐1-­‐60,	   to	   assess	   the	   loss	   of	   pluripotency,	   and	   A2B5,	   as	   a	   measure	   of	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(A)	   	   	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  SSEA-­‐3	   	   	   	  
	  
	  
(B)	   	   	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  TRA-­‐1-­‐60	  
	  
	  
(C)	  	  	  	  	  	  	   	   	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  A2B5	  
	  
	  
Figure	   5.5	   Flow	   cytometric	   analysis	   of	  markers	   of	   stem	   cells	   SSEA-­‐3	   (A)	   and	   TRA-­‐1-­‐60	   (B),	  
and	  a	  marker	  of	  early	  stage	  neural	  cells,	  A2B5	  (C).	  TERA2.cl.SP12	  cells	  were	  incubated	  with	  
either	  ATRA	  or	  neuropathiazol	  (NPT)	  at	  10	  µM,	  1	  µM,	  0.1	  µM,	  0.01	  µM	  or	  0.001	  µM.	  Both	  
stem	  cell	  markers	  remained	  high	  in	  all	  neuropathiazol	  treatments,	  while	  the	  neural	  marker	  
remained	  low.	  Thus	  indicating	  neuropathiazol	  does	  not	  induce	  differentiation	  in	  this	  specific	  
cell	  model	  system.	  ATRA	  exhibited	   its	  classical	  profile	   in	  this	  system.	  Results	  are	  presented	  
with	  ±	  standard	  error	  (SDE),	  n=3.	  Per	  statistical	  analysis	  using	  the	  Student’s	  t-­‐test	  corrected	  
for	  multiple	   testing	   of	   sample	   populations	   using	   the	   Bonferroni	   correction	   there	  were	   no	  
significant	  differences.	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The	  graphs	  clearly	  support	  the	  conclusion	  drawn	  from	  the	  phase	  images.	  Both	  stem	  
cell	   markers,	   SSEA-­‐3	   and	   TRA-­‐1-­‐60,	   remain	   highly	   expressed	   in	   all	   neuropathiazol	  
treatments.	   Additionally,	   A2B5	   remains	   low,	   identical	   to	   the	   control	   cells.	   As	  
expected,	   the	   positive	   control,	   ATRA,	   significantly	   reduced	   the	   expression	   of	   both	  
stem	  cell	  markers,	  while	  dramatically	  up-­‐regulating	  A2B5	  expression	  at	  both	  10	  μM	  
and	   1	   μM.	   From	   this	   data,	   it	   is	   apparent	   that	   neuropathiazol	   is	   unable	   to	   induce	  
differentiation	  of	   pluripotent	   EC	   stem	   cells.	   Furthermore,	   it	   is	   therefore	   likely	   that	  
neuropathiazol	  does	  not	  activate	  the	  retinoic	  acid	  signalling	  pathway,	  and	  associated	  
retinoid	  receptors,	  as	  this	  is	  normally	  associated	  with	  differentiation	  in	  this	  cell	  line.	  
For	   conformation	   of	   this	   hypothesis,	   molecular	   binding	   studies	   on	   the	   retinoid	  
receptors	  would	  be	  required.	  	  	  	  	  	  
	  
5.4.2	  Effect	  on	  Human	  Embryonic	  Neural	  Stem	  Cells	  
	  
In	   a	   follow	   on	   study,	   and	   in	   line	   with	   previous	   work	   carried	   out	   on	   the	   synthetic	  
retinoids	   AH60	   and	   AH61,	   neuropathiazol	   was	   screened	   for	   its	   ability	   to	   induce	  
neurogenesis	  in	  the	  human	  fetal	  neural	  stem	  cell	  line,	  ReNcell	  VM.	  A	  concentration	  
series	  of	  1	  μM,	  0.1	  μM,	  0.01	  μM	  and	  0.001	  μM	  was	  chosen	  in	  accordance	  with	  those	  
previously	   used	   for	   screening	   the	   retinoids,	   as	   it	   was	   hypothesised	   that	  
neuropathiazol	  would	   be	   tolerated	   over	   this	   range.	   ReNcell	   VM	   cell	   cultures	  were	  
plated	   as	   described	   in	   the	   literature	   and	   in	   the	   previous	   Chapter,	   with	  
neuropathiazol	   included	   at	   the	   time	   of	   growth	   factor	   removal.59	   After	   7	   days	   the	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Figure	   5.6	   Morphologies	   of	   ReNcell	   VM	   cells	   after	   7	   days	   treatment.	   Undifferentiated	  
cultures	   (UNDIFF)	   retained	  a	  homogeneous	  appearance	  with	  cells	   layering	  as	   they	  become	  
over	   confluent	   and	   sub-­‐optimal.	   Control	   differentiated	   cultures	   (CON	   DIFF),	   in	   which	   the	  
growth	  factors,	  EGF	  and	  FGF	  were	  removed,	  showed	  areas	  of	  proliferative	  cells	  surrounded	  
by	  more	   sparsely	   populated	   areas	  with	   numerous	   neural	   processes	   visible.	   Those	   treated	  
with	   neuropathiazol	   (NPT)	   also	   display	   a	   highly	   analogous	   phenotype,	   suggesting	   no	  
enhancement	  in	  differentiation.	  Scale	  Bars:	  100	  μm.	  	  
	  
In	  addition,	  all	   treatments	  were	  stained	   for	   the	  neuronal	  markers	  β-­‐III-­‐tubulin,	  NF-­‐
200	   and	   MAP2ab	   to	   assess	   the	   ability	   of	   neuropathiazol	   to	   induce	   neurogenesis.	  
These	   markers	   were	   chosen,	   as	   they	   would	   allow	   for	   a	   direct	   comparison	   to	   the	  
retinoids	  screened	   in	  Chapter	   IV.	  The	  screening	  of	  neuropathiazol	   in	   the	   literature,	  
albeit	   in	  a	  different	  neural	  progenitor	  cell	   line,	  had	  displayed	  positive	  up-­‐regulation	  
of	   these	   and	   similar	   markers.	   The	   immunofluorescent	   micrographs	   for	  
neuropathiazol,	   and	   undifferentiated	   and	   control	   differentiated	   samples,	   inlayed	  
with	  their	  corresponding	  nuclear	  stained	  DAPI	  image,	  are	  displayed	  in	  Figure	  5.7.	  In	  
addition,	  a	  positive	  differentiation	  control	  of	  ATRA	  was	  attained	  (for	  representative	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Figure	  5.7	  Cultures	  of	  ReNcell	  VM	  cells	  were	   induced	  to	  differentiate	   for	  7	  days	  under	  the	  
standard	  differentiation	  protocol	  with	  the	  addition	  of	  neuropathiazol	  (NPT)	  at	  1	  µM,	  0.1	  µM,	  
0.01	   µM	   or	   0.001	   µM.	   Immunological	   evaluation	   of	   β-­‐III-­‐tubulin,	   NF-­‐200	   and	   MAP2ab	  
showed	   enhanced	   β-­‐III-­‐tubulin	   expression	   in	   0.1	   µM	   NPT	   treated	   cultures,	   but	   little	  
increased	  expression	  in	  all	  other	  treatments	  compared	  to	  the	  undifferentiated	  (UNDIFF)	  and	  
control	  differentiated	  (CON-­‐DIFF)	  controls.	  Scale	  bar:	  50	  μm.	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From	   previous	   data	   displayed	   within	   this	   thesis	   it	   is	   known	   that	   retinoid	  
incorporation	   (particularly	   AH61)	   significantly	   up-­‐regulates	   the	   expression	   of	   all	  
three	  markers	   (see	   Chapter	   IV).	   Disappointingly,	   this	   up-­‐regulation	   is	   not	   seen	   for	  
neuropathiazol,	  in	  which	  most	  images	  display	  staining	  profiles	  characteristic	  to	  those	  
of	   the	   undifferentiated	   controls.	   Upon	   quantification,	   again	   achieved	   through	   cell	  
counts,	  there	  was	  clearly	  no	  increase	  in	  expression	  of	  the	  markers	  over	  the	  chosen	  
concentration	   range	   (Figure	   5.8).	   The	   only	   exception	   was	   that	   of	   β-­‐III-­‐tubulin	  
expression	  at	  0.1	  μM,	  although	  this	  was	  not	  significant	  when	  compared	  to	  ATRA,	   it	  
was	   compared	   to	   the	   control	   differentiated	   samples.	   This,	   therefore,	   suggests	  
neuropathiazol	  does	  have	  an	  effect	  in	  this	  cell	  line,	  although	  it	  is	  not	  as	  apparent	  as	  
that	  seen	  for	  some	  retinoid	  treatments,	  most	  notably	  AH61.	  Why	  this	  peaks	  at	  0.1	  
μM	  and	  drops	  off	  at	  the	  higher	  concentration	  of	  1	  μM	  is	  unknown.	  The	  cells	  at	  1	  μM	  
appeared	   normal	   under	   microscopic	   investigation	   with	   no	   signs	   of	   cell	   death,	  




Figure	   5.8	   A	   graph	   displaying	   the	   quantification	   of	   immunological	   data	   as	   performed	   by	  
counting	  positively	  labelled	  cells.	  The	  increased	  number	  of	  β-­‐III-­‐tubulin,	  NF-­‐200	  and	  MAP2ab	  
positive	   cells	   in	   neuropathiazol	   supplemented	   cultures	   was	   not	   significant	   compared	   to	  
control	   differentiated	   cultures	   (Con-­‐Diff),	   with	   the	   exception	   of	   β-­‐III-­‐tubulin	   at	   0.1	   μM.	  
Triplicate	   analysis	   was	   performed	   for	   reproducibility.	   Values	   shown	   represent	   mean	   +	  
standard	   error	   (SDE),	   n=9.	   Per	   statistical	   analysis	   using	   the	   Student’s	   t-­‐test	   corrected	   for	  
multiple	   testing	   of	   sample	   populations	   using	   the	   Bonferroni	   correction	   there	   were	   no	  
significant	  differences.	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  From	  all	   the	  data	  collected,	  neuropathiazol	  appears	   to	  be	   inactive,	  or	  only	   slightly	  
active,	   in	   the	   two	   stem	   cells	   models	   screened.	   Therefore,	   to	   validate	   that	   this	  
molecule	   appears	   to	   be	   specific	   to	   a	   single	   cell	   line,	   its	   activity	   in	   the	   adult	   rat	  
hippocampus	  was	  investigated.	  
	  
5.4.3	  Effect	  on	  Adult	  Rat	  Hippocampal	  Neural	  Progenitor	  Cells	  
	  
Initially,	   identical	   experiments	   were	   undertaken	   as	   described	   in	   the	   literature.250	  
Briefly,	   these	   involved	   assessing	   neuropathiazol’s	   capability	   to	   induce	   selective	  
neurogenesis	   utilising	   immunocytochemistry.	   AHPC	   cells	   were	   exposed	   to	  
neuropathiazol	  at	  10	  μM	  for	  4	  days,	  fixed	  and	  stained	  for	  the	  neuronal	  marker	  β-­‐III-­‐
tubulin	   and	   the	   glial	   marker	   GFAP.	   Both	   phase	   and	   immunological	   images	   are	  




Figure	   5.9	  AHPC	   cells	   exposed	   for	   4	   days	   treatment	  with	   neuropathiazol	   at	   10	  μM.	  Phase	  
images	   (A)	   show	   rounded	   cells	   with	   multiple	   outgrowths.	   Cells	   stained	   with	   markers	   of	  
neurons	   (β-­‐III-­‐tubulin,	   red)	  and	  astrocytes	   (GFAP,	  green)	  display	  neuropathiazol	  specifically	  
induces	  neuronal	  differentiation	  of	  AHPC	  cells	   (B).	  Scale	  bar:	  100	  μm	  (A).	  Scale	  bar:	  50	  μm	  
(B).	  	  
	  
AHPC	  cells	  exposed	  to	  neuropathiazol	  at	  10	  μM	  for	  4	  days	  exhibited	  a	  differentiated	  
morphology,	  with	  multiple	  outgrowths	  on	  each	  cell.	  When	  stained	  for	  both	  neuronal	  
and	  glial	  markers,	  consistent	  with	  the	  literature,	  nearly	  all	  the	  cells	  stained	  positive	  
for	   β-­‐III-­‐tubulin.	   In	   comparison,	   positive	   staining	   for	   GFAP	   was	   rarely	   seen,	   with	  
many	   areas	   not	   displaying	   this	   cell	   type	   (image	   shown	   above	   chosen	   for	  
representation	  of	  both	  cell	  types).	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When	   the	   cells	  were	   cultured	   for	   7	  days,	   they	   also	   stained	  positive	   for	   later	   stage	  
neurons,	  including	  NF-­‐200	  (Figure	  5.10).	  From	  prior	  investigations,	  it	  was	  known	  that	  
ATRA	   is	   toxic	  at	  10	  μM,	  therefore,	  cannot	  be	  directly	  compared	  to	  neuropathiazol.	  
Therefore,	   to	   compare	   both	   compounds	   as	   accurately	   as	   possible,	   the	   highest	  
tolerated	  concentration	  of	  ATRA	  was	  employed,	  suggested	  from	  the	   literature	  as	  2	  
μM.	   Consistent	   with	   data	   presented	   in	   Chapter	   IV,	   ATRA	   displayed	   a	   pleotropic	  
profile	  leading	  to	  the	  expression	  of	  both	  glial	  and	  neuronal	  markers.	  It	  was	  also	  less	  
effective	  at	  inducing	  the	  positive	  expression	  of	  later	  stage	  neuronal	  markers,	  such	  as	  




Figure	   5.10	   AHPC	   cells	   exposed	   for	   7	   days	   treatment	   with	   neuropathiazol	   at	   10	   μM	   and	  
ATRA	   at	   5	   μM.	   Cells	   stained	   with	   markers	   of	   neurons	   (β-­‐III-­‐tubulin,	   red)	   and	   astrocytes	  
(GFAP,	   green)	   display	   neuropathiazol	   specifically	   induces	   neuronal	   differentiation	   of	   AHPC	  
cells	   (A),	   whereas	   ATRA	   is	   pleotropic	   (C).	   Mature	   neurons	   were	   observed	   with	   NF-­‐200	  
(green)	  (B)	  upon	  neuropathiazol	  treatment,	  but	  less	  so	  with	  ATRA	  (D).	  Scale	  bar:	  50	  μm.	  
	  
The	   data	   presented	   above	   supports	   that	   presented	   in	   the	   current	   literature,	  
confirming	   the	   hypothesis	   that	   neuropathiazol	   is	   a	   more	   selective	   and	   potent	  
inducer	   of	   neurogenesis	   than	   ATRA.250	   Preliminary	   cell	   counts	   to	   quantify	   TuJ1	  
expression	   versus	   GFAP	   expression	   further	   supports	   the	   values	   quoted	   in	   the	  
literature,	   that	   neuropathiazol	   differentiates	   90%	  of	  AHPCs	   into	   TuJ1	   positive	   cells	  
(Figure	  5.11).	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Figure	   5.11	   Plot	   displaying	   the	   quantification	   of	   the	   percentage	   expression	   of	   TuJ1	   and	  
GFAP,	  as	  performed	  by	  counting	   labelled	  cell	  bodies.	  Cultures	  of	  AHPCs	   incubated	  with	  10	  
µM	   neuropathiazol	   (NPT)	   or	   2	   µM	   ATRA,	   for	   7	   days,	   subsequently	   fixed	   and	  
immunocytochemically	   stained.	   Using	   ImageJ	   software	   the	   number	   of	   positive	   cell	   bodies	  
were	   counted	   on	   3	   random	   fields	   per	   treatment	   condition.	   10	   µM	   treatment	   of	  
neuropathiazol	   induced	  a	  significant	   increase	  in	  the	  percentage	  expression	  of	  TuJ1	  labelled	  
cells,	  over	  both	  ATRA	  and	  DMSO.	  Values	  shown	  represent	  mean	  +	  standard	  error	  (SDE),	  n=3.	  
*p≤0.05,	  ***p≤0.0005,	  Student’s	  t-­‐test	  corrected	  for	  multiple	  testing	  of	  sample	  populations	  
using	  the	  Bonferroni	  correction.	  	  
	  
	  
The	  literature,	  however,	  did	  not	  assess	  whether	  neuropathiazol	  retained	  its	  potency	  
over	   a	  wider	   concentration	   range.250	   Thus,	   in	   an	   extension	   to	   the	   literature	  work,	  
AHPC	  cells	  were	  cultured	  for	  7	  days	  with	  neuropathiazol	  at	  1	  μM,	  0.1	  μM	  and	  0.01	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  +	  NPT	  1	  μM	   	   	  	  	  	  	  	  	  	  	  	  	  +	  NPT	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  +	  NPT	  0.01	  μM	  
	  
	  
Figure	  5.8	  AHPC	  cells	  exposed	  for	  7	  days	  treatment	  with	  neuropathiazol	  at	  1	  μM,	  0.1	  μM	  and	  
0.01	   μM.	   Cells	   stained	   with	   markers	   of	   neurons	   (β-­‐III-­‐tubulin,	   red)	   and	   astrocytes	   (GFAP,	  
green)	  display	  neuropathiazol	  (NPT)	  is	  inactive	  at	  these	  concentrations.	  Scale	  bar:	  50	  μm.	  
	  
When	  the	  concentration	  of	  neuropathiazol	  was	  lowered,	  inline	  with	  that	  used	  in	  the	  
screening	   of	   the	   retinoids,	   its	   profile	   changed	   significantly.	   Over	   the	   entire	  
concentration	   range	   there	  was	   no	   change	   in	  morphology	   from	   those	   treated	  with	  
only	  the	  vehicle,	  DMSO	  (for	  comparison	  see	  Chapter	  IV).	  Neuronal	  markers	  were	  no	  
longer	  expressed,	  while	   the	  percentage	  expressing	  GFAP	  had	   increased,	   consistent	  
with	   the	   spontaneous	   differentiation	   of	   neural	   stem	   cells	   upon	   growth	   factor	  
withdrawal.346	  These	  results	  suggested	  neuropathiazol	  was	  not	  active	  below	  10	  µM,	  
therefore,	   future	   screening	   should	   take	   place	   at	   10	  µM	  or	   higher,	   once	   a	   viability	  
assay	   has	   been	   employed	   to	   determine	   at	   what	   concentration	   neuropathiazol	  
becomes	  toxic.	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5.5	  Discussion	  
	  
In	  terms	  of	  synthesis,	  there	  are	  a	  number	  of	  other	  potential	  synthetic	  routes,	  which	  
have	  yet	  to	  be	  completed	  and	  fully	  examined.	  These	  have	  the	  potential	  to	  produce	  a	  
number	   of	   analogues	   related	   to	   neuropathiazol,	   which	   would	   be	   interesting	   to	  
screen.	  	  
	  
One	   such	   solution	  would	   be	   to	   attempt	   to	   synthesise	   the	   ring	   at	   the	   start	   of	   the	  
synthesis,	   or	   start	   with	   the	   thiazol	   ring	   and	   substitute	   around	   it.	   One	   prospective	  
route	   would	   be	   to	   start	   with	   4-­‐hydroxy-­‐2-­‐phenyl-­‐1,3-­‐thiazol,	   85,	   a	   commercially	  
available	   compound,	   and	   convert	   this	   to	   the	   corresponding	   chloride,	   86,	   through	  
treatment	   with	   pyridinium	   hydrochloride,	   phosphoric	   acid	   and	   phosphorus	  






Alternatively,	  to	  allow	  for	  more	  variation,	  there	  is	  literature	  reporting	  the	  formation	  
of	  thiazols	  from	  reacting	  substituted	  thiobenzamides,	  87,	  with	  1,3-­‐dichloroacetone,	  
88,	   to	   form	   chloromethyl	   thiazoles,	   89	   (Scheme	   5.19).348	   This	   reaction	   has	   the	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The	   above	   series	   of	   compounds	   would	   be	   one	   carbon	   in	   size	   larger,	   therefore	   to	  
generate	   the	   corresponding	   TMTN	   analogue	   of	   the	   2-­‐phenyl-­‐4-­‐chlorothiazole	   86,	  
substituting	  1,3-­‐dichloroacetone,	  88,	  in	  the	  above	  reaction	  for	  chloroacetyl	  chloride,	  






Alternatively,	   if	   the	   direct	   route	   described	   above	   proved	   unsuccessful	   there	   is	  
literature	   describing	   the	   successful	   synthesis	   of	   4-­‐t-­‐butyldimethylsilyloxy	   thiazoles,	  
92	   (Scheme	   5.21),	   which	   potentially	   could	   then	   be	   deprotected	   to	   the	   alcohol	  
followed	   by	   conversion	   to	   the	   chloride.349	   This	   route	   has	   the	   potential	   to	   be	  







With	  these	  compounds	  in	  hand,	  coupling	  to	  4-­‐methylamino-­‐benzoic	  acid	  ethyl	  ester,	  
81,	  would	  give	  neuropathiazol,	  60.	  Alternatively,	  this	  could	  also	  couple	  to	  the	  TMTN	  
analogue,	   91,	   shown	   in	   scheme	   5.20,	   generating	   the	   desired	   TMTN	   analogue	   of	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Adaption	  of	  the	  synthesis	  involving	  the	  fluorine	  atom,	  by	  initially	  methylating	  on	  the	  
nitrogen,	  would	  then	  allow	  for	  those	  analogues	  also	  to	  be	  accessed.	  Similarly,	  other	  
linker	   groups	   could	   potentially	   be	   investigated,	   including	   oxygen,	   and	   sulphur	   as	  
these	  starting	  materials	  are	  easily	  accessible	  and	  readily	  available.	  
	  
Future	  work	  on	  the	  screening	  initially	  needs	  to	  fully	  quantify	  the	  data	  presented	  on	  
neuropathiazol,	   which	   should	   ideally	   support	   that	   presented	   in	   the	   literature.250	  
Currently,	  only	  a	  concentration	  of	  10	  µM	  has	  been	  screened	  (15	  µM	  was	  presented	  
in	   the	   literature250),	   therefore,	   a	   viability	   assay	   should	   also	   be	   employed	   to	   see	   at	  
what	   concentration	   neuropathiazol	   becomes	   toxic,	   and	   if	   higher	   more	   potent	  
concentrations	  can	  be	  found	  and	  exploited.	  In	  addition,	  rescreening	  neuropathiazol	  
in	   the	   ReNcell	   VM	   cell	   line	   at	   a	   higher	   concentration	   may	   be	   beneficial,	   as	   this	  
compound	   appeared	   to	   behave	   biologically	   appreciably	   different	   to	   that	   of	   the	  
retinoids.	   Current	   data	   suggests	   it	   is	   considerably	   less	   toxic	   than	   the	   retinoid	  
compounds,	   and	   therefore,	   would	   be	   tolerated	   at	   higher	   and	   potentially	   active	  
concentrations.	  	  
	  
Since	  this	  work	  has	  been	  carried	  out,	  the	  same	  group	  to	  publish	  the	  neuropathiazol	  
work	  have	  subsequently	  published	  further	  studies.350	  In	  this	  report	  they	  describe	  the	  
synthesis	   of	   KHS101,	   94	   (Figure	   5.9),	   afforded	   from	   an	   improved	   SAR	   study	   of	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increased	   activity	   and	   improved	   pharmacokinetic	   properties,	   compared	   to	   that	   of	  
neuropathiazol.	  It	  displays	  increased	  neuronal	  differentiation	  properties	  of	  adult	  rat	  
hippocampal	   neural	   progenitor	   cells,	   as	   assessed	   through	   RT-­‐PCR	   for	   NeuroD,	   a	  
neurogenic	   transcription	   factor,	   and	   immunostaining	   for	   TuJ1.	   Similar	   to	  
neuropathiazol,	   it	   appears	   to	   be	   able	   to	   inhibit	   astrocyte-­‐inducing	   signalling	  
pathways	   in	   favour	   of	   neuronal	   differentiation.	   Additional	   mechanistic	   studies	  
showed	  that	  KHS101	  was	  linked	  to	  cell	  cycle	  exit	  and	  specific	  binding	  to	  the	  TACC3	  
protein,	   thus	   suggesting	   KHS101	   mediated	   interference	   with	   TACC3	   accelerates	  
neurogenesis	   through	   negative	   regulation	   of	   the	   cell	   cycle.	   Currently,	   a	   complete	  
understanding	   of	   TACC3	   and	   its	   downstream	   mechanisms	   are	   unknown,	   yet	  
literature	   does	   suggest	   it	   plays	   a	   crucial	   role	   in	   progenitor	   cell	  maintenance.351-­‐355	  
Finally,	   they	   undertook	   an	   in	   vivo	   study	   in	   which	   they	   show	   KHS101	   to	   distribute	  
favourably	   to	   the	  brain,	   increase	  neuronal	  differentiation,	  while	  not	  observing	  any	  




Figure	  5.9	  Structure	  of	  KHS101.	  
	  
In	   addition	   to	   increased	   biological	   activities,	   the	   synthesis	   of	   KHS101	   does	   not	  
involve	  a	  thiazole	  ring	  forming	  step,	  as	  one	  of	  the	  starting	  materials	  ((2-­‐phenyl-­‐1,3-­‐
thiazol-­‐4-­‐yl)methyl	   amine,	   96)	   already	   has	   the	   ring	   preformed.	   Consequently,	   the	  
two	  step	  synthesis	  of	  KHS101	  (summarised	  in	  Scheme	  5.23)	  is	  high	  yielding,	  with	  an	  
overall	   yield	   of	   83%.	   This	   therefore	   makes	   KHS101	   a	   much	   more	   promising	  
compound	   for	   controlling	   AHPC	   differentiation	   than	   neuropathiazol,	   and	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Scheme	  5.23	  Synthetic	  Route	  to	  KHS101.350	  
	  
Overall	   this	   Chapter	   highlights	   that	   small	   molecules,	   such	   as	   neuropathiazol	   and	  
KHS101,	  isolated	  from	  chemical	  library	  screens,	  can	  be	  powerful	  tools	  in	  modulating	  
NPCs	  both	  in	  vitro	  and	  in	  vivo.	  Furthermore,	  a	  number	  of	  other	  small	  molecules	  have	  
been	   described	   in	   the	   literature	   as	   having	   the	   ability	   to	   control	   both	   the	  
differentiation	   and	   self-­‐renewal	   of	   stem/progenitor	   cells.247,	   250,	   350,	   356-­‐360	   These	  
advances	   are	   exciting,	   as	   the	   prospects	   of	   complete	   chemical	   defined	   control	   of	  






































	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Chapter	  V	  
	   209	  
5.6	  Conclusions	  
	  
The	   first	   conclusion	   that	   can	   be	   drawn	   is	   that	   the	   published	   synthetic	   route	   to	  
neuropathiazol	   is	   highly	   inefficient	   and	   challenging.	   Although	   we	   have	   made	  
considerable	  advances	   in	  optimising	  this	  synthetic	  strategy,	   it	   remains	  unlikely	  that	  
this	  approach	  will	  be	  viable,	  especially	  in	  terms	  of	  analogue	  synthesis.	  
	  
From	  the	  preliminary	  biological	  characterisation	  undertaken,	  neuropathiazol	  appears	  
to	   act	   as	   described	   in	   the	   literature.	   This	   is	   very	   interesting,	   considering	   no	   other	  
small	  molecules	   have	   been	   identified	  with	   such	   specific	   neural	   inducing	   activities.	  
Although,	   in	   light	   of	   the	   discovery	   of	   KHS101,	   further	  work	   in	   this	   field	   should	   be	  
invested	   around	   this	   new	   class	   of	   compound,	   and	  not	   that	   of	   neuropathiazol.	   The	  
synthesis	   of	   KHS101	   also	   does	   not	   involve	   the	   problematic	   thiazole	   ring-­‐forming	  
step,	  as	   it	   is	  present	   in	   the	  starting	  material,	   similar	   to	  some	  of	   the	  proposed	  new	  
strategies	  for	  neuropathiazol	  in	  the	  discussion.	  	  
	  
In	   summary,	   novel	   small	  molecules	   identified	   from	   large	   library	   screens,	   have	   the	  
potential	  to	  be	  hugely	  valuable	  in	  the	  stem	  cell	  field.	  Current	  known	  pathways,	  such	  
as	   the	   retinoid	   signalling	   pathway,	   are	   significantly	   useful	   for	   expanding	   our	  
knowledge,	  although	  it	  is	  now	  clear	  that	  there	  are	  numerous	  other	  factors	  and	  many	  
undiscovered	   small	   molecules	   which	   may	   help	   unlock	   the	   overall	   picture.	   Precise	  
control	   of	   native	   adult	   stem	   cells	   opens	   the	   potential	   of	   orally	   delivered	   small	  
molecules	   as	   potential	   regenerative	   therapies.361	   In	   addition,	   there	   has	   been	  
literature	  describing	  how	  cancer	  cells	  have	  stem	  cell-­‐like	  properties,	  sharing	  similar	  
self-­‐renewal	   mechanisms.	   A	   better	   understanding	   of	   stem	   cell	   biology	   may	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6.1	  Concluding	  Remarks	  
	  
The	  work	  within	  this	  thesis	  has	  highlighted	  two	  new	  synthetic	  retinoids,	  which	  have	  
the	  potential	   to	  be	  highly	  useful	   to	  both	   cell	   and	  molecular	  biologists.	  Both,	  AH60	  
and	   AH61,	   have	   been	   established	   as	   being	   more	   resistant	   to	   UV	   induced	  
isomerisation,	  compared	  to	  ATRA.	  Furthermore,	  both	  compounds	  do	  not	  show	  any	  
signs	   of	   degradation	   upon	   long	   term	   exposure	   to	   UV	   light,	   with	   initial	   metabolic	  
studies	  also	   suggesting	   they	  are	  not	  metabolised	   in	   vitro.	   These	   findings	   support	  a	  
common	  theory	  seen	  throughout	  the	  literature,	  that	  more	  stable	  analogues	  of	  ATRA	  
are	  required	  to	  further	  probe	  the	  retinoic	  acid	  signalling	  pathway.	  
	  
Upon	   biological	   screening,	   a	   clear	   SAR	   was	   highlighted,	   as	   none	   of	   the	   ‘short’	  
synthetic	   analogues	   synthesised	   (AH36,	   AH62	   and	   AH66)	   were	   biologically	   active,	  
while	   the	   ‘extended’	   analogue	   (AH98),	  was	  only	  partially	   active.	   This	   suggests	   that	  
the	   overall	   size	   of	   the	   linker	   region	   is	   critical	   in	   conferring	   biological	   activity,	   as	   a	  
small	  reduction	  in	  size	  leads	  to	  a	  complete	  loss	  of	  biological	  activity.	  Conformation	  at	  
the	   terminal	   bond	  was	   additionally	   highlighted	   as	   an	   important	   factor,	   as	   AH60	   is	  
approximately	  10-­‐fold	  less	  potent	  than	  AH61,	  in	  two	  of	  the	  models	  screened	  in	  this	  
work.	   This	   supports	   previous	  work	   carried	   out	   in	  Durham	  on	   EC19	   and	   EC23,	   that	  
small	   changes	   in	  molecular	   shape	   have	   large	   effects	   on	   the	   biological	   roles	   of	   the	  
compounds.	  	  
	  
Additionally,	   the	   synthetic	   retinoids	  AH60	  and	  AH61	  were	   shown	   to	  be	   active	   in	   a	  
number	  of	  different	  model	  systems,	  including	  in	  particular	  pluripotent	  EC	  stem	  cells	  
and	  multipotent	   neural	   stem	   cells.	   Although,	   the	   increased	   activity	   seen	   for	   both	  
AH60	   and	   AH61	   in	   the	   cells	   lines	   mentioned	   above,	   was	   not	   seen	   in	   the	   adult	  
hippocampal	  neural	  progenitor	  cell	  line.	  Currently,	  the	  exact	  reasons	  behind	  this	  are	  
unknown,	  but	  as	  stem	  cell	  differentiation	  is	  regulated	  by	  a	  wide	  number	  of	  signalling	  
pathways,	   and	   small	   molecules,	   this	   cannot	   be	   unexpected.	   These	   findings	   may	  
indeed	  highlight	  differences	  between	  embryonic	  neural	  stem	  cells	  and	  adult	  neural	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progenitors	  in	  their	  developmental	  potency,	  and	  the	  role	  played	  by	  the	  retinoic	  acid	  
signalling	  pathway,	  in	  lineage	  development.	  	  
	  
Overall,	  AH61	  has	  been	  shown	  to	  be	  a	  highly	  active	  synthetic	   retinoid,	  compare	  to	  
that	   of	   ATRA.	   Its	   increased	   activity	   also	   allows	   for	   it	   to	   be	   administered	   at	  
significantly	   lower	   concentrations,	   thereby	   avoiding	   toxic	   levels	   associated	   with	  
ATRA.	   Furthermore,	   early	   indication	   is	   that	   the	   compound	   is	   less	   toxic	   than	  ATRA,	  
and	   synthetic	   retinoid	   EC23,	   thus	   potentially	   making	   it	   a	   viable	   substitute	   for	  
therapeutic	  applications	  associated	  with	  ATRA,	  but	  currently	  limited	  by	  ATRA’s	  high	  
toxicity.	  Future	  work	  will	  undoubtedly	  expand	  on	  the	  current	  preliminary	  biological	  
characterisation	   of	   this	   compound,	   although	   early	   screens	   highlight	   AH61	   as	   the	  
current	  best	  alternative	  to	  ATRA	  for	  in	  vitro	  studies	  in	  these	  systems.	  
	  
In	   addition	   to	   screening	   novel	   retinoids	   an	   un-­‐related	   small	   molecule,	  
neuropathiazol,	   was	   highlighted	   from	   the	   literature	   as	   a	   promising	   and	   exciting	  
target.	  Consequently,	  the	  synthesis	  of	  neuropathiazol	  was	  carried	  out,	  in	  an	  attempt	  
to	  improve	  the	  current	  synthetic	  route,	  and	  characterisation.	  This	  was	  followed	  by	  a	  
more	   comprehensive	   biological	   screen,	   in	   three	   different	   cell	   lines,	   to	   further	  
characterise	  the	  biological	  profile	  of	  the	  compound	  in	  more	  detail.	  This	  highlighted	  
that	  neuropathiazol	  most	   likely	  did	  not	  act	  on	   the	   retinoic	  acid	  signalling	  pathway,	  
but	  elicited	  its	  activity	  through	  another	  currently	  an	  unknown	  pathway/mechanism.	  
Moreover,	  the	  data	  presented	  in	  the	  literature,	  that	  neuropathiazol	  is	  a	  more	  potent	  
inducer	  of	  neurogenesis	  in	  AHPCs	  than	  ATRA,	  was	  confirmed.	  Although,	  currently	  the	  
activity	  elicited	  by	  neuropathiazol,	  appears	  to	  be	  limited	  to	  only	  this	  model.	  As	  more	  
potent	   analogues	   have	   since	   been	   synthesised	   and	   highlighted	   in	   the	   literature,	  
further	   clarification	   and	   optimisation	   of	   neuropathiazol	   was	   abandoned,	   with	   any	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6.2	  Future	  Work	  
	  
• Full	  quantification	  of	  AH60	  and	  AH61	  in	  the	  TERA2.cl.SP12	  cell	   line	  needs	  to	  
be	  completed.	  This	  mainly	  consists	  of	  quantifying	  the	  total	  amount	  of	  protein	  
expressed	  in	  21	  day	  induced	  cell	  cultures.	  Preliminary	  cell	  counts	  have	  been	  
undertaken,	  but	  more	  accurate	  quantification	  is	  required,	  such	  as	  a	  Western	  
Blot.	  	  
	  
• Molecular	   binding	   studies	   also	   need	   to	   be	   carried	   out	   to	   compare	   the	  
affinities	   of	   AH61	   and	   EC23	   to	   that	   of	   ATRA.	   This	   would	   then	   confirm	   the	  
hypothesis	   that	  AH61’s	   increased	  potency	  over	  EC23	   is	  as	  a	  result	  of	  higher	  
receptor	  binding	  affinities.	  
	  
• Analysis	   in	   ES	   cells	   is	   also	   required	   to	   further	   confirm	   the	   ability	   of	   these	  
compounds	   to	   induce	   neuronal	   differentiation	   from	   pluripotent	   stem	   cell	  
systems.	  	  
	  
• Current	   work	   being	   carried	   out	   in	   Durham	   by	   D.	   Tams	   includes	   assessing	  
synthetic	   retinoids,	   EC23	   and	   AH61,	   to	   induce	   neurogenesis	   and	  
neuritogenesis	   from	   differentiated	   suspension	   aggregates	   of	   human	  
pluripotent	  stem	  cells.	  This	  model	  of	  neuritogenesis	  is	  planned	  to	  assess	  the	  
role	  of	  a	  number	  of	  known	  modulators	  of	  axon	  guidance	  and	  to	   investigate	  
the	  mechanism	   by	   which	   the	   use	   of	   these	   retinoids	   enhances	   both	   neural	  
stem	  cell	  commitment	  and	  neurite	  outgrowth.	  
	  
• Finally	  in	  vivo	  studies	  are	  required	  to	  assess	  the	  toxicity	  of	  the	  compounds,	  in	  
addition	   to	   probing	   known	   roles	   associated	   with	   ATRA.	   These	   include	  
neuronal	   remodelling	   in	   the	   hippocampus,	   and	   proliferation	   and	  
differentiation	  of	  keratinocytes,	  as	  assessed	  in	  mouse	  (currently	  being	  tested	  
by	   B.	   Pulman,	   Durham	   University).	   If	   proven	   successful	   futher	   therapeutic	  

















7.1	  Chemical	  Procedures	  
	  
7.1.1	  General	  Procedures	  
	  
	   All	  reactions	  were	  performed	  under	  air	  unless	  specified	  otherwise.	  All	  cross-­‐coupling	  
reactions	  were	   carried	   out	   under	   argon,	   using	   standard	   Schlenk	   techniques	   in	   oven	  dried	  
glassware	  (130	  oC)	  cooled	  under	  a	  positive	  pressure	  of	  argon.	  Degassing	  was	  carried	  out	  by	  a	  




	   All	  reagents	  were	  purchased	  from	  Aldrich,	  Acros,	  Alfa	  Aesar,	  Lancaster,	  Fluorochem	  
and	  Maybridge	  and	  used	  without	  further	  purification	  unless	  otherwise	  stated.	  Dry	  solvents	  
were	  dried	  by	   the	  use	  of	  a	  commercial	   solvent	  purification	  system	  (SPS).	  Petroleum	  ether	  
(40:60)	   refers	   to	   the	   fraction	  of	  petroleum	  ether	   that	  boils	  between	  40	  and	  60	   oC.	  Where	  





	   Thin	   layer	   chromatography	   (TLC)	  was	   performed	   on	   Polygram	   SIL	   G/UV254	   plastic	  
backed	  silica	  gel	  plates.	  Visualisation	  was	  achieved	  using	  a	  UV	  lamp	  at	  254	  nm,	  or	  staining	  
with	   basic	   potassium	   permanganate.	   Column	   chromatography	   was	   carried	   out	   under	  
medium	   pressure	   utilising	   compressed	   air	   on	   silica	   gel,	   40-­‐60	  μ	   60	   Å	   obtained	   from	   Alfa	  
Aesar.	  
	  
7.1.4	  Analytical	  Techniques	  
	  
	   EI-­‐MS	   analyses	   were	   performed	   on	   an	   Agilent	   6890N	   GC	   equipped	   with	   a	   5973N	  
MSD	  Performance	  Turbo	  CI	  running	  an	  EI	  mode,	  and	  an	  Anatune	  Focus	  Autosampler/liquid	  
handler,	  using	  UHP	  helium	  as	  the	  carrier	  gas.	  ES-­‐MS	  analyses	  were	  performed	  on	  a	  Thermo-­‐
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Electron	   Corp.	   Finnigan	   LTQ-­‐FT	  mass	   spectrometer,	   using	   the	   electrospray	   in	   positive	   ion	  
mode	  (ES+)	  to	  generate	  ions.	  
	   Elemental	  analyses	  were	  obtained	  using	  an	  Exeter	  Analytical	  CE-­‐440	  analyser.	  
	   All	  1H	  NMR	  spectra	  were	  analysed	  in	  CDCl3,	  unless	  otherwise	  stated,	  at	  400,	  500	  or	  
700	   MHz	   on	   Varian	   Mercury-­‐400,	   Varian	   Inova-­‐500	   or	   Varian	   VNMRS	   700	   MHz	  
spectrometers	   respectively.	   Spectra	   are	   reported	   as	   chemical	   shift	   δ	   (ppm)	   (number	   of	  
protons,	  multiplicity,	  coupling	  constant	  J	  (Hz),	  assignment).	  All	  peaks	  are	  reported	  using	  the	  
residual	   protic	   solvent	   peak	   of	   CHCl3	   (δH	   =	   7.26	   ppm),	   as	   an	   internal	   reference.	   13C	   NMR	  
spectra	  were	  analysed	   in	  CDCl3	   at	   either	  126,	  or	  176	  MHz	  on	  Varian	   Inova-­‐500,	  or	  Varian	  
VNMRS	   700	  MHz	   spectrometers	   respectively.	   All	   peaks	   reported	   using	   the	   residual	   protic	  
solvent	   peak	   of	   CHCl3	   (δC	   =	   77.00	   ppm)	   as	   an	   internal	   reference.	   11B	   NMR	   spectra	   were	  
recorded	  at	  128	  MHz	  on	  a	  Bruker	  Avance-­‐400	  spectrometer	  as	  parts	  per	  million	  downfield	  
shift	  from	  external	  BF3.OEt2.	  19F	  NMR	  spectra	  were	  recorded	  at	  376	  MHz	  a	  Bruker	  Avance-­‐
400	  spectrometer.	  
	   IR	  spectra	  were	  recorded	  on	  a	  Perkin-­‐Elmer	  Paragon	  1000	  FT-­‐IR	  Spectrometer.	  	  
Melting	   points	   were	   obtained	   on	   a	   Gallenkamp	   Variable	   Heater	   melting	   point	  
apparatus.	  
	  
7.1.5	  Typical	  Procedure	  for	  Sonogashira	  Coupling	  
	  
To	  a	  dried	  Schlenk	  flask	  under	  a	  positive	  pressure	  of	  argon	  was	  added	  alkyliodide	  (1	  
equivalent),	   alkyne	   core	   (1.1	   equivalents)	   and	   triethylamine.	   The	   mixture	   was	   degassed	  
using	  the	  freeze-­‐pump-­‐thaw	  method	  (×3),	  followed	  by	  addition	  of	  palladium(II)	  acetate	  	  (2.5	  
mol	  %),	  triphenylphosphine	  (5	  mol	  %)	  and	  copper(I)	  iodide	  (5	  mol	  %).	  The	  Schlenk	  flask	  was	  
then	  evaporated	  and	  purged	  with	  argon	  (×3)	  and	  stirred	  at	  room	  temperature	  under	  argon.	  
After	  5.5	  hours,	  the	  mixture	  was	  diluted	  with	  diethyl	  ether,	  passed	  through	  Celite™,	  washed	  
with	   5%	   hydrochloric	   acid,	   brine,	   dried	   (MgSO4),	   concentrated	   and	   purified	   by	   silica	   gel	  







7.1.6	  Typical	  Procedure	  for	  Heck-­‐Mizoroki	  Coupling	  
	  
	   To	   a	   dried	   Schlenk	   tube	   under	   a	   positive	   pressure	   of	   argon	   was	   added	   silver(I)	  
acetate	  (1.1	  equivalents),	  palladium(II)	  acetate	  (5	  mol	  %),	  tri(o-­‐tolyl)phosphine	  (10	  mol	  %),	  
and	  dry	  acetonitrile.	  The	  mixture	  was	  degassed	  using	   the	   freeze-­‐pump-­‐thaw	  method	   (×2),	  
followed	  by	  the	  addition	  of	  iodoacrylate	  (1	  equivalent)	  and	  vinylboronate	  (1.15	  equivalents).	  
The	  mixture	  was	  degassed	  using	   the	   freeze-­‐pump-­‐thaw	  method	   (×2)	  and	  heated	   to	  50	  °C	  
with	  vigorous	  stirring.	  After	  24	  hours	  the	  mixture	  was	  cooled,	  diluted	  with	  diethyl	  ether	  and	  
passed	  through	  Celite™,	  washed	  with	  5%	  hydrochloric	  acid,	  water,	  brine,	  dried	  (MgSO4)	  and	  
purified	  by	  silica	  gel	  chromatography	  (ethyl	  acetate:	  petroleum	  ether,	  1:9).	  
	  
7.1.7	  Typical	  Procedure	  for	  Saponification	  of	  Methyl	  Esters	   	  
	  
The	   corresponding	   ester	   (1	   equivalent),	   was	   dissolved	   in	   a	   tetrahydrofuran	   water	  
mixture	  (3:1,	  20	  mL)	  followed	  by	  the	  addition	  of	  LiOH.H2O	  (4	  equivalents).	  The	  mixture	  was	  
stirred	  at	  room	  temperature	  for	  48	  hours	   in	  the	  absence	  of	   light	  after	  which,	  the	  reaction	  
was	  judged	  to	  be	  complete	  by	  TLC.	  The	  mixture	  was	  then	  acidified	  to	  pH	  1	  by	  the	  addition	  of	  
hydrochloric	  acid	  (20%),	  and	  extracted	  with	  diethyl	  ether	  (×2).	  The	  sample	  was	  concentrated	  
under	  vacuum	  to	  give	  the	  crude	  product,	  followed	  by	  re-­‐crystallisation	  from	  acetonitrile.	  
	  
7.1.8	  Specific	  Experimental	  Procedures	  
	  




(E)-­‐5-­‐(5,5,8,8-­‐Tetramethyl-­‐5,6,7,8-­‐tetrahydro-­‐naphthalen-­‐2-­‐yl)-­‐penta-­‐2-­‐en-­‐4-­‐ynoic	   acid	  
methyl	  ester	  (42	  mg,	  0.14	  mmol)	  was	  dissolved	  in	  tetrahydrofuran	  and	  water	  (1:1,	  2.5	  mL),	  
















temperature.	   After	   18	   hours	   the	   reaction	  was	   acidified	   to	   pH	   1-­‐2	   by	   the	   addition	   of	   20%	  
hydrochloric	  acid,	  and	  extracted	  with	  ether	   (2	  ×	  20	  mL),	  dried	   (MgSO4),	   concentrated	  and	  
purified	  by	  silica	  gel	  chromatography	  (ethyl	  acetate:	  petroleum	  ether,	  gradient	  elution).	  The	  
product	  was	  extracted	  as	   a	  pale	   yellow	  oil,	  which	   slowly	   solidified	  and	  was	   re-­‐crystallised	  
from	   petroleum	   ether	   to	   give	   (E)-­‐5-­‐(5,5,8,8-­‐tetramethyl-­‐5,6,7,8-­‐tetrahydro-­‐naphthalene-­‐2-­‐
yl)-­‐penta-­‐2-­‐en-­‐4-­‐ynoic	  acid	  (34	  mg,	  85%)	  as	  a	  white	  crystalline	  solid;	  m.p	  199.6-­‐200.1	  °C;	  ν	  
max/cm-­‐1	  2954	  (br	  OH),	  2198	  (alkyne),	  1682	  (C=O),	  1615	  (C=C),	  1418	  (Sp3	  C-­‐H),	  1297,	  1272,	  
1207,	  1107	  and	  1037;	  1H	  NMR:	  	  400	  MHz,	  CDCl3:	  δH	  1.29	  (6H,	  s,	  2	  ×	  Me),	  1.30	  (6H,	  s,	  2	  ×	  Me),	  
1.70	  (4H,	  s,	  2	  ×	  CH2),	  6.31	  (1H,	  d,	  J	  16.0,	  H2),	  7.10	  (1H,	  d,	  J	  16.0,	  H3),	  7.2	  (1H,	  dd,	  J	  8.0	  and	  
1.5,	  H15),	  7.31	   (1H,	  d,	   J	  8.0,	  H14),	  7.46	   (1H,	  d,	   J	  1.5	  H7);	   13C	  NMR	   (176	  MHz,	  CDCl3)	  δC	  31.9	  
(C16),	  32.0	  (C16),	  34.5	  (C9/12),	  34.7	  (C9/12),	  35.0	  (C10/11),	  35.1	  (C10/11),	  85.7	  (C4),	  101.3	  (C5),	  119.1	  
(C6),	  127.1	  (C3),	  128.3	  (C2),	  128.5	  (C14),	  129.3	  (C15),	  130.8	  (C7),	  145.6	  (C8),	  147.4	  (C13),	  170.8	  
(C1);	  m/z	   (ES)	   281.1545	   (M-­‐,	   C19H22O2,	   requires	   281.1547),	   159	   and	   91;	   Anal.	   Calcd.	   for	  
C19H22O2:	  C,	  80.82;	  H,	  7.85.	  Found:	  C,	  80.54;	  H,	  7.75.	  
	  




(Z)-­‐5-­‐(5,5,8,8-­‐Tetramethyl-­‐5,6,7,8-­‐tetrahydro-­‐naphthalen-­‐2-­‐yl)-­‐penta-­‐2-­‐en-­‐4-­‐ynoic	   acid	  
methyl	   ester	   (115	  mg,	   0.39	  mmol)	  was	   dissolved	   in	   THF:H2O	   (1:1,	   5	  mL),	   followed	  by	   the	  
addition	  of	  lithium	  hydroxide	  (16	  mg,	  0.39	  mmol)	  and	  stirred	  at	  room	  temperature.	  After	  42	  
hours	   the	   reaction	  was	   acidified	   to	   pH	   1-­‐2	   by	   the	   addition	   of	   20%	  hydrochloric	   acid,	   and	  
extracted	  with	  diethyl	  ether	  (2	  ×	  20	  mL),	  dried	  (MgSO4),	  concentrated	  and	  purified	  by	  silica	  
gel	   chromatography	   (ethyl	   acetate:	   petroleum	   ether,	   gradient	   elution).	   The	   product	   was	  
extracted	  as	  a	  pale	  yellow	  oil,	  which	  slowly	  solidified	  and	  was	  re-­‐crystallised	  from	  petroleum	  
ether	  to	  give	  	  (Z)-­‐5-­‐(5,5,8,8-­‐tetramethyl-­‐5,6,7,8-­‐tetrahydro-­‐naphthalene-­‐2-­‐yl)-­‐penta-­‐2-­‐en-­‐4-­‐
ynoic	  acid	  as	  an	  off-­‐white	  solid	  (93	  mg,	  85%);	  m.p.	  132.1-­‐133.7	  °C;	  ν	  max/cm-­‐1	  2956	  (br	  OH),	  


















(500	  MHz,	  CDCl3)	  δH	  1.26	  (6H,	  s,	  2	  ×	  Me),	  1.27	  (6H,	  s,	  2	  ×	  Me),	  1.67	  (4H,	  s,	  2	  ×	  CH2),	  6.16	  (1H,	  
d,	  J	  11.5,	  H2),	  6.49	  (1H,	  d,	  J	  11.5,	  H3),	  7.27	  (2H,	  d,	  J	  1.0,	  H14	  and	  15),	  7.46	  (1H,	  s,	  H7);	  13C	  NMR	  
(176	  MHz,	  CDCl3)	  δC	  29.9	   (C16),	  31.9	   (C16),	  31.9	   (C16),	  34.4	   (C9/12),	  34.7	   (C9/12),	  35.0	   (C10/11),	  
35.1	  (C10/11),	  85.5	  (C4),	  104.5	  (C5),	  119.4	  (C6),	  125.4	  (C3),	  127.0	  (C2),	  127.1	  (C14),	  129.4	  (C15),	  
130.8	   (C7),	   145.5	   (C8),	   147.3	   (C13),	   168.8	   (C1);	  m/z	   (ES)	   281.1545	   (M-­‐,	   C19H22O2,	   requires	  
281.1547),	  260,	  159	  and	  91;	  Anal.	  Calcd.	  for	  C19H22O2:	  C,	  80.82;	  H,	  7.85.	  Found:	  C,	  80.49;	  H,	  
7.84.	  	  	  	  	  	  	  	  
	  




To	   a	   mixture	   of	   1,1,4,4-­‐tetramethyl-­‐1,2,3,4-­‐tetrahydronaphthalene	   (25.00	   g,	   133	   mmol),	  
iodine	  (13.5	  g,	  53	  mmol)	  and	  periodic	  acid	  (6.06	  g,	  27	  mmol)	  was	  added	  glacial	  acetic	  acid	  
(133	  mL),	  water	  (27	  mL)	  and	  concentrated	  sulphuric	  acid	  (98%,	  7	  mL).	  The	  reaction	  mixture	  
was	   heated	   to	   70	   °C	   and	   left	   overnight.	   Upon	   cooling	   a	   precipitate	   formed,	   which	   was	  
filtered	  off,	   dissolved	   in	   hexane,	   and	  passed	   through	   a	   short	   silica	   gel	   column	   (hexane	   as	  
eluent).	  The	  hexane	  was	  evaporated	  and	  the	  residue	  was	  re-­‐crystallised	  from	  ethanol	  to	  give	  
the	  iodide	  as	  a	  white	  crystalline	  solid	  (23.50	  g,	  66%);	  m.p.	  68.2-­‐70.4	  °C	  (lit.228	  69.0-­‐70.0	  °C).	  
All	  spectral	  properties	  were	  identical	  to	  those	  reported	  in	  the	  literature.228	  
	  




6-­‐Iodo-­‐1,1,4,4-­‐tetramethyl-­‐1,2,3,4-­‐tetrahydronaphthalene,	   8,	   (3.14	   g,	   10	   mmol),	  





mL	  Schlenk	   flask,	  which	  was	  evacuated	  and	  purged	  with	  nitrogen	   (×3).	  Triethylamine	   (150	  
mL)	  was	  added	  via	  cannula	  under	  nitrogen,	   followed	  by	  trimethylsilylacetylene	  (1.18	  g,	  12	  
mmol).	   After	   18	   hours	   at	   room	   temperature,	   triethylamine	   was	   evapourated,	   and	   the	  
residue	   re-­‐dissolved	   in	   hexane	   and	   passed	   through	   a	   short	   silica	   gel	   column	   to	   give	   the	  
crude	  product	  as	  a	  pale	  yellow	  oil	  after	  evaporation,	  which	  slowly	  solidified	  to	  give	  an	  off-­‐
white	   solid.	   Re-­‐crystallisation	   from	  ethanol	   gave	   the	   TMS-­‐acetylene	   adduct	   (1.91	   g,	   67%);	  
m.p.	   51.3-­‐53.4	   °C	   (lit.228	   51.0-­‐52.0	   °C).	   All	   spectral	   properties	   were	   identical	   to	   those	  
reported	  in	  the	  literature.228	  
	  




To	   a	   solution	   of	   6-­‐trimethylsilylethynyl-­‐1,1,4,4-­‐tetramethyl-­‐1,2,3,4-­‐tetrahydronaphthalene	  
(2.84	   g,	   10	   mmol)	   in	   methanol	   (70	   mL)	   and	   diethyl	   ether	   (70	   mL)	   was	   added	   sodium	  
hydroxide	   (0.26	   g,	   6.6	  mmol)	   in	   water	   (12	  mL).	   After	   4	   hours	   at	   room	   temperature,	   the	  
mixture	   was	   extracted	   with	   diethyl	   ether,	   washed	   with	   water	   (×3),	   dried	   (MgSO4),	   and	  
evaporated	   to	   give	   6-­‐ethynyl-­‐1,1,4,4-­‐tetramethyl-­‐1,2,3,4-­‐tetrahydronaphthalene	   as	   a	   pale	  
yellow	  oil,	  that	  slowly	  solidified	  to	  give	  a	  white	  solid	  (1.87	  g,	  97%);	  m.p.	  47.8-­‐49.3	  °C	  (lit.228	  
48.0-­‐49.0	  °C).	  All	  spectroscopic	  and	  analytical	  properties	  were	  identical	  to	  those	  reported	  in	  
the	  literature.228	  
	  




A	  stirred	  solution	  of	  methyl	  propiolate	   (5.3	  mL,	  59.6	  mmol)	  and	  sodium	  iodide	  (14.4	  g,	  96	  







was	  poured	  onto	  water	   (100	  mL),	  extracted	  with	  ethyl	  acetate	   (3	  ×	  100	  mL),	  washed	  with	  
saturated	   aqueous	   sodium	   hydrogen	   carbonate	   (4	   ×	   50	   mL),	   saturated	   aqueous	   sodium	  
metabisulphate	   (50	   mL),	   and	   brine	   (50	   mL),	   dried	   (MgSO4)	   and	   evaporated	   to	   give	   the	  
product	  as	  a	  yellow	  oil	  (7.28	  g,	  58%).	  All	  spectral	  properties	  were	  identical	  to	  those	  reported	  
in	  the	  literature.363	  
	  




Methyl	  3-­‐Z-­‐iodoacrylate	  (1.0	  g,	  4.7	  mmol)	  was	  added	  to	  a	  stirred	  solution	  of	  57%	  hydroiodic	  
acid	  (0.1	  mL,	  0.7	  mmol)	  in	  benzene	  (2.5	  mL)	  and	  the	  mixture	  heated	  to	  80	  oC	  under	  argon.	  
After	  20	  hours,	  the	  mixture	  was	  cooled	  and	  partitioned	  between	  water	  (10	  mL)	  and	  diethyl	  
ether	   (10	  mL).	   The	   aqueous	   phase	  was	   extracted	  with	   diethyl	   ether	   (3	   ×	   10	  mL)	   and	   the	  
combined	  organic	  phase	  washed	  with	   saturated	  aqueous	   sodium	  hydrogen	   carbonate	   (15	  
mL),	   5	  %	  aqueous	   sodium	  metabisulphite	   (15	  mL)	   and	  brine	   (15	  mL).	  Drying	   (MgSO4)	   and	  
evaporation	   gave	  methyl	   3-­‐E-­‐iodoacrylate	   as	   a	  white	   solid	   (0.9	   g,	   85%);	  m.p.	   41.6-­‐43.6	   oC	  
(lit.261	   41.0-­‐44.0	   °C).	   All	   spectroscopic	   and	   analytical	   properties	   were	   identical	   to	   those	  
reported	  in	  the	  literature.261	  
	  
(Z)-­‐5-­‐(5,5,8,8-­‐Tetramethyl-­‐5,6,7,8-­‐tetrahydro-­‐naphthalen-­‐2-­‐yl)-­‐penta-­‐2-­‐en-­‐4-­‐ynoic	  acid	  




To	   a	   dried	   Schlenk	   flask	   under	   a	   positive	   pressure	   of	   argon	   was	   added	   methyl	   3-­‐(Z)-­‐





















tetrahydronaphthalene	   (200	   mg,	   0.94	   mmol)	   and	   triethylamine	   (8	   mL).	   The	   mixture	  
degassed	   using	   the	   freeze-­‐pump-­‐thaw	  method	   (3×),	   followed	   by	   addition	   of	   palladium(II)	  
acetate	  (5	  mg,	  0.02	  mmol),	  triphenylphosphine	  (11	  mg,	  0.04	  mmol)	  and	  copper(I)	  iodide	  (8	  
mg,	  0.04	  mmol).	  The	  Schlenk	   flask	  was	  then	  evapourated	  and	  purged	  with	  argon	  (3×)	  and	  
stirred	   at	   room	   temperature	   under	   argon.	   After	   5.5	   hours,	   the	  mixture	   was	   diluted	   with	  
diethyl	   ether	   (60	  mL),	   passed	   through	  Celite™,	  washed	  with	   5%	  hydrochloric	   acid	   (2	   ×	   20	  
mL),	  brine	  (20	  mL),	  dried	  (MgSO4),	  concentrated	  and	  purified	  by	  silica	  gel	  chromatography	  
(ethyl	   acetate:	   petroleum	   ether,	   5:95,	   as	   eluent)	   to	   give	   ester	   as	   a	   pale	   yellow	   oil	   which	  
slowly	  crystallised	  to	  an	  off-­‐white	  solid	  (255	  mg,	  91%);	  ν	  max/cm-­‐1	  2924,	  2200,	  1718,	  1610,	  
1492,	  1460,	  1439,	  1392,	  1218,	  and	  1172;	  1H	  NMR	  (700	  MHz,	  CDCl3)	  δ	  1.26	  (6H,	  s,	  2	  ×	  Me),	  
1.27	  (6H,	  s,	  2	  ×	  Me),	  1.67	  (4H,	  s,	  2	  ×	  CH2),	  3.80	  (3H,	  s,	  OMe),	  6.10	  (1H,	  d,	  J	  11.0,	  H2),	  6.36	  (1H,	  
d,	  J	  11.0,	  H3),	  7.26	  (1H,	  d,	  J	  8.5.	  H14),	  7.28	  (1H,	  dd,	  J	  8.5	  and	  1.5,	  C15),	  7.46	  (1H,	  d,	  J	  1.5	  C7);	  13C	  
NMR	  (176	  MHz,	  CDCl3)	  29.9	  (C16),	  31.9	  (C16),	  32.0	  (C16),	  34.4	  (C9/12),	  34.7	  (C9/12),	  35.1	  (C10/11),	  
35.1	  (C10/11),	  51.7	  (OCH3),	  85.7	  (C4),	  102.6	  (C5),	  119.8	  (C6),	  123.7	  (C3),	  126.9	  (C14),	  127.3	  (C2),	  
129.4	   (C15),	   130.6	   (C7),	   145.4	   (C8),	   146.9	   (C13),	   165.6	   (C1);	   m/z	   (ES)	   319.1669	   (M+Na,	  
C20H24O2-­‐Na+	  requires	  319.1669),	  297,	  279,	  265	  and	  145;	  Anal.	  Calcd.	  for	  C20H24O2:	  C,	  81.04;	  
H,	  8.16.	  Found:	  C,	  81.03;	  H,	  8.22.	  
	  
(E)-­‐5-­‐(5,5,8,8-­‐Tetramethyl-­‐5,6,7,8-­‐tetrahydro-­‐naphthalen-­‐2-­‐yl)-­‐penta-­‐2-­‐en-­‐4-­‐ynoic	  acid	  




To	   a	   dried	   Schlenk	   flask	   under	   a	   positive	   pressure	   of	   argon	   was	   added	   methyl	   3-­‐(E)-­‐
iodoacrylate	   (180	   mg,	   0.86	   mmol),	   6-­‐ethynyl-­‐1,1,4,4-­‐tetramethyl-­‐1,2,3,4-­‐
tetrahydronaphthalene	   (200	   mg,	   0.94	   mmol)	   and	   triethylamine	   (8	   mL).	   The	   mixture	  
degassed	   using	   the	   freeze-­‐pump-­‐thaw	  method	   (3×),	   followed	   by	   addition	   of	   palladium(II)	  
acetate	   (10	  mg,	  0.04	  mmol),	   triphenylphosphine	   (22	  mg,	  0.08	  mmol)	  and	  copper(I)	   iodide	  
















method	  (2×)	  and	  stirred	  at	  room	  temperature	  under	  argon.	  After	  45	  hours,	  the	  mixture	  was	  
diluted	  with	  diethyl	   ether	   (30	  mL),	   passed	   through	  Celite™,	  washed	  with	   5%	  hydrochloric	  
acid	   (2	   ×	   10	   mL),	   brine	   (10	   mL),	   dried	   (MgSO4),	   concentrated	   and	   purified	   by	   silica	   gel	  
chromatography	   (ethyl	   acetate:	   petroleum	   ether,	   5:95,	   as	   eluent)	   to	   give	   ester	   as	   a	   pale	  
yellow	  oil,	  that	  solidified	  to	  an	  off-­‐white	  solid	  (194	  mg,	  71%);	  ν	  max/cm-­‐1	  2953,	  2918,	  2860,	  
2195,	  1719,	  1618,	  1600;	  1H	  NMR	   (700	  MHz,	  CDCl3)	  δ	  1.27	  (6H,	  s,	  2	  ×	  Me),	  1.28	  (6H,	  s,	  2	  ×	  
Me),	  1.68	  (4H,	  s,	  2	  ×	  CH2),	  3.78	  (3H,	  s,	  OMe),	  6.29	  (1H,	  d,	  J	  15.0,	  H2),	  6.99	  (1H,	  d,	  J	  15.0,	  H3),	  
7.23	  (1H,	  dd,	  J	  8.0	  and	  1.5,	  H15),	  7.28	  (1H,	  d,	  J	  8.0,	  H14),	  7.43	  (1H,	  d,	  J	  1.5,	  H7);	  13C	  NMR	  (176	  
MHz,	  CDCl3)	  δC	  31.8	  (C16),	  31.9	  (C16),	  34.4	  (C9/12),	  34.5	  (C9/12),	  35.0	  (C10/11),	  35.1	  (C10/11),	  52.0	  
(OCH3),	  85.7	  (C4),	  99.6	  (C5),	  119.3	  (C6),	  125.9	  (C3),	  127.0	  (C14),	  129.1	  (C2),	  129.2	  (C15),	  130.6	  
(C7),	   145.5	   (C8),	   147.1	   (C13),	   166.7	   (C1);	   m/z	   (ES)	   319.16685	   (M+,	   C20H24O2,	   requires	  







(Z)-­‐5-­‐(5,5,8,8-­‐Tetramethyl-­‐5,6,7,8-­‐tetrahydro-­‐naphthalen-­‐2-­‐yl)-­‐penta-­‐2-­‐en-­‐4-­‐ynoic	   acid	  
methyl	  ester	  was	  dissolved	   in	  THF	   (15	  mL)	  and	  20%	  sodium	  hydroxide	   (15	  mL)	  was	  added	  
drop	  wise	  to	  the	  solution.	  The	  reaction	  mixture	  was	  stirred	  at	  reflux	  (67	  oC)	  for	  72	  hours.	  The	  
reaction	   went	   to	   multiple	   spots	   by	   TLC	   and	   was	   therefore	   stopped,	   cooled	   to	   room	  
temperature.	   The	   reaction	   mixture	   was	   acidified	   to	   pH	   1-­‐2	   by	   the	   addition	   of	   20%	  
hydrochloric	  acid,	  and	  extracted	  with	  diethyl	  ether	  (2	  ×	  20	  mL),	  dried	  (MgSO4),	  concentrated	  
and	   purified	   by	   silica	   gel	   chromatography	   (ethyl	   acetate:	   petroleum	   ether,	   5:95).	   The	  
product	   was	   extracted	   as	   colourless	   crystals	   (15	   mg,	   8%).	   All	   spectral	   properties	   were	  
identical	   to	   those	   reported	   in	   the	   literature.364	  ν	   max/cm-­‐1	   2960,	   2927,	   1696	   (C=O),	   1602,	  











To	  a	  dried	  Schlenk	  tube	  under	  a	  positive	  pressure	  of	  argon	  was	  added	  silver	  (I)	  acetate	  (434	  
mg,	  2.6	  mmol),	  palladium(II)	  acetate	  (27	  mg,	  0.12	  mmol),	  tri(o-­‐tolyl)phosphine	  (73	  mg,	  0.24	  
mmol),	   and	   dry	   acetonitrile	   (10	   mL).	   The	   mixture	   degassed	   using	   the	   freeze-­‐pump-­‐thaw	  
method	  (2×),	   followed	  by	  the	  addition	  of	  methyl	  3-­‐Z-­‐iodoacrylate	  (500	  mg,	  2.4	  mmol)	  and	  
4,4,6-­‐trimethyl-­‐2-­‐vinyl-­‐1,3,2-­‐dioxaborane	   (0.46	  mL,	  2.8	  mmol).	   	   The	  mixture	  was	  degassed	  
using	  the	  freeze-­‐pump-­‐thaw	  method	  (2×)	  and	  heated	  to	  50	  °C	  with	  vigorous	  stirring.	  After	  
23	   hours	   the	  mixture	  was	   cooled,	   diluted	  with	   diethyl	   ether	   (70	  mL)	   and	   passed	   through	  
Celite™,	   washed	   with	   5%	   hydrochloric	   acid	   (10	  mL),	   water	   (20	  mL),	   brine	   (20	  mL),	   dried	  
(MgSO4)	  and	  evaporated	  to	  give	  the	  crude	  product	  as	  a	  yellow	  oil.	  Purification	  by	  silica	  gel	  
chromatography	   (ethyl	   acetate:	   petroleum	   ether,	   1:9,	   as	   eluent)	   gave	   (2Z,4E)-­‐5-­‐(4,4,6-­‐
trimethyl-­‐[1,3,2-­‐dioxaborinan-­‐2-­‐yl])-­‐penta-­‐2,4-­‐dienoic	  acid	  methyl	  ester	  (303	  mg,	  54	  %)	  as	  a	  
pale	  yellow	  oil.	  All	  spectroscopic	  and	  analytical	  properties	  were	  identical	  to	  those	  reported	  





















To	  a	  dried	  Schlenk	  tube	  under	  a	  positive	  pressure	  of	  argon	  was	  added	  silver	  (I)	  acetate	  (430	  
mg,	   2.6	  mmol),	   palladium(II)	   acetate	   (27	  mg,	   0.1	  mmol),	   tri(o-­‐tolyl)phosphine	   (70	  mg,	   0.2	  
mmol),	   and	   a	   solution	   of	  methyl	   3-­‐E-­‐iodoacrylate	   (500	  mg,	   2.4	  mmol)	   in	   dry	   acetonitrile	  
(14.5	  mL).	  The	  mixture	  degassed	  using	  the	  freeze-­‐pump-­‐thaw	  method	  (2×),	  followed	  by	  the	  
addition	  of	  4,4,6-­‐trimethyl-­‐2-­‐vinyl-­‐1,3,2-­‐dioxaborane	  (0.46	  mL,	  2.8	  mmol).	  	  The	  mixture	  was	  
degassed	   using	   the	   freeze-­‐pump-­‐thaw	   method	   (2×)	   and	   heated	   to	   50	   °C	   with	   vigorous	  
stirring.	   After	   21	   hours	   the	   mixture	   was	   cooled,	   diluted	   with	   diethyl	   ether	   (80	   mL)	   and	  
passed	  through	  Celite™,	  washed	  with	  5%	  hydrochloric	  acid	  (20	  mL),	  water	  (40	  mL),	  brine	  (40	  
mL),	  dried	  (MgSO4)	  and	  evaporated	  to	  give	  the	  crude	  product	  as	  a	  yellow	  oil.	  Purification	  by	  
silica	   gel	   chromatography	   (ethyl	   acetate:	   petroleum	   ether,	   1:9,	   as	   eluent)	   gave	   (2E,4E)-­‐5-­‐
(4,4,6-­‐trimethyl-­‐[1,3,2-­‐dioxaborinan-­‐2-­‐yl])-­‐penta-­‐2,4-­‐dienoic	   acid	   methyl	   ester	   (499	   mg,	  
90%)	  as	  a	  pale	  yellow	  oil.	  All	  spectroscopic	  and	  analytical	  properties	  were	  identical	  to	  those	  
reported	  in	  the	  literature.261	  	  
	  




To	   a	   solution	   of	   (2Z,4E)-­‐5-­‐(4,4,6-­‐trimethyl-­‐[1,3,2-­‐dioxaborinan-­‐2-­‐yl])-­‐penta-­‐2,4-­‐dienoic	   acid	  











and	  cooled	  to	   -­‐78	  °C.	   Iodine	  monochloride	   (1.5	  mL	  of	  a	  1.0	  M	  solution	   in	  DCM,	  1.5	  mmol)	  
was	  added	  dropwise,	  and	  the	  mixture	  stirred	  for	  4	  hours.	  Sodium	  methoxide	  (3	  mL	  of	  a	  0.5	  
M	  solution	  in	  MeOH,	  1.5	  mmol)	  was	  then	  added	  dropwise	  and	  the	  mixture	  allowed	  to	  warm	  
to	  room	  temperature.	  After	  30	  minutes	  the	  mixture	  was	  diluted	  with	  diethyl	  ether	  (80	  mL),	  
washed	  with	  5%	  aqueous	  sodium	  metabisulphite	  (40	  mL),	  water	  (40	  mL)	  and	  brine	  (40mL),	  
dried	   (MgSO4)	   and	   evaporated	   to	   give	   the	   crude	   product.	   Purification	   by	   silica	   gel	  
chromatography	   (ethyl	   acetate:	   petroleum	   ether,	   5:95	   as	   eluent,	   cooled	   to	   0	   °C)	   gave	  
(2Z,4Z)-­‐5-­‐iodo-­‐penta-­‐2,4-­‐dienoic	   acid	  methyl	   ester	   as	   a	   pale	   yellow	   oil	   (180	  mg,	   59%).	   All	  
spectroscopic	  and	  analytical	  properties	  were	  identical	  to	  those	  reported	  in	  the	  literature.261	  
	  




A	   solution	   of	   (2E,4E)-­‐5-­‐(4,4,6-­‐trimethyl-­‐[1,3,2-­‐dioxaborinan-­‐2-­‐yl])-­‐penta-­‐2,4-­‐dienoic	   acid	  
methyl	  ester	  (230	  mg,	  1.0	  mmol)	   in	  dry	  tetrahydrofuran	  (5.5	  mL)	  was	  added	  to	  a	  dry	  flask	  
under	  argon	  and	  cooled	  to	  -­‐78	  oC	  in	  the	  absence	  of	  light.	  Sodium	  methoxide	  (2.4	  mL	  of	  a	  0.5	  
M	   solution	   in	   methanol,	   1.2	   mmol)	   was	   added	   dropwise,	   and	   the	  mixture	   stirred	   for	   30	  
minutes.	   Iodine	  monochloride	   (1.5	  mL	   of	   a	   1.0	  M	   solution	   in	   DCM,	   1.5	  mmol)	   was	   then	  
added	   dropwise	   and	   the	   mixture	   stirred	   for	   1	   hour.	   The	   mixture	   was	   warmed	   to	   room	  
temperature,	   diluted	   with	   diethyl	   ether	   (65	   mL),	   washed	   with	   5%	   aqueous	   sodium	  
metabisulphite	  (35	  mL),	  water	  (35	  mL)	  and	  brine	  (35	  mL),	  dried	  (MgSO4)	  and	  evaporated	  to	  
give	  the	  crude	  product.	  Purification	  by	  silica	  gel	  chromatography	  (ethyl	  acetate:	  petroleum	  
ether,	  5:95	  as	  eluent,	  cooled	  to	  0	  oC)	  gave	  (2E,4E)-­‐5-­‐iodopenta-­‐2,4-­‐dienoic	  acid	  methyl	  ester	  
as	  a	  white	  solid	  (200	  mg,	  87	  %);	  m.p.	  57.3-­‐60.6	  °C	  (lit.265	  56.0-­‐61.0	  oC).	  All	  spectroscopic	  and	  













Methyl	  tetrolate	  (5.0	  g,	  50.5	  mmol),	  sodium	  iodide	  (11.4	  g,	  75.8	  mmol)	  and	  acetic	  acid	  (18	  
mL)	  were	  heated	  to	  reflux	  for	  1.5	  hours.	  The	  solution	  was	  then	  cooled	  to	  room	  temperature,	  
and	   partitioned	   between	   80	   mL	   of	   water	   and	   80	   mL	   of	   ether.	   The	   aqueous	   layer	   was	  
extracted	  and	  washed	  with	  diethyl	  ether	   (2	  ×	  20	  mL),	  after	  which	   the	  organic	   layers	  were	  
combined,	   washed	  with	   saturated	   sodium	   hydrogen	   carbonate	   (2	   ×	   40	  mL),	   10%	   sodium	  
thiosulfate	   (40	   mL),	   and	   brine	   (40	   mL).	   Drying	   (MgSO4)	   and	   concentration	   yielded	   (Z)-­‐3-­‐
iodobut-­‐2-­‐enoic	  acid	  methyl	  ester	  as	  a	  pale	  yellow	  liquid	  (10.8	  g,	  95%).	  All	  spectroscopic	  and	  
analytical	  properties	  were	  identical	  to	  those	  reported	  in	  the	  literature.268	  
	  




A	  solution	  of	  (Z)-­‐3-­‐iodobut-­‐2-­‐enoic	  acid	  methyl	  ester	  (10.8	  g,	  47.8	  mmol)	  and	  HI	  (0.6	  g,	  4.8	  
mmol)	  in	  benzene	  (100	  mL)	  were	  heated	  to	  reflux	  for	  24	  hours	  and	  then	  allowed	  to	  cool	  to	  
room	  temperature.	  The	  mixture	  was	  partitioned	  between	  water	  (100	  mL)	  and	  diethyl	  ether	  
(150	  mL),	  followed	  by	  the	  aqueous	  phase	  being	  extracted	  with	  diethyl	  ether	  (2	  ×	  25	  mL).	  The	  
combined	  organic	  phases	  were	  then	  washed	  with	  saturated	  sodium	  hydrogen	  carbonate	  (50	  
mL),	   5%	   sodium	   thiosulfate	   (50	  mL)	   and	   brine	   (50	  mL).	   Drying	   (MgSO4)	   and	   evaporation	  
yielded	   the	   crude	   as	   a	   pale	   yellow	   oil.	   Purification	   by	   silica	   gel	   chromatography	   (ethyl	  
acetate:	  petroleum	  ether,	  5:95,	  as	  eluent)	  yielded	  (E)-­‐3-­‐iodobut-­‐2-­‐enoic	  acid	  methyl	  ester	  as	  
a	   colourless	  oil	   (4.0	   g,	   37%)	  and	   recovered	   (Z)-­‐3-­‐iodobut-­‐2-­‐enoic	   acid	  methyl	   ester	   (4.3	   g,	  














To	  a	  dried	  Schlenk	  flask	  flask	  under	  a	  positive	  pressure	  of	  argon	  was	  added	  (Z)-­‐3-­‐iodobut-­‐2-­‐
enoic	   acid	   methyl	   ester	   (360	   mg,	   1.7	   mmol),	   6-­‐ethynyl-­‐1,1,4,4-­‐tetramethyl-­‐1,2,3,4-­‐
tetrahydronaphthalene	   (400	   mg,	   1.9	   mmol)	   and	   triethylamine	   (10	   mL).	   The	   mixture	   was	  
degassed	   using	   the	   freeze-­‐pump-­‐thaw	   method	   (3×),	   followed	   by	   the	   addition	   of	  
palladium(II)	   acetate	   (20	   mg,	   0.1	   mmol),	   triphenylphosphine	   (44	   mg,	   0.2	   mmol)	   and	  
copper(I)	   iodide	   (32	   mg,	   0.2	   mmol).	   The	   mixture	   degassed	   using	   the	   freeze-­‐pump-­‐thaw	  
method	  (2×)	  and	  stirred	  at	  room	  temperature	  under	  argon.	  After	  24	  hours	  the	  reaction	  was	  
diluted	  with	  ether	  (80	  mL),	  passed	  through	  Celite™,	  washed	  with	  5%	  hydrochloric	  acid	  (2	  ×	  
20	  mL),	  brine	  (20	  mL),	  dried	  (MgSO4)	  and	  concentrated	  under	  vacuum	  to	  give	  an	  orange	  oil.	  
Purification	   by	   silica	   gel	   column	   chromatography	   (ethyl	   acetate:	   petroleum	   ether,	   5:95)	  
yielded	  the	  product	  as	  a	  pale	  yellow	  oil	   (336	  mg,	  63%).ν	  max/cm-­‐1	  2955,	  2923,	  2864,	  2190,	  
1716,	  1611,	  1440,	  1375,	  1254,	  1194,	  1129	  and	  1041;	  1H	  NMR	  (700	  MHz,	  CDCl3)	  δ	  1.27	  (6H,	  s,	  
H16),	  1.28	  (6H,	  s,	  H16),	  1.68	  (4H,	  s,	  H10	  and	  11),	  2.14	  (3H,	  d,	  J	  1.0,	  H17),	  3.77	  (3H,	  s,	  OMe),	  6.01	  
(1H,	  d,	  J	  1.0,	  H2),	  7.27	  (1H,	  d,	  J	  8.0,	  H14),	  7.29	  (1H,	  dd,	  J	  8.0	  and	  2.0,	  H15),	  7.46	  (1H,	  d,	  J	  2.0,	  
H7);	   13C	  NMR	   (176	  MHz,	  CDCl3)	  δC	  25.6	   (C17),	  31.9	   (C16),	  32.0	   (C16),	  34.4	   (C9/12),	  34.6	   (C9/12),	  
35.1	  (C10/11),	  35.2	  (C10/11),	  51.5	  (OMe),	  87.6	  (C4),	  101.5	  (C5),	  119.9	  (C6),	  123.6	  (C2),	  126.9	  (C14),	  
129.4	  (C15),	  130.5	  (C7),	  135.5	  (C3),	  145.3	  (C8),	  146.7	  (C13),	  165.8	  (C1);	  m/z	  (ES)	  311.2011	  (M+H,	  




























To	  a	  dried	  Schlenk	  flask	  flask	  under	  a	  positive	  pressure	  of	  argon	  was	  added	  (E)-­‐3-­‐iodobut-­‐2-­‐
enoic	   acid	   methyl	   ester	   (360	   mg,	   1.7	   mmol),	   6-­‐ethynyl-­‐1,1,4,4-­‐tetramethyl-­‐1,2,3,4-­‐
tetrahydronaphthalene	   (400	   mg,	   1.9	   mmol)	   and	   triethylamine	   (10	   mL).	   The	   mixture	   was	  
degassed	   using	   the	   freeze-­‐pump-­‐thaw	   method	   (3×),	   followed	   by	   the	   addition	   of	  
palladium(II)	   acetate	   (20	   mg,	   0.1	   mmol),	   triphenylphosphine	   (44	   mg,	   0.2	   mmol)	   and	  
copper(I)	   iodide	   (32	   mg,	   0.2	   mmol).	   The	   mixture	   degassed	   using	   the	   freeze-­‐pump-­‐thaw	  
method	  (2×)	  and	  stirred	  at	  room	  temperature	  under	  argon.	  After	  24	  hours	  the	  reaction	  was	  
diluted	  with	  ether	  (80	  mL),	  passed	  through	  Celite™,	  washed	  with	  5%	  hydrochloric	  acid	  (2	  ×	  
20	  mL),	  brine	  (20	  mL),	  dried	  (MgSO4)	  and	  concentrated	  under	  vacuum	  to	  give	  an	  orange	  oil.	  
Purification	   by	   silica	   gel	   column	   chromatography	   (ethyl	   acetate:	   petroleum	   ether,	   5:95)	  
yielded	  the	  product	  as	  a	  pale	  yellow	  oil	   (530	  mg,	  99%).ν	  max/cm-­‐1	  2957,	  2195,	  1715,	  1612,	  
1433,	  1342,	  1269,	  1198,	  1180	  and	  1135;	  1H	  NMR	  (700	  MHz,	  CDCl3)	  δ	  1.27	  (6H,	  s,	  H16),	  1.28	  
(6H,	  s,	  H16),	  1.68	  (4H,	  s,	  H10	  and	  11),	  2.40	  (3H,	  d,	  J	  1.5,	  H17),	  3.73	  (3H,	  s,	  OMe),	  6.15	  (1H,	  q,	  J	  1.5,	  
H2),	  7.21	  (1H,	  dd,	  J	  8.0	  and	  1.5,	  H15),	  7.27	  (1H,	  d,	  J	  8.0,	  H14),	  7.41	  (1H,	  d,	  J	  1.5,	  H7);	  13C	  NMR	  
(176	  MHz,	  CDCl3)	  δC	   20.3	   (C17),	   31.9	   (C16),	   32.0	   (C16),	   34.5	   (C9/12),	   34.7	   (C9/12),	   35.1	   (C10/11),	  
35.1	  (C10/11),	  51.5	  (OMe),	  90.5	  (C4),	  94.9	  (C5),	  119.4	  (C6),	  123.4	  (C2),	  127.0	  (C14),	  129.2	  (C15),	  
130.5	  (C7),	  138.8	  (C3),	  145.5	  (C8),	  146.8	  (C13),	  166.9	  (C1);	  m/z	  (ES)	  311.2011	  (M+H,	  C21H27O2,	  




























acid	  methyl	  ester	  (336	  mg,	  1.1	  mmol)	  was	  added	  to	  a	  stirred	  solution	  of	  lithium	  hydroxide	  
(135	  mg,	  3.3	  mmol)	  in	  a	  tetrahydrofuran	  water	  mixture	  (3:1,	  20	  mL)	  at	  room	  temperature.	  
After	   72	   hours	   the	   reaction	   was	   judged	   to	   be	   complete	   and	   acidified	   to	   pH	   1/2	   by	   the	  
addition	  of	  20%	  hydrochloric	  acid,	  extracted	  with	  diethyl	  ether	  (20	  mL),	  dried	  (MgSO4)	  and	  
concentrated	   to	   the	   crude	   as	   a	   yellow	   powder.	   Purification	   by	   silica	   gel	   column	  
chromatography	   (ethyl	   acetate:	   petroleum	   ether,	   9:1)	   yielded	   6-­‐hydroxy-­‐4-­‐methyl-­‐6-­‐
(5,5,8,8-­‐tetramethyl-­‐5,6,7,8-­‐tetrahydro-­‐naphthalen-­‐2-­‐yl)-­‐5,6-­‐dihydro-­‐pyran-­‐2-­‐one	   as	   a	  
bright	  yellow	  solid	  (329	  mg,	  97%).	  ν	  max/cm-­‐1	  2962,	  2360,	  1746,	  1456,	  1364,	  1271	  and	  1129;	  
1H	  NMR	  (700	  MHz,	  CDCl3)	  δH	  1.25	  (6H,	  s,	  H16),	  1.26	  (6H,	  s,	  H16),	  1.66	  (4H,	  s,	  H10	  and	  11),	  2.10	  
(3H,	  d,	  J	  2.0	  H17),	  3.03	  (1H,	  d,	  J	  14.0,	  H4),	  3.21	  (1H,	  d,	  J	  14.0,	  H4),	  5.67	  (1H,	  d,	  J	  2.0,	  H2),	  7.01	  
(1H,	  dd,	  J	  8.0	  and	  2.0,	  H15),	  7.16	  (1H,	  d,	  J	  2.0,	  H7),	  7.22	  (1H,	  d,	  J	  8.0,	  H14);	  13C	  NMR	  (176	  MHz,	  
CDCl3)	  δC	  13.1	  (C17),	  32.0	  (C16),	  32.0	  (C16),	  32.1	  (C16),	  32.1	  (C16),	  34.3	  (C9/12),	  34.4	  (C9/12),	  35.2	  
(C10/11),	   35.2	   (C10/11),	   42.6	   (C4),	   107.6	   (C5),	   119.0	   (C2),	   127.1	   (C14),	   127.8	   (C15),	   128.7	   (C7),	  
129.8	   (C6),	   144.5	   (C13),	   145.4	   (C8),	   166.9	   (C3),	   170.9	   (C1);	   m/z	   (ES)	   337.1774	   (M+Na,	  






























acid	  methyl	  ester	  (85	  mg,	  0.3	  mmol)	  was	  added	  to	  a	  stirred	  solution	  of	  lithium	  hydroxide	  (46	  
mg,	  1.1	  mmol)	  in	  a	  tetrahydrofuran	  water	  mixture	  (3:1,	  20	  mL)	  at	  room	  temperature.	  After	  
48	  hours	  the	  reaction	  was	  judged	  to	  be	  complete	  and	  acidified	  to	  pH	  1/2	  by	  the	  addition	  of	  
20%	   hydrochloric	   acid,	   extracted	   with	   diethyl	   ether	   (20	   mL),	   dried	   (MgSO4)	   and	  
concentrated	   to	   give	   an	   off-­‐white	   solid.	   Re-­‐crystallisation	   from	   acetonitrile	   yielded	   the	  
product	  as	  an	  off-­‐white	  crystalline	   solid	   (25	  mg,	  31%).	  ν	  max/cm-­‐1	  2912,	  2197,	  1688,	  1602,	  
1428,	  1296,	  1225	  and	  1145;	  1H	  NMR	  (700	  MHz,	  CDCl3)	  δ	  1.27	  (6H,	  s,	  H16),	  1.28	  (6H,	  s,	  H16),	  
1.68	  (4H,	  s,	  H10	  and	  11),	  2.41	  (3H,	  d,	  J	  1.5	  H17),	  6.18	  (1H,	  d,	  J	  1.5,	  H2),	  7.22	  (1H,	  dd,	  J	  8.0	  and	  1.5,	  
H15),	  7.28	  (1H,	  d,	  J	  8.0,	  H14),	  7.42	  (1H,	  d,	  J	  1.5,	  H7);	  13C	  NMR	  (176	  MHz,	  CDCl3)	  δC	  20.6	  (C17),	  
31.9	  (C16),	  32.0	  (C16),	  34.5	  (C9/12),	  34.7	  (C9/12),	  35.0	  (C10/11),	  35.1	  (C10/11),	  90.5	  (C4),	  96.2	  (C5),	  
119.3	  (C6),	  122.4	  (C2),	  127.1	  (C14),	  129.2	  (C15),	  130.6	  (C7),	  141.3	  (C3),	  145.5	  (C8),	  147.0	  (C13),	  

































To	  a	  dried	  Schlenk	  tube	  under	  a	  positive	  pressure	  of	  argon	  was	  added	  (Z)-­‐3-­‐iodobut-­‐2-­‐enoic	  
acid	  methyl	  ester	  (500	  mg	  2.2	  mmol),	  dry	  acetonitrile	  (15	  mL),	  palladium(II)	  acetate	  (25	  mg,	  
0.1	  mmol),	  tri(o-­‐tolyl)phosphine	  (67	  mg,	  0.2	  mmol),	  silver(I)	  acetate	  (402	  mg,	  2.4	  mmol)	  and	  
4,4,6-­‐trimethyl-­‐2-­‐vinyl-­‐1,3,2-­‐dioxaborane	  (399	  mg,	  0.4	  mL,	  2.6	  mmol),	  the	  mixture	  degassed	  
using	   freeze-­‐pump-­‐thaw	  method	   (3×)	  and	  heated	   to	  50	  °C	  with	  vigorous	   stirring.	  After	  22	  
hours	  the	  mixture	  was	  cooled,	  diluted	  with	  ether	  (80	  mL),	  passed	  through	  Celite™,	  washed	  
with	  5%	  hydrochloric	   acid	   (20	  mL),	  water	   (40	  mL)	   and	  brine	   (40	  mL).	  Drying	   (MgSO4)	   and	  
evaporation	   gave	   the	   crude	   product	   as	   an	   orange	   oil.	   Purification	   by	   silica	   gel	  
chromatography	   (ethyl	   acetate:	   petroleum	   ether,	   1:9,	   as	   eluent)	   gave	   methyl	   (2Z,4E)-­‐3-­‐
methyl-­‐5-­‐(4,4,6-­‐trimethyl-­‐1,3,2-­‐dioxaborinan-­‐2-­‐yl)	   penta-­‐2,4-­‐dienoate	   (432	   mg,	   78%)	   as	   a	  























To	  a	  dried	  Schlenk	  tube	  under	  a	  positive	  pressure	  of	  argon	  was	  added	  (E)-­‐3-­‐iodobut-­‐2-­‐enoic	  
acid	  methyl	  ester	  (940	  mg	  4.2	  mmol),	  dry	  acetonitrile	  (15	  mL),	  palladium(II)	  acetate	  (47	  mg,	  
0.2	  mmol),	   tri(o-­‐tolyl)phosphine	   (128	  mg,	   0.4	  mmol),	   silver(I)	   acetate	   (758	  mg,	   4.5	  mmol)	  
and	   4,4,6-­‐trimethyl-­‐2-­‐vinyl-­‐1,3,2-­‐dioxaborane	   (752	   mg,	   0.8	   mL,	   4.9	   mmol),	   the	   mixture	  
degassed	  using	  freeze-­‐pump-­‐thaw	  method	  (3	  x)	  and	  heated	  to	  50	  °C	  with	  vigorous	  stirring.	  
After	  22	  hours	  the	  mixture	  was	  cooled,	  diluted	  with	  ether	  (80	  mL),	  passed	  through	  Celite™,	  
washed	  with	  5%	  hydrochloric	  acid	  (20	  mL),	  water	  (40	  mL)	  and	  brine	  (40	  mL).	  Drying	  (MgSO4)	  
and	   evaporation	   gave	   the	   crude	   product	   as	   an	   orange	   oil.	   Purification	   by	   silica	   gel	  
chromatography	   (ethyl	   acetate:	   petroleum	   ether,	   1:9	   as	   eluent)	   gave	   (2E,4E)-­‐3-­‐methyl-­‐5-­‐
(4,4,6-­‐trimethyl-­‐[1,3,2]-­‐dioxaborinan-­‐2-­‐yl)-­‐penta-­‐2,4-­‐dienoic	   acid	   methyl	   ester	   (780	   mg,	  
74%)	  as	  a	  clear	  oil;	  ν	  max/cm-­‐1	  2976,	  2359,	  1710,	  1596,	  1393,	  1327,	  1290,	  1229	  and	  1153;	  1H	  
NMR	  (700	  MHz,	  CDCl3)	  δH	  1.28	  (3H,	  d,	  J	  6.0,	  H11),	  1.30	  (3H,	  s,	  H10),	  1.31	  (3H,	  s,	  H10),	  1.51	  (1H,	  
t,	  J	  13.0,	  H8),	  1.80	  (1H,	  dd,	  J	  13.0	  and	  2.5,	  H8),	  2.25	  (3H,	  d,	  J	  1.0,	  H6),	  3.70	  (3H,	  s,	  OMe),	  4.21-­‐
4.27	   (1H,	  m,	  H7),	   5.87	   (1H,	   s,	  H2),	   5.93	   (1H,	  d,	   J	   18.0,	  H5)	   and	  6.92	   (1H,	  d,	   J	   18.0,	  H4);	   13C	  
NMR(176	  MHz,	  CDCl3)	  δC	  13.5	   (C6),	  23.3	   (C10),	  28.3	   (C11),	  31.4	   (C12),	  46.1	   (C8),	  51.3	   (OMe),	  
65.2	   (C7),	   71.3	   (C9),	   121.0	   (C2),	   129-­‐130	   (C5)	   149.2	   (C4),	   153.2	   (C3)	   and	   167.8	   (C1);	  δB	   (128	  
MHz,	  CDCl3)	  26	  (brs);	  m/z	   (ES)	  252.1643	  (M,	  C13H21BO4,	  requires	  252.1642).	  237,	  221,	  196,	  

























To	  a	  dried	  Schlenk	  tube	  under	  a	  positive	  pressure	  of	  argon	  was	  added	  a	  solution	  of	  (2Z,4E)-­‐
3-­‐methyl-­‐5-­‐(4,4,6-­‐trimethyl-­‐[1,3,2]-­‐dioxaborinan-­‐2-­‐yl)-­‐penta-­‐2,4-­‐dienoic	   acid	   methyl	   ester	  
(150	  mg,	   0.6	  mmol),	   in	   dry	   tetrahydrofuran	   (3	  mL),	   and	   the	   tube	   cooled	   to	   -­‐78	   °C	   in	   the	  
absence	  of	   light.	  Sodium	  methoxide	   (1.5	  mL	  of	  a	  0.5	  M	  solution	   in	  MeOH,	  0.7	  mmol)	  was	  
added	  dropwise	  and	  the	  mixture	  stirred	  for	  30	  minutes,	  followed	  by	  the	  addition	  of	  iodine	  
monochloride	   (1	   mL	   of	   a	   1.0	  M	   solution	   in	   DCM,	   1.0	   mmol)	   dropwise.	   The	  mixture	   was	  
stirred	  for	  1	  hour,	  warmed	  to	  room	  temperature,	  diluted	  with	  diethyl	  ether	  (40	  mL),	  washed	  
with	  5%	  sodium	  metabisulphite	  (20	  mL),	  water	  (20	  mL)	  and	  brine	  (20	  mL).	  Drying	  (MgSO4)	  
and	   evaporation	   gave	   the	   crude	   product	   as	   an	   orange	   oil.	   Purification	   by	   silica	   gel	  
chromatography	  (ethyl	  acetate:	  petroleum	  ether,	  1:9,	  as	  eluent),	  gave	  the	  product	  as	  an	  oil,	  
which	  slowly	  crystallised	  to	  an	  off-­‐white	  solid	  (147	  mg,	  98%);	  ν	  max/cm-­‐1	  3068	  (C-­‐H	  stretch),	  
2982	  (Sp3	  C-­‐H),	  2946	  (Sp3	  C-­‐H),	  1710	  (C=O),	  1612	  (C=C),	  1553,	  1432	  (Sp3	  C-­‐H),	  1382,	  1241,	  
1192	  and	  1150;	  1H	  NMR	  (500	  MHz,	  CDCl3)	  δH	  1.98	  (3H,	  d,	  J	  1.2,	  H6),	  3.72	  (3H,	  s,	  OMe),	  5.66	  
(1H,	  s,	  H2),	  6.94	  (1H,	  d,	  J	  15.0,	  H5),	  8.61	  (1H,	  d,	  J	  15.0,	  H4);	  13C	  NMR	  (126	  MHz,	  CDCl3)	  δC	  20.5	  
(C6),	  51.5	  (OCH3),	  87.2	  (C5),	  117.4	  (C2),	  142.7	  (C4),	  149.6	  (C3),	  166.4	  (C1);	  m/z	   	  (EI)	  252	  (M+),	  
























To	  a	  dried	  Schlenk	  tube	  under	  a	  positive	  pressure	  of	  argon	  was	  added	  a	  solution	  of	  (2E,4E)-­‐
3-­‐methyl-­‐5-­‐(4,4,6-­‐trimethyl-­‐[1,3,2]-­‐dioxaborinan-­‐2-­‐yl)-­‐penta-­‐2,4-­‐dienoic	   acid	   methyl	   ester	  
(700	  mg,	  2.8	  mmol),	   in	  dry	  THF	   (10	  mL),	   and	   the	   tube	  cooled	   to	   -­‐78	   oC	   in	   the	  absence	  of	  
light.	   Sodium	   methoxide	   (6.9	   mL	   of	   a	   0.5	   M	   solution	   in	   MeOH,	   3.5	   mmol)	   was	   added	  
dropwise	   and	   the	   mixture	   stirred	   for	   30	   minutes,	   followed	   by	   the	   addition	   of	   iodine	  
monochloride	   (4.7	  mL	  of	   a	  1.0	  M	   solution	   in	  DCM,	  4.7	  mmol)	  dropwise.	   The	  mixture	  was	  
stirred	  for	  1	  hour,	  warmed	  to	  room	  temperature,	  diluted	  with	  diethyl	  ether	  (80	  mL),	  washed	  
with	  5%	  sodium	  metabisulphite	  (30	  mL),	  water	  (30	  mL)	  and	  brine	  (30	  mL).	  Drying	  (MgSO4)	  
and	   evaporation	   gave	   the	   crude	   product	   as	   an	   orange	   oil.	   Purification	   by	   silica	   gel	  
chromatography	  (ethyl	  acetate:	  petroleum	  ether,	  1:9,	  a	  eluent),	  gave	  the	  product	  as	  a	  clear	  
oil	  (602	  mg,	  86%);	  All	  spectral	  and	  analytical	  properties	  were	  identical	  to	  those	  reported	  in	  
the	  literature.366	  ν	  max/cm-­‐1	  3070	  (C-­‐H	  stretch),	  3013	  (Sp3	  C-­‐H),	  2943	  (Sp3	  C-­‐H),	  1708	  (C=O),	  
1612	  (C=C),	  1433	  (Sp3	  C-­‐H),	  1386,	  1359,	  1234,	  1190	  and	  1153;	  1H	  NMR	  (400	  MHz,	  CDCl3)	  δH	  
2.24	  (3H,	  d,	  J	  1.2,	  H6),	  3.71	  (3H,	  s,	  OMe),	  5.74	  (1H,	  q,	  J	  0.8,	  H2),	  6.89	  (1H,	  d,	  J	  15.0,	  H5),	  7.10	  
(1H,	  d,	   J	  15.0,	  H4);	   13C	  NMR	  δC	   (126	  MHz,	  CDCl3)	  δC	  13.6	   (C6),	  51.5	   (OMe),	  84.8	   (C5),	  120.0	  
























(2Z,4E)-­‐5-­‐Iodo-­‐3-­‐methyl-­‐penta-­‐2,4-­‐dienoic	  acid	  methyl	  ester	  (325	  mg,	  1.3	  mmol),	  6-­‐ethynyl-­‐
1,1,4,4-­‐tetramethyl-­‐1,2,3,4-­‐tetrahydronaphthalene	  (331	  mg,	  1.6	  mmol)	  and	  triethylamine	  (6	  
mL)	  were	  added	  to	  a	  dried	  Schlenk	  tube	  and	  the	  mixture	  degassed	  using	  the	  freeze-­‐pump-­‐
thaw	  method	  (3×).	  Palladium(II)	  acetate	  (14	  mg,	  0.1	  mmol),	  triphenylphosphine	  (32	  mg,	  0.1	  
mmol)	  and	  copper(I)	  iodide	  (23	  mg,	  0.1	  mmol),	  were	  then	  added	  and	  the	  mixture	  degassed	  
by	   freeze-­‐pump-­‐thaw	   (3×).	   The	   mixture	   was	   stirred	   at	   room	   temperature	   for	   5	   hours,	  
diluted	  with	  ethyl	   acetate	   (80	  mL),	   passed	   through	  Celite™,	  washed	  with	  5%	  hydrochloric	  
acid	   (20	  mL,	  2×),	  brine	   (20	  mL),	  dried	   (MgSO4)	   and	   concentrated.	  Purification	  by	   silica	   gel	  
chromatography	  (Petroleum	  ether:	  ethyl	  acetate,	  95:5,	  as	  eluent)	  yielded	  the	  product	  as	  an	  
off-­‐white	   solid	   (380	  mg,	  88%);	  ν	  max/cm-­‐1	  2956	   (Sp3	  C-­‐H),	  2192	   (alkyne),	  1713	   (C=O),	  1610	  
(C=C),	  1453,	  1432	  (Sp3	  C-­‐H),	  1228	  and	  1155;	  1H	  NMR	  (400	  MHz,	  CDCl3)	  δH	  1.28	  (6H,	  s,	  H18),	  
1.29	  (6H,	  s,	  H18),	  1.68	  (4H,	  s,	  H12	  and	  13),	  2.04	  (3H,	  d,	  J	  1.2,	  H19),	  3.74	  (3H,	  s,	  OCH3),	  5.73	  (1H,	  s,	  
H2),	  6.23	  (1H,	  d,	  J	  16.0,	  H5),	  7.22	  (1H,	  dd,	  J	  1.5	  and	  8.0,	  H17),	  7.27	  (1H,	  d,	  J	  8.0,	  H16),	  7.44	  (1H,	  
d,	  J	  1.5,	  H9),	  8.17	  (1H,	  d,	  J	  16.0,	  H4);	  13C	  NMR	  (126	  MHz,	  CDCl3)	  δC	  20.6	  (C19),	  31.9	  (C18),	  32.0	  
(C18),	   34.5	   (C11/14),	   34.6	   (C11/14),	   35.1	   (C12/13),	   35.2	   (C12/13),	   51.5	   (OMe),	  88.2	   (C6),	   96.3	   (C7),	  
115.9	  (C5),	  118.3	  (C2),	  120.2	  (C8),	  126.9	  (C16),	  129.0	  (C17),	  130.4	  (C9),	  137.7	  (C4),	  145.4	  (C10),	  
146.2	   (C15),	   149.8	   (C3),	   166.6	   (C1);	   m/z	   (ES)	   354.2424	   (M+NH4+,	   C23H32O2N1,	   requires	  
354.2428),	   337,	   299,	   279	   and	   237;	   Anal.	   Calcd	   for	   C23H28O2:	   C,	   82.10;	   H,	   8.39.	   Found:	   C,	  





























Methyl	  (2E,4E)-­‐5-­‐iodo-­‐3-­‐methylpenta-­‐2,4-­‐dienoate	  (500	  mg,	  1.98	  mmol),	  6-­‐ethynyl-­‐1,1,4,4-­‐
tetramethyl-­‐1,2,3,4-­‐tetrahydronaphthalene	   (509	  mg,	  2.4	  mmol)	   and	   triethylamine	   (10	  mL)	  
were	  added	  to	  a	  dried	  Schlenk	  tube	  and	  the	  mixture	  degassed	  using	  the	  freeze-­‐pump-­‐thaw	  
method	  (3x).	  Palladium(II)	  acetate	  (22	  mg,	  0.1	  mmol),	  triphenylphosphine	  (52	  mg,	  0.2	  mmol)	  
and	   copper(I)	   iodide	   (38	  mg,	   0.2	   mmol),	   were	   then	   added	   and	   the	  mixture	   degassed	   by	  
freeze-­‐pump-­‐thaw	  (3×).	  The	  mixture	  was	  stirred	  at	   room	  temperature	   for	  5	  hours,	  diluted	  
with	  ethyl	  acetate	  (80	  mL),	  passed	  through	  Celite™,	  washed	  with	  5%	  hydrochloric	  acid	  (2	  ×	  
20	   mL),	   brine	   (20	   mL),	   dried	   (MgSO4)	   and	   concentrated.	   Purification	   by	   silica	   gel	  
chromatography	  (Petroleum	  ether:	  ethyl	  acetate,	  95:5,	  as	  eluent)	  yielded	  the	  product	  as	  a	  
yellow	  oil	  (510	  mg,	  76%);	  ν	  max/cm-­‐1	  2956	  (Sp3	  C-­‐H),	  2192	  (alkyne),	  1715	  (C=O),	  1608	  (C=C),	  
1490,	  1434	  (Sp3	  C-­‐H),	  1358,	  1232	  and	  1154;	   1H	  NMR	  500	  MHz,	  CDCl3:	  δH	  1.27	   (6H,	  s,	  H18),	  
1.28	  (6H,	  s,	  H18),	  1.68	  (4H,	  s,	  H12	  and	  13),	  2.31	  (3H,	  d,	  J	  1.2,	  H19),	  3.73	  (3H,	  s,	  OCH3),	  5.84	  (1H,	  s,	  
H2),	  6.24	  (1H,	  d,	  J	  16.0,	  H5),	  6.70	  (1H,	  d,	  J	  16.0,	  H4),	  7.21	  (1H,	  dd,	  J	  1.5	  and	  8.0,	  H17),	  7.26	  (1H,	  
d,	  J	  8.0,	  H16),	  7.41	  (1H,	  d,	  J	  1.5,	  H9);	  13C	  NMR	  (126	  MHz,	  CDCl3)	  δC	  13.4	  (C19),	  31.9	  (C18),	  32.0	  
(C18),	   34.5	   (C11/14),	   34.6	   (C11/14),	   35.1	   (C12/13),	   35.1	   (C12/13),	   51.5	   (OMe),	  87.6	   (C6),	   96.0	   (C7),	  
114.7	  (C5),	  120.1	  (C2),	  120.4	  (C8),	  127.0	  (C16),	  128.9	  (C17),	  130.3	  (C9),	  143.7	  (C4),	  145.4	  (C10),	  
146.3	   (C15),	   151.4	   (C3),	   167.4	   (C1);	  m/z	   (ES)	  337.2164	   (M+H+,	  C23H29O2,	   requires	  337.2162),	  
































dien-­‐6-­‐ynoic	  acid	  methyl	  ester	   (200	  mg,	  0.6	  mmol),	  was	  dissolved	   in	  a	  THF	  water	  mixture	  
(3:1,	  10	  mL)	  followed	  by	  the	  addition	  of	  lithium	  hydroxide	  (200	  mg,	  2.4	  mmol).	  The	  mixture	  
was	   stirred	   at	   room	   temperature	   for	   48	   hours	   in	   the	   absence	   of	   light	   after	   which,	   the	  
reaction	  was	  judged	  to	  be	  complete	  by	  TLC.	  The	  mixture	  was	  then	  acidified	  to	  pH	  1	  by	  the	  
addition	  of	  20%	  hydrochloric	  acid,	  and	  extracted	  with	  diethyl	  ether	  (2	  ×	  20	  mL).	  Purification	  
by	   silica	   gel	   chromatography	   (ethyl	   acetate:	   petroleum	   ether,	   1:9,	   followed	   by	   gradient	  
elution)	  yielded	  the	  product	  as	  a	  yellow	  powder,	  which	  was	  re-­‐crystallised	  from	  acetonitrile	  
to	  give	  a	  bright	  yellow	  solid	   (148	  mg,	  77%);	  m.p.	  226.9-­‐227.8	  °C;	  ν	  max/cm-­‐1	  2500-­‐3500	  (br	  
OH),	  2190	  (alkyne),	  1676	  (C=O),	  1609	  (C=C),	  1487,	  1454,	  1364,	  1279,	  1258,	  1249,	  and	  1188;	  
1H	  NMR:	  (500	  MHz,	  CDCl3)	  δH	  1.27	  (6H,	  s,	  H18),	  1.28	  (6H,	  s,	  H18),	  1.67	  (4H,	  s,	  H12	  and	  13),	  2.08	  
(3H,	  d,	  J	  1.0,	  H19),	  5.76	  (1H,	  s,	  H2),	  6.28	  (1H,	  d,	  J	  16.0,	  H5),	  7.23	  (1H,	  dd,	  J	  1.5	  and	  8.0,	  H17),	  
7.26	  (1H,	  d,	  J	  8.0,	  H16),	  7.44	  (1H,	  d,	  J	  1.5,	  H9),	  8.10	  (1H,	  d,	  J	  16.0,	  H4);	  13C	  NMR:	  (126	  MHz,	  
CDCl3)	  δC	  20.9	  (C19),	  31.9	  (C18),	  32.0	  (C18),	  34.5	  (C11/14),	  34.6	  (C11/14),	  35.1	  (C12/13),	  35.2	  (C12/13),	  
88.1	   (C6),	   97.1	   (C7),	   116.8	   (C5),	   117.6	   (C2),	   120.1	   (C8),	   126.9	   (C16),	   129.1	   (C17),	   130.5	   (C9),	  
137.2	   (C4),	  145.4	   (C10),	  146.3	   (C15),	  152.1	   (C3),	  170.5	   (C1);	  m/z	   (ES)	  321.1860	   (M-­‐,	  C22H26O2,	  
requires	  321.1860),	  260,	  186,	  159	  and	  91;	  Anal.	  Calcd	  for	  C22H26O2:	  C,	  81.95;	  H,	  8.13.	  Found:	  






























dien-­‐6-­‐ynoic	  acid	  methyl	  ester	   (510	  mg,	  1.5	  mmol),	  was	  dissolved	   in	  a	  THF	  water	  mixture	  
(3:1,	  20	  mL)	  followed	  by	  the	  addition	  of	  lithium	  hydroxide	  (250	  mg,	  5.9	  mmol).	  The	  mixture	  
was	   stirred	   at	   room	   temperature	   for	   48	   hours	   in	   the	   absence	   of	   light	   after	   which,	   the	  
reaction	  was	  judged	  to	  be	  complete	  by	  TLC.	  The	  mixture	  was	  then	  acidified	  to	  pH	  1	  by	  the	  
addition	  of	  20%	  hydrochloric	  acid,	  and	  extracted	  with	  diethyl	  ether	  (2	  ×	  20	  mL).	  The	  sample	  
was	   concentrated	   under	   vacuum	   to	   give	   the	   crude	   as	   a	   yellow	   powder.	   This	   was	   re-­‐
crystallised	  from	  acetonitrile	  to	  yielded	  the	  product	  as	  a	  bright	  yellow	  crystalline	  solid	  (394	  
mg,	   82%);	  m.p.	   205.1-­‐206.7	   °C;	  ν	   max/cm-­‐1	   2500-­‐3500	   (br	  OH),	   2194	   (alkyne),	   1679	   (C=O),	  
1604	  (C=C),	  1488,	  1459,	  1255	  and	  1185;	  1H	  NMR:	  (700	  MHz,	  CDCl3)	  δH	  1.27	  (6H,	  s,	  H18),	  1.28	  
(6H,	  s,	  H18),	  1.68	  (4H,	  s,	  H12	  and	  13),	  2.32	  (3H,	  d,	  J	  1.0,	  H19),	  5.87	  (1H,	  s,	  H2),	  6.29	  (1H,	  d,	  J	  16.0,	  
H5),	  6.73	  (1H,	  d,	  J	  16.0,	  H4),	  7.21	  (1H,	  dd,	  J	  1.5	  and	  8.0,	  H17),	  7.27	  (1H,	  d,	  J	  8.0,	  H16),	  7.41	  (1H,	  
d,	  J	  1.5,	  H9);	  13C	  NMR:	  (126	  MHz,	  CDCl3)	  δC	  13.6	  (C19),	  31.9	  (C18),	  32.0	  (C18),	  34.4	  (C11/14),	  34.6	  
(C11/14),	  35.1	  (C12/13),	  35.1	  (C12/13),	  87.5	  (C6),	  96.6	  (C7),	  115.6	  (C5),	  119.9	  (C2),	  120.0	  (C8),	  127.0	  
(C16),	  129.0	   (C17),	  130.3	   (C9),	  143.5	   (C4),	  145.4	   (C10),	  146.4	   (C15),	  153.7	   (C3),	  172.0	   (C1).	  m/z	  
(ES)	   321.1858	   (M-­‐,	   C22H26O2,	   requires	   321.1860),	   260,	   186,	   159	   and	   91;	   Anal.	   Calcd	   for	  































To	  a	  dried	  Schlenk	  tube	  under	  a	  positive	  pressure	  of	  argon	  was	  added	  palladium(II)	  acetate	  
(16.5	  mg,	  0.1	  mmol),	  silver(I)	  acetate	  (296	  mg,	  1.6	  mmol),	  tri(o-­‐tolyl)phosphine	  (45	  mg,	  0.1	  
mmol),	   methyl	   (2E,4E)-­‐5-­‐iodo-­‐3-­‐methylpenta-­‐2,4-­‐dienoate	   (0.37	   g,	   1.5	   mmol)	   and	  
acetonitrile	   (10	  mL).	   The	  mixture	  was	   degassed	  using	   the	   freeze-­‐pump-­‐thaw	  method	   (2×)	  
followed	  by	   the	   addition	  of	   4,4,6-­‐trimethyl-­‐2-­‐vinyl-­‐1,3,2-­‐dioxaborane	   (265	  mg,	   1.7	  mmol).	  
Finally	   the	  mixture	  was	  degassed	  by	   freeze-­‐pump-­‐thaw	   (2×)	  before	  being	  heated	   to	  50	  °C	  
with	  vigorous	  stirring.	  After	  22	  hours	  the	  reaction	  was	  cooled	  to	  room	  temperature,	  diluted	  
with	   ether	   (60	   mL),	   passed	   through	   Celite™,	   washed	   with	   5%	   hydrochloric	   acid	   (20	   mL),	  
water	   (40	   mL)	   and	   brine	   (20	   mL),	   dried	   (MgSO4)	   and	   concentrated	   under	   vacuum.	   The	  
product	  was	  purified	  by	  silica	  gel	  column	  chromatography	  (ethyl	  acetate:	  petroleum	  ether,	  
1:9)	   to	   give	   the	  product	   as	   a	  pale	   yellow	  oil	   (274	  mg,	   67%).	  ν	   max/cm-­‐1	   2973,	   1711,	   1614,	  
1391,	  1303,	  1237,	  and	  1150;	  1H	  NMR	  (700	  MHz,	  CDCl3)	  δH	  1.28	  (3H,	  d,	  J	  6.0,	  H13),	  1.31	  (3H,	  s,	  
H12),	  1.31	  (3H,	  s,	  H12),	  1.51	  (1H,	  t,	  J	  14.0,	  H10),	  1.80	  (1H,	  dd,	  J	  14.0	  and	  3.0,	  H10),	  2.30	  (3H,	  s,	  
H8),	  3.71	  (3H,	  s,	  OMe),	  4.21-­‐4.27	  (1H,	  m,	  H9),	  5.68	  (1H,	  d,	  J	  17.0,	  H4),	  5.81	  (1H,	  s,	  H2),	  6.36	  
(1H,	  d,	  J	  17.0,	  H7),	  6.63	  (1H,	  dd,	  J	  17.0	  and	  11.0,	  H6)	  and	  6.99	  (1H,	  dd,	  J	  17.0	  and	  11.0,	  H5);	  
13C	   NMR	   (176	  MHz,	   CDCl3)	   δC	   13.9	   (C8),	   23.3	   (C13),	   28.3	   (C12),	   31.4	   (C12),	   46.1	   (C10),	   51.2	  
(OMe),	  65.1	   (C9),	   71.1	   (C11),	   119.9	   (C2),	   130.0-­‐132.0	   (C7),	   136.6	   (C6),	   137.9	   (C4),	   146.0	   (C5),	  
152.6	   (C3)	  and	  167.5	   (C1);	  m/z	   (ES)	  278.1802	   (M,	  C15H24BO4,	   requires	  278.1798).	  190,	  174,	  
























To	  a	  dried	  Schlenk	  tube	  under	  a	  positive	  pressure	  of	  argon	  was	  added	  (2E,4E,6E)-­‐3-­‐methyl-­‐
7-­‐(4,4,6-­‐trimethyl-­‐[1,2,3]-­‐dioxaborinan-­‐2-­‐yl)-­‐hepta-­‐2,4,6-­‐trienoic	   acid	   methyl	   ester	   (0.2	   g,	  
0.7	  mmol)	  in	  dry	  tetrahydrofuran	  (5	  mL)	  The	  mixture	  was	  cooled	  to	  -­‐78	  oC	  in	  the	  absence	  of	  
light,	  followed	  by	  the	  addition	  of	  sodium	  methoxide	  (1.8	  mL	  of	  a	  0.5	  M	  solution	  in	  methanol,	  
0.9	  mmol).	  After	  30	  minutes	   iodine	  monochloride	  (1.2	  mL	  of	  a	  0.5	  M	  solution	   in	  DCM,	  1.2	  
mmol)	  was	  added	  and	  stirred	  for	  1	  hour.	  The	  reaction	  was	  warmed	  to	  room	  temperature,	  
diluted	  with	  diethyl	  ether	  (30	  mL),	  washed	  with	  sodium	  metabisulphite	  (30	  mL),	  water	  (30	  
mL),	  and	  brine	  (30	  mL),	  dried	  (MgSO4)	  and	  concentrated	  to	  give	  an	  orange	  oil.	  Purification	  
by	   silica	  gel	   chromatography	   (ethyl	   acetate:	  petroleum	  ether,	  1:9,	   cooled	   to	  0	  °C)	   yielded	  
the	  product	  as	  a	  pale	  yellow	  oil	  (131	  mg,	  65%). ν	  max/cm-­‐1	  2946	  (Sp3	  C-­‐H),	  1710	  (C=O),	  1609	  
(C=C),	  1557,	  1433	  (Sp3	  C-­‐H),	  1390,	  1357,	  1238,	  1189	  and	  1152;	  1H	  NMR	  (500	  MHz,	  CDCl3)	  δH	  
2.31	  (3H,	  d,	  J	  1.0,	  C8),	  3.73	  (3H,	  s,	  OMe),	  5.87	  (1H,	  s,	  H2),	  6.28	  (1H,	  d,	  J	  15.0,	  H4),	  6.51	  (1H,	  dd,	  
J	  15.0	  and	  11.0,	  H5),	  6.62	  (1H,	  d,	  J	  15.0,	  H7),	  and	  7.16	  (1H,	  dd,	  J	  15.0	  and	  11.0,	  H6);	  13C	  NMR	  
(126	  MHz,	  CDCl3)	  δC	  13.8	  (C8),	  51.4	  (OMe),	  83.4	  (C7),	  120.7	  (C2),	  133.8	  (C5),	  136.3	  (C4),	  	  145.0	  
(C6),	   151.8	   (C3),	   167.5	   (C1);	  m/z	   (ES)	   277.9799	   (M,	  C9H11IO2,	   requires	   277.9798).	   247,	   219,	  
























(2E,4E,6E)-­‐7-­‐Iodo-­‐3-­‐methyl-­‐hpta-­‐2,4,6-­‐trienoic	   acid	  methyl	   ester	   (130	  mg,	   0.467	  mmol),	   6-­‐
ethynyl-­‐1,1,4,4-­‐tetramethyl-­‐1,2,3,4-­‐tetrahydronaphthalene	   (120	   mg,	   0.565	   mmol)	   and	  
triethylamine	   (5	  mL)	  were	  added	   to	  a	  dried	  Schlenk	   tube	  and	   the	  mixture	  degassed	  using	  
the	   freeze-­‐pump-­‐thaw	  method	   (3×).	   Palladium(II)	   acetate	   (4.5	   mg,	   0.02	   mmol),	   triphenyl	  
phosphine	  (10.5	  mg,	  0.04	  mmol)	  and	  copper(I)	  iodide	  (7.6	  mg,	  0.04	  mmol)	  were	  then	  added	  
and	  the	  mixture	  degassed	  by	  freeze-­‐pump-­‐thaw	  (3×)	  and	  stirred	  at	  room	  temperature	  for	  5	  
hours.	  The	   reaction	  was	  diluted	  with	  ether	   (60	  mL),	  passed	   through	  Celite™,	  washed	  with	  
5%	   hydrochloric	   acid	   (2	   ×	   20	  mL),	   brine	   (20	  mL),	   dried	   (MgSO4)	   and	   concentrated	   under	  
vacuum	   to	   give	   an	   orange	   oil.	   Purification	   by	   silica	   gel	   column	   chromatography	   (ethyl	  
acetate:	   petroleum	  ether,	   5:95)	   yielded	   the	   product	   as	   a	   pale	   yellow	  oil	   (122	  mg,	   72%).ν	  
max/cm-­‐1	  2955,	  2181,	  1709,	  1604,	  1435,	  1358,	  1240,	  and	  1153;	  1H	  NMR	  (700	  MHz,	  CDCl3)	  δH	  
1.27	  (6H,	  s,	  H21),	  1.28	  (6H,	  s,	  H21),	  1.67	  (4H,	  s,	  H14	  and	  15),	  2.31	  (3H,	  s,	  H20),	  3.71	  (3H,	  s,	  OMe),	  
5.82	  (1H,	  s,	  H2),	  5.99	  (1H,	  d,	  J	  15.0,	  H7),	  6.34	  (1H,	  d,	  J	  15.0,	  H4),	  6.67	  (1H,	  dd,	  J	  15.0	  and	  11.0,	  
H5),	  6.74	  (1H,	  dd,	  J	  15.0	  and	  11.0,	  H6),	  7.19	  (1H,	  dd,	  J	  8.0	  and	  1.5,	  H19),	  7.27	  (1H,	  d,	  J	  8.0,	  H18),	  
7.39	   (1H,	  d,	   J	  1.5,	  H11);	   13C	  NMR	  (176	  MHz,	  CDCl3)	  δC	  13.9	   (C20),	  31.9	   (C21),	  31.9	   (C21),	  34.6	  
(C13/16),	   34.6	   (C13/16),	   35.1	   (C14/15),	   35.1	   (C14/15),	   51.3	   (OMe),	   88.2	   (C8),	   95.5	   (C9),	   98.8	   (C3),	  
115.0	  (C7),	  120.2	  (C2),	  120.4	  (C10),	  127.0	  (C18),	  128.8	  (C19),	  130.1	  (C11),	  134.0	  (C5),	  137.5	  (C4),	  
140.6	   (C6),	  145.3	   (C12),	  146.1	   (C17),	  167.5	   (C1);	  m/z	   (ES)	  363.2322	   (M+H,	  C25H31O2,	   requires	  

































trien-­‐8-­‐ynoic	   acid	  methyl	   ester	   (120	  mg,	   0.331	  mmol)	  was	   added	   to	   a	   stirred	   solution	   of	  
lithium	  hydroxide	  (42	  mg,	  0.993	  mmol)	  in	  a	  tetrahydrofuran	  water	  mixture	  (3:1,	  10	  mL)	  at	  4	  
°C.	  After	  the	  reaction	  was	  judged	  to	  be	  complete	  by	  TLC	  the	  reaction	  mixture	  was	  acidified	  
to	  pH	  1/2	  by	   the	  addition	  of	  20%	  hydrochloric	   acid,	   extracted	  with	  diethyl	   ether	   (20	  mL),	  
dried	   (MgSO4)	   and	   concentrated	   to	   give	   an	   orange	   oil.	   Purification	   by	   silica	   gel	  
chromatography	  (petroleum	  ether:	  ethyl	  acetate,	  9:1)	  yielded	  the	  product	  as	  a	  yellow	  solid	  
(100	  mg,	  87%)	   in	  a	   ratio	  of	   two	   isomers	   (1:0.4).	   1H	  NMR	   (700	  MHz,	  CDCl3)	  δH	  1.26	   (6H,	   s,	  
H21),	  1.27	  (6H,	  s,	  H21),	  1.67	  (4H,	  s,	  H14	  and	  15),	  2.32	  (3H,	  s,	  H20),	  5.85	  (1H,	  s,	  H2),	  6.01	  (1H,	  d,	  J	  
14.0,	  H7),	  6.36	  (1H,	  d,	  J	  14.0,	  H4),	  6.68-­‐6.77	  (2H,	  m,	  H5	  and	  6),	  7.19	  (1H,	  dd,	  J	  8.0	  and	  1.5,	  H19),	  
7.28	  (1H,	  d,	  J	  8.0,	  H18),	  7.39	  (1H,	  d,	  J	  1.5,	  H11).	  13C	  NMR	  (176	  MHz,	  CDCl3)	  δC	  14.1	  (C20),	  31.9	  
(C21),	  31.9	  (C21),	  32.0	  (C21),	  34.4	  (C13/16),	  34.6	  (C13/16),	  35.1	  (C14/15),	  35.1	  (C14/15),	  88.1	  (C8),	  95.8	  
(C9),	  99.0	  (C3),	  115.6	  (C7),	  119.4	  (C2),	  120.2	  (C10),	  126.9	  (C18),	  128.8	  (C19),	  130.2	  (C11),	  134.8	  
(C5),	   137.2	   (C4),	   140.5	   (C6),	   145.4	   (C12),	   146.1	   (C17),	   154.4	   (C1);	  m/z	   (ES)	   347.2016	   (M-­‐H,	  



































4-­‐(2-­‐Phenyl-­‐thiazol-­‐4-­‐ylamino)-­‐benzoic	   acid	   ethyl	   ester	   (0.10	   g,	   0.3	  mmol)	  was	   added	   to	   a	  
suspension	  of	  NaH	  (20	  mg,	  0.5	  mmol)	  in	  dry	  THF	  (5	  mL)	  at	  0	  oC	  and	  stirred	  for	  10	  minutes.	  
Methyl	   iodide	  (0.71	  g,	  5.0	  mmol)	  was	  then	  added	  and	  stirred	  for	  20	  minutes.	  The	  reaction	  
mixture	  was	  diluted	  with	  ethyl	  acetate	  (40	  mL),	  washed	  with	  brine	  (40	  mL),	  dried	  (MgSO4),	  
filtered	   and	   concentrated	   under	   vacuum.	   Purification	   by	   flash	   column	   chromatography	  
(ethyl	   acetate:	  hexanes,	  1:7),	   gave	  an	  off-­‐white	   solid.	  Re-­‐crystallisation	   from	   toluene	  gave	  
the	  product	  as	  a	  bright	  yellow	  solid	  (0.86	  g,	  83%).	  All	  spectral	  and	  analytical	  properties	  were	  
identical	   to	   those	   reported	   in	   the	   literature.250	   ν	   max/cm-­‐1	   3102,	   1693,	   1604,	   1509,	   1277,	  
1184	  and	  1103;	  1H	  NMR	  (500	  MHz,	  CDCl3)	  δ	  1.38	  (3H,	  t,	  J	  7.0,	  CH3),	  3.52	  (3H,	  s,	  CH3),	  4.34	  
(2H,	  q,	  J	  7.0,	  CH2),	  6.67	  (1H,	  s,	  H8),	  7.12	  (2H,	  dd,	  J	  9.0,	  H11	  H15),	  7.43	  (3H,	  m,	  H1	  H2	  H6),	  7.95	  
(4H,	  m,	  H3	  H5	  H12	  H14);	  13C	  NMR	  (126	  MHz,	  CDCl3)	  14.7	  (C18),	  39.3	  (C19),	  60.7	  (C17),	  102.9	  (C8),	  
116.3	  (C11	  C15),	  121.8	  (C13),	  126.4	  (C3	  C5),	  129.2	  (C2	  C6),	  130.4	  (C1),	  131.0	  (C12	  C14),	  133.7	  (C4),	  
151.5	   (C10),	   157.2	   (C9),	   166.2	   (C7),	   166.9	   (C16);	   m/z	   (ES)	   339.1162	   (M+H,	   C19H19O2N2S1,	  
requires	  339.1162).	  
	  




Chloroacetic	  acid	  (2.00	  g,	  21.0	  mmol),	  benzocaine	  (3.3	  g,	  20.0	  mmol)	  and	  boric	  acid	  (63	  mg,	  
1.0	   mmol)	   were	   dissolved	   in	   toluene	   (100	   mL)	   and	   heated	   to	   reflux	   using	   Dean-­‐Stark	  
apparatus.	   After	   96	   hours,	   the	   reaction	   was	   cooled	   to	   room	   temperature,	   concentrated	  








































mL),	   saturated	   sodium	  hydrogen	   carbonate	   (150	  mL),	   and	  brine	   (100	  mL),	   dried	   (MgSO4),	  
and	  concentrated	  to	  give	  a	  white	  solid.	  Re-­‐crystallisation	  from	  toluene	  yielded	  the	  product	  
as	  a	  white	  fluffy	  solid	  (3.24	  g,	  67%);	  m.p.	  121.1-­‐122.4	  °C;	  ν	  max/cm-­‐1	  3343,	  2985,	  2904,	  1683,	  
1598,	  1534,	  1404	  and	  1272;	  1H	  NMR	  (700	  MHz,	  CDCl3)	  δ	  1.40	  (3H,	  t,	  J	  7.0,	  CH3),	  4.21	  (2H,	  s,	  
CH2),	  4.37	  (2H,	  q,	  J	  7.0,	  CH2),	  7.65	  (2H,	  d,	  J	  9.0,	  H4),	  8.05	  (2H,	  d,	  J	  9.0,	  H3),	  8.36	  (1H,	  brs,	  NH);	  
13C	  NMR	  (176	  MHz,	  CDCl3)	  14.5	   (C9),	  43.1	   (C7),	  61.2	   (C8),	  119.3	   (C4),	  127.2	   (C2),	  131.1	   (C3),	  
140.8	  (C5),	  164.1	  (C6),	  166.1	  (C1);	  m/z	  	  (ES)	  242	  (M+)	  and	  228;	  Anal.	  Calcd.	  for	  C11H12ClNO3:	  C,	  
54.67;	  H,	  5.00;	  N,	  5.86.	  Found:	  C,	  54.75;	  H,	  4.93;	  N,	  5.56.	  
	  




To	   a	   solution	   of	   thiobenzamide	   (0.60	   g,	   4.4	  mmol)	   in	   DMF	   (5	  mL)	  was	   added	   ethyl	   4-­‐(2-­‐
chloroacetoamido)benzoate	   (1.03	   g,	   4.3	  mmol).	   The	   reaction	   was	   stirred	   at	   80	   oC	   for	   12	  
hours	  under	  argon	  and	   the	  DMF	  was	   removed	  under	   vacuum,	   to	   yield	  a	  brown	   solid.	  Re-­‐
crystallisation	   from	   IPA,	   followed	   by	   silica	   gel	   column	   chromatography	   (ethyl	   acetate:	  
hexanes,	   1:1),	   and	   subsequent	   re-­‐crystallisation	   from	   IPA	   yielded	   the	   product	   as	   a	   green	  
solid	   (0.85	  g,	  65%);	   1H	  NMR	  (500	  MHz,	  CDCl3)	  δ	  1.40	   (3H,	   t,	   J	  7.0,	  CH3),	  4.37	   (2H,	  q,	   J	  7.0,	  
CH2),	  6.63	  (1H,	  s,	  H8),	  6.95	  (1H,	  broad	  singlet,	  NH),	  7.17	  (	  2H,	  d,	  J	  8.8,	  H11	  H15),	  7.46	  (3H,	  m,	  
H1	  H2	  H6),	  7.94	  (2H,	  m,	  H3	  H5),	  8.01	  (2H,	  d,	   J	  8.8,	  H12	  H14);	   13C	  NMR	  (126	  MHz,	  CDCl3)	  14.7	  
(C18),	  60.8	  (C17),	  95.5	  (C8),	  115.0	  (C11	  C15),	  122.3	  (C13),	  126.4	  (C3	  C5),	  129.3	  (C2	  C6),	  130.5	  (C1),	  


































Magnesium	   turnings	   (110	   mg,	   4.6	   mmol)	   were	   heated	   under	   argon	   followed	   by	   the	  
dropwise	   addition	   of	   6-­‐iodo-­‐1,1,4,4-­‐tetramethyl-­‐1,2,3,4-­‐tetrahydronaphthalen	   (1.00	   g,	   3.2	  
mmol)	   in	   tetrahydrofuran	   (20	  mL),	   and	   heated	   to	   reflux	   followed	   by	   the	   addition	   of	   1,2-­‐
dibromoethane	   (0.20	   g,	   1.1	   mmol).	   After	   initiation	   the	   remaining	   iodide	   was	   added	  
dropwise	  over	  a	  further	  30	  minutes.	  Upon	  complete	  addition	  the	  reaction	  was	  kept	  at	  reflux	  
for	   30	   minutes,	   cooled	   to	   room	   temperature	   followed	   by	   dropwise	   addition	   to	   a	   stirred	  
solution	  of	  methyl	  chloroformate	  (0.42	  g,	  4.8	  mmol)	  at	  -­‐78	  oC	  under	  argon.	  After	  30	  minutes	  
the	  reaction	  mixture	  was	  warmed	  to	  room	  temperature,	  washed	  with	  5%	  hydrochloric	  acid	  
(40	  mL),	  brine	  (40	  mL),	  dried	  (MgSO4),	  and	  concentrated	  under	  vacuum.	  Purification	  by	  silica	  
gel	  column	  chromatography	  (ethyl	  acetate:	  petroleum	  ether,	  15:85)	  yielded	  the	  product	  as	  a	  
clear	   oil.	   All	   spectral	   and	   analytical	   properties	   were	   identical	   to	   those	   reported	   in	   the	  
literature.367;	  ν	  max/cm-­‐1	  2957,	  2930,	  2864,	  1719,	  1254,	  1191	  and	  1116;	  1H	  NMR	  (700	  MHz,	  
CDCl3)	  δ	  1.29	  (6H,	  s,	  2xCH3),	  1.32	  (6H,	  s,	  2xCH3),	  1.70	  (4H,	  s,	  2xCH2),	  3.89	  (3H,	  s,	  OCH3),	  7.36	  
(1H,	  d,	  J	  8.0,	  H10),	  7.78	  (1H,	  dd,	  J	  8.0	  &	  1.5,	  H11),	  8.03	  (1H,	  d,	  J	  1.5,	  H3);	  13C	  NMR	  (176	  MHz,	  
CDCl3)	  31.9	  (2xCH3),	  32.0	  (2xCH3),	  34.6	  (CH2),	  34.8	  (CH2),	  52.0	  (OCH3),	  126.8	  (C11),	  126.9	  (C10),	  
127.7	   (C2),	  128.3	   (C3),	  145.3	   (C4),	  150.5	   (C9),	  167.5	   (C1);	  m/z	   (ES+)	  247.1694	   (M+,	  C16H23O2,	  
























5,5,8,8-­‐Tetramethyl-­‐5,6,7,8-­‐tetrahydronaphthalene-­‐2-­‐carboxylic	   acid	   methyl	   ester	   (5.00	   g,	  
20.3	  mmol)	  was	  dissolved	  in	  a	  1:1	  mixture	  of	  tetrahydrofuran	  and	  water	  (100	  mL),	  followed	  
by	  the	  addition	  of	  lithium	  hydroxide	  (5.10	  g,	  121.8	  mmol).	  The	  reaction	  was	  stirred	  at	  room	  
temperature	   for	   72	   hours.	   Diluted	   with	   10%	   sodium	   hydroxide	   (150	   mL),	   extracted	   with	  
diethyl	  ether	  (2	  ×	  150	  mL),	  the	  aqueous	  layer	  acidified	  to	  pH	  1/2	  with	  20%	  hydrochloric	  acid,	  
extracted	  with	  diethyl	  ether	  (2	  ×	  150	  mL),	  dried	  (MgSO4)	  and	  concentrated	  under	  vacuum	  to	  
yield	  a	  white	  solid	  (3.7	  g,	  79%);	  m.p.	  209.4-­‐210.9	  °C;	  ν	  max/cm-­‐1	  2500-­‐3500	  (br)	  1682,	  1608,	  
1455,	  1423,	  1361,	  1311,	  1292	  and	  1266;	  1H	  NMR	  (500	  MHz,	  CDCl3)	  δ	  1.31	  (6H,	  s,	  2xCH3),	  1.32	  
(6H,	  s,	  2xCH3),	  1.71	  (4H,	  s,	  2xCH2),	  7.40	  (1H,	  d,	  J	  8.3,	  H10),	  7.84	  (1H,	  dd,	  J	  8.3	  &	  1.8,	  H11),	  8.08	  
(1H,	   d,	   J	   1.8,	   H3);	   13C	   NMR	   (126	  MHz,	   CDCl3)	   31.9	   (2xCH3),	   32.0	   (2xCH3),	   34.6	   (C5/8),	   35.0	  
(C5/8),	  35.0	  (C6/7),	  35.1	  (C6/7),	  126.7	  (C2),	  127.1	  (C10),	  127.4	  (C11),	  129.1	  (C3),	  145.6	  (C4),	  151.7	  
(C9),	  172.4	  (C1);	  m/z	  (ES)	  255.1358	  (M+Na,	  C15H20O2Na1,	  requires	  255.1356),	  218,	  176.	  	  	  	  	  
	  




5,5,8,8-­‐Tetramethyl-­‐5,6,7,8-­‐tetrahydronaphthalene-­‐2-­‐carboxylic	  acid	  (2.00	  g,	  8.6	  mmol)	  was	  
dissolved	   in	   toluene	   (150	  mL)	   followed	  by	   the	   addition	   of	   a	   catalytic	   amount	   of	   dimethyl	  
formamide	   (0.2	   mL)	   and	   oxalyl	   chloride	   (1.30	   g,	   10.4	   mmol).	   The	   reaction	   mixture	   was	  
stirred	  at	  room	  temperature	  for	  10	  minutes,	  before	  being	  concentrated	  under	  vacuum,	  to	  
yield	  off	  white	  oil.	  Addition	  of	  a	  large	  excess	  of	  35%	  aqueous	  ammonia	  solution	  (50	  mL)	  at	  –






















room	   temperature,	   diluted	  with	   brine	   (50	  mL),	   extracted	  with	   diethyl	   ether	   (2	   ×	   50	  mL),	  
dried	   (MgSO4)	   and	   concentrated	   under	   vacuum	   to	   yield	   a	  white	   solid	   (1.80	   g,	   88%);	  m.p.	  
148.2-­‐149.4	  °C;	  ν	  max/cm-­‐1	  3437,	  3170,	  2954,	  2922,	  2863,	  1641,	  1613,	  1553,	  1395,	  1277	  and	  
1141;	  1H	  NMR	  (700	  MHz,	  CDCl3)	  δ	  1.27	  (6H,	  s,	  2xCH3),	  1.29	  (6H,	  s,	  2xCH3),	  1.69	  (4H,	  s,	  2xCH2),	  
6.00	  (1H,	  bs,	  NH),	  6.13	  (1H,	  bs,	  NH),	  7.35	  (1H,	  d,	  J	  8.2,	  H10),	  7.49	  (1H,	  dd,	  J	  8.2	  &	  2.0,	  H11),	  
7.81	  (1H,	  d,	  J	  2.0,	  H3);	  13C	  NMR	  (176	  MHz,	  CDCl3)	  31.7	  (2xCH3),	  31.7	  (2xCH3),	  34.4	  (C5),	  34.5	  
(C8),	  34.8	  (C6/7),	  34.9	  (C6/7),	  124.1	  (C11),	  126.1	  (C3),	  126.8	  (C10),	  130.5	  (C2),	  145.5	  (C4),	  149.4	  
(C9),	  169.8	  (C1);	  m/z	  (ES+)	  232.1696	  (M+H,	  C15H22ON,	  requires	  232.1696).	  
	  




5,5,8,8-­‐Tetramethyl-­‐5,6,7,8-­‐tetrahydronaphthalene-­‐2-­‐carboxylic	   acid	   amide	   (200	   mg,	   0.9	  
mmol),	  and	  Lawessons	  Reagent	  (199	  mg,	  0.5	  mmol)	  were	  stirred	  at	  room	  temperature	  in	  dry	  
toluene	  under	  argon	   for	  24	  hours.	  The	   reaction	  mixture	  was	  concentrated	  under	  vacuum,	  
followed	  by	  purification	  by	  flash	  silica	  gel	  column	  chromatography	  (dichloromethane,	  100%)	  
to	  yield	  the	  titled	  compound	  as	  a	  yellow	  solid	  (200	  mg,	  97%);	  m.p.	  174.9-­‐176.3	  °C;	  ν	  max/cm-­‐1	  
3380,	  3276,	  3150,	  2956,	  2918,	  2855,	  2368,	  2012,	  1638,	  1615,1458,	  1406,	  1321,	  1280,	  1263	  
and	  1155;	  1H	  NMR	  (500	  MHz,	  CDCl3)	  δ	  1.28	  (6H,	  s,	  2xCH3),	  1.31	  (6H,	  s,	  2xCH3),	  1.69	  (4H,	  s,	  
2xCH2),	  7.23	  (1H,	  bs,	  NH),	  7.33	  (1H,	  d,	  J	  8.3	  H10),	  7.59	  (1H,	  dd,	  J	  8.3	  &	  2.1,	  H11),	  7.82	  (1H,	  bs,	  
NH),	  7.84	  (1H,	  d,	  J	  2.1,	  H3);	  13C	  NMR	  (126	  MHz,	  CDCl3)	  31.9	  (2xCH3),	  32.0	  (2xCH3),	  34.7	  (C5),	  
34.8	   (C8),	   35.0	   (C6/7),	   35.1	   (C6/7),	   124.1	   (C11),	   125.9	   (C3),	   127.1	   (C10),	   136.7	   (C2),	   145.5	   (C4),	  






















5,5,8,8-­‐Tetramethyl-­‐5,6,7,8-­‐tetrahydronaphthalene-­‐2-­‐carboxylic	   acid	   amide	   (200	   mg,	   0.9	  
mmol),	   and	   Lawessons	   Reagent	   (199	  mg,	   0.5	  mmol)	  were	   stirred	   at	   reflux	   in	   dry	   toluene	  
under	   argon	   for	   2	   hours.	   The	   reaction	   mixture	   was	   cooled	   to	   room	   temperature,	  
concentrated	   under	   vacuum,	   followed	   by	   purification	   by	   silica	   gel	   flash	   column	  
chromatography	  (hexane:	  dichloromethane,	  2:3)	  to	  yield	  the	  product	  as	  a	  white	  crystalline	  
solid	  (121	  mg,	  57%);	  m.p.	  68.3-­‐68.9	  °C;	  ν	  max/cm-­‐1	  2964,	  2919,	  2855,	  2226,	  1604,	  1489,	  1455,	  
1397,	  1361,	  1276	  and	  1183;	   1H	  NMR	  (700	  MHz,	  CDCl3)	  δ	  1.27	   (12H,	  s,	  4xCH3),	  1.68	   (4H,	  s,	  
2xCH2),	  7.37	  (2H,	  d,	  J	  0.7	  H10	  &	  H11),	  7.58	  (1H,	  s,	  H3);	  13C	  NMR	  (176	  MHz,	  CDCl3)	  31.5	  (2xCH3),	  
31.6	  (2xCH3),	  34.3	  (C5),	  34.5	  (C8),	  34.7	  (C6	  &	  C7),	  109.3	  (C2),	  119.5	  (C1),	  127.5	  (C10),	  128.8	  (C11),	  
130.8	  (C3),	  146.3	  (C4),	  150.6	  (C9);	  m/z	  (EI+)	  213.1512	  (M+,	  C15H19N,	  requires	  213.1512).	  
	  




To	  a	  stirred	  solution	  of	  4-­‐amino-­‐2-­‐fluorobenzoic	  acid	  (0.50	  g,	  3.2	  mmol)	  in	  ethanol	  (25	  mL),	  
cooled	  to	  0	  oC,	  was	  added	  thionyl	  chloride	  (0.58	  g,	  4.8	  mmol)	  dropwise	  over	  10	  minutes.	  The	  
reaction	  was	  heated	  to	   reflux	   for	  18	  hours,	  cooled	  to	   room	  temperature,	  and	  the	  ethanol	  
removed	  under	  vacuum.	  The	  solid	  was	  re-­‐dissolved	  in	  ethyl	  acetate	  (100	  mL),	  washed	  with	  
sodium	  hydrogen	  carbonate	   (100	  mL),	  dried	   (MgSO4),	   and	   concentrated	  under	   vacuum	   to	  
give	   the	   desired	   compound	   as	   a	   white	   solid	   (550	   mg,	   93%).	   All	   spectral	   and	   analytical	  
properties	   were	   identical	   to	   those	   reported	   in	   the	   literature.368	   m.p.	   123.8-­‐125.2	   °C;	   ν	  
max/cm-­‐1	  3421,	  3337,	  2984,	  1689,	  1630,	  1609,	  1569,	  1366,	  1346,	  1266,	  1248,	  1146	  and	  1077;	  






















CH2),	  6.33	  (1H,	  dd,	  J	  13.0	  &	  2.5,	  H4),	  6.40	  (1H,	  dd,	  J	  8.5	  &	  2.5,	  H6),	  7.75	  (1H,	  t,	  J	  8.5,	  H7);	  13C	  
NMR	   (126	  MHz,	  CDCl3)	  δ	   14.6	   (CH3),	  60.8	   (CH2),	  102.0	   (d,	   J	   26.0,	  C4),	  108.3	   (d,	   J	   10.0,	  C2),	  
110.2	  (C6),	  134.0	  (d,	  J	  2.5,	  C7),	  152.7	  (d,	  J	  12.0,	  C5),	  164.2	  (d,	  J	  258.0,	  C3),	  164.8	  (d,	  J	  4.0,	  C1);	  
19F	  NMR	  (376	  MHz,	  CDCl3)	  δ	  -­‐108.1	  (dd,	  J	  13.5	  &	  8.5);	  m/z	  (ES+)	  184.0766	  (M+,	  C9H11O2N1F1,	  
requires	  184.0768)	  and	  153;	  Anal.	  Calcd.	  for	  C9H10FNO2:	  C,	  59.01;	  H,	  5.50;	  N,	  7.65.	  Found:	  C,	  
59.00;	  H,	  5.50;	  N,	  7.57.	  
	  




Chloroacetic	  acid	   (53	  mg,	  0.6	  mmol),	  4-­‐amino-­‐2-­‐fluorobenzoic	  acid	  ethyl	  ester	   (98	  mg,	  0.5	  
mmol)	  and	  boric	  acid	   (2	  mg,	  0.1	  mmol),	  were	  dissolved	   in	   toluene	   (20	  mL)	  and	  heated	   to	  
reflux	   using	   a	   Dean-­‐Stark	   apparatus.	   After	   56	   hours	   the	   reaction	   was	   cooled	   to	   room	  
temperature,	   concentrated	   under	   vacuum,	   dissolved	   in	   ether	   (40	   mL),	   washed	   with	   5%	  
hydrochloric	  acid	  (40	  mL),	  saturated	  sodium	  hydrogen	  carbonate	  (40	  mL),	  and	  brine	  (40	  mL),	  
dried	  (MgSO4),	  and	  concentrated	  to	  give	  an	  off-­‐white	  solid.	  Re-­‐crystallisation	  from	  toluene	  
yielded	   the	   product	   as	   a	  white	   fluffy	   solid	   (90	  mg,	   64%);	  m.p.	   111.9-­‐113.9	   °C;	  ν	   max/cm-­‐1	  
3348,	  2982,	  2910,	  1692,	  1621,	  1597,	  1533,	  1509,	  1478,	  1401,	  1335,	  1261,	  1195,	  1141	  and	  
1087;	  1H	  NMR	  (500	  MHz,	  CDCl3)	  δ	  1.38	  (3H,	  t,	  J	  7.0,	  CH3),	  4.20	  (2H,	  s,	  CH2),	  4.37	  (2H,	  q,	  J	  7.0,	  
CH2),	  7.25	  (1H,	  d,	  J	  8.0,	  H6),	  7.65	  (1H,	  d,	  J	  12.5,	  H4),	  7.93	  (1H,	  t,	  J	  8.0,	  H7),	  8.46	  (1H,	  brs,	  NH);	  
13C	  NMR	  (126	  MHz,	  CDCl3)	  δ	  14.5	  (CH3),	  43.1	  (CH2Cl),	  61.6	  (CH2),	  108.2	  (d,	  J	  28.0,	  C4),	  114.8	  
(d,	  J	  4.0,	  C6),	  115.3	  (d,	  J	  10.0,	  C2),	  133.2	  (d,	  J	  2.0,	  C7),	  142.2	  (d,	  J	  12.0,	  C5),	  162.8	  (d,	  J	  260.0,	  
C3),	  164.1	  (d,	  J	  4.0,	  C1),	  164.4	  (C8);	  19F	  NMR	  (376	  MHz,	  CDCl3)	  δ	  -­‐106.0	  (dd,	  J	  12.5	  &	  8.0);	  m/z	  	  
(ES-­‐)	  258	  (M-­‐);	  Anal.	  Calcd.	  for	  C11H11ClFNO3:	  C,	  50.88;	  H,	  4.27;	  N,	  5.39.	  Found:	  C,	  51.17;	  H,	  


























To	   a	   dry	   two-­‐neck	   flask	   under	   argon	   was	   added	   4-­‐methylamino-­‐benzoic	   acid	   ethyl	   ester	  
(0.08	   g,	   0.4	   mmol),	   in	   dry	   DCM	   (5	   mL).	   The	   reaction	   mixture	   was	   cooled	   to	   −	   78	   oC,	  
triethylamine	  (0.07	  mL,	  0.5	  mmol)	  was	  added,	   followed	  by	  chloroacetyl	  chloride	   (0.04	  mL,	  
0.5	  mmol),	  dropwise.	  After	  10	  minutes	  the	  reaction	  was	  warmed	  to	  room	  temperature	  and	  
stirred	  for	  18	  hours.	  The	  reaction	  mixture	  was	  evaporated,	  and	  purified	  by	  silica	  gel	  column	  
chromatography	  (chloroform:	  ethyl	  acetate;	  4:1)	  to	  yield	  the	  product	  as	  a	  white	  solid	  (0.06	  
g,	  55	  %);	  1H	  NMR	  (700	  MHz,	  CDCl3)	  δ	  1.39	  (3H,	  t,	  J	  7.2,	  CH3),	  3.33	  (3H,	  s,	  NCH3),	  3.85	  (2H,	  s,	  
CH2),	  4.39	  (2H,	  q,	  J	  7.2,	  CH2),	  7.32	  (2H,	  d,	  J	  8.5,	  H4),	  8.11	  (2H,	  d,	  J	  8.5,	  H3);	  13C	  NMR	  (176	  MHz,	  
CDCl3)	  14.5	  (C9),	  38.1	  (C10),	  41.5	  (C7),	  61.6	  (C8),	  127.1/127.6	  (C4),	  130.8	  (C2),	  131.6/131.8	  (C3),	  
146.8	  (C5),	  165.6	  (C1),	  166.3	  (C6);	  m/z	  	  (EI)	  257	  (M+H),	  206,	  179,	  150,	  134	  and	  90.	  
	  




To	  a	   stirred	   solution	  of	  4-­‐methyl	   aminobenzoic	  acid	   (0.07	  g,	  0.5	  mmol)	   in	  ethanol	   (5	  mL),	  
cooled	  to	  0	  oC,	  was	  added	  thionyl	  chloride	  (0.05	  mL,	  0.7	  mmol)	  dropwise.	  The	  reaction	  was	  
warmed	  to	  room	  temperature,	  followed	  by	  heating	  at	  reflux	  for	  18	  hours.	  Upon	  completion,	  
the	   reaction	  was	  cooled	   to	   room	  temperature,	  and	  evaporated.	  The	   reaction	  mixture	  was	  
re-­‐dissolved	   in	   ethyl	   acetate	   (100	  mL),	  washed	  with	  NaHCO3	   (50	  mL),	   dried	   (MgSO4),	   and	  
concentrated	  under	  vacuum	  to	  yield	  the	  product	  as	  a	  white	  solid	  (0.08	  g,	  97	  %);	  m.p.	  65.5-­‐
66.5	   oC	   (lit.370	   66-­‐67	   oC);	   1H	  NMR	   (400	  MHz,	   CDCl3)	  δ	   1.36	   (3H,	   t	   J	   7.1,	   CH3),	   2.87	   (3H,	   s,	  



























9.0,	  Ar	  2.0	  &	  6.0);	  13C	  NMR	  (100	  MHz,	  CDCl3)	  14.5	  (CH3),	  30.2	  (NCH3),	  60.1	  (CH2),	  111.1	  (C3	  
C5),	  118.6	  (C1),	  131.5	  (C2	  C6),	  152.8	  (C4),	  166.9	  (C=O);	  m/z	  (ES)	  180.1018	  (M+H),	  C10H14O2N1,	  
requires	  180.1019)	  and	  152.	  
	  




To	  a	   suspension	  of	  Pd/C	   (0.29	  g,	   0.3	  mmol)	   in	  2-­‐propanol	   (20	  mL)	  was	  added	  ammonium	  
formate	  (0.87	  g,	  13.8	  mmol)	  dissolved	  in	  water	  (2	  mL).	  The	  reaction	  mixture	  was	  stirred	  for	  
1	   minute	   to	   activate	   the	   Pd/C.	   4-­‐Aminobenzoic	   acid	   (0.38	   g,	   2.8	   mmol)	   and	   para-­‐
formaldehyde	   (0.83	   g,	   27.5	  mmol)	   were	   then	   added,	   and	   the	   reaction	  mixture	   stirred	   at	  
room	   temperature	   for	   18	   hours.	   The	   reaction	   mixture	   was	   filtered	   through	   Celite™,	  
concentrated	   under	   vacuum,	   re-­‐dissolved	   in	   ethyl	   acetate,	   washed	   with	   brine,	   dried	  
(MgSO4),	  and	  concentrated	  under	  vacuum.	  Purification	  by	  silica	  gel	  column	  chromatography	  
(chloroform:	  ethyl	  acetate;	  2:1)	  yielded	   the	  product	  as	  a	  white	   solid	   (0.137	  g,	  33	  %);	  m.p.	  
152-­‐153	  oC	  (lit.369	  151.5-­‐152.5	  oC).	  All	  spectral	  properties	  were	  identical	  to	  those	  reported	  in	  
the	   literature.369	   1H	  NMR	  (500	  MHz,	  CDCl3)	  δ	  2.91	   (3H,	   s,	  CH3),	  6.57	   (2H,	  d,	   J	  8.8	  Ar),	  7.94	  

















7.2	  Biological	  Procedures	  
	  
7.2.1	  General	  Cell	  Culture	  
	  
Cells	  were	  cultured	  in	  a	  humidified	  atmosphere	  of	  5%	  CO2	  in	  air	  at	  37	  °C,	  in	  a	  CO2	  incubator	  
(Sanyo).	   Cultures	   were	   handled	   in	   using	   aseptic	   techniques	   in	   a	   class	   (II)	   bio-­‐safety	   flow	  
hood	   (ESCO	   Airstream	   or	   BSC-­‐EN).	   Cultures	   incubated	   with	   retinoid	   compounds	   were	  
handled	   in	   reduced	   light	  conditions	   to	  account	   for	   the	   instability	  of	  ATRA.	  All	  plastic-­‐wear	  
was	   purchased	   from	   Nunc	   or	   Becton	   Dickinson	   unless	   otherwise	   stated.	   Phase	   contrast	  
images	  of	  growing	  cultures	  were	  obtained	  using	  a	  light	  microscope	  (Nikon	  Diaphot	  300)	  and	  
photomicrographs	   captured	   using	   digital	   photography	   (Nikon).	   H2O	   refers	   to	   high	   purity	  
water	  unless	  otherwise	  stated.	  Precise	  media	  recipes	  and	  culture	  techniques	  are	  described	  
here	  on	  in	  under	  specific	  cell	  line	  procedures.	  
	  
7.2.2	  Test	  Compound	  Stocks	  
	  
In	  preparation	  for	  use	  in	  cell	  culture	  experiments,	  stock	  solutions	  of	  synthetic	  compounds,	  
ATRA	  (Sigma)	  and	  13cRA	  (Sigma)	  were	  prepared	   in	  DMSO	  (Sigma)	   to	  concentrations	  of	  10	  
mM.	  Aliquotted	  stock	  solutions	  were	  stored	  at	  –	  80	  oC	  in	  the	  dark.	  
	  
7.2.3	  F9	  Cell	  Procedures	  
	  
The	  cells	  used	  were	  a	  kind	  gift	  from	  Prof.	  Colin	  A.	  B.	  Jahoda,	  Durham	  University.	  
	  
7.2.3.1	  Tissue	  culture	  
F9	   cells	   were	   cultured	   in	   Dulbecco’s	   Modified	   Eagle’s	   Medium	   (DMEM)	   (Sigma)	  
supplemented	  with	  50	  mL	  of	  10%	  fetal	  calf	  serum	  (FCS)	  (Gibco),	  5	  mL	  of	  2	  mM	  L-­‐Glutamine,	  
1.1	   mL	   of	   Penicillin/Streptomycin	   solution	   (200	   active	   units)	   (Gibco)	   and	   0.5	   µg/ml	  






7.2.3.2	  Lac	  Z	  Staining	  Protocol	  
Cells	  were	  grown	  in	  24-­‐well	  culture	  plates	  seeded	  at	  400,000	  cells/well	  in	  0.8	  mL	  of	  standard	  
growth	  media.	  After	  6	  hours	  the	  media	  is	  changed	  with	  the	  addition	  of	  any	  test	  compounds	  
being	  added	  to	  the	  media.	  After	  18	  hours	  incubation	  the	  cultures	  were	  fixed	  in	  ice-­‐cold	  4%	  
paraformaldehyde	  (Sigma)	  in	  phosphate-­‐buffered	  saline	  (PBS)	  for	  1	  hour	  at	  4	  oC,	  followed	  by	  
three	  washes	  in	  rinse	  buffer	  (prepared	  from	  2.36	  g	  of	  Sodium	  Phosphate	  (Sigma),	  0.038	  g	  of	  
Magnesium	  Chloride	  (Sigma),	  20	  mg	  of	  Sodium	  Deoxycholate	  (Sigma),	  40	  µL	  NP40S	  Tergitol	  
Solution	  (Sigma),	  in	  PBS	  solution	  to	  a	  total	  volume	  of	  200	  mL	  at	  a	  pH	  of	  7.3)	  for	  a	  minimum	  
of	   5	  minutes.	   Cultures	  were	   immediately	   stained	   using	   freshly	   prepared	   staining	   solution	  
(prepared	   from	   25	  µL	   of	   Potassium	   Ferricyanide	   from	   a	   0.2	  M	   stock,	   25	  µL	   of	   Potassium	  
Ferrocyanide	  from	  a	  0.2	  M	  stock	  and	  25	  µL	  X-­‐Gal	  from	  40	  mg/mL	  stock	  made	  up	  to	  1	  mL	  in	  
Rinse	  Buffer)	  (250	  µL	  per	  well)	  for	  18	  hours	  at	  room	  temperature	  in	  the	  absence	  of	  light.	  	  	  
	  
7.2.4	  TERA2.cl.SP12	  Cell	  Procedures	  
	  
7.2.4.1	  Tissue	  Culture	  
Human	  pluripotent	  TERA2.cl.SP12	  embryonal	  carcinoma	  stem	  cells	  were	  maintained	  under	  
standard	  laboratory	  conditions	  as	  described	  by	  Przyborski.209,211	  In	  brief,	  cells	  were	  cultured	  
in	   DMEM	   (Sigma)	   supplemented	  with	   10%	   FCS	   (Gibco),	   2mM	   L-­‐glutamine	   and	   100	   active	  
units	  each	  of	  penicillin	  and	  streptomycin	  (Gibco).	  Cultures	  were	  passaged	  using	  acid-­‐washed	  
glass	  beads	  (VWR)	  unless	  a	  single-­‐cell	  suspension	  was	  required	  for	  counting,	  in	  which	  case	  a	  
0.25%	  trypsin	  EDTA	  (Cambrex)	  solution	  was	  used.	  Cultures	  intended	  for	  flow	  cytometric	  and	  
RT-­‐PCR	   analysis	   were	   set	   up	   in	   T25	   flasks	   (Becton	   Dickinson)	  while	   12-­‐well	   plates	   (Nunc)	  
were	  used	  for	  immunocytochemical	  studies	  and	  cell	  viability/apoptopic	  analysis.	  	  
	  
7.2.4.2	  MTS	  Cell	  Viability	  Assay	  
Cells	  were	  cultured	  on	  24-­‐well	  plates	  (Nunc).	  50,000	  cells	  per	  well	  were	  seeded	  and	  either	  
cultured	   in	   proliferation	   media	   (control),	   or	   differentiation	   media	   containing	   compounds	  
under	  investigation.	  Cells	  were	  cultured	  for	  up	  to	  14	  days,	  with	  samples	  analysed	  at	  3,	  7	  and	  
14	  day	  time	  points.	  For	  the	  assay	  200	  µl	  of	  MTS	  reagent,	  CellTiter	  96	  AQueous	  One	  Solution	  
Cell	   Proliferation	   Assay	   (Promega)	   was	   added	   to	   1	   mL	   of	   media	   per	   well.	   A	   control	   well	  
containing	  no	  cells	  was	  also	  set	  up	  in	  an	  identical	  manner.	  The	  solutions	  were	  titurated	  then	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incubated	   for	   4	   hours	   at	   37	   oC.	   The	   resulting	   colorimetric	   change	   was	   recorded	   as	   an	  
absorbance,	   read	   at	   490	   nm	   on	   a	  Nanodrop	   Spectrophotometer	  ND-­‐100™.	   All	   conditions	  
were	  carried	  out	   in	  triplicate	  and	  were	  standardised	  against	   the	  no-­‐cell	  control	   to	  remove	  
any	  background	  absorbance.	  	  
	  
7.2.4.3	  Flow	  Cytometry	  
Flow	   cytometry	   analysis	   was	   carried	   out	   on	   live	   cells	   using	   antibodies	   recognising	   cell	  
surface	  markers.	  The	  expression	  of	  markers	  indicative	  of	  the	  stem	  cell	  (SSEA-­‐3	  (University	  of	  
Iowa	   Hybridoma	   Bank)	   and	   TRA-­‐1-­‐60	   (generous	   gift	   from	   Prof.	   P.	   Andrews,	   University	   of	  
Sheffield))	   or	  neural	   cell	   (A2B5,	  R&D	  Systems)	  phenotype	  was	  determined	   to	   indicate	   the	  
status	  of	  cellular	  differentiation	  by	  TERA2.cl.SP12	  cells.	  Suspensions	  of	  single	  EC	  cells	  of	  their	  
differentiated	  derivatives	  were	  formed	  by	  the	  addition	  of	  1	  mL	  0.25%	  trypsin/EDTA	  solution.	  
The	   cell	   suspension	   was	   divided	   accordingly	   for	   flow	   cytometry	   and	   RT-­‐PCR	   (see	   later)	  
analysis	   accordingly.	   Cells	   were	   added	   to	   a	   96-­‐well	   plate	   (0.2	   x	   106	   cells	   per	   well)	   as	   a	  
suspension	   in	  wash	   buffer	   (0.1%	  bovine	   serum	   albumin	   (BSA)	   in	   PBS)	   for	   incubation	  with	  
primary	   (1:20	   SSEA-­‐3	   and	   TRA-­‐1-­‐60,	   or	   1:10	   A2B5)	   and	   fluorescein	   isothiocyanate	   (FITC)-­‐
conjugated	  secondary	  antibody	  (Sigma,	  1:100)	  as	  previously	  described.	  Labelled	  cells	  were	  
analysed	   in	   a	   Guave	   EasyCyte™	   Plus	   System	   (Millipore)	   flow	   cytometer.	   Thresholds	  
determining	  the	  numbers	  of	  positively	  expressing	  cells	  were	  set	  against	  the	  negative	  control	  
antibody	  P3X	  (used	  neat,	  generous	  gift	  from	  Prof.	  P.	  Andrews,	  University	  of	  Sheffield).	  
	  
7.2.4.4	  Real	  Time	  quantitative	  PCR	  (RT-­‐PCR)	  
RT-­‐PCR	  was	  carried	  out	  on	  cells	  immediately	  lysed	  after	  treatment	  with	  0.25%	  trypsin/EDTA.	  
Commercial	   RNA	   extraction	   kits	   and	   procedures	   (Qiagen)	   and	   reverse	   transcription	  
procedures	   (Applied	   Biosystems)	   were	   followed.	   In	   brief,	   cells	   were	   lysed,	   homogenised	  
using	  a	  20-­‐gauge	  needle,	  and	  passed	  through	  an	  RNeasy	  spin	  column.	  DNase	  digestion	  was	  
carried	  out,	  before	  the	  RNA	  was	  extracted	  from	  the	  column	  as	  a	  suspension	  in	  RNase	  free	  
water.	  Amounts	  of	  RNA	  extracted	  were	  determined	  using	  a	  Nanodrop	  Spectrophotometer	  
ND-­‐100™,	  followed	  by	  analysis	  on	  a	  1%	  Agrose	  gel.	  Reverse	  transcription	  was	  then	  carried	  
out	   using	   a	   high-­‐capacity	   cDNA	   reverse	   transcription	   kit	   and	   a	   thermal	   cycler.	   cDNA	  was	  
stored	  at	  –	  20	  oC	  before	  analysis	  by	  RT-­‐PCR.	  The	  expression	  of	  specific	  genes	   indicative	  of	  
pluripotency,	   Nanog	   (Hs02387400_g1,	   Applied	   Biosystems)	   and	   Oct-­‐4	   (Hs03005111_g1,	  
Chapter	  VII	  
 254	  
Applied	   Biosystems)	   and	   neural	   and	   ventral	   phenotype,	   Pax6	   (Hs00240871_m1,	   Applied	  
Biosystems)	   were	   investigated	   and	   quantified	   against	   GAPDH	   (4333764F,	   Applied	  
Biosystems).	  RT-­‐PCR	  analysis	  was	  done	  on	  an	  Applied	  Biosystems	  RT-­‐PCR	  system.	  
	  
7.2.4.5	  Immunocytochemistry	  
Cells	  were	  grown	  in	  12-­‐well	  culture	  plates	  for	  immunocytochemical	  analysis.	  Confluent	  
cultures	  of	  stem	  cells	  and	  their	  differentiated	  derivatives	  were	  fixed	  in	  ice-­‐cold	  4%	  
paraformaldehyde	  (Sigma)	  in	  PBS	  for	  30	  minutes	  at	  room	  temperature,	  followed	  by	  three	  
washes	  in	  PBS.	  Cell	  membranes	  were	  permeabilised	  by	  treatment	  with	  1%	  Triton-­‐X-­‐100	  
(Sigma)	  in	  PBS	  for	  10	  minutes	  at	  room	  temperature.	  Non-­‐specific	  binding	  of	  antibodies	  was	  
blocked	  using	  a	  solution	  of	  1%	  goat	  serum	  (Sigma)	  in	  PBS	  containing	  0.2%	  Tween-­‐20	  (Sigma).	  
Fixed	  cells	  were	  incubated	  with	  blocking	  solution	  on	  a	  bench-­‐top	  shaker	  for	  30	  minutes	  at	  
room	  temperature.	  Primary	  antibodies:	  β-­‐III-­‐Tubulin	  (Covance,	  1:600);	  NF-­‐200	  (Sigma,	  
1:200)	  were	  diluted	  in	  blocking	  solution	  and	  incubated	  with	  the	  cells	  for	  1	  hour	  at	  room	  
temperature.	  After	  washing	  (three	  times	  for	  a	  minimum	  of	  15	  minutes	  at	  room	  temperature	  
in	  PBS)	  cells	  were	  incubated	  in	  FITC-­‐conjugated	  secondary	  antibody	  (Alexafluor	  488	  
(Molecular	  Probes,	  1:600)	  and	  Cy3	  (Jackson	  Labs,	  1:600))	  for	  1	  hour.	  After	  two	  washes	  in	  
PBS	  for	  15	  minutes	  the	  cells	  were	  incubated	  with	  PBS	  containing	  Hoechst	  33342	  nuclear	  
staining	  dye	  (Molecular	  Probes,	  1:1000)	  for	  15	  minutes	  before	  the	  cells	  were	  stored	  in	  PBS.	  
Imaging	  was	  performed	  on	  a	  fluorescent	  microscope	  under	  restricted	  light	  conditions	  (Nikon	  
Diaphot	  300).	  Fluorescence	  photomicrographs,	  including	  Hoecsht	  33342,	  were	  acquired	  
using	  the	  appropriate	  filter	  sets	  and	  customised	  digital	  camera	  (Nikon).	  	  
	  
7.2.5	  ReNcell	  VM	  Procedures	  
	  
7.2.5.1	  Cell	  culture	  
All	  plastic-­‐ware	  was	  purchased	  from	  Nunc	  unless	  otherwise	  stated.	  Before	  use,	  plastic-­‐wear	  
was	  coated	  with	  laminin	  solution	  (Sigma)	  diluted	  in	  DMEM:F12	  to	  20	  μg/ml.	  	  For	  coating	  of	  
T75	  flasks,	  5	  mL	  of	  diluted	  laminin	  solution	  was	  added	  per	  flask	  and	  incubated	  at	  37	  °C	  for	  at	  
least	  6	  hours.	  	  Flasks	  were	  washed	  twice	  with	  media	  prior	  to	  use.	  ReNcell	  197VM	  progenitor	  
cells	  (Millipore)	  were	  cultured	  in	  serum	  free	  conditions	  using	  methods	  previously	  described	  
by	  Donato	  et	  al.57	  Briefly,	  DMEM:F12	  (1:1,	  Gibco)	  was	  supplemented	  with	  B27	  (Invitrogen),	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2	   mM	   L-­‐Glutamine	   (Sigma),	   0.5	   mL	   Gentamycin	   (Gibco),	   and	   1	   mL	   50	   mg/ml	   Heparin	  
solution	   (Sigma).	   	   For	   proliferation,	   20	   ng/mL	   FGF	   and	   20	   ng/mL	   EGF	  were	   added	   to	   the	  
media	  immediately	  prior	  to	  use.	  	  Cultures	  were	  passaged	  using	  0.25%	  trypsin	  EDTA	  solution	  
and	  trypsin	  action	  was	  inhibited	  with	  soy-­‐bean	  trypsin	  inhibitor	  solution	  (Sigma).	  
	  
7.2.5.2	  Differentiation	  Protocol	  
Cultures	  were	   incubated	  with	   trypsin	   to	  obtain	  a	  single	  cell	   suspension	  as	  outlined	  above,	  
and	   100,000	   cells/well	   were	   seeded	   into	   laminin-­‐treated	   12	   well	   plates.	   	   Cultures	   were	  
allowed	   to	   reach	   75%	   confluency	   whereupon	   media	   was	   replaced	   with	   standard	  
differentiation	  media,	  without	  (differentiation	  control)	  or	  with	  retinoid	  supplementation,	  as	  
previously	  described	  by	  Christie	  et	  al.59	  Briefly,	  standard	  differentiation	  media	  was	  made	  up	  
as	  described	  above,	  but	  without	  FGF	  of	  EGF.	   	   Initial	  experiments	  used	  retinoids	  at	  a	  single	  
concentration	   of	   1	  µM.	   Subsequent	   concentration	   effects	  were	   investigated	   at	   1	  µM,	   0.1	  
µM,	  0.01	  µM	  and	  0.001	  µM	  concentrations.	  Cultures	  were	  incubated	  for	  7	  days	  before	  being	  
processed	  for	  further	  analysis.	  
	  
7.2.5.3	  Phase	  Contrast	  Microscopy	  
Phase	  contrast	   images	  of	  growing	  cultures	  were	  obtained	  using	  a	   light	  microscope	   (Nikon	  
Diaphot	  300)	  and	  photomicrographs	  captured	  using	  digital	  photography	  (Nikon).	  
	  
7.2.5.4	  Immunocytochemistry	  
Cell	  fixing	  was	  performed	  by	  incubation	  with	  ice-­‐cold	  4%	  PFA	  in	  PBS	  (Sigma)	  for	  30	  minutes	  
at	  RT,	   followed	  by	  3	  washes	  with	  PBS.	   	  Cell	  membranes	  were	  permeablised	  by	   treatment	  
with	   1%	   Triton-­‐X-­‐100	   (Sigma)	   in	   PBS	   for	   10	   minutes	   at	   room	   temperature.	   Non-­‐specific	  
binding	   of	   antibodies	   was	   blocked	   using	   a	   solution	   of	   1%	   goat	   serum	   (Sigma)	   in	   PBS	  
containing	   0.2%	   Tween-­‐20	   (Sigma).	   	   Dilution	   of	   primary	   antibodies	   was	   carried	   out	   in	  
blocking	  solution,	  and	  incubated	  with	  the	  cells	  for	  1	  hour	  at	  room	  temperature	  (β-­‐III-­‐Tubulin	  
antibody	   (Covance)	   was	   diluted	   1:600.	   NF-­‐200	   antibody	   (AbCam)	   was	   diluted	   1:200.	  
MAP2ab	  antibody	  (Sigma)	  was	  diluted	  1:400).	  Cells	  were	  washed	  3	  times	  for	  15	  minutes	  in	  
PBS	   followed	   by	   one	   hour	   incubation	   in	   the	   dark	   at	   RT	   with	   appropriately	   diluted	   FITC-­‐
conjugated	   (Alexafluor	   488,	   diluted	  1:600)	   or	   Cy3-­‐conjugated	   (JacksonLabs,	   diluted	  1:600)	  
secondary	  antibody.	   	  A	   further	  2	  washes	  of	  PBS	  were	  carried	  out	   in	   the	  dark,	   followed	  by	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incubation	  with	  1	  µg/mL	  Hoechst	  33342	  nuclear	  staining	  dye	  (Molecular	  Probes,	  diluted	  in	  
PBS).	   Cultures	  were	  washed	   twice	  more	   in	   PBS,	   and	   left	   in	   the	   final	  wash	   for	   immediate	  
imaging.	  Fixed	  and	  immunostained	  cultures	  were	  examined	  using	  a	  fluorescent	  microscope	  
under	   restricted	   light	   conditions	   (Nikon	   Diaphot	   300).	   Hoechst	   33342	   images	   and	   the	  
corresponding	   fluorescent	   photomicrographs	   were	   collated	   and	   stored	   using	   the	  
appropriate	  filter	  sets	  and	  an	  adapted	  digital	  camera	  (Nikon).	   	  Triplicate	  experiments	  were	  
carried	  out	  for	  reproducibility.	  
	  
7.2.6	  Adult	  Hippocampal	  Progenitor	  Cells	  (AHPC)	  
	  
7.2.6.1	  Cell	  Culture	  
All	  plastic-­‐ware	  was	  purchased	  from	  Nunc.	  Before	  use,	  plastic-­‐ware	  was	  coated	  with	  poly-­‐L-­‐
ornithine	   (Sigma)	   diluted	   in	   H2O	   to	   10	   µg/mL	   for	   12-­‐24	   hours	   at	   room	   temperature	   in	   a	  
tissue	  culture	  hood.	  The	  culture-­‐ware	  was	  then	  washed	  2	  times	  with	  sterile	  H2O,	   followed	  
by	  coating	  in	  laminin	  in	  sterile	  PBS	  at	  5	  µg/mL	  for	  24	  hours	  at	  37	  oC	  in	  an	  incubator.	  Excess	  
laminin	  was	   then	   removed	   through	  aspiration,	   the	   flasks	   sealed	  and	  wrapped	   in	  cling	   film	  
and	  stored	  at	  -­‐20	  oC	  for	  up	  to	  6-­‐8	  months.	  	  
	  
Before	  use	   the	   flasks	  were	  warmed	   to	   room	   temperature,	   and	  washed	   in	  PBS.	  Cells	  were	  
cultured	   under	   serum	   free	   conditions	   at	   all	   times	   as	   outlined	   in	   protocols	   from	   the	   Salk	  
Institute.58,218	   To	   expand	   the	   cell	   cultures	   proliferative	   media	   was	   used,	   consisting	   of	  
DMEM/F12	  (high	  glucose)	  (Gibco),	  supplemented	  with	  1	  x	  N2	  supplement	  (Gibco),	  2	  mM	  L-­‐
glutamine	   (Sigma),	  20	  ng/mL	  bFGF	   (Sigma,	   just	  added	  before	  use)	  and	  100	  active	  units	  of	  
penicillin/streptomycin	  (Gibco).	  To	  maintain	  optimum	  cultures,	  media	  was	  changed	  every	  3	  
days,	   and	   cultures	   were	   passaged	   at	   ~90	  %	   confluence.	   To	   passage	   cells,	   the	  media	   was	  
aspirated,	  1	  mL	  trypsin-­‐versene	  solution	  (Cambrex)	  added	  and	  rocked	  gently	  over	  the	  cells,	  
with	  any	  excess	  immediately	  removed.	  Cells	  were	  dislodged	  from	  the	  plastic-­‐ware	  by	  gentle	  
tapping,	   and	   re-­‐suspended	   in	   10	   mL	   DMEM/F12.	   The	   suspension	   was	   pelleted	   by	  
centrifugation	  at	  12000	  rpm	  for	  3	  minutes.	  The	  supernatant	  was	  removed	  and	  the	  pellet	  re-­‐
suspended	  in	  1	  mL	  proliferation	  media	  and	  triturated	  to	  gain	  a	  single	  cell	  suspension.	  Cells	  
then	  went	  a	  1:5	  to	  1:10	  split	  depending	  on	  cell	  number	  and	  were	  transferred	  to	  new	  poly-­‐L-­‐




7.2.6.2	  Differentiation	  Protocol	  
AHPC	  cell	  cultures	  were	  induced	  to	  differentiate	  with	  the	  introduction	  of	  1	  µM	  ATRA	  (Sigma)	  
diluted	   in	   DMSO,	   or	   test	   compounds	   diluted	   in	   DMSO,	   into	   the	   media,	   alongside	   the	  
reduction	   of	   bFGF	   concentration	   down	   to	   1	   ng/mL.	   In	   preparation	   for	   each	   experiment,	  
cultures	  which	  had	  reached	  ~90	  %	  confluence	  were	  treated	  with	  trypsin-­‐versene	  solution	  to	  
obtain	   a	   single	   cell	   suspension	   as	   outline	   previously.	   Cell	   number	   was	   subsequently	  
determined	   using	   a	   haemocytometer	   under	   a	   light	   microscope.	   Unless	   otherwise	   stated,	  
cells	   were	   seeded	   at	   100,000	   cells	   per	   well	   in	   a	   4-­‐well	   plate	   (Nunc).	   Cultures	   were	  
maintained	  for	  up	  to	  14	  days,	  with	  the	  media	  refreshed	  every	  3	  days.	  	  	  	  	  	  
	  
7.2.6.3	  Immunocytochemistry	  
Cell	  fixing	  was	  performed	  by	  incubation	  with	  ice-­‐cold	  4%	  PFA	  in	  PBS	  (Sigma)	  for	  30	  minutes	  
at	  RT,	   followed	  by	  3	  washes	  with	  PBS.	   	  Cell	  membranes	  were	  permeablised	  by	   treatment	  
with	   1%	   Triton-­‐X-­‐100	   (Sigma)	   in	   PBS	   for	   10	   minutes	   at	   room	   temperature.	   Non-­‐specific	  
binding	   of	   antibodies	   was	   blocked	   using	   a	   solution	   of	   1%	   goat	   serum	   (Sigma)	   in	   PBS	  
containing	   0.2%	   Tween-­‐20	   (Sigma).	   	   Dilution	   of	   primary	   antibodies	   was	   carried	   out	   in	  
blocking	  solution,	  and	  incubated	  with	  the	  cells	  for	  1	  hour	  at	  room	  temperature	  (β-­‐III-­‐Tubulin	  
antibody	   (Covance)	  was	  diluted	  1:600.	  NF-­‐200	  antibody	   (AbCam)	  was	  diluted	  1:200).	  Cells	  
were	  washed	  3	  times	  for	  15	  minutes	  in	  PBS	  followed	  by	  one	  hour	  incubation	  in	  the	  dark	  at	  
RT	   with	   appropriately	   diluted	   FITC-­‐conjugated	   (Alexafluor	   488,	   diluted	   1:600)	   or	   Cy3-­‐
conjugated	   (JacksonLabs,	   diluted	   1:600)	   secondary	   antibody.	   	   A	   further	   2	   washes	   of	   PBS	  
were	  carried	  out	   in	  the	  dark,	   followed	  by	   incubation	  with	  1	  µg/mL	  Hoechst	  33342	  nuclear	  
staining	  dye	   (Molecular	  Probes,	  diluted	   in	  PBS).	  Cultures	  were	  washed	  twice	  more	   in	  PBS,	  
and	   left	   in	   the	   final	  wash	   for	   immediate	   imaging.	  Fixed	  and	   immunostained	  cultures	  were	  
examined	  using	  a	   fluorescent	  microscope	  under	   restricted	   light	   conditions	   (Nikon	  Diaphot	  
300).	   Hoechst	   33342	   images	   and	   the	   corresponding	   fluorescent	   photomicrographs	   were	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Empirical	  formula	   C22H26O2	  
Formula	  weight	   322.43	  
Temperature/K	   393(2)	  
Crystal	  system	   monoclinic	  
Space	  group	   P21/n	  
a/Å	   8.5727(3)	  
b/Å	   19.6233(9)	  
c/Å	   11.7421(6)	  
α/°	   90.00	  
β/°	   109.958(9)	  
γ/°	   90.00	  
Volume/Å3	   1856.68(14)	  
Z	   4	  
ρcalcmg/mm3	   1.153	  
m/mm‑1	   0.072	  
F(000)	   696	  
Crystal	  size/mm3	   0.42	  ×	  0.20	  ×	  0.12	  
2Θ	  range	  for	  data	  collection	   4.16	  to	  55°	  
Index	  ranges	   -­‐11	  ≤	  h	  ≤	  10,	  -­‐25	  ≤	  k	  ≤	  23,	  -­‐15	  ≤	  l	  ≤	  15	  
Reflections	  collected	   15914	  
Independent	  reflections	   4264[R(int)	  =	  0.0299]	  
Data/restraints/parameters	   4264/0/231	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Goodness-­‐of-­‐fit	  on	  F2	   1.040	  
Final	  R	  indexes	  [I>=2σ	  (I)]	   R1	  =	  0.0422,	  wR2	  =	  0.1067	  
Final	  R	  indexes	  [all	  data]	   R1	  =	  0.0592,	  wR2	  =	  0.1171	  




Atom	   Atom	   Length/Å	   	  	   Atom	   Atom	   Length/Å	  
O1	   C21	   1.3229(16)	   	  	   C6	   C7	   1.3974(19)	  
O2	   C21	   1.2249(17)	   	  	   C6	   C15	   1.4361(18)	  
C1	   C2	   1.532(2)	   	  	   C7	   C8	   1.3747(19)	  
C1	   C9	   1.5282(18)	   	  	   C8	   C9	   1.4021(18)	  
C1	   C11	   1.5385(19)	   	  	   C9	   C10	   1.4064(17)	  
C1	   C12	   1.536(2)	   	  	   C15	   C16	   1.2015(19)	  
C2	   C3	   1.512(2)	   	  	   C16	   C17	   1.4201(18)	  
C3	   C4	   1.5331(18)	   	  	   C17	   C18	   1.3404(18)	  
C4	   C10	   1.5327(17)	   	  	   C18	   C19	   1.4536(18)	  
C4	   C13	   1.5333(18)	   	  	   C19	   C20	   1.3449(18)	  
C4	   C14	   1.5405(17)	   	  	   C19	   C22	   1.5028(18)	  
C5	   C6	   1.3951(17)	   	  	   C20	   C21	   1.4681(18)	  




Atom	   Atom	   Atom	   Angle/˚	   	  	   Atom	   Atom	   Atom	   Angle/˚	  
C2	   C1	   C11	   110.24(12)	   	  	   C7	   C8	   C9	   122.65(12)	  
C2	   C1	   C12	   107.96(12)	   	  	   C8	   C9	   C1	   118.90(11)	  
C9	   C1	   C2	   110.19(10)	   	  	   C8	   C9	   C10	   118.03(12)	  
C9	   C1	   C11	   108.78(11)	   	  	   C10	   C9	   C1	   123.07(11)	  
C9	   C1	   C12	   111.06(11)	   	  	   C5	   C10	   C4	   118.20(11)	  
C12	   C1	   C11	   108.59(12)	   	  	   C5	   C10	   C9	   118.92(11)	  
C3	   C2	   C1	   111.96(11)	   	  	   C9	   C10	   C4	   122.85(11)	  
C2	   C3	   C4	   112.64(11)	   	  	   C16	   C15	   C6	   178.07(14)	  
C3	   C4	   C13	   107.51(11)	   	  	   C15	   C16	   C17	   178.25(15)	  
C3	   C4	   C14	   110.11(10)	   	  	   C18	   C17	   C16	   124.08(12)	  
C10	   C4	   C3	   110.33(10)	   	  	   C17	   C18	   C19	   125.37(12)	  
C10	   C4	   C13	   111.30(10)	   	  	   C18	   C19	   C22	   117.95(11)	  
C10	   C4	   C14	   108.94(10)	   	  	   C20	   C19	   C18	   117.77(12)	  
C13	   C4	   C14	   108.63(11)	   	  	   C20	   C19	   C22	   124.28(12)	  
C6	   C5	   C10	   122.21(11)	   	  	   C19	   C20	   C21	   126.08(12)	  
C5	   C6	   C7	   118.45(12)	   	  	   O1	   C21	   C20	   113.08(12)	  
C5	   C6	   C15	   121.20(12)	   	  	   O2	   C21	   O1	   122.86(12)	  
C7	   C6	   C15	   120.35(12)	   	  	   O2	   C21	   C20	   124.01(12)	  
C8	   C7	   C6	   119.62(12)	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